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Abstract 
Introduction 
Drug-related problems (DRPs) are a major burden on healthcare systems. Once detected, 
the resolution of these DRPs has the potential to reduce healthcare costs and improve 
patient outcomes. Community pharmacists are ideally placed to detect and prevent DRPs, 
with the resolution of a DRP being termed a clinical intervention. 
Aims 
Utilising an electronic documentation system, the aim of this project was to determine the 
number and nature of DRPs detected and clinical interventions performed by Australian 
community pharmacists. The project also aimed to identify the pharmacy and pharmacist 
factors that influenced the frequency with which clinical interventions were both 
performed and documented. 
Methods 
An electronic documentation system was designed and integrated into the existing 
dispensing software of 186 pharmacies in three States of Australia (NSW, Victoria and 
Tasmania) to allow pharmacists to record details about the clinical interventions they 
performed in order to prevent or resolve DRPs. Participating pharmacies were randomly 
allocated to three groups: Group One had documentation software; Group Two had 
documentation software plus a timed reminder to document interventions; and Group 
Three had documentation software, timed reminder and an electronic decision support 
prompt. Pharmacists were trained in the use of the software system and also completed 
several surveys gathering information about demographics, professional attitude, 
personality traits and clinical knowledge. Pharmacists classified DRPs, entered 
recommendations they made, and estimated the clinical significance of the intervention. 
An observational sub-study, which included 24 pharmacies without any documentation 
software, was also completed to determine current practice. 
Results 
Over 12 weeks, 531 participating pharmacists dispensed 2,013,923 prescriptions for 
483,147 patients and documented 6,230 interventions, resulting in a median intervention 
rate of 2.4 interventions in 1000 prescriptions or 0.24%. Of these 6,230 interventions, 282 
were attributed to the electronic prompt in Group Three and were removed prior to 
analysis. No significant differences were seen in the overall intervention rate between the 
       iii | P a g e   
 
three groups, however the presence of the prompt in Group Three significantly increased 
the number of interventions performed on the prompted medications. As expected, the 
‘software’ pharmacies had a significantly higher documentation rate compared to the ‘no 
software’ pharmacies. There was a significant decline in the number of interventions 
documented over the trial period. 
Commonly, pharmacists’ interventions were related to drug selection problems (30.7%) 
and educational issues (23.7%). Recommendations were often related to a change in 
therapy (40.1%), such as a change of drug or dose, or provision of information (34.7%). 
When a referral recommendation was made, this was almost uniformly to the prescriber 
(91.3%). Nearly half of the interventions (42.6%) were classified as having a higher clinical 
significance by the documenting pharmacists, with these interventions most commonly 
associated with undertreatment or toxicity DRPs. Drug groups most commonly subject to 
an intervention included antibiotics, glucocorticoids, and opioids. The antibiotics were 
commonly associated with DRPs due to allergies, incorrect doses and drug interactions, 
with the glucocorticoids and opioids often associated with dosing issues. An independent 
expert panel of 23 experts (5 physicians, 10 GPs and 8 pharmacists) was commissioned to 
assess the economic value of a sample of 200 interventions. The pharmacist’s assessment 
of the clinical significance appeared to correlate well with the economic value (p < 0.001), 
showing that the more clinically significant the pharmacist thought the intervention was, 
the higher the cost saving to the Australian government.  
Original prescriptions were associated with significantly more interventions than repeat 
prescriptions (p < 0.001), most likely due to original prescriptions having a higher 
incidence of drug selection errors, drug interactions and education requirements 
compared to repeat prescriptions. As expected, more interventions were performed on 
older patients (p < 0.001), most likely due to the larger number of medications they were 
taking. Analysis of the observational sub-study revealed that only 49% of performed 
interventions were documented within the electronic software system, suggesting that 
the number of interventions performed may actually be twice the number documented 
within the software.  
Multiple regression analysis was used to produce a model to predict the pharmacy’s 
intervention rate. Two models were created, the ‘pharmacist workload’ model and the 
‘prescription volume’ model, however, both model fits were poor and could only explain 
10.1% and 11.8% of the variance, respectively. The ‘pharmacist workload’ model had 
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three significant factors: high pharmacist workload; annual financial turnover; and, 
whether the pharmacy catered for aged care facilities. Pharmacies that had higher 
pharmacist workload, a higher financial turnover and catered for aged care facilities 
tended to have lower intervention rates. The ‘prescription volume’ model had five 
significant factors: high prescription volume; moderate prescription volume; annual 
financial turnover; location in or near a medical centre; and, participation in other 
pharmacy trials. Pharmacies with a higher prescription volume, a higher financial turnover 
and concurrent participation in other trials tended to have lower intervention rates on 
average, whilst medical centre pharmacies tended to have higher intervention rates on 
average. Despite the poor model fit, these factors would logically have a significant impact 
on the pharmacist’s workload, indicating that the busier the pharmacy and pharmacists 
are, the lower the intervention rate is likely to be as there would be less time to perform 
and document clinical interventions. This theory was also supported by the bivariate 
analyses which showed that the intervention rate of the pharmacy was significantly 
correlated with the workload during the trial, with the busier pharmacies having a lower 
intervention rate. The observational sub-study also identified workload as a key factor 
that influenced the pharmacy’s intervention rate. 
A separate analysis was performed on the individual pharmacist data. The logistic 
regression model was 65.8% successful in predicting whether a pharmacist would have a 
high intervention rate using four variables: average number of continuing professional 
development (CPD) hours completed per year; level of software training; clinical 
knowledge score; and professional attitude score. The pharmacists who completed more 
CPD hours per year and who had a higher clinical knowledge score, higher level of training 
and a more positive professional attitude tended to have higher intervention rates.  
Conclusions 
Use of the software, including its electronic prompts, significantly increased the 
documentation of clinical interventions by pharmacists. Professional development 
strategies and policies which foster improvements to pharmacy workload and pharmacist 
clinical knowledge can be expected to further improve pharmacists’ clinical intervention 
rate, and therefore decrease the healthcare costs associated with DRPs. 
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1 Chapter 1: Introduction 
Within today’s healthcare system, the use of medications or drugs form an essential part 
of the treatment plan for many chronic and acute medical conditions. However, the use of 
medications also carries the risk of experiencing an effect that was not intended, and 
these risks must be weighed up against the potential benefit that the patient will receive. 
These unwanted effects, as well as other issues with drug therapy, are often termed drug-
related problems. 
1.1 Drug-related problems 
A drug-related problem (DRP) is broadly defined in the literature as ‘an event or 
circumstance involving drug treatment that actually or potentially interferes with the 
patient experiencing an optimum outcome of medical care’1, and can be broadly related to 
errors (in prescribing and dispensing), adverse events, or adherence issues.2-4 As noted in 
the definition, DRPs can be actual, for example when the patient taking the drug is 
exhibiting a known adverse event, or potential, such as when the patient is at increased 
risk of a known adverse event. The definition of a DRP is therefore more encompassing 
than that of an adverse drug reaction/event (ADR/ADE), which the World Health 
Organisation defines as ‘any response to a medication that is noxious, unintended and 
occurs at doses used for prophylaxis, diagnosis or therapy’5 and therefore tends to only 
include the actual DRPs without identifying the potential DRPs.  
1.1.1 Incidence and types of DRPs 
Many studies have looked at the incidence of DRPs within both the hospital and 
community environment, and have attempted to quantify the expense of these DRPs, 
often through the extent of hospitalisation. As mentioned in the previous section, DRPs 
are usually referred to as ADRs or ADEs once the patient is experiencing the unwanted 
effects and has been hospitalised. Preventability of the ADRs is also often reported, with 
many being possibly prevented through adequate medication checking and patient 
education. 
The elderly have in particular been identified as being at an increased risk of DRPs due to a 
combination of physiological decline (such as reduced renal and hepatic function), co-
morbidities (leading to a higher incidence of drug-disease and drug-drug interactions, as 
well as polypharmacy), and adherence problems (often due to frailty, decreased dexterity 
and memory problems).6 Several studies have also identified that patients experiencing a 
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DRP are more likely to be taking a greater number of medications2,7, and the elderly are 
often over-represented in the number of medication-related hospital admissions.2,8 In 
addition, many of the highest risk medications which are most commonly associated with 
DRPs (see section 1.1.2) are frequently used in the elderly, thereby greatly increasing the 
risk.6 
1.1.1.1 International perspective 
Internationally, ADRs are listed as a frequent cause of morbidity, hospital admission and 
mortality, with studies reporting anywhere between 0.4% up to 15% of admissions to 
medical inpatient services resulting from DRPs.2,3,9-14 In 1994, a US study estimated that 
adverse drug reactions (ADRs) were the sixth leading cause of death in the USA after heart 
disease, cancer, stroke, pulmonary disease and accidents, but ahead of pneumonia and 
diabetes15,16, and ADRs continue to be a large drain on the healthcare system. 
Furthermore, anywhere between 37% to 60% of these admissions were considered 
preventable.9,13 
A 1998 review of US-based studies showed that the incidence of ADRs resulting in hospital 
admission was 4.7% (95% CI = 3.1 – 6.2), with fatalities occurring in 0.13% (95% CI = 0.04 – 
0.21) of cases.15 Another US study found that 21 of the 281 admissions to a medical 
intensive care unit over a 19-week study period were due to an adverse drug reaction, 
with 18 (85.7%) being deemed preventable and 4 (19.0%) ending in patient death.12 
Another US study in a small 413-bed teaching hospital found that 290 admissions over the 
3-year study period were due to ADRs, and 126 (43.5%) were deemed preventable.17 The 
most common causes of the ADR were overdose (85 or 67.5%, such as a documented toxic 
drug concentration or lab test), drug interaction (36 or 28.6%) and underdose (30 or 
23.8%).17 A Dutch study found that out of 2238 acute admissions to hospital, 5.1% (95% CI 
= 4.3 – 6.1) were caused by an ADR, with 40% judged to be avoidable.18 A meta-analysis by 
Dutch researchers found that approximately 5% of all hospital admissions were drug-
related, with the elderly being at the greatest risk of ADR-related admission, with up to 
88% of these admissions deemed preventable.8 An English study found that 1225 
admissions in 18820 patients were due to an ADR, with 72% deemed preventable.19 A 
study from Saudi Arabia identified that over a 28-day period, 14.7% of hospital admissions 
through the emergency department were due to or suspected to be caused by a drug-
related problem, with 83% considered to be preventable.11 The most common types of 
DRPs were failure to receive medication (47.2%), an adverse drug reaction (24.5%) and 
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drug overdose (11.3%).11 Another study showed non-compliance as the most common 
cause of medication-related hospital admissions.14 
Although these DRPs result in a hospital admission, they originate in ambulatory care 
patients within the community setting. A recent systematic review of the prevalence of 
ADEs in ambulatory care found 6 studies where the prevalence rates of ADEs ranged from 
2.8% to 34.7% (median = 12.8%; IQR = 5.5 – 24.5).20 Interestingly, the median ADE 
prevalence rate for two retrospective studies was 4.15% (range = 2.8 – 5.5%) versus 20.1% 
(IQR = 9.9 – 34.7) in the four prospective studies20, perhaps indicating that retrospective 
studies do not capture all ADE cases. Four of these studies included data on preventable 
ADEs which ranged from 11% to 27.5% (median = 16.5%; IQR 12.0 – 23.8).20 A US study 
showed that 25% of ambulatory care patients (95% CI = 20 – 29) had experienced an ADE 
with approximately 39% thought to be preventable.  The preventable ADEs tended to be 
related to the central nervous system (33%), gastrointestinal events (22%), and 
cardiovascular events (18%), and were caused by selection of an inappropriate drug (45%), 
incorrect dose (10%) and incorrect frequency of use (10%).7 
1.1.1.2 Australian perspective 
As in other countries, DRPs in Australia are a major burden on the healthcare system, with 
many resulting in admission to hospital or visits to general practitioners (GPs) each year. In 
2002, it was reported that more than 140,000 Australians were hospitalised every year as 
a result of DRPs, and approximately 50% of these DRPs were potentially preventable.21 In 
2008, Roughead et al. reviewed the available literature regarding drug-related hospital 
admissions in Australia, identifying nine studies which found that 2-3% of all hospital 
admissions were reported to be medication-related and 75% of these were potentially 
preventable.4 The elderly were again identified as being most susceptible, with the 
number of unplanned medication-related hospital admissions rising from the average of 2-
3% to greater than 30% in patients aged 75 years and older.22 ADRs tended to be the most 
common cause of medication-related admission, but undertreatment was also identified 
as a major contributor.23 
An Australian General Practice study published in 2006 estimated that 10.4% of patients 
visiting their GP had experienced a DRP within the last six months, with GPs classifying 
23.2% (95% CI = 17.4 – 29.15) as preventable.24 Another Australian study reviewed case 
notes of 1000 ambulatory patients and identified that 902 (90%) of patients had a current 
drug-related problem.25 The majority of patients were experiencing more than one DRP 
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with their current regimen, with 33.4% requiring additional therapeutic monitoring, 27% 
using an inappropriate medication, 25% using insufficient medication and 21% using the 
appropriate medication but at an incorrect dosage or frequency.25 Only 19% of patients 
were experiencing an ADR, highlighting the number of DRPs that could be occurring 
without patients experiencing any symptoms (potential DRPs).25 
1.1.2 Medications involved in DRPs 
Internationally, a systematic review revealed that the majority (51%) of all preventable 
drug-related hospital admissions involved antiplatelets (16%), diuretics (16%), non-
steroidal anti-inflammatory agents (NSAIDs; 11%) or anticoagulants (8%).10 The reasons 
for the occurrence of the DRP was also detailed, with admissions being caused by adverse 
drug reactions or overtreatment, undertreatment and poor patient adherence issues.10 
Adverse drug reactions and overtreatment were most commonly associated with 
antiplatelets, diuretics and NSAIDs; undertreatment problems with antiepileptics; and 
patient adherence problems with diuretics, diabetic agents and antiepileptics.10 Another 
study found that insulin (19%), antiasthmatic agents (13%) and chemotherapeutic agents 
(11%) were the drugs most commonly associated with a medication-related admission.11 
Of the 126 preventable medication-related hospital admissions found in a US study, 
warfarin (37.3%) and anticonvulsants (19.8%) were found to be the most commonly 
implicated medications, with cardiac agents and NSAIDs also commonly implicated.17 
Inpatient ADRs were also identified, with opiates (24.3%) and antibiotics (24.3%) being the 
most commonly implicated medications. A separate US study detailing the adverse drug 
reactions requiring admission to a medical intensive care unit found that aspirin was the 
most commonly implicated medication, being identified as the cause of 28.6% of 
medication-related admissions.12 A systematic analysis of 11 years of US data showed that 
the drugs most frequently associated with an ADE were antimicrobials (14.0%; 95% CI = 
12.0 – 16.4), hormones and synthetic substitutes (11.4%; 95% CI = 9.2 – 14.0), and 
cardiovascular agents (10.9%; 95% CI = 8.7 – 13.3), whereas cardiac glycosides (12.8%; 
95% CI = 8.6 – 18.6), anticoagulants (11.2%; 95% CI = 7.5 – 16.3), anticonvulsants (7.0%; 
95% CI = 4.4 – 11.1), and antineoplastics (6.5%; 95% CI = 3.7 – 11.2) were the most 
common drugs associated with medication-related hospital admissions.2 
In the community setting, a systematic review of studies in ambulatory care patients 
found that cardiovascular, anti-infective and analgesic drugs were most commonly 
associated with ADEs.20 A US study in ambulatory care patients found that selective 
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serotonin reuptake inhibitors, antihypertensives and NSAIDs had the highest number of 
ADRs recorded.7 When the numbers of prescriptions were taken into account, 
corticosteroids, non-narcotic analgesics and penicillins had the highest rate of ADRs.7 
Interestingly, the highest rates of preventable or modifiable ADRs occurred with selective 
serotonin reuptake inhibitors, calcium channel blockers and NSAIDs.7 
Within Australia, similar classes of medications are involved in the DRPs causing hospital 
admission. Anticoagulants, NSAIDs and cardiovascular drugs (including antihypertensives, 
diuretics, vasodilators and cardiac glycosides), antineoplastics, hypoglycaemic agents and 
opioids are mentioned as the most common drugs to be associated with a medication-
related hospital admission.22 An Australian study in Western Australia found that the drug 
categories that were most commonly associated with medication-related admissions were 
cardiovascular agents (17.5%), analgesics (including NSAIDs; 16.5%), 
anticoagulants/antiplatelets (9.0%), and antibiotics (9.0%).26 However, the authors noted 
that these were the most extreme cases of ADRs due to the incident requiring 
hospitalisation, and that other medications may be associated with ADRs in an ambulatory 
care setting. In a study in the community setting, cardiovascular (26.3%), nervous system 
(17.9%), alimentary tract (13.9%) and respiratory system (10.9%) medications were the 
most commonly implicated in DRPs experienced by ambulatory care patients.25 
1.1.3 Cost of DRPs 
A study in the USA estimated that for every dollar spent on prescription medications, 
another dollar is spent on problems relating to their use.27 In Australia, a 2003 study 
estimated that approximately 1% of health expenditure was related to ADEs,22 and as 
health expenditure continues to increase annually with an aging population, the amount 
spent on ADEs is also likely to increase. In 2009/10, the Australian Government listed 8.5 
million hospital admissions throughout Australia, with the average cost of each 
hospitalisation estimated to be $4133 for an average stay of 3.6 days.28 If 2-3% of all 
hospital admissions in Australia were due to DRPs4, this equates to 170,000-255,000 
hospital admissions per year, with nearly 75% (or 127,500-191,250) identified as being 
preventable.4 Therefore, the detection and resolution of DRPs within the community 
before hospital admission is necessary has the potential to save an estimated $526 to 
$790 million to the Australian healthcare system annually. 
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1.2 Role of the pharmacist 
There has been considerable interest in interventions that may result in early detection 
and prevention of DRPs before hospital attendance or admission is necessary, thereby 
decreasing the associated morbidity and mortality. Many of the DRPs occur in patients 
who may not visit a GP or are not aware that their symptoms may be indicative of a DRP, 
therefore the community pharmacy may be their first contact with a health professional.29 
Community pharmacists are well-respected, highly-trained, and accessible health 
professionals, making them ideally situated to detect, prevent, and resolve DRPs in the 
community setting during the course of routine dispensing and counselling.30 The process 
of a pharmacist identifying and preventing or resolving a DRP can be termed a clinical 
intervention. For the purposes of this project, a clinical intervention by a pharmacist was 
defined as ‘any professional activity by the pharmacist directed towards improving the 
quality use of medicines and resulting in a recommendation for a change in the patient’s 
medication therapy, means of administration or medication-taking behaviour’. 
Interventions can also be classified into a further two groups, reactive and proactive. 
Reactive interventions require the pharmacist to resolve the DRP before the dispensing 
process can continue, and often involve DRPs relating to drug selection, drug interactions, 
and inappropriate doses. Proactive interventions generally occur during the interaction 
with a patient and require the pharmacist to be ‘proactive’ to detect the DRPs. Proactive 
interventions often involve DRPs relating to undertreatment or toxicity. 
1.2.1 Routine pharmacy services  
Currently, community pharmacists detect and resolve DRPs during the course of their 
routine prescription-related activities. The Pharmaceutical Defence Limited’s Guide to 
Good Dispensing31 details the steps involved in the dispensing process: 
 Prescription check 
 Computer input 
 Drug selection 
 Labelling 
 Label check 
 Assembling prescription 
 Patient collects the prescription  
 Final check 
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These steps aim to avoid prescription errors, both from the prescriber and from the 
pharmacist, and potential DRPs can be detected during various stages of the dispensing 
process (Figure 1-1). 
 
Figure 1-1: Stage of dispensing process and common DRPs identified during each 
stage 
These basic dispensing activities often provide sufficient information to demonstrate the 
presence of an actual or potential DRP. The combination of the patient’s dispensing 
history of previous prescriptions and the interaction of the pharmacist with the patient 
will often provide sufficient information on which to assess the presence of a DRP. Some 
DRPs will be evident purely from the physician’s prescription (such as drug interactions 
and incorrect doses), while others require information from the patient (such as 
compliance problems and adverse effects).32-34 
1.2.2 Additional professional services 
In addition to routine dispensing practices, a broader range of strategies to reduce DRPs 
have also been employed within community pharmacy. These strategies are based on the 
Prescription 
check 
• Incorrect patient details 
• Administrative issues 
• Missing/incorrect directions 
Computer  
input 
• History check for consistency of treatment 
• Compliance 
• Drug-drug and drug-disease interactions 
• Duplications 
Prescription 
assembly 
• Dispensing errors including bar code scanning 
• Correct medication, dose, frequency for 
indication 
Patient 
collection 
• Counselling 
• Adverse effects 
• Adherence 
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introduction of an expanded service model, where pharmacists (who have often 
undergone additional training) conduct a formal review of a patient’s medications, or 
carry out other professional services as an extension of their normal daily dispensing 
activities. These additional processes and services increase the information available to 
the pharmacist concerning the patient and thereby, present increased opportunities to 
detect DRPs. For example, dispensing a prescription for an antihypertensive agent may 
appear to be correct, however measuring the patient’s blood pressure within the 
pharmacy can determine if the therapy is effective and may detect a DRP, such as 
undertreatment, that would not have been visible to the pharmacist without this 
additional service. Provision of these additional professional activities is an extension of 
the pharmacist’s traditional dispensing and counselling roles and it is likely that these 
expanded activities will increase the number of DRPs detected and resolved. 
1.2.3 Examples of the expanded service model 
DRPs can arise in all phases of the medicines management cycle, from the initial decision 
to prescribe a medication to the desired outcome being achieved (Figure 1-2), and as a 
result, strategies to reduce DRPs can target particular aspects of the cycle. 
 
Figure 1-2: The medicines management cycle (Stowasser et al.35) 
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Clinical pharmacy services within the hospital environment have consistently shown to 
lead to the detection and resolution of DRPs, and therefore have the potential to 
substantially reduce healthcare costs.36,37 This success led to the implementation of similar 
services for high risk community patients. Pharmacy-based services and activities that 
reduce DRPs have become an accepted part of the drug-related management of patients 
in both hospital and community settings. Many of the services involve ongoing review of 
the appropriateness, effectiveness and potential adverse effects of medications. As such, 
the involvement of pharmacists in the management of medications in various clinical 
settings is an established and important component of reducing DRPs. Within the 
community environment, pharmacists are involved in most of the steps of the medicines 
management cycle and there are already many strategies in place to decrease the number 
of DRPs. 
1.2.3.1 Clinical decision support systems (CDSS) 
CDSS helps prescribers and pharmacists improve drug selection errors, and therefore act 
within the medicine order and issue part of the medicines management cycle. CDSS 
mainly include drug interaction alerts that warn the prescriber and dispensing pharmacist 
of hazardous combinations38,39, but options for additional CDSS could also improve 
therapeutic management for the patient. For example, CDSS can be used in the 
prescribing software to ensure the recommended medication is prescribed for specific 
conditions, such as a specific antibiotic being recommended when the prescriber selects a 
specific infection. In the pharmacy environment, CDSS can be used to provide alerts for 
recommended medications for particular conditions (for example, encouraging the use of 
vitamin D and calcium supplements in a patient using long-term corticosteroids) or 
recommending interventions that pharmacists could perform based on the patient’s 
medication history (for example, discussing a dose decrease for a patient on a high-dose 
proton-pump inhibitor).40 
1.2.3.2 Computerisation 
Computerisation is commonplace within both the prescribing and dispensing area, and 
again acts within the medicine order and issue part of the medicines management cycle. 
The use of computer-generated prescriptions is intended to reduce errors associated with 
poor handwriting.41-47 This was shown by Whitehead et al., where a comparison of 
pharmacist interventions with handwritten and computerised prescriptions in Western 
Australian community pharmacies indicated a reduction of “administrative” prescribing 
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interventions associated with wrong package sizes or specification of dose.48 Additional 
computerisation through the use of bar-code scanners to “double-check” against the 
prescription has also assisted in reducing human error rate49, therefore decreasing the 
number of selection errors that occur in the pharmacy environment. As detailed above, 
computerisation has also allowed CDSS such as drug interaction alerts to become 
commonplace within both the prescribing and dispensing environments. 
1.2.3.3 Professional services within the pharmacy 
In addition to technological advances that have improved the prescribing and dispensing 
process, a number of professional services are now offered within the community 
pharmacy environment within Australia.  
Consumer medicines information (CMI) 
CMIs are leaflets providing information about a medication, such as its use, dose and side-
effects. The leaflets are created by the pharmaceutical companies that manufacture the 
medication and are worded in a way so that the general population can understand. The 
introduction of CMIs into the pharmacy environment aimed to improve the medication 
and medical condition knowledge of consumers (or patients) within Australia, however 
there is a lack of data detailing consumer knowledge decreasing the risk of DRPs. 
Pharmacies are encouraged to offer a CMI with every dispensed prescription and are 
compensated for the CMIs that they print. The law in several States of Australia also 
details specific medications, such as isotretinoin, where a CMI must be provided to the 
patient on a regular basis due to the severe adverse effects. The provision of CMIs aims to 
improve the patient’s understanding of their medications and therefore, most likely 
improve their compliance. Most CMIs are also available online for all consumers to 
access.50 
Home medication reviews (HMRs) 
A Home Medication Review (HMR) is where an accredited pharmacist interviews the 
patient about their understanding of their medications and medical conditions, either 
within their own home or within their local pharmacy, and forwards a report of 
recommendations to the patient’s GP.51 HMRs increase the amount of information 
provided to the patient with regards to their medication, therefore also aiming to improve 
the patient’s compliance with their therapies. HMRs can also improve the distribution and 
storage of medications, especially if the interview takes place within the patient’s home. 
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Medicines use review (MUR) 
MURs are a new concept that is currently being trialled by the Australian Government. 
Essentially, a pharmacist undertaking a MUR completes a similar process of a HMR, where 
the pharmacist determines the patients’ understanding of their medications and medical 
conditions, with the exception that it is undertaken within the pharmacy and the 
pharmacist creates a handout for the patient with no specific report for the GP.52 Simple 
measures such as this could increase the patient’s understanding of their medications and 
therefore improve compliance. MURs have been available in the United Kingdom for 
several years, with the UK National Health Service53 recommending MURs as a routine 
part of helping older consumers manage their medication. 
Dose administration aids (DAAs) 
Dose administration aids provide patients with their medications pre-packed on the 
correct day at the correct time of day. Patients usually receive one week’s worth of 
medication at a time and the most common system used by pharmacies is 
Webstercare®54, where the pharmacy packs and provides the medication in a sealed 
blister pack. Alternatively, patients can also take responsibility for their own medications 
and pack a dosette box (a small plastic box of varying sizes) by themselves. The use of 
dose administration aids (including both compartmentalised box and blister pack devices) 
in high risk patients has been shown to improve compliance with medications and reduce 
error rates during medication administration.55 Within Australia, war veterans are eligible 
to receive this packing service for free56, and for many patients, it takes a lot of confusion 
out of their medication management. 
Disease management programs 
Many pharmacies offer disease management programs, ranging from simple blood 
pressure monitoring to more complex diabetes and cholesterol management. The 
interaction with the patients aims to help them understand their medications and the 
monitoring required for their disease, therefore aiming to improve the management of 
several chronic diseases.  
Summary of professional services 
Professional services aim to improve patient understanding and compliance, as well as 
improve therapeutic management of the patient, and therefore act within the medicine 
order, distribution, administration and transfer of information parts of the medicines 
management cycle. Detecting DRPs is another professional service provided by 
       12 | P a g e   
 
pharmacists within the community pharmacy environment, but its importance is often 
overlooked. 
1.2.4 Process of identifying a DRP 
Within community pharmacy, there are several aspects to the identification of a DRP, 
which may or may not lead to an intervention. For example, a pharmacist may identify a 
potential DRP, but further discussion with the patient resolves the DRP and an 
intervention is not required. An example of this may be the patient presenting a new 
prescription for a higher strength of irbesartan, but the pharmacist confirms with the 
patient that their blood pressure was elevated, therefore their GP increased their 
irbesartan dose. Alternatively, the pharmacist may ask the patient about the higher 
strength of irbesartan, which the patient was not expecting, leading to the pharmacist 
undertaking an intervention, such as contacting the GP, to determine if the change was 
intentional. In another example, a DRP may be present, but the pharmacist does not 
recognise it, perhaps due to a lack of knowledge or a lack of time, therefore an 
intervention does not occur. There are therefore several factors in the process of 
identifying a clinical intervention and the process leading to an intervention can be seen in 
Figure 1-3. 
 
Figure 1-3: The process leading to an intervention 
Patient presents a prescription
Opportunity for 
intervention
No opportunity for 
intervention
Opportunity not 
recognised by 
pharmacist
Opportunity 
recognised by 
pharmacist
Pharmacist does not 
intervene
Pharmacist does 
intervene
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1.3 Community pharmacists and clinical interventions: a 
review of previous literature 
As stated in section 1.1, the term DRP can be considered a description for situations where 
a drug’s desired outcome is actually or potentially interfered with and is broadly related to 
errors, adverse events or adherence issues. As stated in section 1.2, the detection and 
resolution of these DRPs is termed a clinical intervention. Many studies use definitions of 
interventions that vary from this or specifically address prescription errors, and 
consequently, comparisons between studies are difficult. In addition, many of the studies 
are international and as community pharmacy practice differs between each country, the 
intervention studies also differ. Interpretation and comparisons between studies is further 
complicated by the use of different methodologies for the collection of the information.  
In the following section, available international and Australian studies of the role of the 
community pharmacist in detecting and resolving DRPs are reviewed. The studies are 
summarised in Table 1-1 and have been further examined in the following paragraphs. 
Many of the studies focus on identification of problems detected directly from the 
prescription and therefore only report on a proportion of possible DRPs. Although using 
the term “clinical” interventions or DRPs, many of the studies report on interventions 
relating to correction of prescriptions due to administrative or legislative requirements 
(for example missing or incorrect patient details) which would not usually be considered 
clinical in nature. Therefore, where possible, a clinical intervention frequency has been re-
calculated by examining the definitions used for the events documented. These clinical 
intervention frequencies are a more relevant method of comparison between the studies, 
due to the differences in definitions. The literature selected has been limited to that which 
involves community pharmacists’ detection and resolution of DRPs in their routine daily 
activities, and articles that report on interventions associated with enhanced service 
provision models have not been included.
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Primary author 
and date of 
publication 
Practice setting 
Method and duration 
of recording period 
Definition of documented 
intervention 
Types of DRP recorded Documentation method 
Published frequency of DRPs and 
estimated/calculated clinical 
intervention (CI) frequency 
Rupp, 1988
57
 
9 community 
pharmacies in Indiana, 
USA 
Intern pharmacist 
recorded prescription 
errors resolved by 
themselves and their 
preceptor over 2 weeks 
Anything that requires a 
pharmacist to interrupt their 
routine dispensing activities to 
resolve 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Prescription error report 
form completed by an 
intern pharmacist 
192 interventions from 5874 
prescriptions (3.27%) 
95 CIs from 5874 prescriptions 
(1.62%) 
Rupp, 1992
58
 
89 pharmacies in 5 
states of the USA 
Recording of 
interventions by an 
observer for 5 days 
Any prescription related problem 
that required pharmacists to 
interrupt their routine dispensing 
activities 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper based “Pharmacy 
Intervention Record” 
683 interventions from 33,011 
prescriptions (2.07%) 
371 CIs from 33,011 prescriptions 
(1.12%) 
Rogers, 1994
59
 
28 community 
pharmacies in the 
United Kingdom 
Prospective recording 
by dispensing 
pharmacists for 18 
months 
Not stated, but included 
definitions of 10 categories of 
recordable events 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper based intervention 
recording form 
1862 interventions (denominator 
not reported) 
1646 CIs (denominator not 
reported) 
Dobie, 1994
60
 
4 community 
pharmacies in Texas, 
USA 
Prospective recording 
by dispensing 
pharmacists for 1500 
consecutive new 
prescriptions 
Not stated, but used other 
techniques from Rupp
57,58
 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper based “Pharmacy 
Intervention Record” 
60 interventions from 6000 new 
prescriptions (1.00%) 
34 CIs from 6000 new 
prescriptions (0.57%) 
Irvine-Meek, 
1994
61
 
21 community 
pharmacies in New 
Brunswick, Canada 
Prospective recording 
for 10 consecutive 
weeks 
Not stated 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper based “standard 
forms” 
555 interventions from ~176,650 
prescriptions (~0.31%) 
199 CIs from ~176,650 
prescriptions (~0.11%) 
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Primary author 
and date of 
publication 
Practice setting 
Method and duration 
of recording period 
Definition of documented 
intervention 
Types of DRP recorded Documentation method 
Published frequency of DRPs and 
estimated/calculated clinical 
intervention (CI) frequency 
Greene, 1995
62,63
 
23 community 
pharmacies in West 
London 
Prospective self-
reporting over 4 
months 
All possible medication and 
prescription related problems 
that might be encountered by a 
community pharmacist, including 
those arising from OTC 
medications. 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Incident report forms 
174 incidents from 281,900 
prescriptions (0.06%) 
166 CIs from 181,100 
prescriptions in actively 
participating pharmacies (0.09%) 
Claesson, 1995
64
 
36 community and 
hospital discharge 
pharmacies in Sweden 
Prospective recording 
by dispensing 
pharmacist for 2 weeks 
Errors which, in the opinion of 
the dispensing pharmacist, called 
for an intervention 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper based intervention 
recording form 
2176 errors requiring 
intervention from 76,956 
prescriptions (2.83%) 
255 CIs from 76,956 prescriptions 
(0.33%) 
Poston, 1995
65
 
527 pharmacies in 
Canada  
Prospective recording 
by 1360 dispensing 
pharmacists for 2 
weeks 
All interventions that led to a 
check or change in drug therapy 
during the screening, dispensing 
and monitoring process for new 
and repeat prescriptions 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper-based 
interventions recording 
form 
8933 interventions in ~619,164 
prescriptions (~1.44%) 
5467 CIs in ~619,164 
prescriptions(~0.88%) 
Smith, 1996
66
 
9 small hospitals and 9 
health centres in 3 
states of the USA 
Prospective recording 
by dispensing 
pharmacists for 6 
months 
“Cognitive service interventions” 
divided into 4 broad categories 
(incorrect information, 
inappropriate drug, clinical 
problems and prescription 
clarification) 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper form or 
computerised quality 
assurance system 
(Resource Patient 
Management System) 
1446 interventions (0.6%) 
(denominator not reported but 
calculated as ~241,000) 
873 CIs from ~241,000 
prescriptions (0.36%) 
Caleo, 1996
32,33
 
29 community 
pharmacies in 3 States 
of Australia 
Prospective recording 
of interventions for 4 
weeks 
Any change effected by a 
pharmacist to a PBS prescription 
item and/or contact with a health 
professional concerning a PBS 
prescription item 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper based intervention 
recording form 
1273 interventions from 89,326 
prescriptions (1.43%) 
258 CIs from 89,326 prescriptions 
(0.29%) 
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Primary author 
and date of 
publication 
Practice setting 
Method and duration 
of recording period 
Definition of documented 
intervention 
Types of DRP recorded Documentation method 
Published frequency of DRPs and 
estimated/calculated clinical 
intervention (CI) frequency 
Hulls, 1996
67
 
25 community 
pharmacies in New 
Zealand 
Prospective recording 
by dispensing 
pharmacists for 2 
weeks 
Any action taken to clarify or 
change a prescription to optimise 
the patient’s drug therapy and/or 
minimise the risk of harmful 
effects 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper based “Pharmacy 
Intervention Form” 
modified from Rupp’s 
study
57,58
 
357 interventions from 19,581 
new prescriptions (1.82%) 
154 CIs from 19,581 new 
prescriptions (0.79%) 
Knapp, 1998
27
 
31 community 
pharmacies in California 
Retrospective analysis 
of all interventions for 1 
year (1995) 
Presumed Rupp definition
58
 with 
actions and outcomes also 
documented 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper based “Pharmacy 
Intervention Form” 
modified from Rupp’s 
work
57,58
 
688 DRPs from 93,483 
prescriptions (0.74%) 
276 CIs from 93,483 prescriptions 
(0.30%) 
Westerlund, 
1999
68
 
144 pharmacists, 
prescriptionists and 
pharmacy technicians 
from 128 different 
pharmacies in Sweden 
Prospective recording 
on alternate days, half a 
day at a time, for 2 
months 
A broad definition of DRPs- “ A 
circumstance of drug therapy 
that may interfere with a desired 
therapeutic objective” 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Data collection form 
designed as a postcard 
1098 DRPs from 82,200 
prescriptions (1.34%); required 
1469 interventions to resolve  
964 prescription DRPs from 
82,200 prescriptions (1.17%) 
Hawksworth, 
1999
69
 
14 community 
pharmacies in England 
Prospective recording 
by dispensing 
pharmacists for 1 week 
of each month for 1 
year 
Where the prescribed item could 
have been dispensed without 
contact with the prescriber – 
“proactive” interventions 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Not stated 
Only CIs appeared to be 
recorded; 1503 CIs from 201,000 
prescriptions (0.75%) 
Van Mil, 2001
70
 
17 community 
pharmacies in the 
Netherlands 
Prospective recording 
by dispensing 
pharmacists for 4 
weeks 
Pharmaceutical services (care 
activities) that resulted from 
computer generated alerts  
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Computerised recording 
of care activity codes 
(CACs) in the medication 
history 
12,487 CACs from 134,132 
prescriptions (9.31%) 
3606 CIs from 134,132 
prescriptions (2.69%) 
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Primary author 
and date of 
publication 
Practice setting 
Method and duration 
of recording period 
Definition of documented 
intervention 
Types of DRP recorded Documentation method 
Published frequency of DRPs and 
estimated/calculated clinical 
intervention (CI) frequency 
Buurma, 2001
71,72
 
141 Dutch community 
pharmacies 
Prospective case-
control study, data 
collected on 1 
nominated day 
Prescriptions requiring 
modification, excluding minor 
administrative aspects 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper “registration form” 
2014 modifications from 47,374 
prescriptions (including 
prescribed ‘non-medicines’) 
(4.25%) 
400 CIs for 36,625 prescription 
only medicine prescriptions 
(1.09%) 
Westein, 2001
73
 
23 community 
pharmacies in the 
Zeeland region of the 
Netherlands 
Case control study of 
patients - controls and 
interventions recorded 
by dispensing 
pharmacists for 1 week 
Any action taken by a pharmacist 
that led to clarification or change 
of a prescription 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Standardised intervention 
log forms 
337 interventions from 39,357 
prescriptions (0.86%) 
255 CIs from 39,357 prescriptions 
(0.65%) 
Whitehead, 
2002
48
 
18 community 
pharmacies in Perth, 
Western Australia 
Prospective recording 
by dispensing 
pharmacists for 4 
weeks 
Any actions taken that result in a 
change in the patient’s therapy 
and/or the written prescription  
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Prescription Intervention 
Form 
222 interventions from 34,491 
prescriptions (0.64%) 
75 CIs from 34,491 prescriptions 
(0.22%) 
Quinlan, 2002
74
 
34 community 
pharmacies in England 
Prospective recording 
by dispensing 
pharmacists for 2 
weeks 
Not stated 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Royal Pharmaceutical 
Society’s Intervention 
audit form 
419 interventions from 60,525 
prescription items (0.69%) 
248 CIs from 60,525 prescriptions 
(0.41%) 
Leemans, 2003
75
 
124 community 
pharmacists in Belgium 
Prospective recording 
by dispensing 
pharmacists for 2 
weeks 
List of 16 technical and clinical 
interventions provided within the 
article. 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper based form 
3552 interventions from 87,647 
prescriptions (4.05%); 1044 
clinical interventions from 87,647 
prescriptions (1.19%) 
588 CIs from 87,647 prescriptions 
(0.67%) 
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Primary author 
and date of 
publication 
Practice setting 
Method and duration 
of recording period 
Definition of documented 
intervention 
Types of DRP recorded Documentation method 
Published frequency of DRPs and 
estimated/calculated clinical 
intervention (CI) frequency 
Andersson, 2003
76
 
20 pharmacies in 
Sweden 
Prospective recording 
by dispensing 
pharmacists for 2 
weeks 
“A circumstance of drug therapy 
that may interfere with a desired 
therapeutic objective”- as per 
Westerlund et al.
68
 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Postcard sized data 
collection form as per 
Westerlund et al.
68
 
1465 DRPs from ~104,000 
prescriptions and OTC sales 
(1.41%) 
637 CIs from 63,929 prescriptions 
(1.00%) 
Benrimoj, 2003
34
 
40 community 
pharmacies in Sydney, 
Australia 
Prospective recording 
by dispensing 
pharmacists for 1 week, 
followed by 2 weeks of 
recording after an 
education program 
Definitions for 19 different 
clinical interventions provided. 
Interventions further categorised 
as proactive (could be dispensed 
without further contact with the 
prescriber or patient) or reactive 
(could not be dispensed without 
further contact) 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Intervention 
documentation form 
762 interventions from 87,130 
prescriptions (0.87%) 
375 proactive interventions from 
87,130 prescriptions (0.43%) 
Chen, 2005
77
 
9 community 
pharmacies in 
Nottingham, England 
Prospective recording 
by dispensing 
pharmacists for 1 
month 
Any problems identified in the 
process of dispensing that might:  
1) interfere with the dispensing 
of prescriptions, or  
2) be potentially harmful to 
patients 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper based intervention 
recording form 
196 prescribing problems from 
32,403 items dispensed (0.60%) 
93 CIs from 32,403 items (0.29%) 
Hämmerlein, 
2007
78
 
1146 community 
pharmacies in Germany 
Prospective recording 
by dispensing 
pharmacists for 1 week 
(NB:- Pharmacies were 
allowed to choose 
which week they would 
record the DRPs) 
An event or circumstance 
involving drug therapy that 
actually or potentially interferes 
with desired health outcomes. 
Definitions for 10 DRP types (with 
a total of 72 subtypes) were 
identified. 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Standardised paper form 
10,427 interventions recorded 
from an estimated 1,833,600 
prescriptions (actual number not 
reported) (0.57%)  
6628 CIs from 1,833,600 
prescriptions (0.36%) 
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Primary author 
and date of 
publication 
Practice setting 
Method and duration 
of recording period 
Definition of documented 
intervention 
Types of DRP recorded Documentation method 
Published frequency of DRPs and 
estimated/calculated clinical 
intervention (CI) frequency 
Krähenbühl, 
2008
79
 
20 community 
pharmacies in the 
French-speaking part of 
Switzerland 
Prospective recording 
by dispensing 
pharmacists for 4 
weeks 
An event or circumstance 
involving drug therapy that 
actually or potentially interferes 
with desired health outcomes. 
Definitions for 17 DRP types were 
identified and management of 
the intervention was also 
recorded. 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Computerised 
documentation system 
integrated into the 
dispensing software 
736 technical interventions from 
38,663 prescriptions (1.90%) 
287 CIs from 38,663 prescriptions 
(0.74%) 
Tenni, 2009
80,81
 
(Previous 
PROMISe trial) 
52 pharmacies in 
Melbourne, Australia 
Prospective recording 
by dispensing 
pharmacists for 8 
weeks 
Any professional activity by the 
pharmacist directed towards 
improving the quality use of 
medicines and resulting in a 
recommendation for a change in 
the patient’s medication therapy, 
means of administration or 
medication-taking behaviour 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Computerised 
documentation system 
integrated into the 
dispensing software 
2385 CIs from 435,520 
prescriptions (0.55%) 
Warholak, 2009
82
 
68 chain pharmacies in 
five States of USA 
Prospective recording 
of interventions on 
electronic prescriptions 
by dispensing 
pharmacists for 14 
consecutive days 
Any e-prescription problem that 
required a pharmacist to resolve 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper-based form 
submitted by fax or mail 
113 interventions from 2690 e-
prescriptions (4.20%) 
51 CIs from 2690 prescriptions 
(1.90%) 
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Primary author 
and date of 
publication 
Practice setting 
Method and duration 
of recording period 
Definition of documented 
intervention 
Types of DRP recorded Documentation method 
Published frequency of DRPs and 
estimated/calculated clinical 
intervention (CI) frequency 
Braund, 2010
83
 
20 pharmacies in 
Dunedin, New Zealand 
Prospective recording 
by dispensing 
pharmacists for 1 week 
Used an intervention grading 
system developed by the 
Pharmaceutical Society of New 
Zealand e.g. Grade 1 = legal 
aspects up to Grade 5/6 = 
prevented a serious threat to 
health such as an interaction 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper-based tally forms 
with data being entered 
by the researchers at the 
end of the trial  
1551 interventions from 24,059 
prescriptions (6.45%) 
134 CIs from 24,059 prescriptions 
(0.56%) 
Haavik, 2011
84
 
12 pharmacies in 
Norway 
Prospective recording 
by dispensing 
pharmacists for 5 or 10 
weeks 
Not stated, but categories of 
interventions indicate any 
prescription errors were to be 
documented 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Paper-based form 
2385 interventions from 85,475 
prescriptions (2.79%) 
405 CIs from 85,475 prescriptions 
(0.47%) 
Sanchez, 2011
85
 
1 pharmacy in Madrid, 
Spain 
Prospective recording 
by dispensing 
pharmacist at the end 
of each day for 6 
months 
Any problems identified in the 
process of dispensing that might:  
1) interfere with the dispensing 
of prescriptions, or  
2) be potentially harmful to 
patients 
 Prescription Errors 
 Adverse Events 
 Adherence Issues 
Computerised 
documentation system 
355 interventions from 23,995 
prescriptions (1.48%) 
238 CIs from 23,995 prescriptions 
(0.99%) 
Table 1-1: Summary of intervention studies in community pharmacy (adapted from Tenni86)
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1.3.1 Rupp et al. (United States of America)57 
Probably the earliest fully published study in the area of community pharmacists’ 
interventions was conducted in Indiana in 1987 and published by Rupp et al. in 1988. For a 
two-week period, student pharmacists were asked to document any prescriber-generated 
problem that was identified by themselves or by their preceptor that required an active 
intervention by the pharmacist to correct or resolve. The intervention was documented on 
a ‘Prescription Error Report Form’ by the student pharmacist who may have been active in 
the resolution process, therefore this study would be considered an observational study, 
as the dispensing pharmacist did not have to disrupt their workflow to document the 
intervention. As pharmacists were often unaware of what constituted an intervention, the 
student pharmacists were given a list of scenarios that may require documentation on the 
reporting form, including scenarios where the pharmacist requires clarification from the 
prescriber, the pharmacist changes the prescription, the pharmacist consults drug 
information or literature, or the pharmacist gives verbal or written information to the 
patient beyond what is ‘usual’. 
During the study, 192 interventions (involving 153 prescription products) were identified 
from 5874 new prescriptions, resulting in an intervention rate of 3.27%. Deficiencies in the 
prescription (such as illegible and/or incomplete prescriptions, or prescriptions that 
violated legal requirements) were responsible for 97 of the 192 interventions and would 
not be considered a clinical intervention according to the definition in section 1.2. 
Therefore, the number of clinical interventions appeared to be 95, resulting in a clinical 
intervention rate of 1.62%. The most common errors were incorrect dose/regimen (30 or 
3.16%) and the patient not understanding their regimen which required additional 
counselling (13 or 13.7%). The number of repeat prescriptions was not stated in the 
article; therefore, the frequency of errors with repeat prescriptions within this study 
remains unknown. 
The time of day for each intervention was also noted, with a peak number recorded 
between 10-11am (22 interventions) and 4-5pm (23 interventions). No relationship was 
identified between the type of pharmacy (independent versus chain pharmacies) and the 
number of interventions performed. The majority of interventions occurred in female 
patients (64.7%) in the 19-65 year age group (60.1%). 
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Although over 20 years have passed since this study was conducted, this publication 
remains a landmark paper referred to by almost all authors in the area. The methodology 
was clearly presented and a number of authors have utilised some or all of the techniques 
in other studies, as seen in the following paragraphs. One of the most innovative aspects 
of Rupp’s methodology was the use of observers to record the interventions, which meant 
that the pharmacists did not have any significant additional workload in terms of 
recording their activities. 
Interestingly, the pilot study conducted to refine the reporting form recognised that 
pharmacists resolved prescription order problems so routinely that they did not recognise 
the resolution as an intervention. This problem was therefore first identified in 1988, yet 
the recognition of what constitutes an intervention has plagued several studies since. It 
also identified that pharmacists have poor access to the full medical profile of patients 
(such as accurate medical histories or test results), and that improved access may also 
help to identify and resolve errors within the community pharmacy environment. Rupp et 
al. also detailed that as the number of prescriptions increased, the number of prescription 
errors detected would also increase, but that there was most likely a theoretical ‘cut-off 
point’ where the dispensing workload became too high and detection rates may decrease. 
This discussion point was later proven by many different studies looking at intervention 
rates compared to workloads within the pharmacy.  
1.3.2 Rupp et al. (USA)58 
The authors considered the range of pharmacies and pharmacists in the original study in 
198857 to be limited, and used the techniques piloted to form the basis for a larger study 
which was conducted in 1990. The larger study involved the documentation of 
prescription problems by trained observers (final year pharmacy students) in 89 
pharmacies in five states of the USA. Again, the observers were asked to record any 
prescription problem that required the pharmacist to interrupt their routine dispensing 
process in order to resolve it. The intervention information was collected using a 
‘Prescription Intervention Report’ form, which included: 
 general descriptive information about the prescription order, the prescriber and 
the patient, 
 a narrative description of the pharmacist’s intervention, including the reason for 
the intervention and the names of all drugs involved, 
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 a list of all prescription medications that the patient was taking at the time of the 
intervention, 
 all sources of information that the pharmacist consulted during the intervention, 
and 
 outcome(s) of the intervention and the final state of the prescription. 
The observers also collected information about the pharmacy, pharmacists and workload 
statistics, such as dispensing volume.  
These authors reported 683 interventions from 33,011 new prescriptions, resulting in a 
rate of 2.07%. More than one intervention could occur with each prescription; therefore, 
623 prescriptions were associated with the 683 interventions. The number of repeat 
prescriptions dispensed was 20,930, however the number of interventions on repeat 
prescriptions was not specified, and therefore remained unknown. Of the 683 
interventions, 312 (45.6%) related to omitted prescription information (such as 
incomplete or illegible prescriptions) and would therefore not be considered a clinical 
intervention under the definition in section 1.2. Therefore, 371 clinical interventions were 
recorded, resulting in an observed clinical intervention rate of 1.12%. The most common 
reasons for pharmacist intervention in these prescriptions were incorrect dose/regimen 
(142 or 38.3%), incorrect drug/indication (39 or 10.5%) and drug-drug interactions (30 or 
8.08%). From the 681 drugs that were associated with the 683 interventions (some 
prescriptions required more than one intervention), the ones most commonly requiring a 
prescription intervention were anti-infectives (158 or 23.2%), dermatological drugs (75 or 
11.0%), narcotic analgesics (55 or 8.1%) and hormones (36 or 5.3%). However, 
prescription volumes for these medications were not recorded, therefore the authors 
noted that it was unknown if the number of interventions were disproportionate to their 
relative prescription volume. Two independent evaluators agreed that the pharmacist’s 
intervention avoided definite harm to the patient in 128 of the 623 prescriptions (20.6%). 
There was no significant difference in intervention rates seen between chain and 
independently-owned pharmacies, resulting in the authors noting that a pharmacist’s 
willingness and ability to intervene is more a function of the individual pharmacist in the 
store, rather than the store itself. Pharmacists at pharmacies with a ‘low volume’ of 
prescriptions (defined as less than 11.3 prescriptions per hour) had significantly higher 
intervention rates than pharmacists at pharmacies with a ‘high volume’ of prescriptions (p 
< 0.05), with the authors noting that pharmacists’ willingness or ability to intervene 
decreases as the volume of dispensed prescriptions increases. The authors also noted the 
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possibility of selection bias within the pharmacists, as the pharmacists were all preceptors 
to the pharmacy student observers, and therefore may have been different from a 
‘typical’ pharmacist in regards to willingness and motivation to participate. 
1.3.3 Rogers et al. (United Kingdom)59 
In 1994, Rogers et al. published a study that involved reporting of clinical interventions by 
28 pharmacies in the United Kingdom. Pharmacists were asked to record clinical 
interventions for 18 months, and return their paper-based intervention record forms 
every six weeks. Pharmacies provided records for 1862 clinical interventions (range = 1 –
473) during the data collection. The authors used an intervention collection form that 
included information on the type of intervention, the drugs involved (using the BNF 
classification system) and the type of patient (from a list of “at-risk” patient types, 
including asthmatics, CV disease, diabetics, elderly etc.). No clear definition of the events 
to be documented was given in the paper, but the types of clinical interventions reported 
indicate that the events were predominantly related to prescription modifications and 
errors. The category options can be seen in Table 1-2. 
Category code 
Number 
of events 
Total % 
Contraindicated prescribed drug 145 7.8 
Contraindicated OTC drug 66 3.5 
Emergency supply of prescription-only medicine 106 5.7 
Drug interaction between two drugs on presented prescription 197 10.6 
Drug interaction with a drug previously dispensed 278 14.9 
Drug interaction with OTC medicine 35 1.9 
Prescription error - incorrect drug on presented prescription 272 14.6 
Prescription error - incorrect strength on presented prescription 366 19.7 
Prescription error - incorrect dose on presented prescription 282 15.1 
Prescription error - incomplete/incorrect patient details 110 5.9 
Miscellaneous 5 0.3 
Total 1862 100.0 
Table 1-2: Intervention codes used and resulting frequencies found by Rogers et al.59 
Interventions involving a prescription error (incorrect strength, incorrect dose, incorrect 
drug or incorrect patient details) accounted for 55.3% (1030) of the interventions. A 
further 27.4% (510) were interventions relating to drug interactions, either with 
prescription or over the counter (OTC) medications (Table 1-2). There were no problems 
reported that related to adverse events or adherence/compliance issues. Interventions 
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involving emergency supply and incomplete/incorrect patient details would not be 
considered clinical under the definition in section 1.2, therefore removal of these 216 
interventions would result in 1646 clinical interventions. 
The 1862 interventions were associated with 2563 drugs, with multiple drugs being 
involved with some interventions. The most common drug groups involved in the 
interventions were cardiovascular system (657 or 25.6%), central nervous system (450 or 
17.6%), infectious disease (347 or 13.5%) and respiratory system (319 or 12.5%). When 
the at-risk patient groups were examined, several frequent associations were found: 
 Asthmatic patients (194 or 10.4%) were associated with a higher number of 
interventions involving contraindicated prescription products (44 from 145 or 
30.3%) and emergency supplies (29 from 106 or 27.4%) 
 Patients with cardiovascular disease (303 or 16.3%) were associated with a higher 
number of interventions involving contraindicated non-prescription products (17 
from 66 or 25.8%) and drug interactions (94 from 510 or 18.4%) 
 Diabetic patients (71 or 3.8%) were associated with a higher number of 
interventions involving contraindicated prescription products (23 from 145 or 
15.9%)  
 Elderly patients (330 or 17.7%) were associated with a higher number of 
interventions involving drug interactions (131 from 510 or 25.7%) 
During the data collection, the dispensing systems of some pharmacies were 
computerised, whereas others were still paper-based. The authors noted that significantly 
more interventions were documented in the computerised pharmacies (p < 0.01), 
especially those involving drug interactions. The authors also noted that computerisation 
helped to overcome errors due to illegible handwriting. 
Unfortunately, this paper did not report a denominator in terms of patient and 
prescription numbers, despite the fact that the information must have been recorded, as 
the authors noted that no pharmacy reported an intervention rate higher than 2%. This 
means an accurate intervention rate could not be calculated. Also, the long data collection 
period and the relatively passive data collection process led to a large variation in 
reporting rates. The authors mentioned that 13 of the 28 pharmacies ceased participation 
for the last eight months of the data collection period due to changes of ownership and/or 
management, which would have lead to a significant decline in the amount of data 
collected. Given the small amount of interventions recorded, it is likely that the 
documented interventions were subjected to selection by the participating pharmacists.  
       26 | P a g e   
 
1.3.4 Dobie and Rascati (United States of America)60 
Dobie and Rascati aimed to measure the incidence and types of interventions in four 
community pharmacies in rural Texas in 1994, as well as assign a financial value to these 
services. They used methods very similar to those used by Rupp et al.57,58, however the 
interventions were recorded by the dispensing pharmacist rather than an observer. No 
definition for an intervention was provided, however presumably it was the same as 
Rupp’s definition of ‘any prescription problem that required the pharmacist to interrupt 
their routine dispensing process in order to resolve it’, as the pharmacists were trained 
using tools developed by Rupp. Again, the pharmacists only recorded interventions from 
new prescriptions and each pharmacy continued recording until 1500 consecutive new 
prescriptions were dispensed (approximately two months). 
Pharmacists recorded 60 interventions from 6000 new prescriptions, resulting in an 
intervention rate of 1.00%. The 60 interventions related to only 47 prescriptions, 
indicating several prescriptions required multiple interventions. As per Rupp’s study 
(section 1.3.2), 26 errors (43.3%) were due to incomplete or illegible prescriptions, and 
therefore would not be considered a clinical intervention according to the definition in 
section 1.2. This resulted in 34 interventions (56.7%) that were clinical in nature, resulting 
in a clinical intervention rate of 0.57%. The most common reasons for a pharmacist 
intervention in these 34 cases were inappropriate dose/regimen/strength (10 or 29.4%), 
patient concern/question (7 or 20.6%) and over- or under-utilisation of the medication by 
the patient (14.7%). Fifty-one drugs were associated with the 60 interventions, with anti-
infectives being the most commonly involved (10 or 19.6%). Of the 47 prescriptions, a 
pharmacist and a physician evaluator agreed that harm to the patient (such as side-
effects, inadequate control, or allergy) would have occurred if 22 (46.8%) of the 
interventions were not undertaken by the pharmacist. After several calculations, it was 
determined that the cost avoidance was $20,795, which is a cost saving of approximately 
$346.60 per intervention or $3.47 per prescription. 
It is interesting to compare the overall intervention rate reported within this study (1.00%) 
compared to that found by Rupp et al.58 (2.07%). Both studies used the same 
methodology, with the only difference being that Rupp used observers to document the 
activities, whereas Dobie and Rascati asked the pharmacists who performed the 
intervention to document it. This gives some indication of the potential difference that is 
achieved using the observer technique. It is possible that the number of performed 
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interventions increased with the presence of an observer, however the more likely 
scenario is that the proportion of documentation is different, due to the recording 
pharmacists not documenting the intervention either due to lack of time, lack of 
motivation, or not realising it was an intervention in the first place. 
1.3.5 Irvine-Meek et al. (Canada)61 
In 1994, Irvine-Meek et al. published a paper concerning a study of drug therapy 
interventions undertaken in community pharmacies in the South-Western New Brunswick 
region of Canada. The study was conducted over a ten week period from June to August 
1992, and all pharmacies in the region were invited to participate. The authors used a 
“check box” recording form which involved the pharmacist selecting a major category and 
subcategory for each intervention. Information concerning daily prescription workload 
and staffing levels was also collected from each pharmacy. No definition of the types of 
interventions that pharmacists were asked to record was given in the paper, however, it 
seems from the nature of the results, that many of the recorded events were non-clinical, 
and involved clarification of third party payments or confirmation of dose and authenticity 
of the prescription. 
These authors reported a total of 555 interventions in five major categories. Based on 
each pharmacy’s estimate of their daily prescription volume, it is possible to estimate that 
the total number of prescriptions dispensed during the course of the study was 176,650, 
giving an intervention frequency of 0.31%. The pharmacists reported that the average 
time to perform an intervention was 6.16 minutes. 
Table 1-3 shows the interventions documented by the community pharmacists. The 
majority of the interventions were either related to contact with third party insurers (179 
or 32.3%) or clarification of the intent of the prescriber or administrative issues with the 
prescription (119 or 21.4%). In addition, it is unlikely that the organising of an additional 
repeat prescription (92 or 16.6%) would have a clinical basis. Therefore, the clinical 
intervention frequency can be estimated as 199 clinical interventions from approximately 
176,650 prescriptions or 0.11%. 
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Category of 
intervention 
Subcategory of 
intervention 
Number 
Subcategory Category 
# % # % 
Clarification 
Drug 26 4.7 
119 21.4 
Dose 64 11.5 
Quantity 16 2.9 
Signature 5 0.9 
Physician 3 0.5 
Authenticity 5 0.9 
Changes 
Drug 40 7.2 
76 13.7 
Dose 35 6.3 
Quantity 1 0.2 
Signature 0 0.0 
Notification to 
physician 
Drug allergy 9 1.6 
139 25.0 
Drug interaction 6 1.1 
Side effects 3 0.5 
Drug duplication 3 0.5 
Pregnancy 0 0.0 
Breastfeeding 0 0.0 
Over-compliance 6 1.1 
Non-compliance 3 0.5 
Additional refill 92 16.6 
Other 17 3.1 
Involving third 
party insurers 
Generic requests 4 0.7 
179 32.3 
Non-benefit 16 2.9 
Call third party 120 21.6 
Income assistance 39 7.0 
Drug information 
In pharmacy 7 1.3 
42 7.6 
Halifax  8 1.4 
Manufacturer 8 1.4 
Other 19 3.4 
Total 555 
Table 1-3: Interventions recorded by Irvine-Meek et al.61 
As with many other studies, there was a variation in the intervention reporting rate 
amongst the participating pharmacies. Using the published information for daily volume of 
prescriptions, it was possible to calculate an estimated intervention rate for 19 of the 
participating pharmacies (Table 1-4), however this rate includes all recorded interventions 
not just the interventions deemed clinical. 
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Pharmacy 
Number of 
interventions 
Approximate 
number of 
prescriptions  
Intervention 
rate 
1 10 3850 0.26 
2 13 4200 0.31 
3 18 12250 0.15 
4 129 12950 1.00 
5 13 7000 0.19 
6 19 14000 0.14 
7 28 6300 0.44 
8 6 14000 0.04 
9 32 28000 0.11 
10 3 12600 0.02 
11 22 7000 0.31 
12 20 10500 0.19 
13 27 7700 0.35 
14 17 2500 0.68 
15 7 8400 0.08 
16 7 1750 0.40 
17 5 9800 0.05 
18 12 5000 0.24 
19 18 5600 0.32 
Table 1-4: Intervention rate for 19 of the participating pharmacies61 
This calculated rate was then compared to the reported daily prescription volume, 
showing a significant negative correlation (Spearman’s rho = -0.482, N = 19, p = 0.004), 
indicating that as the number of daily prescriptions increased, the number of documented 
interventions decreased. Although an increase in the number of prescriptions dispensed 
can present a greater number of opportunities for identification of DRPs, it also 
substantially increases the pharmacist’s workload, reducing the available time for each 
prescription, and therefore reducing the time available to detect and resolve DRPs. While 
there are many factors involved in the frequency of reporting of interventions, this is one 
of the few studies with sufficient published information to enable the establishment of a 
relationship between workload and intervention frequency. 
1.3.6 Greene (United Kingdom)62,63 
In 1995, Greene published the results of a study of prescription incidents that were 
recorded over a four month period (October 1986 to January 1987) by pharmacists in 23 
pharmacies in West London. Pharmacists were asked to record all possible medication and 
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prescription related problems that might be encountered by a community pharmacist, 
including those arising from OTC or pharmacist recommended medications. Importantly, 
participating pharmacists were discouraged from recording self-evident errors, such as 
obvious inadvertent overdoses or “indispensable” prescriptions with missing or invalid 
entries (Table 1-5). This constraint was intended to restrict the intervention reports to 
those where the pharmacist required the use of his or her professional skills to resolve the 
problem and was different to other studies conducted at the time that focused solely on 
prescription errors. In addition, the study also excluded problems that were brought to 
the pharmacist’s attention by the patient, ensuring that the recorded problem was 
detected by the pharmacist. Pharmacists were asked to complete an incident report form 
and return them to the researchers at set intervals during the study. 
Type of incident Total % 
In
cl
u
si
o
n
s 
Frequency of presentation 12.1 
Changed drug or dosage form 18.5 
Changed dose or timing 22.9 
Inappropriate dose or timing 4.7 
Drug/drug interaction 13.8 
Drug/condition interaction 10.6 
Miscellaneous 1.2 
Ex
cl
u
si
o
n
s Self-evident errors 
16.2 Undispensable (due to a gross error) 
Detected by patient 
Total 100 
Table 1-5: Type of intervention codes used and frequencies found by Greene62,63 
A total of 340 incidents were reported during the entire study period (including the pilot 
period), of which 55 (16.2%) were deemed “self-evident” or patient detected problems 
(Table 1-5). The most common valid intervention type was changed dose or timing (78 or 
22.9%; Table 1-5). When the interventions from the pilot period and the “self-evident” 
interventions were removed, 174 valid interventions remained. These were associated 
with an estimated 281900 prescriptions, resulting in a clinical intervention rate of 0.06%. 
Most interventions (64.4%) were completed within five minutes. 
As with many other studies, there was significant variation in reporting rates between 
pharmacies, with 10 pharmacies providing less than the pre-determined threshold of one 
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intervention per month. The remaining 13 “active participation” pharmacies were 
responsible for 166 intervention reports associated with an estimated 181,100 
prescriptions, resulting in a clinical intervention rate of 0.09%. This intervention frequency 
is one of the lowest reported in the literature and may be related to the relatively passive 
process for recording interventions and the strict exclusion of trivial administrative 
interventions. 
The most common drug groups involved (according to the BNF) were CNS drugs excluding 
analgesics (20%; most commonly benzodiazepines and monoamine oxidase inhibitors), 
cardiovascular drugs (17%; most commonly nitrates, beta-blockers and potential 
drug/disease interactions with hypertension) and anti-infectives (13%). 
Each incident report was graded according to its clinical significance as follows; 0 (trivial; 
10.9%), 1 (not serious; 25.6%), 2 (serious; 47.6%) and 3 (very serious; 15.9%). Problems 
with prescriptions for patients taking 7 or more items were never trivial, however in 
contrast with other studies, the authors did not detect any significant differences between 
the seriousness of the incidents and the number of other medications that the patient was 
concurrently taking. 
1.3.7 Claesson et al. (Sweden)64 
In 1995, Claesson et al. published a study of prescription errors identified by personnel at 
36 Swedish community and hospital pharmacies during March 1992. Pharmacists were 
asked to record all prescription errors, including those not requiring a pharmacist’s 
intervention, on specially designed forms for a two week period.  
The authors reported a total of 32,132 errors from 76,956 prescriptions, representing an 
error frequency of 41.7%. Of these, 2176 were considered by the dispensing pharmacist to 
require an intervention before the prescription could be dispensed, resulting in an 
intervention rate of 2.83%. Many of these were “errors of omission” (such as illegible or 
incomplete prescriptions), with only 255 of the 2176 incidents meeting the definition of a 
clinical intervention in section 1.2. This resulted in a clinical intervention rate of 0.33%. On 
average, a prescription with an error took an extra seven minutes to dispense, but varied 
between 1 and 180 minutes. 
This study focused on prescription errors only and DRPs related to patient adherence or 
adverse effects were not recorded. As stated by the authors, Swedish pharmacists were 
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not permitted to keep pharmacy records of previously dispensed medications at the time 
of the study, which would further limit the range of DRPs that could be identified. 
1.3.8 Poston et al. (Canada)65 
Poston et al. published the initial results of a nationwide study of community pharmacists’ 
interventions in 1995. This paper reported on the largest single community pharmacy 
intervention study in the literature, with valid data being obtained from 527 pharmacies. 
All interventions that led to a check or change in drug therapy during the screening, 
dispensing and monitoring process for new and repeat prescriptions were recorded. The 
authors specifically excluded routine administrative interventions such as incomplete or 
illegible prescriptions, and routine counselling of patients. Two separate data collection 
periods took place for interventions relating to prescription and OTC medications, with 
each period lasting 2 weeks. 
The authors reported 7190 prescriptions with 8933 DRPs from an approximate 619,164 
prescriptions (mean of 1404 prescriptions in two weeks for each of the 441 pharmacies 
collecting prescription data), resulting in an approximate intervention rate of 1.44%. Of 
these, 3466 (38.8%) were related to drug distribution or supply issues, and therefore not 
considered a clinical intervention under the definition in section 1.2. The remaining 5467 
interventions resulted in an approximate clinical intervention rate of 0.88%. The most 
common drug-related problems were the need for patient information outside routine 
counselling (927 or 10.4%) and drug interactions/allergies/side-effects (871 or 9.8%; Table 
1-6). 
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Category of problem # % 
Drug distribution and supply 3466 38.8 
Patient information 927 10.4 
Drug interactions/drug allergies/drug side effects 871 9.8 
Formulation and product-related issues 275 3.1 
Abuse/misuse 95 1.1 
Therapeutic problems  
- Dose different from previous script 775 8.7 
- Wrong strength/clarify strength 563 6.3 
- Dose too high 437 4.9 
- Wrong drug 352 3.9 
- Dose too low 303 3.4 
- Drug duplication 270 3.0 
- Contraindications 119 1.3 
- Other 480 5.4 
Total 8933 100 
Table 1-6: Drug-related problems reported by Poston et al.65 
The clinical intervention frequency was slightly higher than other studies at 0.88%, which 
may have occurred due to the inclusion of patient information requests. Although the 
authors collected information about participating pharmacies and pharmacists, this 
information was not compared to any other reported factors. However, the authors did 
note that the 144 independent pharmacies had a higher average intervention rate 
compared to the 156 chain stores, but the significance of this difference was not reported. 
1.3.9 Smith and Christensen (United States of America)66 
In 1996, Smith and Christensen published the results of a study of pharmacists’ 
interventions conducted in 18 pharmacies servicing the Native American population in 
three States of the USA for six months during 1992. Nine small hospital dispensaries and 
nine health centre dispensaries participated in the study. Pharmacists recorded 
interventions either on a purpose designed form or with an existing quality assurance 
software system if it was present in the pharmacy.  
These authors grouped DRPs into four general types: 
 Incorrect information, including wrong dosage, wrong dosage form, wrong 
interval, non-formulary medication and wrong patient 
 Inappropriate drug, including suboptimal drug based on patient’s condition and 
drug of choice 
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 Clinical problems, including contraindications, drug-drug interactions, drug-
disease interactions, adverse drug effects and drug duplication 
 Prescription clarification, including missing components and transcription errors 
Over the six months, 1446 interventions were recorded, with the authors reporting an 
average intervention rate of 0.6% ± 0.42% (range = 0.12 – 1.84), implying that 
approximately 241,000 prescriptions were dispensed. Prescription clarifications were 
responsible for 573 (39.6%) of the interventions, and did not appear to be clinical in 
nature according to the definitions provided within the article. Therefore, 873 clinical 
interventions were recorded, resulting in an approximate clinical intervention rate of 
0.36%. This study was one of only a few that utilised an electronic intervention recording 
system, albeit only for some of the pharmacies involved, however the authors did not 
estimate the frequency of reports that were manually prepared compared to those that 
were submitted in electronic form.  
The authors also noted a decline in intervention rates over the trial. The four pharmacy 
sites with the largest variation in reporting rates over the 6 month period were shown to 
have a statistically significant decline (p < 0.01 in all cases), whereas the declines in other 
pharmacies were not significant. 
1.3.10 Caleo et al. (Australia)32,33 
In 1996, Caleo et al. published two papers on a study of clinical interventions recorded in 
29 pharmacies in three States of Australia. Pharmacists recorded 1273 interventions from 
89,326 prescription items dispensed over a 4-week data collection period, resulting in a 
mean intervention rate of 1.43% ± 1.4% (median = 1.1%). 
The authors further divided the interventions into reactive and proactive interventions; 
 Reactive intervention: where dispensing could not have occurred without further 
consultation 
 Proactive intervention: where dispensing could have occurred without further 
consultation, which may or may not have resulted in a change in therapy 
Of the 1273 interventions recorded, 1015 (79.7%) were reactive and related to issues of 
clarification of prescription issues, such as omission of dose/directions (368 or 36.3%), 
omission of strength (160 or 15.8%), incorrect quantity (130 or 12.8%), and omission of 
quantity (121 or 11.9%). These clarification interventions are unlikely to have any clinical 
consequences and would therefore not be considered a clinical intervention under the 
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definition in section 1.2. The remaining 258 (20.3%) of the interventions were proactive, 
resulting in a clinical intervention rate of 0.29%. The types of proactive interventions can 
be seen in Table 1-7. 
Category of proactive intervention # % 
Incorrect strength 64 24.8 
Drug/drug interaction 47 18.2 
Incorrect dose 35 13.6 
Inappropriate/incorrect dosage form 32 12.4 
Dose/strength query 27 10.5 
Incorrect drug 22 8.5 
Side effect 14 5.4 
Drug query 10 3.9 
Drug allergy 7 2.7 
Total 258 100 
Table 1-7: Frequency and types of proactive interventions found by Caleo et al.32,33 
Two-thirds of proactive interventions resulted in a change to the patient’s therapy. An 
expert panel assessed that the clinical interventions performed by community pharmacists 
saved the healthcare system an average of $191.78 per 10,000 prescription items and that 
84% of cases resulted in a positive outcome for the patient. The authors also noted no 
significant correlation between the pharmacy’s intervention rate and total prescription 
volume, the location of the pharmacy or the number of nursing homes, and there was a 
significant reduction in intervention rates over time (p < 0.01). As with many other studies, 
there seemed to be no reports of problems relating to compliance, or the presence of 
actual or potential adverse effects. 
1.3.11 Hulls and Emmerton (New Zealand)67 
In 1996, Hulls and Emmerton published the results of a study conducted in 25 pharmacies 
in New Zealand over a period of two weeks. The authors largely used the data collection 
techniques described by Rupp et al.57,58, but again used self-reporting like Dobie and 
Rascati60, not observers. An intervention was defined as ‘any action taken to clarify or 
change a prescription to optimise the patient’s drug therapy and/or minimise the risk of 
harmful effects’. Routine counselling, the use of cautionary and advisory labels, and 
clerical alterations for government reimbursement were specifically excluded. 
Information was collected using a ‘Prescription Intervention Form’ that included: 
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 the patient’s gender and approximate age, 
 the reason for intervention (grouped into four categories: prescribing omission, 
prescribing error, drug interaction and drug therapy monitoring problem), 
 the details of the problem (free text), 
 the action(s) taken, 
 the outcome(s), and 
 the estimated time taken in resolving the problem. 
The pharmacies reported 370 interventions in total, however two pharmacies that 
reported 13 interventions did not report any prescription volume data, therefore only 357 
interventions were used to determine the intervention rate. During the two weeks, 19,581 
new prescriptions were dispensed, resulting in an intervention rate of 1.82% (range = 0.3 – 
6.7% per pharmacy).  
Of the total 370 interventions, 216 (58.4%) were errors of omission relating to prescription 
requirements (such as illegible or incomplete prescriptions), therefore would not be 
considered clinical interventions under the definition in section 1.2. The remaining 154 
interventions would be considered clinical in nature, resulting in a clinical intervention 
rate of 0.79%. It is important to note, however, that only the number of new prescriptions 
were recorded (not repeat prescriptions), therefore the actual intervention rate is likely to 
be much lower. 
The pharmacists reported the interventions took a mean of 4.1 ± 5.1 minutes to resolve, 
with 83.3% being resolved in five minutes or less. Clinical significance of the interventions 
was determined by the researchers from six levels of significance, with the majority of 
interventions (66.8%) resulting in an improvement in patient care (Table 1-8). 
Clinical significance classification % of total 
Intervention is detrimental to patient health 0.0 
Intervention is of no significance to patient care 10.0 
Intervention is significant but does not result in an improvement in 
patient care 23.2 
Intervention is significant and results in an improvement in patient care 65.2 
Intervention is very significant and prevents major organ damage or an 
adverse reaction of similar importance 1.6 
Intervention is potentially life-saving 0.0 
Total 100 
Table 1-8: Clinical significance of the interventions as determined by Hulls and 
Emmerton67 
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Although information was collected about additional factors (such as pharmacy location, 
number of full-time pharmacists and number of prescriptions dispensed), the authors did 
not compare it to the intervention rate and therefore influencing factors were not 
detailed within the paper. It is also interesting to note that the intervention rate was again 
lower than that seen by Rupp et al.57,58, despite the use of similar methodology. As with 
the Dobie and Rascati study60, this could be attributed to the use of self-reporting rather 
than the use of observers. 
1.3.12 Knapp et al. (United States of America)27 
In 1998, Knapp et al. published the results of an intervention study that was undertaken in 
a pharmacy services program for 22,000 patients in California. All 31 pharmacies in the 
area participated as part of their contract and documented their interventions for the year 
of 1995, with the information being collated retrospectively. Pharmacies were required to 
document any problems relating to a prescription, the action taken and the outcome on 
forms based on the work of Rupp et al.57,58 Documentation of interventions was 
remunerated at the rate of $40 to $80 per intervention. No clear definition of the DRP was 
mentioned in the article, but as other aspects of the Rupp et al. studies were used57,58, it is 
assumed that Rupp’s definition was also used.  
A total of 637 interventions were reported during the calendar year, and the authors were 
able to analyse information pertaining to 595 of these interventions. From these 595 
interventions, 688 DRPs were identified and during the 1995 calendar year, 93,483 
prescriptions were dispensed. This resulted in an intervention rate of 0.74% (range = 0 – 
4.1). Many of the documented problems (412 or 60.0%) related to non-clinical drug 
selection issues (such as brand substitutions) or prescription errors. The remaining 276 
problems were either clinical problems (209 or 30.4%) or direct patient requests for 
information (67 or 9.7%), resulting in an estimated clinical intervention rate of 0.30%. 
Information concerning the number of interventions and prescription volumes for each of 
the 31 pharmacies was available (with the data from the pharmacies with the lowest 
performance rates being combined) and there was a wide variation between the 
pharmacies (Table 1-9).  
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Pharmacy 
Number of 
interventions 
Number of 
prescriptions 
Intervention 
rate 
1 16 387 4.13 
2 142 3496 4.06 
3 37 1154 3.21 
4 27 1110 2.43 
5 9 453 1.99 
6 47 2443 1.92 
7 164 13134 1.25 
8 33 2662 1.24 
9 9 732 1.23 
10 7 658 1.06 
11 42 4368 0.96 
12-20 104 39289 0.26 
21-31 0 23597 0.00 
Total 637 93483 0.68 
Table 1-9: Intervention rates of 31 pharmacies recorded by Knapp et al.27 
Analysis using this data showed a significant correlation between the number of 
prescriptions dispensed and the intervention rate (Spearman’s rho = -0.56, N = 13, p = 
0.049), indicating that as the number of prescriptions increased, the pharmacy’s 
intervention rate decreased. The authors suggested three factors that could have 
contributed to the lower intervention rates seen in this study compared to others. Firstly, 
pharmacists could have intervened but not recorded, a trend which has previously been 
identified.57 Secondly, the reimbursements were paid to the pharmacy, and therefore may 
not have been passed on to the individual pharmacists, possibly decreasing their 
motivation for documenting the interventions. Thirdly, although all pharmacies were 
represented at the training session, not all participating pharmacists attended, therefore it 
was unknown if they understood the documentation system. The authors stated that an 
increase in intervention rates would likely occur if opportunities and incentives for 
documentation were widely available. The authors also stated that the number of 
prescription errors would be likely to decrease with a decrease in the number of 
handwritten prescriptions due to computerisation. 
1.3.13 Westerlund et al. (Sweden)68 
In 1999, Westerlund et al. published the results of a study conducted in 1996 in Sweden. 
For two months, 128 pharmacies recorded DRPs on a postcard sized data collection form 
       39 | P a g e   
 
for half a day on alternate days, rotating between morning and afternoon, and included 
the following information: 
1. Type of problem (14 options; see Table 1-10) 
2. Type of intervention (10 options; see Table 1-10) 
3. Problem drug (open-ended) 
4. Whether the problem was detected by the participant or the patient 
5. Patient’s age, gender and number of concurrently prescribed drugs 
6. Time taken to resolve the problem 
From the 128 pharmacies, 144 staff members were recruited and included 34 
pharmacists, 71 “prescriptionists” (University-trained dispensing technicians), and 39 
pharmacy technicians. Staff also tallied the number of patients they served during the 
data collection period and information was collected for both prescription and non-
prescription medicines. 
A broad definition of DRPs was used in order to maximise the scope of the problems 
detected, with the authors noting that most previous studies had only examined 
prescription errors, without collecting data on other areas, such as compliance and 
education. Therefore, any problem that occurred because of “a circumstance of drug 
therapy that may interfere with a desired therapeutic objective” was considered 
recordable. Consequently, the information collected contained DRPs that related to 
prescription errors, adverse events and adherence issues. Definitions were provided for 
each of 14 categories of DRP and the participants were also requested to document the 
interventions made in order to resolve the problem (Table 1-10). 
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Types of problems Types of interventions 
Uncertain aim of drug Patient medication counselling 
Underuse of medication Practical instruction to patient 
Overuse of medication Patient referred to prescriber 
Other dosage problem Prescriber informed only 
Drug duplication Prescriber asked for information 
Drug-drug interaction Intervention approved by prescriber 
Therapy failure Intervention disapproved by prescriber 
Side effect Switch of drug 
Difficulty swallowing tablet Referral to colleague 
Difficulty opening container Other intervention 
Other practical problem 
Language deficiency 
Prescribing error 
Other drug-related problem 
Table 1-10: Types of problems and interventions identified by Westerlund et al.68 
A total of 1098 DRPs were recorded from an estimated 82,200 prescriptions dispensed, 
resulting in a rate of 1.34%. However, the authors noted that 134 DRPs were related to 
OTC medications, but no estimate was made of the number of OTC sales made during the 
data collection period. Therefore, only 964 DRPs could be included in the calculation, 
resulting in a prescription-related intervention rate of 1.17%. 
Unfortunately, the article reported most results as percentages and graphs, resulting in 
the actual number of problems and interventions being estimates. The most common type 
of DRP identified from prescription medications was uncertainty of the purpose of the 
medication (14.5%), which could be deemed an adherence issue. Other common 
adherence issues included practical difficulty using devices (11.8%), opening containers 
(3.0%), and swallowing the medication (2.25%), as well as language deficiency (3.0%). 
Dosage problems accounted for 25.5% of all DRPs, including overuse (7.0%), underuse 
(5.2%) and other dosage problem (such as frequency and timing; 13.3%). The study also 
reported 1469 interventions were required to resolve the DRPs. Due to the large number 
of adherence issues detected, the most common intervention was patient medication 
counselling (749 or 51.0%) followed by practical instruction to the patient (280 or 19.1%). 
Participants reported the interventions took from 1 to 60 minutes to resolve, with the 
median time being 3 minutes for pharmacists, 4 minutes for prescriptionists and 5 
minutes for pharmacy technicians. 
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The 923 drugs involved were classified by their ATC class87, with the most common drugs 
involved being respiratory drugs (192 or 20.8%), nervous system (164 or 17.8%) and 
cardiovascular drugs (110 or 11.9%). The top 10 drugs and their associated problems can 
be seen in Table 1-11. 
Rank Compound Most common problem(s) 
1 Budesonide nasal turbuhaler Practical problems 
2 Timolol eye drops 
Difficulty opening container; 
Other practical problems 
3 Salmeterol diskhaler 
Practical problems; 
Uncertainty of aim or function of drug 
4 Budesonide turbuhaler 
Practical problems; 
Uncertainty of aim or function of drug 
5 Dextropropoxyphene 
Uncertainty of aim or function of drug; 
Dosage problems 
6 Terbutaline turbuhaler 
Practical problems; 
Uncertainty of aim or function of drug 
7 
Dextropropoxyphene + 
paracetamol in combination 
Dosage problems; Overuse; 
Drug duplication 
8 
Codeine + paracetamol in 
combination 
Side effects; Drug duplication; 
Difficulty swallowing tablets 
9 Frusemide slow release 
Underuse; 
Prescribing errors 
10 Citalopram Dosage problems 
Table 1-11: Top 10 problem-related drugs identified by Westerlund et al.68 
The study also identified a difference between the number of problems detected by the 
three different types of staff. The median number of problems detected per 100 
prescriptions was higher for pharmacists (6.1) compared to prescriptionists (2.6) and 
pharmacy technicians (1.1), possibly indicating that a higher level of training corresponds 
to a higher intervention rate. 
Interestingly, the authors found more problems occurring in children and young adults, 
compared to the elderly. The authors felt this was due to the elderly having chronic 
conditions and therefore being more closely monitored by their physician, leading to DRPs 
being resolved earlier in their therapy. The authors also found that 75% of patients were 
taking two or less medications, which is most likely due to the larger number of younger 
patients with drug-related problems identified within this study. Additionally, the authors 
noted that Swedish pharmacies did not have access to patient medication profiles at the 
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time of the study and therefore, poor access to the patient’s medical history may have 
contributed to the lower number of interventions. 
1.3.14 Hawksworth et al. (United Kingdom)69 
In 1999, Hawksworth et al. published the results of a study where 14 community 
pharmacies in England recorded clinical interventions for one randomly selected week of 
each month for a 12 month period. Pharmacists were specifically requested to not record 
reactive interventions (where the prescribed item could not be dispensed without 
contacting the prescriber), or non-clinical interventions relating to administrative or legal 
issues. Thus, all the interventions recorded in this study appeared to be clinical in nature 
and could be included as a clinical intervention under the definition in section 1.2. 
During the study, participating pharmacists recorded 1503 clinical interventions from 
201,000 prescription items, resulting in a clinical intervention rate of 0.75%. The options 
for classifying the interventions were: 
1. Missing drug 
2. Drug not required 
3. Discuss information about a drug 
4. Change a drug 
5. Alter the formulation 
6. Enquiry about the dose 
7. Enquiry about the dosage interval 
8. Recommend the monitoring of plasma parameters to check efficacy and safety of 
a drug regimen 
9. Discuss a complete drug review of the patient’s therapy with prescriber 
10. Other 
The most common intervention reported was to query the dose (23.8%), however the 
authors did not report the number of interventions within the other groups. Most 
commonly, interventions involved medications acting on the cardiovascular or central 
nervous systems. The average time taken to perform an intervention was 8.11 ± 3.70 
minutes and the pharmacists who dispensed less prescriptions spent more time per 
intervention, however this trend was not statistically significant. 
A clinical panel assessed all 1503 interventions to determine the likelihood that it 
improved the management of the patient’s therapy or prevented harm to the patient 
(such as hospital admission). The panel found that 755 (50.2%) only provided information 
to the prescriber, and therefore did not directly affect patient outcomes. This resulted in 
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748 interventions that improved efficacy or prevented harm, resulting in an estimated 
‘cost-saving’ intervention rate of 0.37%. Of these 748 interventions, 242 (32.4%) were 
rated as possibly preventing a hospital admission, with the panel estimating that 19 of the 
242 (7.9%; or 1.3% of all 1503 interventions) definitely prevented a hospital admission. 
The authors noted a significant correlation; as the number of prescriptions dispensed by 
the pharmacy increased, the number of interventions recorded decreased (p = 0.013). It 
was surmised that this could be due to several factors, such as dispensing overload or 
pharmacist experience, however no further comparisons were made. 
1.3.15 van Mil et al. (The Netherlands)70 
In 2001, van Mil et al. published the results of a study conducted in 17 community 
pharmacies in the Netherlands. One of the main objectives of their study was to 
determine the pharmaceutical services (or interventions) that resulted from the use of a 
computer generated alert (CGA) program that had been used in the Netherlands since 
1985. All dispensing software in the pharmacies involved in the study had the capacity to 
generate these alerts and the alerts were based on a database provided by the Royal 
Dutch Association for the Advancement of Pharmacy. The dispensing system also allowed 
for the recording of care activity codes (CACs) in each patient’s medication history. The 
available CACs were: 
 IA: Interaction 
 CI: Contraindication 
 OV: Allergy 
 DB: Possible duplicate medication 
 NM: Unclear prescription 
 ST: Questionable strength 
 DS: Dosage different from previous prescription 
 EU: Drug dispensed for the first time 
 PT: Possibly incorrect patient data 
 HV: Unusual quantity 
For each of the CACs documented in the dispensing system, an outcome was also 
documented. Fundamentally, this consisted of an active change (e.g. change made, advice 
provided, information provided), or effectively no change (e.g. problem previously solved 
or not relevant, no change made, no information provided).  
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During the course of the study, a CGA was activated on 45,404 occasions. This resulted in 
12,487 active changes documented from 134,132 prescriptions (9.31%). However, as can 
be seen by the CACs listed above, not all of these interventions could be considered 
clinical. When the non-clinical interventions were removed (relating to codes NM, EU, PT 
and HV), 3606 CACs remained, resulting in an estimated clinical intervention rate of 
2.69%. This clinical intervention rate was considerably higher than that reported in other 
studies. One possible reason for this is the method of identification of potential DRPs and 
the way these were brought to the attention of the dispensing pharmacist. In this study, 
45,404 CGAs were raised, representing 33.9% of all prescriptions. These alerts prompted 
the pharmacist to examine potential DRPs, such as drug interactions, contraindications, 
and inappropriate dosages, and thus may have initiated more proactive interventions in 
the process. Although pharmacists were able to continue dispensing without intervening 
by overriding the CGA, many may have chosen to intervene simply because they were 
prompted. Although the majority of these alerts did not result in an active change (usually 
because the problem had been addressed previously or was not relevant), 12,487 CACs 
with active changes were documented; therefore, 27.5% of CGAs resulted in a change or 
advice being provided. A second possible reason for the high frequency of interventions is 
the nature of the documentation. Most of the other studies use a paper based recording 
system, whereas this study used a computerised system. Overall, 33.8% of prescriptions 
had a CGA raised and 24.6% of all prescriptions had a CAC documented, therefore given 
this high frequency of documentation, entering the CACs is presumably a relatively routine 
task that does not interrupt workflow, which is an important consideration for any 
documentation system. 
1.3.16 Buurma et al. (The Netherlands)71,72 
In 2001, Buurma et al. examined the nature, frequency and determinants of prescription 
modifications undertaken by Dutch community pharmacists. Pharmacists in 141 
pharmacies (9% of all Dutch pharmacies) were asked to record all modifications to 
prescriptions that were performed on a single pre-determined day, and also to collect a 
random control prescription to match the modified prescription. 
Pharmacists modified 2014 of the 47,374 prescriptions dispensed during the trial, 
resulting in an intervention rate of 4.25%. The total number of modifications varied 
between pharmacies, ranging from 0 to 100 recorded modifications. Of these, 1802 
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modifications and 36,625 prescriptions were for medications (as opposed to non-medicine 
prescription items such as needles, dressings and incontinence aids), resulting in an 
intervention rate of 4.92% for prescription medications. As defined by ATC groupings87, 
modifications were most commonly required on medications acting on the nervous 
system (311 or 17.3%), respiratory system (252 or 14.0%), alimentary tract and 
metabolism (227 or 12.6%), and cardiovascular system (216 or 12.0%). In 219 of the 1802 
cases (12.2%), the modification was triggered by a computer generated alert (such as a 
change in the therapeutic regimen, drug interactions, contraindications or drug 
duplication). Handwritten prescriptions were three times more likely to require 
modification compared to computer-generated prescriptions (OR = 3.30; 95% CI = 2.90 – 
3.75), but no significant differences were detected between the number of modifications 
in original versus repeat prescriptions. Interestingly, in the Netherlands, some GP practices 
can directly access their patient’s pharmacy records online and the study showed the 
prescriptions from GPs with no online access needed modifying significantly more often 
than GPs with access (OR = 1.61; 95% CI = 1.33 – 1.94). The benefits of this information 
flow was previously predicted by Rupp et al.57 in 1988, who states that improving 
pharmacist access would help to identify and resolve errors within the community 
pharmacy environment (section 1.3.1), and therefore, the reverse flow of information 
from the pharmacy to the prescriber is also likely to help decrease errors. 
Data was also compared between the patients with modified prescriptions and the control 
patients. There was no significant difference in the gender of the two groups, however 
patients in the 40-65 years age group were less likely to require a prescription 
modification compared to the young and elderly patients (OR = 0.74; 95% CI = 0.64 – 
0.86), with the authors reasoning that this may be due to a difference in the level of care 
or vulnerability between the age groups. A higher number of respiratory medication 
prescriptions required modifications compared to the controls (OR = 1.48; 95% CI = 1.23 –
1.79), whereas a decreased number of nervous system medications required 
modifications (OR = 0.71; 95% CI = 0.61 – 0.83). 
The majority of modifications (1294 or 71.8%) involved clarification of the prescription or 
were related to non-specification of dose, insufficient patient data, non-specified strength 
or wrong dosage form, and therefore, would not be considered a clinical intervention 
according to the definition in section 1.2. Only 400 modifications (22.2%) on prescription 
medications were classified as corrections of prescription errors which could have led to 
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clinical consequences (such as wrong dose, wrong medication, contraindication, allergy or 
drug duplication), resulting in an estimated clinical intervention rate of 1.09%. The study 
did not allow for interventions due to adherence issues or adverse effects, and due to the 
recruitment process, the authors noted that possibly only the more proactive and 
enthusiastic pharmacies had participated in the study. 
Workload statistics were also recorded for each pharmacy. On average, the number of 
prescriptions dispensed per day was 259.8 ± 99.8 (range = 34 – 609) and the number of 
personnel (including pharmacists and trained dispensary technicians) was 6.0 ± 1.9 (range 
= 2.0 – 13.5). This resulted in an average workload of 55.9 ± 15.4 (range = 19.6 – 105.2) 
prescriptions per staff member per day. Despite collecting this data, the authors did not 
compare it to the intervention rate of each pharmacy, but instead used the data to 
compare to the national Dutch averages to ensure a representative sample. 
An additional paper by Buurma et al. published in 2004 looked at the clinical value of the 
pharmacist’s prescription modifications using five panels (each with 4 health 
professionals).72 The panels found that 77.0% of interventions were positively modified, 
likely to result in a better outcome for the patient. The panel did not feel that 11.8% had 
any effect on the patient (“neutral”), whereas 8.2% of modifications may have had a 
negative impact on the patient (3.0% remained unknown). Of the positive outcomes, 758 
(49.8%) were judged to have prevented an ADR and 444 (29.2%) improved the 
effectiveness of the therapy, with 120 (8.6%) preventing an ADR and improving therapy 
effectiveness. 
1.3.17 Westein et al. (The Netherlands)73 
In 2001, Westein et al. published the results of a study of intervention reports collected 
from pharmacies in the Zeeland region of the Netherlands during one week in May 1998. 
Pharmacists were asked to record details of interventions on a standardised intervention 
log form and also to collect details of a control prescription from the same day for a 
patient of the same gender and age. Interventions were defined as “any action taken by a 
pharmacist that led to a clarification or change of a prescription”.  
The 23 pharmacies reported 337 interventions from 39,357 prescriptions dispensed during 
the week long study, resulting in an average intervention rate of 0.86% ± 0.49% (range = 
0.13 – 1.94). Through comparison of the intervention and control patients, the authors 
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determined that original prescriptions had a significantly higher intervention rate than 
repeat prescriptions (OR = 1.75, 95% CI = 1.18 – 2.33). Other patient determinants such as 
a prescription from a specialist physician, more than three prescribers, more than 15 
prescriptions in the preceding 3 months and more than 3 different medications, also had a 
higher odds ratio than the controls, however the differences were not significant. The 
patients with a prescription resulting in an intervention were predominantly female 
(66.2%) and also tended to be older than 65 years (41.8%). The medications that were 
more likely to require an intervention were antibiotics (usually due to an interaction), 
respiratory drugs (usually due to a deviation from an earlier prescription) and 
cardiovascular drugs. 
The authors classified the reasons for the interventions in the same manner as Rupp et 
al.57,58, with errors of omission resulting in 82 (24.1%) interventions. These problems were 
usually associated with incomplete prescriptions where the prescription could not be 
dispensed without further clarification, and therefore would not be considered clinical in 
nature according to the definition in section 1.2. After these were removed, the remaining 
255 interventions resulted in an estimated clinical intervention rate of 0.65%. 
The authors also noted that individual pharmacies encountered between 303 and 1673 
computer generated alerts (approximately 41% of all prescriptions), however only 2% of 
these signals lead to an intervention, which is similar to the rate of intervention from CGAs 
seen by van Mil et al.70 They also highlighted the fact that pharmacists probably increased 
their intervention activities during the week of the trial and that there was no feasible way 
to determine the number of potential interventions that were missed by the pharmacists.  
1.3.18 Whitehead et al. (Australia)48 
A study of prescription interventions recorded in 18 community pharmacies in Western 
Australia was published in 2002 by Whitehead et al. The information was collected over a 
four week period in 2001 using a paper-based intervention recording form. Pharmacists 
recorded any actions taken that resulted in a change in the patient’s therapy and/or the 
written prescription and the researchers further classified the interventions as clinical or 
administrative in nature. 
A total of 222 interventions were recorded from 34,491 prescriptions, resulting in an 
intervention rate of 0.64%. Interventions were more common in original (1.14%) 
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compared to repeat (0.16%) prescriptions and interestingly, clinical interventions 
appeared to occur more frequently than expected in computer generated compared to 
handwritten prescriptions. Of these 222 interventions, 75 were deemed clinical in nature, 
resulting in an estimated clinical intervention rate of 0.22%. As with other studies, the 
focus was on prescription related problems with few problems being related to patient 
issues, such as adverse reactions and adherence issues. 
1.3.19 Quinlan et al. (United Kingdom)74 
In 2002, Quinlan et al. published a short article concerning a study aimed at assessing the 
frequency and types of intervention in community pharmacies. Information was collected 
using the Royal Pharmaceutical Society’s Intervention Audit Form from 34 pharmacies 
over a two week period in October 2001. No clear definition of an intervention was given 
in the paper, but a list of intervention types indicated that they collected information on 
prescription anomalies and administrative errors, as well as clinical interventions such as 
possible adverse effects.  
Pharmacies recorded 419 prescription interventions from 60,525 prescription items, 
resulting in an intervention rate of 0.69% (range = 0.13 – 2.77). Of these interventions, 171 
(40.8%) related to prescription administrative problems (such as no GP signature, illegible, 
not conforming with legal requirements, not remunerated in drug tariff, or a 
supply/availability problem), and therefore, would not be considered a clinical 
intervention under the definition in section 1.2. The remaining 248 interventions 
appeared to be clinical in nature, resulting in an estimated clinical intervention rate of 
0.41%. 
1.3.20 Leemans et al. (Belgium)75 
In 2003, Leemans et al. published the results of a study involving 124 community 
pharmacists in Belgium that was conducted over 2 weeks during October 2000. The 
authors used a data collection form that had been previously tested in a group of 30 
pharmacists and this form was used to differentiate between technical and clinical 
interventions. No definition of the events to be documented was given in the paper, but a 
list of technical and clinical interventions was provided (Table 1-12). 
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Technical interventions Clinical interventions 
 Insufficient or excessive number of drugs 
(e.g. number of tablets) 
 Interactions 
 Number of packages incompatible with 
reimbursement guidelines 
 Contraindications 
 Incorrect name of the drug  Missing or incorrect advice 
 Way of administration incorrect or missing  Missing or incorrect dose regimen 
 Supply problems (e.g. running out of stock)  Duplication of therapy 
 Illegible  Non compliance 
 Product does not exist  Follow up necessary 
 Wrong drug prescribed (due to similar 
packages) 
 Abuse 
Table 1-12: Types of interventions documented by Leemans et al.75 
Overall, 3552 interventions were reported from 87,647 prescriptions during the two week 
study, resulting in an intervention rate of 4.05% (mean number of interventions = 8.4 ± 
13.4; range = 0 – 127). Of the 3552 interventions, only 1044 interventions were 
considered clinical according to the classifications shown in Table 1-12, resulting in a 
clinical intervention rate of 1.19%. 
When the categories of clinical interventions were further examined, categories such as 
missing advice (342 interventions) and missing dose (114 interventions) were considered 
clinical by the authors, however would not be considered clinical in nature according to 
the definition in section 1.2. Therefore, once these interventions were removed, the 
estimated clinical intervention rate was 0.67% (588 clinical interventions from 87,647 
prescriptions). The most common clinical intervention was an interaction (148 or 25.2%), 
of which 124 (83.8%) were listed as ‘serious’ or ‘very serious’. The authors also reported 
no differences between the number of interventions recorded and the location of the 
pharmacy, type of dispensing software used in the pharmacy, or the age of the 
pharmacist. 
1.3.21 Andersson et al. (Sweden)76 
In 2003, Andersson et al. published the results of a study of pharmacist interventions 
collected in 20 randomly selected pharmacies in Sweden over two weeks in 1998. The 
study used the methods and definitions employed by their Swedish colleagues 
(Westerlund et al.68, see section 1.3.13). Pharmacists documented their interventions on a 
postcard-sized form which were then collated by the research team. 
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A total of 1465 DRPs associated with the 63,929 prescriptions and approximately 40,000 
OTC sales were recorded during the period, resulting in an overall DRP detection rate of 
1.41%. Pharmacies returned an average of 86 documentation forms each (range = 26 – 
171), with the average time needed to solve each problem being less than 10 minutes in 
96% of cases. When only considering prescription items, the resulting clinical intervention 
rate was 1.00% (637 interventions from 63,929 prescriptions; Table 1-13). 
Problem 
Prescription 
medications 
OTC and other 
medications 
Total 
# % # % # % 
Patient uncertain about purpose or 
use of the medicine 
167 26.2 520 62.8 687 46.9 
• Uncertain of purpose of the medicine 117 18.4 415 50.1 532 36.3 
• Incorrect use or handling 50 7.8 39 4.7 89 6.1 
• Self-care not appropriate 0 0.0 66 8.0 66 4.5 
Interactions, side-effects or lack of 
effect 
102 16.0 156 18.8 258 17.6 
• Drug-drug interactions 34 5.3 29 3.5 63 4.3 
• Side effects 62 9.7 99 12.0 161 11.0 
• Lack of effect 6 0.9 28 3.4 34 2.3 
Problems caused by prescribers 124 19.5 6 0.7 130 8.9 
• Drug duplication 16 2.5 1 0.1 17 1.2 
• Prescribing error 108 17.0 5 0.6 113 7.7 
Practical handling problems 80 12.6 24 2.9 104 7.1 
• Difficulty swallowing tablets 12 1.9 6 0.7 18 1.2 
• Difficulty opening container 9 1.4 1 0.1 10 0.7 
• Other practical problem 59 9.3 17 2.1 76 5.2 
Dosage problems 68 10.7 23 2.8 91 6.2 
• Under-dosage 25 3.9 8 1.0 33 2.3 
• Over-dosage 43 6.8 15 1.8 58 4.0 
Other problems 96 15.1 99 12.0 195 13.3 
• Language problems 6 0.9 2 0.2 8 0.5 
• Problems caused by the pharmacy 11 1.7 3 0.4 14 1.0 
• Other practical problem 79 12.4 94 11.4 173 11.8 
 Total 637 100.0 828 100.0 1465 100.0 
Table 1-13: Classification system for DRPs and number and type of problems detected 
(from Andersson et al.76) 
As shown in Table 1-13, the authors used 16 categories to identify the problems, with the 
most common problems with prescription medications being the patient was uncertain 
about the purpose or use of the medicine (26.2%) or problems caused by prescribers 
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(19.5%). The authors also noted in their discussion that a large number of pharmacists 
reported that they had identified more problems and made more interventions than they 
documented, a problem which had previously been noted in the study by Dobie and 
Rascati60. 
1.3.22 Benrimoj et al. (Australia)34 
In 2003, Benrimoj et al. published the results of a comprehensive study of clinical 
interventions in community pharmacies in Sydney, Australia. The study was designed with 
multiple arms and aimed to examine the effect of remuneration and two different 
educational programs on clinical intervention rates within the pharmacies. 
Pharmacists recorded intervention details on a purpose-designed intervention reporting 
form. Thirty of the pharmacies were randomly selected and ten were conveniently 
sampled, comprising pharmacists who had previously attended additional educational 
sessions. Baseline data was collected from all participating pharmacies, and the 
educational programs and remuneration were provided to the pharmacists after this 
baseline data collection period (Figure 1-4). 
 
Figure 1-4: Study design and results for proactive interventions found by Benrimoj et al.34 
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Definitions for 19 different clinical interventions were provided and interventions were 
then further categorised as proactive (which could be dispensed without further contact 
with the prescriber or patient) or reactive (which could not be dispensed without further 
contact). The definitions covered a range of situations relating to errors in prescriptions 
and potential adverse effects, however there were no problems that directly addressed 
issues of patient education resulting in adherence issues. The 19 different intervention 
types and their presumed category of reactive or proactive can be seen in Table 1-14. 
Proactive interventions Reactive interventions 
Incorrect strength Illegible handwriting 
Incorrect or inappropriate dose Omission of dose or directions 
Incorrect drug Omission of dosage form 
Incorrect or inappropriate dosage form Omission of strength 
Incorrect quantity Omission of quantity 
Adverse effects Not on PBS  
Drug/drug interaction Item unavailable 
Drug allergy Organising prescription for a patient 
Dose or strength query Prescribing information 
Drug query 
Table 1-14: Intervention types recorded in the Benrimoj et al. study34 
The study reported a total of 762 interventions resulting from 87,130 prescriptions during 
the course of the three weeks, resulting in an intervention rate of 0.87%. Of these, 387 
(50.8%) were reactive interventions that were predominantly related to errors or 
omissions in required information on the prescription, and would not be regarded as 
clinical in nature under the definition in section 1.2. The remaining 375 were proactive 
interventions, therefore resulting in an estimated clinical intervention rate of 0.43%. 
There were significant differences amongst the pharmacies in terms of proactive 
intervention frequency at baseline and differences in the effects of the educational 
program and remuneration. Groups B and C (the groups that had educational programs 
provided) had a short lived increase in intervention rates during week 1, but rates for both 
groups fell below their baseline levels during week 2. Groups A and D showed a gradual 
decline in intervention rates. All pharmacies showed a rate of interventions below 
baseline levels at 2 weeks. The authors concluded that payment of a fee for service alone 
did not increase clinical intervention rates and that a specific educational program 
together with a fee for service remuneration lead to a short term increase in intervention 
rates. 
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The variation between the groups’ intervention rates at baseline indicates that there may 
be characteristics of particular pharmacists and pharmacies that either influence 
intervention rates or rates of documentation of interventions. Group C, whose 
pharmacists had a higher level of previous continuing education participation, had the 
highest proactive intervention rate at baseline, which may imply that clinical knowledge is 
a factor in intervention rate. However, the study did not collect information about 
pharmacy and pharmacist characteristics, therefore the authors were unable to determine 
any additional reasons for the differences in intervention rates. 
1.3.23 Chen et al. (United Kingdom)77 
In 2005, Chen et al. published the results of a study of interventions recorded by 
community pharmacists which was undertaken during 2000 and 2001. Pharmacists in nine 
community pharmacies in England were asked to record situations where problems were 
detected in the dispensing process that either: 
 interfered with the dispensing of prescriptions (e.g. incomplete prescriptions, 
prescriptions with incorrect information) or 
 were potentially harmful to the patient (e.g. potentially hazardous drug 
interactions, inappropriate doses or directions, contraindications, adverse drug 
reactions, allergies or drug duplications) 
Information was recorded on a data collection form that had been previously piloted in 
several pharmacies. The information gathered included the age and gender of the patient, 
the time spent by the pharmacist dealing with the problem, the type of problem, the 
possible cause of the problem and the total number of prescriptions dispensed at each 
pharmacy. 
There were 196 problems identified from 32,403 items dispensed, resulting in an 
intervention rate of 0.60% (range = 0.2 – 1.9). The majority of problems reported were 
related to incomplete, illegible or incorrect prescriptions (131 or 67%) and were therefore 
considered non-clinical in nature according to the definition in section 1.2. Analysis of the 
results revealed that 93 would be considered clinical interventions, therefore resulting in 
an estimated clinical intervention rate of 0.29%. The pharmacists reported that they spent 
an average of 5.7 minutes per problem (median = 5 minutes; range = 0.2 – 48). 
The authors reported a negative correlation between dispensing volume and problem 
reporting rate (Pearson coefficient = -0.69, p = 0.041), with the two pharmacies with the 
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lowest dispensing volume having the highest reporting rate. The nearly ten-fold variation 
between the intervention rates of the individual pharmacies was thought to be due to a 
combination of factors, such as the experience of the pharmacist, incentives, dispensing 
volume and workload, different dispensing systems and pharmacy location, however none 
of these factors (except prescription volume) was measured during the data collection. 
Pharmacists were also asked to record why they thought the prescribing problem had 
occurred in the first place. Pharmacists did not record this for every problem, however the 
most common reasons reported were transcribing/typing errors (30 or 15.3%), 
prescriber’s lack of knowledge about a drug or product (29 or 14.8%), and poor 
communication between GPs, pharmacists and/or patients (25 or 12.8%). 
1.3.24 Hämmerlein (Germany)78 
In 2007, Hämmerlein et al. published the results of a study documenting DRPs in 1146 
German pharmacies for one week during 2005. Pharmacists were asked to record any 
event or circumstance that actually or potentially interfered with desired health 
outcomes. The authors designed a standardised form for the pharmacists to document the 
DRP including patient age and gender, drug involved, whether the prescription was an 
original or repeat, time needed for resolution of the DRP, free-text description of the DRP 
and its management. After the trial, two members of the research team classified each of 
the DRPs into the PI-Doc System88 which had been modified to include a total of 72 
categories. 
The study reported that on average each pharmacy served 900 patients and dispensed 
1600 prescriptions and OTC drugs during the week, however actual numbers were not 
reported. Overall, 10,427 DRPs were recorded from approximately 1,833,600 
prescriptions, resulting in an approximate intervention rate of 0.57% and was equivalent 
to 9.1 DRPs per pharmacy per week. The most common DRPs identified were wrong data 
on the prescription (such as wrong dose or drug) with 1889 (28.5%), safety or 
effectiveness issues (such as interactions or contraindications) with 1872 (28.2%) and 
patient knowledge issues (such as patient ignorant of correct dose or insufficient 
knowledge about their condition or medication) with 1468 (22.2%). The most common 
medications involved included NSAIDs, cardiovascular drugs (such as beta-blockers and 
ACE-inhibitors), insulin, inhaled beta2 agonists and antidepressants. The median time for 
DRP resolution was 5 minutes (range = 1 – 210). The PI-Doc System recorded all types of 
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DRPs, including technical problems, therefore from the 10,427 DRPs, only 6628 were 
considered a clinical intervention under the definition in section 1.2, resulting in an 
estimated clinical intervention rate of 0.36%. 
The main limitations of this study were the short time frame of only one week and the 
pharmacies were able to choose which week they wished to record their DRPs, which may 
have increased the actual intervention rate. 
1.3.25 Krähenbühl (Switzerland)79 
In 2008, Krähenbühl et al. published the results of a study documenting DRPs in 20 Swiss 
pharmacies over four consecutive weeks in 2005. Pharmacists were asked to record any 
event or circumstance that actually or potentially interfered with desired health 
outcomes. The authors designed an electronic intervention recording system that was 
integrated with the dispensing software, which was similar to the PROMISe design 
described within section 1.3.26. Pharmacists were asked to electronically categorise the 
DRPs based on the Pharmaceutical Care Network Europe (PCNE) classifications89 which 
included the type of DRP, its potential negative outcome, its management and the 
individuals involved. This four-step plan allowed documentation of 17 different DRP types, 
of which 10 were considered clinical interventions by the authors and also met the 
conditions according to the definition in section 1.2. 
From the 38,663 prescriptions dispensed over the four weeks, pharmacists documented 
287 clinical DRPs corresponding to an average clinical intervention rate of 0.74%. The most 
common DRPs identified were wrong dosage (91 or 31.7%), drug-drug interactions (45 or 
15.7%), wrong drug regimens (33 or 11.5%) and adherence problems (27 or 9.4%). The 
study also had 736 technical problems recorded against the prescriptions, resulting in an 
average technical intervention rate of 1.90%. The most common technical problem was a 
discrepancy between the prescription and the medication record (208 or 28.3%), with 63% 
of these problems occurring due to a physician error. 
Over the four week study, the authors noted that the mean overall clinical intervention 
rate decreased from 1.04% in the first week to 0.45% in the fourth week, with 15 of the 20 
pharmacies recording a decline. Pharmacies did not receive any incentives for 
participation in the trial and the authors believed that this may have contributed to the 
declining intervention rate. The authors also noted that the clinical intervention rate 
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varied between the individual pharmacies (range = 0.0 – 2.6%), however no contributing 
factors to this difference were discussed. 
This study closely resembles the main methodological points of the previous PROMISe 
study81 as it was one of the only studies that used an integrated electronic system to 
document the DRPs. Like PROMISe, the participating pharmacies also volunteered and 
they received no incentives for participation, plus the authors separated clinical DRPs and 
technical problems. 
1.3.26 Previous PROMISe trial (Australia)80,81 
In 2005, the Pharmacy Recording Of Medication Incidents and Services electronic 
documentation system (PROMISe) study examined clinical interventions recorded in 
community pharmacies in Australia and was conducted in 52 pharmacies in Melbourne. 
Pharmacists used a computerised intervention documentation system that was integrated 
within their dispensing software to record ‘any professional activity by the pharmacist 
directed towards improving the quality use of medicines and resulting in a 
recommendation for a change in the patient’s medication therapy, means of 
administration or medication-taking behaviour’. This definition encompassed all 
prescription errors, adverse events and adherence issues, and pharmacists used the 
DOCUMENT classification system90,91 to classify each intervention (see Chapter 2 for 
details on the development of the DOCUMENT system). 
Over the eight week trial, participating pharmacists recorded 2385 clinical interventions 
from 435,520 prescriptions, resulting in a clinical intervention rate of 0.55%. The majority 
of interventions were due to drug selection problems (22.7%), dosage problems (19.4%) 
or education or information problems (17.4%). Drug groups associated with the most 
clinical interventions according to ATC groupings87 were drugs for diabetes (261 or 10.9%), 
drugs for respiratory disorders (120 or 5.0%) and antibiotics (119 or 5.0%). However, due 
to all prescriptions being collected during the trial period, intervention rates could also be 
calculated on each drug group. When the number of prescriptions was also considered, 
the drug groups with the highest intervention rates were drugs for diabetes (1.87%), anti-
diarrhoeals (1.46%), anti-anaemic preparations (1.23%) and systemic corticosteroids 
(0.93%). Further evaluation of the types of problems within specific drug groups of 
interest established that common interventions included: 
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 Compliance problems with anti-diabetic medications 
 Drug selection and dosage problems with antibiotics 
 Provision of information with respiratory agents (most often relating to 
demonstration of a device) 
 Dose problems with corticosteroids  
 Dose and drug selection problems with cardiovascular agents 
 Drug selection problems with anti-inflammatory agents 
 Untreated indications with antithrombotic agents 
Remuneration had a small, short term effect on intervention rate in some pharmacies, but 
did not appear to have a significant effect overall. Increased prescription workload caused 
a marked decrease in intervention frequency in the majority of pharmacies. An 
intervention prompt promoting the use of aspirin in diabetic patients was effective in 
prompting 201 specific interventions in the pharmacies where it was installed and also 
contributed to the large number of interventions on drugs used in diabetes. The prompt 
also increased the overall intervention rate by almost two-fold in pharmacies where the 
prompt was installed. Participating pharmacists were also asked to complete an 
assessment of their clinical problem solving skills, however no correlation was seen 
between the clinical problem solving score of the pharmacists and their intervention rate. 
1.3.27 Warholak and Rupp (USA)82 
In 2009, Warholak and Rupp published a study examining the number of errors detected 
on electronic prescriptions that were resolved by community pharmacist interventions. 
Seven chain pharmacy organisations were approached to participate, resulting in 68 
participating pharmacies in five States of the USA (Massachusetts, New York, 
Pennsylvania, Maryland and Nevada). Despite the study being performed on e-
prescriptions, the pharmacist still recorded their interventions on a paper form, which was 
then faxed or mailed to the researchers. The data collection period was over three months 
in 2006, with each pharmacy recording their interventions for a period of 14 consecutive 
days. 
Pharmacists recorded 113 interventions on 2690 e-prescription items, resulting in an 
intervention rate of 4.20%. The most common reason for intervention was omitted 
information (37 or 32.7%), however these interventions would not be considered clinical 
in nature according to the definition in section 1.2. Another 25 interventions were also not 
clinical in nature (illegal prescriptions, non-formulary drugs etc.), resulting in 51 clinical 
interventions and an estimated clinical intervention rate of 1.90%. The clinical 
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interventions included insufficient dose (11 or 21.6%), excessive dose (9 or 17.6%) and 
excessive quantity/duration (7 or 13.7%). From the 113 recorded interventions, the most 
common drug groups involved were central nervous system agents (19 or 16.8%), 
cardiovascular agents (18 or 15.9%), anti-infective agents (15 or 13.3%), and hormones 
and synthetic substitutes (13 or 11.5%). Each intervention took an average of 6 minutes to 
resolve. The authors also reported that the intervention rate was much higher on new e-
prescriptions compared to repeat prescriptions, however it was not reported if this 
difference was significant. 
This study showed a higher intervention rate than other studies, however the authors 
point out that this may have been due to the focus on e-prescriptions which was relatively 
new technology for many prescribers at the time. They felt that the number of errors 
would decrease as the prescribing became more familiar with the technology and the 
software vendors improved their systems. It was also interesting to note that the 
pharmacists recorded their intervention on paper forms, despite the intervention being 
conducted on e-prescriptions. By incorporating the reporting system into the e-
prescription technology, the number of interventions documented is likely to be 
increased. 
1.3.28 Braund et al. (New Zealand)83 
In 2010, Braund et al. published a study conducted in Dunedin, New Zealand in 2008. The 
study enrolled 24 pharmacies, however only 20 pharmacies completed any data entry 
during the trial. The study was conducted for four weeks, however only 6 pharmacies 
completed data collection for the full four weeks, therefore only the first week of data 
(when all pharmacies completed all data forms) was used for analysis. Participating 
pharmacists were asked to record information about performed interventions on a paper-
based tally form and the data was collated by the researchers at the end of the trial. 
Pharmacists were asked to record the ‘grade’ of the intervention as according to the 
Pharmaceutical Society of New Zealand’s recommendations. The grades were: 
 Grade 1: Bureaucratic (such as non-compliance with subsidy or legislative 
requirements) 
 Grade 2: Saved patient money by generic substitution or similar intervention  
 Grade 3: Clarified or interpreted prescriber’s instructions  
 Grade 4: Optimised drug therapy such as by improving compliance or patient 
lifestyle  
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 Grade 5: Prevented a moderate to serious threat to health  
 Grade 6: Prevented a potentially life threatening incident  
Grade 4 was not used during the study as the researchers wished to only record reactive 
interventions and Grade 4 interventions were considered proactive, therefore compliance 
issues were not documented. Other information that was collected on the form included 
the time spent on the intervention and the prescription count for each day. 
Over the first week of data collection, 1551 interventions were recorded from 24,059 
prescriptions, resulting in an average intervention rate of 6.45% (range = 2.3 – 32.3). The 
time spent on the 1551 interventions was 1684 minutes, resulting in an average time of 
1.09 minutes per intervention. The study also found a negative correlation between 
intervention rates and the number of prescriptions dispensed; as the dispensing volume 
increased, the intervention rate decreased (Pearson coefficient = -0.46, p = 0.042). 
The grading system used in this study did not allow the pharmacist to note what the DRP 
was (such as drug selection errors or dosing errors) that required an intervention, and 
therefore the nature of the interventions remains unknown. However it appears that only 
Grade 5 and 6 would be considered a clinical intervention under the definition in section 
1.2, and with only 134 interventions coded as Grade 5/6, the estimated clinical 
intervention rate was 0.56%. Although Grade 5/6 was only coded in 8.6% of interventions, 
they took 50% of the total time to resolve, indicating that it took the pharmacist more 
time to perform these interventions. 
A significant decrease in participation was seen during this study, where 20 pharmacies 
recorded data in the first week but only 6 pharmacies completed data collection for the 
full four weeks. The authors did not give any reasons for this finding and it is likely that the 
intervention rate during the first week was inflated, given that other studies have also 
reported a significant decline over the weeks of their trial.34,79 
1.3.29 Haavik et al. (Norway)84 
In 2011, Haavik et al. published an article describing two clinical intervention studies 
conducted in Norway. Nine community pharmacies documented their interventions for a 
five week period in 2004, with two hospital outpatient pharmacies and one community 
pharmacy documenting their interventions for a ten week period in 2006. Participating 
pharmacists were trained in the use of the system and asked to document any 
prescription errors requiring intervention. 
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Pharmacists recorded 2385 interventions on 85,475 prescriptions, resulting in an 
intervention rate of 2.79%. Of the four identified categories of interventions (formal 
errors, formal omissions, errors with potential clinical effects, omissions with potential 
clinical effects), only ‘errors with potential clinical effects’ would be considered clinical in 
nature. Approximately 405 interventions were due to errors with potential clinical effects, 
resulting in an estimated clinical intervention rate of 0.47%. 
The authors reported that most of the interventions were on new prescriptions (82.0%) 
that were computer-generated (65.5%), however it was not stated if these differences 
were significant. An expert panel consisting of 8 pharmacists and 8 physicians examined a 
sample of 124 of the interventions and determined that 106 (85.5%) were potentially 
clinically significant. Within these 124 examined interventions, the most common drug 
groups involved (according to ATC groupings87) were anti-bacterials for systemic use (24 or 
19.4%), analgesics (12 or 9.7%) and anti-asthma agents (12 or 9.7%). 
The authors note that the use of computer-generated prescribing based on electronic 
patient records can reduce the error rate of prescriptions, however it can also introduce 
different kinds of errors such as choosing the wrong drug or wrong patient, as seen in this 
study. 
1.3.30 Sanchez and Campos (Spain)85 
A Spanish study was completed in one community pharmacy in Madrid, where prescribing 
error data was recorded in a computerised system for a 6-month period in 2009. All of the 
available ‘prescription error’ categories were not detailed within the article, however 
pharmacists were encouraged to record ‘any problems identified in the process of 
dispensing that might interfere with the dispensing of prescriptions (such as incomplete or 
incorrect prescriptions), or be potentially harmful to patients (such as drug interactions, 
inappropriate doses or directions, contraindications, ADRs, allergies and drug 
duplications)’. 
The study reported 355 recorded interventions and 23,995 prescriptions dispensed, 
resulting in an intervention rate of 1.48%. Removing the 117 interventions that were 
recorded due to ‘incorrect prescription, size, quantity, illegality’, this left an estimated 
clinical intervention rate of 0.99% (238 interventions from 23,995 prescriptions). 
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The information was recorded by a pharmacist at the end of each day using the hard-copy 
prescriptions. This eliminated the need for the pharmacist to document the intervention 
at the time, which may have led to an increased intervention rate compared to other 
studies. However, this system would not be practical long-term within a community 
pharmacy setting as it required information to be entered separate from the dispensing 
system. 
1.3.31 Summary of the literature concerning community pharmacy 
interventions 
As can be seen in Table 1-1 and the summary of each of the studies, there is a wide range 
of reported rates of clinical interventions in community pharmacies ranging from 0.09% to 
2.69%.27,32-34,48,57-75,77-80,82-85 Direct comparison of the studies is difficult due to the 
differences in the definition of a clinical intervention, as many studies focused only on 
prescription errors.32,33,48,64 The studies also showed differences in data collection 
methods, where observational studies tended to detect a higher number of interventions 
than self-reporting studies.57,58,60,61,67 This may have occurred due to the participating 
pharmacists not recognising their intervention or not having enough time to record it. One 
study found that pharmacists admitted post-trial that they had performed many 
interventions that they did not document76, which is likely to have occurred in many of the 
studies. 
New prescriptions were commonly identified as requiring more interventions than repeat 
prescriptions.48,57,58,73,84 Most studies found that the use of computerised prescriptions 
decreased the number of interventions (often due to a decrease in the number of illegible 
prescriptions27,59,71,72,84), whereas another study found an increased rate of intervention 
required in e-prescriptions.82 
The most common type of error detected by pharmacists was dosing 
issues32,33,57,58,60,61,68,69,75,78,79, followed by drug-drug interactions.32,33,58,65,78,79 Other 
common problems included lack of patient understanding or a compliance issue57,60,68,78,79, 
incorrect drug58,61, incorrect strength32,33,60 or allergies65. When reported within the 
literature, the majority of studies showed that most interventions improved patient 
outcomes.58,60,69,71,72,84 
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The most common drug groups involved in interventions were cardiovascular 
agents59,62,63,68,69,71-73,78, central nervous system agents59,62,63,68,69,71,72, respiratory system 
agents59,68,71-73,84 and anti-infectives58-60,62,63,73,84. Other problematic drug groups identified 
included dermatological agents58, narcotic analgesics58, hormones and substitutes58, 
alimentary tract agents71,72, NSAIDs78 and other analgesics84. 
Many of the studies reported pharmacies where little or no documentation occurred, 
resulting in a large range of individual intervention rates. Most commonly, prescription 
volumes or pharmacist workloads were identified as a major contributor, with a higher 
prescription volume usually leading to a decreased intervention rate.27,32,33,58,61,69,71,72,77,83 
Other factors examined for their influence included location of pharmacy32,33, independent 
versus chain pharmacies65, number of nursing homes32,33, reimbursements27,34, use of 
electronic prompts70,73, type of dispensing software75, pharmacist 
willingness/motivation58, training/educational sessions27,34, level of education68 and the 
age of the pharmacist75. Some studies also found overall decreases in intervention rates 
over the course of the trial.32-34,66,79,83 
Some studies also reported average times to perform the interventions, with values 
ranging from an average of 1 to 8 minutes.61-64,67-69,77,78,83 Very few studies used 
computerised documentation systems66,70,79, with paper-based recording likely to have 
contributed to lower intervention rates. 
1.4 Factors influencing the delivery of pharmacy services 
Despite identifying a large range in intervention rates between pharmacies, the previous 
articles published on clinical intervention studies often omit comparisons between the 
intervention rates and influencing factors. As seen in the previous section, clinical 
intervention studies in community pharmacy have reported high prescription volumes and 
high pharmacist workloads as a common contributor to low intervention 
rates32,33,61,69,71,72,77,83, however there are many other possible contributing factors that are 
not routinely reported. Clinical interventions are considered a cognitive pharmaceutical 
service, along with five other pharmacy services: provision of drug information; provision 
of pharmacy and pharmacist-only medications; medication management services; 
preventative care services for patients with chronic conditions; and, participating in 
therapeutic decisions.92 It was therefore necessary to examine a broader range of 
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pharmacy services to determine additional influencing factors that may contribute to 
these individual differences between pharmacies and pharmacists. 
1.4.1 Implementation and continuing provision of pharmacy 
services 
There are a multitude of factors that can influence the implementation or continuing 
delivery of a pharmacy service. As early as 1979, a short article was published detailing the 
three key barriers that needed to be overcome to increase the pharmacist’s ability to 
provide pharmacy services: pharmacist knowledge/competency; interaction with other 
health professionals; and, reimbursement.93 An overview of pharmaceutical care 
published in 2004 identified several areas that must be satisfied for effective 
implementation of a pharmacy service: specific practice standards; adequate 
documentation mechanisms; appropriate inter-professional relationships between 
pharmacists and physicians; and, overcoming the barriers identified by the pharmacist 
themselves.94 An overview of the implementation issues arising within the field of health 
promotion within Canada published in 2006 found that the main barriers to 
implementation were the lack of interest of the participants, lack of funds/resources and 
lack of skilled staff.95 A Danish study in 1999 surveyed pharmacists regarding the barriers 
to implementing pharmaceutical care in their practice, with pharmacists citing staff 
shortages, lack of computer support and lack of engagement with patients as the main 
barriers to pharmaceutical care implementation.96 A literature review conducted in 
Australia identified two main components with four areas that influence the 
implementation of cognitive services in community pharmacy, where both individual and 
organisational level factors need to be considered in order to successfully implement 
cognitive services (Table 1-15).97 
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 Training in clinical and other skills 
 Identification of motivators 
 Identification of learning resources 
 Motivational strategies 
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Internal pharmacy environment 
 Pharmacy design/layout 
 Planning and goal setting 
 Documentation of service provision 
 Utilisation of support staff and task delegation 
 Quality assurance and improvement 
 Evaluation of performance and outcomes 
 Description/definition of service 
 Use of technology 
 Policies and procedures manual 
 Appointment cards 
 Software reminders 
External pharmacy environment 
 Relationships with patients, prescribers and payers 
 Target population identification 
 Support from a researcher or other pharmacists 
 Feedback from pseudo-patrons 
Business and financial 
  Reimbursement for service provision 
  Merchandising plan 
  Business plan 
  Marketing strategies 
  Resource assessment - financial and human 
  Management of resources 
  Packaging services together 
Table 1-15: Components of the process for the implementation of cognitive services97 
A further review identified specific individual and organisational facilitators that 
contributed to successful practice change (Table 1-16).98 
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Individual facilitators 
Pharmacist competence Professional satisfaction 
Education and training for pharmacy 
assistants 
Pharmacists' knowledge of cognitive services 
Education and training for pharmacists 
Pharmacists' attitudes towards cognitive 
services 
Communication skills 
Pharmacists' confidence in ability to provide 
cognitive services 
Motivation Autonomy 
Leadership skills Attitude of pharmacy staff 
Organisational facilitators 
Physical environment (such as adequate 
space/privacy and workflow) 
Interaction with other pharmacists 
Culture of the pharmacy Support of management 
Remuneration/incentives Access to reference literature 
Sufficient and qualified staff/manpower Pharmacist-patient relationship 
Use of pharmacy technicians Marketing 
Delegation of tasks 
Support from professional organisations 
and/or government 
Innovative practice orientation Low prescription volume 
Patient demand/expectations Rural location 
Relationship with doctors 
Legislation requiring or supporting provision 
of services 
Equipment and technology (such as 
computers) 
Attitude/perception of doctors 
Access to patient information/records Attitude/perception of patients 
Documentation system Examples from leading practitioners 
Profile within the local community External advisors or mentors 
Attention for special patient groups Evidence of benefits of services 
Use of protocols 
 
Table 1-16: Facilitators that can improve the implementation of cognitive services98 
Numerous studies have been published and reported on the difficulties on implementing 
and maintaining delivery of services within the pharmacy environment, with many 
reporting on the initiatives required to overcome these difficulties. The following section 
reviews the barriers and facilitators to implementation and maintaining service delivery 
within these studies on a variety of different pharmacy services. 
1.4.1.1 Raisch 199399 
An early study examining perceived barriers to providing cognitive services was 
undertaken in 1993 in the USA. Cognitive services were defined as counselling patients 
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and evaluating prescription orders before dispensing them (presumably detecting 
prescription errors), which were not a mandatory part of a pharmacist’s duties at the 
time. Barriers were divided into four types: 
 Situational barriers (such as working conditions and economic factors) 
 Cognitive barriers (such as lack of knowledge or ability to perform the service) 
 Legal barriers (such as the influence of regulations for pharmacy practice) 
 Attitudinal barriers (such as the pharmacist’s beliefs about themselves, other 
health professionals and patients) 
Pharmacists were given a list of barriers and required to rate them on a 5-point Likert 
scale, where 1 = least important and 5 = most important. A score of 0 indicated that the 
pharmacist did not feel the barrier was applicable. A total of 64 pharmacists returned the 
questionnaires, with excessive workload identified as the most common barrier (score = 
2.9 ± 1.7), indicating that the pharmacists perceived that they did not have enough time to 
perform cognitive services. Other important barriers were lack of privacy (score = 1.9 ± 
1.2), patients being uninterested in counselling (score = 1.9 ± 1.3) and poor store layout 
(such as a physical barrier between the pharmacist and the patient; score = 1.8 ± 1.6). 
An arbitrary ‘rate’ of providing cognitive services was also calculated by the number of 
patient counselling events or number of prescriber interactions divided by the number of 
prescriptions dispensed. Two barriers were found to be directly linked with the rates of 
provision of cognitive services, workload (p = 0.02) and peer pressure (p = 0.02), with 
pharmacists who perceived they had an excessive workload or perceived peer pressure 
(presumably the pressure to dispense rather than provide cognitive services) having a 
lower rate of providing cognitive services. 
The authors noted that pharmacists were currently only reimbursed for dispensing 
medications, rather than for cognitive services, which therefore affected the amount of 
time that a pharmacist could spend on cognitive services. It was therefore an interesting 
finding that pharmacists did not feel lack of financial payment was an important barrier to 
providing cognitive services (score = 1.0 ± 1.0). A limitation of the study was that 
pharmacists were not asked to identify or measure any internal barriers, such as lack of 
education, which may have also influenced the provision of cognitive services. 
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1.4.1.2 Latif 1998100 
In 1998, a survey was administered to pharmacists in the USA to examine the effects of 
workload pressure and beliefs of their employers or patients on their clinical decision 
making behaviour. Statements with 7-point Likert scale answers were used to determine 
the perceived beliefs of employers and patients, whereas the workload was measured by 
taking the number of prescriptions dispensed and accounting for the number of support 
staff at the time. 
One hundred and thirty-one pharmacists completed the survey. The study found that 
workload pressures did not influence the provision of pharmaceutical care (p = 0.686), but 
that the perceived beliefs of the employers and patients accounted for 7.6% of the 
variance (p = 0.003). This was in contrast to other studies that found that workload did 
affect the provision of services and could be explained by several possibilities. The authors 
noted that the measure of workload was not sensitive enough to capture the true 
relationship. However, it also appears that the reporting procedure was not very robust, 
with pharmacists self-reporting any clinical decision making they made on the last five 
patients with chronic conditions, which did not capture the longer timeframe over which 
additional clinical decisions were most likely made. 
1.4.1.3 Christensen and Hansen 1999101 
A 1999 study aimed to determine the characteristics of pharmacies and pharmacists that 
were associated with the provision of cognitive services. Surveys were administered to the 
pharmacy owner/manager (to complete on behalf of the pharmacy) and each employee 
pharmacist enrolled in a larger trial that was examining reimbursement of cognitive 
services in community pharmacies in Washington, USA. The authors provided two sets of 
results: a model which predicted whether a pharmacy/pharmacist would perform any 
cognitive services, as well as a model to predict the rate of cognitive services provided. 
The performance rate of cognitive services was defined as the number of services 
performed per 1000 prescriptions dispensed, which was similar to intervention studies in 
section 1.3. 
The participants were split into two groups based on remuneration; Group One received 
reimbursement for the documentation of cognitive services, whereas Group Two did not. 
The authors received 76 pharmacy questionnaires and 162 pharmacist questionnaires 
from Group One, and 62 pharmacy and 126 pharmacist questionnaires from Group Two. 
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Overall, the authors noted that the documentation of cognitive services was strongly 
linked to reimbursement. 
Pharmacy characteristics 
A logistic regression analysis was used to determine a model to predict whether a 
pharmacy would perform any cognitive services (performer vs non-performer). The 
variables that were significant and consequently included in the pharmacy model were 
perceptions of the pharmacist-in-charge about the usefulness of documenting cognitive 
services and the number of full-time pharmacists in the pharmacy. Together, these two 
factors had an overall prediction rate of 66.7%, with more ‘performers’ being correctly 
identified (88.1%) compared to ‘non-performers’ (31.4%). This shows the effect that 
attitude can have on the implementation of pharmacy programs, as the likelihood of the 
pharmacy performing cognitive services increased with a motivated pharmacist-in-charge. 
The number of full-time pharmacists was significantly correlated with several other 
factors, such as pharmacy size and prescription volume, indicating that workload was also 
a significant factor in the ability to provide cognitive services. 
A multiple regression analysis was also performed to determine the factors that influence 
the rate of cognitive services performed by the pharmacy. The model explained 
approximately 24% of the variance between the pharmacies, with three significant factors 
contributing to the model: reimbursement; monthly prescription volume; and, percentage 
of prescriptions dispensed to Medicaid recipients (government assistance for low income 
families). Pharmacies that were reimbursed, that dispensed less prescriptions per month, 
but a higher percentage of Medicaid prescriptions, had a higher rate of documenting 
cognitive services. 
Pharmacist characteristics 
A logistic regression analysis was also used to determine a model to predict whether a 
pharmacist would perform any cognitive services (performer vs non-performer). The 
variables that were included in the pharmacist model were pharmacist position, 
perceptions of how burdensome the task of documentation was, and percentage of sales 
from prescriptions. The model had an overall prediction rate of 61%, with more 
‘performers’ being correctly identified (79%) compared to ‘non-performers’ (33%). 
Pharmacist owner-managers who did not find the documentation of cognitive services to 
be burdensome were more inclined to document cognitive services. Interestingly, there 
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were no significant associations with reimbursement, training, first year of practice, or 
attitudes and beliefs in the pharmacist model. 
A multiple regression analysis was also performed on the pharmacist data to determine 
the factors that influence the rate of cognitive services performed, therefore all 
pharmacists that recorded no cognitive services during the trial were excluded prior to the 
analysis. The model explained approximately 32% of the variance between the 
pharmacists, with five significant factors contributing to the model: monthly prescription 
volume; reimbursement; percentage of prescriptions dispensed to Medicaid recipients; 
medical centre location; and, rural location. The only differences between the pharmacy 
and pharmacist model was the addition of the medical centre and rural location factors. 
The authors showed that the medical centre pharmacies had a higher percentage of sales 
relating to prescriptions, which may explain its influence, and surmised that rural 
pharmacies may have a higher documentation rate of cognitive services due to an 
increased rapport with patients. 
One limitation of this study is the way that prescription volume and pharmacist workloads 
were measured. Pharmacists were asked to record a “typical” prescription volume, rather 
than record the actual number of prescriptions dispensed, which may have affected the 
accuracy of the workload calculations. 
1.4.1.4 Dunlop and Shaw 200216 
A survey administered to 348 New Zealand pharmacists aimed to determine their 
understanding of pharmaceutical care and barriers that prevent implementation of 
professional services to improve pharmaceutical care.16 The factors that were identified as 
barriers to the provision of pharmaceutical care included lack of time (87.0%), lack of 
reimbursement (81.9%) and lack of patient demand (64.1%). The pharmacists also felt that 
adequate knowledge and an adequate documentation process was necessary to 
implement pharmaceutical care. 
1.4.1.5 Westerlund et al. 2003102 
Westerlund et al. published the results of a survey administered to pharmacists 
participating in a study that electronically documented DRPs relating to OTC products. The 
questions aimed to determine the ease of use of the system and identify some of the 
factors that the pharmacists believed impacted on their use of the system. 
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Of the 447 pharmacists that had participated in the OTC study, 376 (84%) responded to 
the survey. Interestingly, 139 (37%) of the respondents had not recorded any 
interventions during the 10-week documentation period, allowing the researchers to 
attempt to quantify the differences between the ‘performers’ and ‘non-performers’. Most 
of the respondent pharmacists seemed highly motivated to document DRPs and the 
resulting interventions, with the authors noting that even the non-performers felt the 
documentation system was important to pharmacy practice. A significant relationship was 
found between the perceived interest in the project and the DRP documentation rate (p = 
0.004). Almost 40% of participants did not perceive any time constraints to documenting 
the DRPs, with no significant difference detected between the perceived time constraints 
and the documentation rate, which is in contrast to results found by other studies. In 
general, the authors concluded that there was a need to change the attitudes among 
pharmacists and convert practice orientation towards professional service in order to 
improve patient care. 
1.4.1.6 Svarstad et al. 2004103 
A study published in 2004 used mystery shoppers to determine factors that influenced 
patient counselling in community pharmacies. The shoppers presented three new 
prescriptions to the 306 pharmacies in eight States of the USA and recorded the level of 
interaction with the pharmacist, as well as estimated pharmacist and pharmacy 
demographics. 
The shoppers found that an increased level of pharmacist interaction occurred with 
younger pharmacists (less than 35 years) who were working in less busy pharmacies. 
Pharmacists working in States with an increased intensity of regulations mandating 
counselling also had an increased level of pharmacist interaction, suggesting that legal 
requirements can have a significant impact on pharmacy practice. No interaction was 
found between the pharmacy type (chain vs independent) and the level of patient 
counselling, with the authors concluding that the busyness of the pharmacy was a better 
predictor of patient interaction compared to pharmacy type. 
1.4.1.7 Becker et al. 2005104 and 2007105 
Two studies by Becker et al. identified specific factors that contribute to the likelihood 
that a pharmacist will dispense a drug that interacts with another drug the patient is 
taking concurrently. Firstly, a literature review was undertaken that identified seven 
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papers that discussed contributing factors. From the papers, three different groups of 
factors were identified: 
 Relationship between the pharmacist and prescriber, where patients with a single 
primary-care physician and a single dispensing pharmacy were less likely to 
receive interacting medications 
 Quality of the medication surveillance software, where the number of dispensed 
interacting medications can be decreased by the software, but too many or too 
few alerts can also contribute to an increased number of dispensed interacting 
medications 
 Pharmacy organisation and the knowledge of the pharmacist, both of which affect 
how the pharmacist manages the alerts provided within the software 
Taking this knowledge, the authors then designed a study to examine the factors 
influencing the dispensing of 10 common drug-drug interactions (such as macrolides and 
digoxin, or beta-blockers and beta2 agonists). The only drug-drug interaction where 
commonalities were found was between macrolides and digoxin, where pharmacies that 
dispensed this combination regularly were medical centre pharmacies and pharmacies 
using one specific software system. This may indicate the effect that software alerts can 
have on the dispensing of drug-drug interactions, with the authors noting that this 
software system was not as advanced in their alert systems as some of the other programs 
on the market. However, the authors also noted that the pharmacist’s attitude in using 
any of the software systems may have contributed to the effectiveness of the alerts, 
therefore the software systems themselves cannot be held fully accountable. 
1.4.1.8 Irujo et al. 2007106 
A Spanish study in 2005 examined the factors that influenced the under-reporting of ADRs 
within community pharmacies by comparing pharmacists that had reported an ADR within 
the last year compared to pharmacists that had not. Using a case-control method, 18 
pharmacists who had reported an ADR were compared to 60 control pharmacists. The 
authors found that the factors positively associated with ADR reporting were older 
pharmacists with more years of experience, increased participation in educational 
activities related to the detection and resolution of DRPs, and a higher score on a 
knowledge survey delivered as part of the study. 
1.4.1.9 Roberts et al. 2008107 
A large amount of research has also been completed within Australia which aimed to 
identify the factors that influence practice change overall within the pharmacy 
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environment, including factors that influence the introduction of new cognitive services. A 
43-item quantitative survey using statements answered with a 5-point Likert scale was 
designed using organisational theory framework and mailed to 2000 community 
pharmacies within Australia. 
Out of 2000 pharmacies, 735 responded with a yield of 1303 individual questionnaires 
(each pharmacy could provide a completed survey from the pharmacy owner, a 
pharmacist employee and a pharmacy assistant). Factor analysis revealed 7 factors that 
explained 48.8% of the total variance: relationships with physician; remuneration; 
pharmacy layout; patient expectation; manpower and staff; communication and 
teamwork; and, external support and assistance. The authors suggested requirements for 
successful practice change for each factor (Table 1-17). 
Factor Requirements for successful practice change 
Relationship with physicians Build rapport with local physicians 
Remuneration Provide incentive payments or a fee-for-service 
Pharmacy layout 
Provide a private or designated area for service 
delivery 
Patient expectation React to the patient's needs 
Manpower/staff 
Decrease workforce shortages and provide 
additional staff for implementation 
Communication and 
teamwork 
Involve the whole pharmacy team in the 
implementation process, not just the pharmacy 
owner 
External support and 
assistance 
Provide support for planning and implementing 
change, as well as clinical support for the service 
Table 1-17: The seven key areas in implementing practice change identified by 
Roberts et al.107 
1.4.1.10 Uema et al. 2008108 
A 2005 study into the perceived barriers to pharmaceutical care in Argentina examined 
the responses from 90 pharmacist questionnaires. The options were not pre-defined as 
seen in a similar study99, therefore the pharmacists were required to formulate five 
barriers to the implementation of pharmaceutical care in their own words and also rank 
their importance. 
Some pharmacists reported less than 5 barriers in their questionnaire, resulting in 90 
responses that detailed 323 situations that were considered barriers. Researchers 
analysed the questionnaires and manually grouped similar responses together, with the 
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results showing that the three most important barriers were lack of time, lack of specific 
training and lack of communication skills with patients (Table 1-18). Interestingly, lack of 
reimbursement was only stated as a barrier in 3 (3.3%) questionnaires, which is in contrast 
to other reported studies.16,109 
Barrier # % 
Lack of time 82 25.4 
Lack of specific training 56 17.3 
Lack of communication skills with patients 37 11.5 
Lack of space 25 7.7 
Lack of acceptance of a need for a pharmacist by the health system 17 5.3 
Lack of human resources or personnel 16 5.0 
Lack of communication skills with health team 15 4.6 
Lack of motivation/compromise 14 4.3 
Disorganisation in the use of resources 14 4.3 
Lack of specific software/technological resources 10 3.1 
Lack of funds or financial resources 5 1.5 
Occasional patients 5 1.5 
Lack of documentation skills 4 1.2 
Difficulties to access drug information 4 1.2 
Lack of reimbursement 3 0.9 
Others 7 2.2 
Not a barrier 9 2.8 
Total 323 100.0 
Table 1-18: Barriers to the implementation of pharmaceutical care reported by 
Argentinian pharmacists108 
When the importance rankings were analysed, lack of time was indicated as the major 
barrier in 53 (58.9%) of the questionnaires. Interestingly, when these barriers were then 
compared to the pharmacist’s year of graduation, lack of time appeared more frequently 
in the pharmacists that had graduated a longer time ago. This may indicate a higher level 
of efficiency in the more recently graduated pharmacists, who may perceive that they 
require less time to implement new services. The newly graduated pharmacists may also 
be more willing to change, and therefore do not see the implementation of a new 
pharmacy service as an inconvenience. The ranking of lack of time as the most important 
barrier was affected by the number of pharmacists working within the pharmacy. When 
only one pharmacist was present, 66% believed lack of time was a major barrier, but this 
decreased to 54% when two pharmacists were present and 40% when three pharmacists 
were present. This may be therefore linked to pharmacist workload, as a higher number of 
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available pharmacists will most likely decrease the overall workload, therefore allowing 
more time to provide professional services. Also, the authors classified 90% of the barriers 
as being ‘internal’ to the pharmacy and pharmacist, highlighting that simple alterations to 
these factors could increase the implementation of pharmaceutical care. 
The authors noted that the sample could not be considered representative, as the survey 
was distributed at continuing professional development (CPD) events and it is possible 
that participating pharmacists were already more motivated to implement pharmaceutical 
care. The majority of the respondents were female (81%), which may have also caused a 
bias in the results. The authors did not define what ‘pharmaceutical care’ was on the 
survey form and stated that it was a fairly new concept in Argentina, therefore it is also 
possible that the participating pharmacists did not fully understand the purpose of the 
survey. 
1.4.1.11 Latif and Boardman 200853 
A 2006 study aimed to investigate the factors that influenced the number of medication 
use reviews (MURs) performed by community pharmacists in the UK. Questionnaires were 
distributed to 280 pharmacists with 167 respondents (59.6%). The factors that were found 
to significantly affect the number of reviews performed were: 
 Current position (employee and managing pharmacists performed more MURs 
than locums) 
 Weekly hours (pharmacists working more than 20 hours per week performed 
more MURs) 
 Access to a practical consultation area (pharmacists with access performed more 
MURs) 
Gender, years since qualification, additional post-graduate qualifications and pharmacy 
size did not appear to influence the number of MURs performed. 
Pharmacists were also asked to answer 16 attitudinal statements on a 5-point Likert scale, 
of which 6 statements assessed their beliefs on barriers to performing MURs. The 
pharmacists felt lack of time (74%), lack of support staff (74%) and lack of a suitable 
consultation area (64%) were barriers to the performance of MURs. Pharmacist opinions 
regarding remuneration were varied, with 50% believing that an adequate financial 
incentive would increase the number of MURs performed but 38% disagreeing with this 
statement. 
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1.4.1.12 Zardain et al. 2009110 
A survey was undertaken in Spain in 2005 to identify the psychosocial determinants that 
influence the implementation of pharmaceutical care. Using a survey that was validated 
prior to the study, the authors identified that a community pharmacist would be more 
likely to implement pharmaceutical care if the pharmacist had a positive attitude, believed 
they were capable of performing the services, and observed colleagues performing the 
service with the perception that they were supported to also perform the service 
themselves. Information regarding demographics and professional experience was 
collected, as well as a range of statements to gauge the participants’ attitudes, social 
influence, self-efficacy, motivations and needs.  
The survey was completed by 1925 pharmacy owners in the five different stages of 
implementation: pre-contemplation (have not considered adopting pharmaceutical care, n 
= 1255); contemplation (considering adopting pharmaceutical care in the next 6 months, n 
= 322); preparation (willing to implement pharmaceutical care within the next month, n = 
120); action (have been implementing pharmaceutical care for up to six months, n = 33); 
and, maintenance (have been implementing pharmaceutical care for over six months, n = 
195). The survey found that as the respondents moved from the pre-contemplation to the 
implementation stage, their attitude and self-efficacy scores increased, indicating that the 
pharmacists who were already implementing pharmaceutical care had a more positive 
attitude towards the service and felt more competent to provide the service. 
A logistic regression analysis was performed to create a prediction model for whether a 
pharmacist would perform pharmaceutical care (where the pharmacists were in the 
‘action’ or ‘maintenance’ stage). The final model explained 50% of the change of 
behaviour from ‘not performing’ to ‘performing’, with the following covariates being 
significant: 
 Training in pharmaceutical care (OR = 13.92; 95% CI = 5.37 – 36.08) 
 High self-efficacy score (OR = 3.19; 95% CI = 2.38 – 4.28) 
 Presence of assistant pharmacists (OR = 1.70; 95% CI = 1.02 – 2.80) 
 High attitude score (OR = 1.03; 95% CI = 1.01 – 1.04) 
This indicates that training was the most influential factor in this study, with pharmacists 
who were trained being 14 times more likely to perform pharmaceutical care. As 
predicted by the authors, a pharmacist’s positive attitude and belief in their ability to 
perform the service were also influential. Interestingly, the presence of additional 
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pharmacists also had an influence on the performance of pharmaceutical care, which may 
indicate that the additional pharmacists contributed to a more efficient workload 
distribution. 
The identified barriers also differed between pharmacists in the five different stages. 
Pharmacists in the pre-contemplation or contemplation stages identified the need for 
more training courses, practice guidelines and specific software. Pharmacists in the 
maintenance stage identified the need for better communication between pharmacists 
and other members of the healthcare team (such as doctors and hospital physicians). This 
indicates that the barriers that need to be overcome to allow implementation of 
pharmaceutical services often differ to the barriers identified whilst maintaining the 
provision of the service. 
1.4.1.13 Lounsbery et al. 2009109 
A 2007 survey of outpatient-based pharmacists within the USA aimed to determine the 
barriers that affected the implementation of a medication management service and the 
continued provision of the service.109 The study found that for the 194 pharmacists not 
currently offering the service, implementation was affected by the lack of additional 
staffing (89.6%), poor access to the patient’s medical information (84.0%), lack of physical 
space to perform the services (80.3%), lack of ability to obtain compensation (79.8%) and 
lack of an efficient documentation system (77.7%). Many pharmacists also felt that they 
did not understand the components of the service, which also affected their motivation to 
implement it.  
For the 776 pharmacists currently offering the service, continued provision of the service 
was affected by lack of adequate compensation (70.8%), inability to obtain adequate 
compensation (67.3%), and lack of recognition as a healthcare provider (62.2%). 
Interestingly, once the service had been introduced, significantly less pharmacists 
identified with staffing levels and physical space being a barrier to offering the service.109 
Many factors identified surrounded the ability to change the pharmacist’s practice, and 
once this had been achieved, continued remuneration was required to maintain offering 
the service. Again, it also highlighted the difference between the perceived barriers to 
implement services compared to the perceived barriers to maintaining the provision of 
the service. 
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1.4.1.14 Gastelurrutia et al. 2009111 
A qualitative study was undertaken in Spain to determine the facilitators for practice 
change within Spanish community pharmacies. Thirty-three semi-structured interviews 
were undertaken, with 15 practitioners (pharmacists currently working in a pharmacy 
providing cognitive services) and 18 ‘strategists’ (pharmacists currently involved with the 
design and implementation of cognitive services). From the interviews, 12 facilitators for 
practice change were identified, which were grouped into four domains: 
 Pharmacists – the need for more clinical education; the need for clearer messages 
from professional leaders about the future of pharmacy; and, the need for a 
change in pharmacist attitude in regards to practice change 
 Pharmacies – the need for a change in reimbursement (by reducing income for 
dispensing and increasing income for cognitive services); and, the need to change 
the structure of pharmacies (increasing their size, increasing the number of 
pharmacists and providing private areas for patient care) 
 Pharmaceutical profession – the need for the governing bodies to take leadership 
in the implementation of professional programs; the need for a decrease in 
administrative workload; the need to reduce the gap between research and the 
practice environment; and, the need for more practical research on effectiveness 
and efficiency 
 Miscellaneous – the need to increase patient demand for cognitive services; the 
need to improve relationships between pharmacists and physicians; the need for 
greater support from healthcare authorities; and, the need for marketing of 
cognitive services and their benefits to the public and other healthcare 
professionals. 
Interestingly, the practitioners and the strategists ranked the importance of the 
facilitators differently. Practitioners felt that remuneration was the most important 
facilitator, followed by increasing clinical education, legal support, and marketing of 
cognitive services. Strategists felt that clinical education was the most important 
facilitator, followed by the attitude of the pharmacist, communication with the primary 
healthcare team, and the provision of adequate tools for implementation. This highlights 
the disconnect that pharmacists often feel when trying to implement research projects, as 
the views of the researchers that design the services are often very different to the views 
of the pharmacists implementing the service. 
1.4.1.15 Gadkari et al. 2009112 
A study conducted in non-metropolitan pharmacies in the USA examined the pharmacy 
characteristics associated with the provision of drug therapy services (including 
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medication management services and disease state management programs). Pharmacy 
owner/managers were approached to complete a survey that collected data about the 
pharmacy’s demographics, as well as staffing, services offered, prescription workload and 
service orientation (assessed by 3 statements answered by a 5-point Likert scale). 
The study received 115 completed responses from pharmacists in non-metropolitan areas 
and a logistic regression analysis was run on eight factors to create a model to predict 
whether a pharmacy would provide any drug therapy services. The following four factors 
contributed significantly to the model: 
 Pharmacy provides immunisation (p = 0.01) 
 Service orientation measure where pharmacy owners were supportive of their 
staff if they wished to increase service provision (p = 0.01) 
 Prescription workload per pharmacist (p = 0.03) 
 Pharmacy located in a rural area as opposed to a regional centre (p = 0.04) 
The factors that were not significant to the model were staffing levels (additional 
pharmacists and presence of technicians/interns), number of dispensing-aiding 
technologies (including barcode scanners, electronic ordering system etc.), and whether 
the pharmacy was independent or part of a chain. The limitation of this study was that it 
was self-reported, and therefore, the actual workloads and staffing levels may have been 
different in practice. 
1.4.1.16 Garrett and Reeves 2009113 
An analysis of the attitudes of Australian pharmacists that influenced the reporting of 
interventions within a public hospital environment was published in 2009. All public 
hospitals across New South Wales were using an incident reporting system, and survey 
responses were received from 79 pharmacists representing 78% of all pharmacists using 
the system. Despite most pharmacists believing that performing clinical interventions 
were part of their role and that the interventions improved patient outcomes, pharmacists 
generally did not perceive the recording of the interventions as important. The most 
commonly reported barriers to recording interventions were lack of time (34%), 
difficulties with the computer system (17%) and lack of feedback (14%). This study 
highlighted the need for a change in attitude in the pharmacists, where education on the 
importance of recording interventions to create a more complete patient record may 
improve the use of a documentation system. 
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1.4.1.17 Mandt et al. 2010114 
A Norwegian study examined prescription intervention practices in community pharmacy 
through the use of focus groups. The 14 participants discussed their working procedures 
and professional judgements related to prescription interventions during two focus 
groups. From the participants, the authors identified two main dispensing processes: 
active dispensing where information was extracted through communication with the 
patient and through decision support, and fast dispensing where information was only 
extracted from the current prescription. All pharmacists identified that active dispensing 
was the ideal procedure, but that fast dispensing was the process used when time was 
limited. The pharmacists identified that both the detection and documentation of 
interventions suffered when fast dispensing was practiced. Facilitators that increased 
prescription interventions were proactive patients, adequate information technology 
(many Norwegian pharmacies have electronic links to the patient’s prescription history), 
and a pharmacy layout that allowed interaction with the patients during the dispensing 
process.  
1.4.1.18 Blake and Madhavan 2010115 
In 2010, a study was published that aimed to provide a model to predict a community 
pharmacist’s likelihood to provide a medication management service. Pharmacists were 
asked to answer statements on a 7-point Likert scale to determine the barriers to 
providing services. Out of the 256 survey responses, only 174 were included, as the 
remaining surveys were answered by pharmacists not currently practicing in community 
pharmacy. The pharmacists indicated that the major barriers to providing a medication 
management service were lack of time and attitude of the physician. The major facilitators 
were the willingness of the patient to participate and the educational background of the 
pharmacist. This can be seen in Table 1-19 where low mean scores indicate barriers and 
high mean scores indicate facilitators. 
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Barriers/facilitators Mean SD 
Lack of time 3.08 1.88 
Physician attitudes 4.23 1.47 
Lack of reimbursement 4.34 1.92 
Legal liability 4.56 1.68 
Lack of patient counselling area 4.57 2.06 
Adequate support staff 4.58 1.97 
Lack of confidence 4.98 1.69 
Employer 5.10 1.65 
Lack of customer loyalty 5.23 1.70 
Educational background 5.24 1.50 
Patients' willingness to participate 5.69 1.18 
Table 1-19: Barriers and facilitators to the provision of a medication management 
service found by Blake and Madhavan115 
A principal components analysis was conducted to determine what factors significantly 
contributed to the provision of a medication management service. It showed that a three-
factor solution could explain 53.3% of the variance, with the three factors being perceived 
ability to respond to patient interest (grouping confidence, educational background, 
patients’ willingness and legal liability together), pharmacy-related factors (grouping 
counselling area, time, customer loyalty and reimbursement together), and enabling 
factors (grouping physician attitudes, employer and adequate support staff together). 
Practice setting and demographic variables (such as gender, job status and highest degree 
earned) were not significant predictors of the provision of a medication management 
service. 
The authors also noted that the majority of pharmacists (73.8%) indicated that, if given 
the choice, they were likely or very likely to work in a pharmacy that provides medication 
management services compared to a pharmacy that does not. This indicated that there is 
considerable interest to provide these services from an employee point of view. 
1.4.2 Analysis of specific influencing factors  
Studies consistently report barriers both for the individual (the pharmacist) and the 
organisation (the pharmacy) in the implementation and continuing provision of 
professional services within the pharmacy. The following section explores studies that 
specifically aimed to measure the effects of commonly reported barriers, such as 
workflow design, workload, education, reimbursement, technology and practice change. 
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1.4.2.1 Workflow design and pharmacy layout 
A 1999 study of Irish pharmacists aimed to quantify the actual percentage of time a 
community pharmacist spent on professional services, rather than rely on self-reporting 
post-activity or direct observation.116 The study estimated that 49% of a pharmacist’s time 
was spent engaged in professional activities (such as assessing prescription 
appropriateness, checking accuracy, counselling, training staff), 29% on semi-professional 
activities (such as labelling the products and administration tasks) and 22% on non-
professional tasks (such as inventory, housework and non-professional conversations). 
This study was repeated 10 years later117, and found that 49% of a pharmacist’s time was 
spent engaged in professional activities, 31% on semi-professional activities and 20% on 
non-professional tasks, demonstrating that the composition of pharmacist workloads had 
not changed in the previous 10 years. The authors identified that the 20% of time spent on 
non-professional tasks (including 8% of time on inventory activities which could easily be 
delegated to a non-pharmacist) was underutilising a pharmacist’s professional skills, 
indicating that redistribution of the pharmacist’s responsibilities would likely increase the 
amount of time spent on professional activities. 
Another study examined an interesting alteration of workflow within a community 
pharmacy employing two pharmacists.118 One pharmacist was nominated as a ‘clinical 
community pharmacist’ whose sole role was to analyse drug therapy, educate patients, 
field therapeutic questions from patients and document interventions. The second 
pharmacist completed all the administrative tasks and fielded all phonecalls to the 
pharmacy, thus removing the non-clinical distractions from the clinical pharmacist. Several 
dispensary technicians were also utilised, each with specific tasks to complete within the 
dispensing process, with all positions aimed to eliminate distractions from the clinical 
pharmacist. During a 6-month period, 221 clinical interventions were made and the 
authors noted several cases where patient outcome was significantly improved. Most 
importantly, the same number of staff members were utilised, but in a different capacity, 
therefore little or no extra cost was incurred to redesign the pharmacy workflow in this 
way.118 Improving the workflow design within a community pharmacy could therefore 
significantly improve the amount of time a pharmacist spends on professional services. 
A different study also made alterations within the dispensing area to improve the level of 
patient counselling119, which would increase the amount of interaction with the patient 
and therefore, most likely increase the number of interventions detected by the 
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pharmacist. In this study, the use of space within the dispensary was improved and the 
responsibility of technicians was increased, ensuring that the pharmacist’s time for patient 
interaction was at a maximum level. The study found that with the redesign, the 
pharmacist involvement with data entry was significantly decreased (61% to 10%; p < 
0.001) and the number of offers of oral counselling to the patient was significantly 
increased (5% to 85%; p < 0.001). Unfortunately, the number of actual counselling 
sessions did not increase, with the authors reporting that this was due to the patients 
often declining a counselling session with the pharmacist.119 Again, this simple redesign of 
existing infrastructure achieved better interactions between the pharmacist and patient, 
therefore allowing an increase in the level of pharmaceutical care provided. The study also 
highlighted a barrier that could have an extensive impact on the provision of cognitive 
services, as patients may also require education to ensure they understand the expertise 
of the pharmacist. 
1.4.2.2 Workload 
In previous sections, several studies have been identified where workload and prescription 
volume have significantly affected the number of professional services provided by 
pharmacists, including the documentation of clinical interventions.27,33,61,69,71,77,83 
Similarly, another study examined the effect of pharmacist workload on the dispensing of 
drug-drug interactions (DDI).120 The study found that the factors which significantly 
contributed to an increased risk of dispensing a potential DDI included pharmacist 
workload (OR = 1.03; 95% CI = 1.03 – 1.05) and pharmacy staffing (OR = 1.10; 95% CI = 
1.09 – 1.11). Other factors included various technologies, such as sophisticated telephone 
systems, electronic receipt of orders, and the ability to modify DDI alert-screening 
sensitivity. These findings suggest that as pharmacies process more prescriptions per 
hour, they are likely to dispense more potential DDIs. This most likely occurs due to the 
pharmacists becoming busier, and therefore less likely to detect DDIs, evaluate DDI 
warnings within the software, or act on those warnings. The mean number of 
prescriptions processed per pharmacist hour was 14.1 ± 4.9 and the relative risk of 
dispensing a potential DDI increased by 3% for each additional prescription processed per 
pharmacist hour (OR = 1.03; 95% CI = 1.028 – 1.034). The authors noted that the patient 
outcomes were not measured, therefore the rate of adverse effects experienced by the 
patients in this study as a result of the dispensed drug-drug interaction was not known120, 
however one clinical intervention study found that 83.8% of interventions involving drug-
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drug interactions would have resulted in serious or very serious consequences if the 
pharmacist had not intervened75, implying that the resolution of drug-drug interactions is 
extremely important. 
Despite this apparent overwhelming other evidence, some studies have found no 
correlation between the pharmacist workload and the rate of delivering pharmacy 
services.100 For example, one study found there was not a significant correlation between 
the pharmacist workload (measured as prescription volume per hour) and the rate of 
counselling within the pharmacy.119 The actual workload of the pharmacist can be difficult 
to measure, which ultimately could contribute to the variations seen between the studies. 
1.4.2.3 Education 
Poor clinical knowledge and lack of continuing education of the pharmacist have also been 
identified as factors that affect the provision of services. One study examined the effect of 
an intensive training program on the ability of pharmacists to identify DRPs and required 
pharmacists to commit to 40 hours of face-to-face training sessions, 10 weeks of structure 
and process changes, then 14 months of case-based assignments.121 The study found a 
significant improvement in the pharmacist’s ability to manage DRPs from the middle of 
the education period and the end of the education period (p = 0.008), indicating the 
benefit that education can have on the detection of DRPs.121 Unfortunately, this level of 
commitment to continuing education would not be achievable by the majority of 
community pharmacists, either due to lack of time or lack of motivation. 
As described in section 1.3.22, the Benrimoj study34 examined the difference in 
intervention rate between pharmacists with different levels of education. Of the four 
study groups within the trial, the two groups that received education had a higher 
intervention rate, however this difference was not statistically significant.34 The 
interventions by the more highly trained pharmacists also appeared to provide increased 
cost savings compared to the basic education group and the control group.122 
A Swedish study examined the effectiveness of providing a counselling model to 
pharmacists to detect DRPs in specific drug groups.123 The study found that pharmacists 
using the counselling model had a documented intervention rate of 10.9%, with nearly 
25% of patients using NSAIDs experiencing a drug-related problem. Therefore, providing 
pharmacists with a more structured and consistent way to detect DRPs may increase their 
ability to provide pharmaceutical care and intervention rate. 
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A recent study in the USA compared traditional CE (such as didactic lectures) to CPD (more 
targeted workshops and self-directed learning) to determine which form of continuing 
education was better. The 91 pharmacists self-reported that the targeted CPD increased 
their clinical knowledge, skills and attitudes as well as improved the level of patient care 
they provide124, which may lead to an increased provision of professional services. These 
pharmacists also reported better interactions with other health-care providers and 
initiated new practice changes as a result of their education activities.124 Unfortunately, 
pharmacists within this study also reported that lack of time was a barrier to completing 
the additional activities within the CPD model124, making the level of commitment needed 
for the basic CE model more appealing to the majority of community pharmacists.  
A Belgian study examined the differences between pharmacists who undertook CE 
training (attendees) and the pharmacists that did not (absentees).125 The authors found 
that more women attended CE activities compared to men (p = 0.021), and that more 
owners attended compared to employees (p < 0.001). The pharmacists were also asked to 
list the factors influencing their attendance with gathering practical knowledge and 
keeping knowledge up to the standard listed as the most motivating factors, with the 
authors noting that maintaining this level of knowledge would be extremely beneficial for 
their patients. Older pharmacists tended to feel more duty-driven than their younger 
counterparts which increased their attendance at CE events. Interestingly, women were 
more driven to attend CE events if there was a reward (p < 0.001), whereas men were 
more likely to attend based on the learning activity itself (p = 0.006). Barriers to 
attendance were also reported, where females were more influenced by the distance to 
classes (p < 0.001), reluctance to make the trip (p < 0.001), and family commitments (p < 
0.001), whereas their male counterparts were more influenced by concurrent activities 
such as sport (p = 0.038) and the belief that they do not have to continue to learn (p = 
0.013).125 Some of the differences in the provision of professional services may therefore 
be linked to demographics, as the levels of commitment to continuing education, and 
therefore the level of clinical knowledge, may differ between genders and employment 
position. 
A study regarding the benefits of continuing education was also conducted in India, where 
CE was not mandatory and often not available to the pharmacists.126 The authors found 
that in the 48 participant pharmacists, CE improved their patient counselling skills and 
professional skills (such as BP and BSL monitoring), and more importantly, they began to 
       85 | P a g e   
 
implement this knowledge and skills into their everyday practice which would be likely to 
improve patient outcomes. The authors also identified that self-motivation was an 
important strategy in overcoming the barrier of implementing new services.126 
Amongst other health professionals, trends have also been noted between continuing 
medical education (CME) and physician performance. Several studies have concluded that 
CME improved physician performance127-130 and, in some cases, health outcomes for 
patients128, demonstrating that continuing education can improve the level of service 
provision amongst several different health professionals.  
1.4.2.4 Reimbursement 
Several studies have indicated that adequate remuneration could provide an increase in 
the provision of cognitive services.  The Benrimoj study34 examined the effect of a fee-for-
service remuneration for the documentation of clinical interventions. The remuneration 
only group did not have a significantly different intervention rate to the control group, 
therefore it was concluded that payment of a fee-for-service alone did not increase clinical 
intervention rates.34 Despite this, many pharmacists and pharmacies continually report 
that a lack of adequate (or any) remuneration is a significant barrier to the 
implementation and continuing provision of professional services. 
1.4.2.5 Computerisation 
Several studies have noted that the computerisation of the prescribing process has 
decreased the number of prescription errors overall, as the errors occurring from illegible 
handwritten prescriptions have been decreased dramatically.27,48,71 However, two studies 
have also noted that computerisation can increase the number of prescription errors 
relating to drug selection, where the physician can accidentally select an incorrect drug 
from the drop-down boxes.84,131 Also, a study in the USA showed that the average 
workload per hour within an automated pharmacy was double that of a non-automated 
pharmacy (59 ± 7.26 compared to 24 ± 16.28)132, showing that as computerisation 
increases the efficiency of the pharmacy, it also increases the pharmacy’s workload.  As 
seen in previous sections, higher workloads have frequently been associated with a lower 
provision rate of professional services. 
A study was conducted in a large hospital pharmacy department in 1993 to determine the 
effect of a switch from manual to electronic documentation of clinical interventions.133 
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The manual documentation of interventions was seen as cumbersome and time-
consuming, and required a large amount of manpower to process the manual forms and 
provide summaries. An electronic documentation system was designed to alleviate this, 
and was successfully implemented. The electronic system also provided a dramatic 
increase in the number of interventions recorded in a 3-month period from the previous 
year, which the authors attributed to the system’s ease of use and decreased time 
required to record. The system also allowed pharmacists to benchmark themselves 
against their peers, by calculating a cumulative cost saving that their interventions 
caused.133 This study highlights the need for electronic documentation to be seamlessly 
linked with the pharmacist’s daily tasks and the effect that motivation can have on the 
recording. 
1.4.2.6 Use of CDSS and prompts 
CDSS have been used within the literature to increase the accuracy of prescribing and 
dispensing medications, such as through the use of pop-up warnings indicating a potential 
problem should the physician or pharmacist continue with the process.6 Unfortunately, 
some studies have also shown that pharmacists override the prompts on a regular basis. A 
Swiss study published in 2007 showed that 56.7% of drug-drug interaction alerts were 
overridden by the community pharmacists.134 Pharmacies were able to choose the level of 
interaction severity that the computer system should detect, and the pharmacies that 
selected to only report severe interactions had a much lower override level of 35.2%.134 
This implies that pharmacists can become immune to the alerts (known as prompt 
fatigue), especially when the prompts are trivial, therefore decreasing their ability to 
detect and act on serious interactions when they are displayed. Another study examining 
the pharmacy predictors of the dispensing of DDIs found that the pharmacies with higher 
rates of dispensing DDIs were more likely to have computer systems that provided 
detailed information on the DDI.120 Again, this could be attributed to prompt fatigue or 
desensitisation, as the pharmacists may have less time to evaluate the wealth of 
information they are provided and therefore are more likely to ignore or override the 
alert. A Swedish study examined the effect of an electronic barrier to prevent dispensing 
errors in community pharmacies.135 The barrier could not be overridden by the 
pharmacist, resulting in a significant decrease in dispensing errors during the trial.135 
However, this system may not be seen as practical in reality, as there may be situations 
where the dispensing error has been corrected and needs to be overridden. Another study 
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in the USA published in 2007 reported a significant decrease in the number of eight critical 
drug-drug interactions dispensed once an alert system was activated (p = 0.013), however 
the authors again noted that the alert produced ‘excess noise’ which would contribute to 
prompt fatigue.38 Another study examining the habits of prescribing physicians found that 
physicians accepted only 9.2% of drug interaction alerts and 23.0% of allergy alerts.39 The 
physicians accepted high-severity alerts only slightly more often than the moderate- or 
low-severity alerts (10.4%, 7.3% and 7.1% respectively; p < 0.001). The authors surmised 
that the high override rate of all alerts indicated that most active physicians felt that the 
alerts were more of a nuisance than an asset.39 
The use of CDSS has wider ranging capabilities than just detecting drug interactions, for 
example, alerts can be used to improve the quality use of medications. The previous 
PROMISe study in 2005 incorporated a prompt into the dispensing system that 
encouraged pharmacists to assess the suitability of commencing aspirin in diabetic 
patients.136 A decision support prompt appeared with each dispensing of an oral 
antidiabetic agent, provided the patient was not already taking aspirin. During the study, 
the pharmacies in the prompted arm recorded 201 interventions regarding the use of 
aspirin in diabetic patients, with none of these interventions recorded in the non-prompt 
arm. The prompt also improved the overall intervention rate, indicating that the prompt 
may have triggered pharmacists to record other interventions as well. The authors also 
noted a decline in the intervention rate over the six week trial, attributing this decline to 
the pharmacists experiencing ‘prompt fatigue’.136 
A review of the use of prompts within prescribing software that aimed to highlight 
interactions as well as improve quality use of medications also determined some of the 
facilitators and barriers to the appropriate use of the system.137 Fundamental issues 
included the availability and accessibility of the hardware, sufficient technical support and 
training in the use of the system, the level of system integration into clinical workflow, and 
the relevance and timeliness of the prompts. The authors again noted that the effect of 
alert fatigue was present, with some physician participants noting that they felt they may 
become desensitised to the alerts and therefore miss important information.137 
1.4.2.7 Practice change 
Several studies have also identified the need for the pharmacy and pharmacist to be 
flexible and willing to adapt their practice to incorporate changes, as increasing the level 
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of training, number of staff and reimbursements will not always be sufficient to 
implement services. An exploratory study conducted in the USA found that there were a 
variety of factors that supported practice change within pharmacy, including improving 
resources (such as upskilling staff), involvement in demonstration projects (such as 
actively promoting pharmacy services within the pharmacy), regular environmental 
scanning (such as providing services requested by the customers or benchmarking 
themselves against other local pharmacies) and regular interaction with advocates for 
pharmacy practice change (such as pharmacy associations or innovative practitioners).138 
As expected, this implies that the more motivated pharmacists are the ones who are more 
likely to change and adapt as new practices and programs become available. 
A qualitative study also performed in Australia found four pharmacy business models that 
affected the pharmacy’s ability to implement cognitive services; classic community 
pharmacy, retail destination pharmacy, health care solution pharmacy and networked 
pharmacy.139 The classic community pharmacy did not feel any immediate threat from the 
external environment and service provision was not the focus at these pharmacies, with 
many services being out-sourced. They were generally smaller in size, had a limited ability 
to implement new services, and were generally owner-operated with the owners fairly 
reluctant to change. Retail destination pharmacies were generally manager-operated, part 
of a corporate banner groups and much larger in physical size, and they often used 
technology to improve their efficiency. They tended to not be service-orientated, and 
regarded supermarkets and department stores as their competitors. Health care solution 
pharmacies had made a conscious decision to promote themselves as professional, health 
care providers, often in response to external stimulus (such as a discount pharmacy 
opening within the local area). These pharmacies were predominantly independent and 
owner-operated, with the delegation of specific tasks to other staff that were trained in 
that area. These pharmacies also used technology to improve their efficiency and improve 
their provision of the services. The networked pharmacies were connected via a shared 
ownership structure, which improved the abilities to provide services and often shared the 
responsibilities amongst the pharmacies.139 Different types of pharmacies will have 
different capabilities of implementing services, with some types requiring more assistance 
to implement services. In addition, there are several characteristics that can be used to 
identify an innovative pharmacy which may be more likely to implement new services. 
Characteristics such as liking to work in a team environment, placing a high value on the 
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professional aspects of practice, and a large team of staff that have a strong desire to be 
helpful to people, tend to be common characteristics to innovative pharmacies.92 It is 
therefore important to consider the type of pharmacy as a factor when considering their 
ability to implement and maintain the provision of cognitive services. 
A Canadian study examined the culture of pharmacy by asking pharmacists to answer the 
simple question “what does a pharmacist do?”.140 The study found that the responses 
could be grouped into three categories: product focused (such as dispensing medications, 
counselling on medications, procuring the correct medications), patient focused (such as 
addressing patients’ medication needs, interacting with health professionals, managing 
and monitoring drug therapy, providing pharmaceutical care), or ambiguous (such as 
vague statements about ‘helping patients’ or ‘providing services’, which could not be 
easily grouped). The study found that 57% of pharmacists used dispensing or product 
focused terms in their first response, indicating that the pharmacists’ self-perception is 
that they are simply a ‘dispenser’. Successful pharmacy practice change, and a 
consequential increase in the provision of professional services, will therefore only be 
attained if the pharmacists begin to believe that they are patient-centred practitioners. 
Pharmacists need to become comfortable with the transition towards patient-centred 
care before a pharmaceutical care model could be fully embraced. The authors noted that 
attempts to address the commonly identified barriers of lack of time, training, 
remuneration and support from other health professionals did not always increase the 
adoption rate of cognitive services, surmising that the pharmacists’ underlying attitudes 
and beliefs are impeding the desired changes in pharmacy practice.140 
Another study aimed to quantify the factors that influenced a pharmacist’s behaviour.141 
The resulting regression model explained 57% of the variance with the most important 
predictor being past behaviour. Other significant factors were perceived behavioural 
control (defined as the perceived ease or difficulty of performing the task) and 
behavioural intention (the intention to perform a task). Current attitude and social norm 
(beliefs about other people’s opinions of the participant’s behaviour) did not appear to be 
significantly associated with a pharmacist’s behaviour.141 These findings indicate the 
importance of practice change, as past behaviour has a significant influence on future 
behaviour. 
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A study in the USA aimed to determine the factors influencing pharmacists’ enrolment in 
an electronic prescription monitoring program.142 The factors that influenced the non-
enrolled pharmacists were time available to access the system once enrolled, availability 
of internet access and time available to enrol. On the contrary, the factors that influenced 
the enrolled pharmacists were being able to assist with decreasing doctor shopping, being 
able to assist with decreasing drug diversion and the usefulness of the system at their 
practice site.142 Again, this may highlight the need for practice change, as the responses 
from the enrolled pharmacists appear to demonstrate more motivated individuals that are 
keen to make a difference within their profession. 
Another review of the implementation of pharmaceutical care94 found that barriers differ 
depending on where the pharmacist was in the implementation process: 
 Those already offering pharmaceutical care were concerned with educational 
issues and communication with physicians 
 Those who were intending to start offering pharmaceutical care were concerned 
with lack of time, skills and reimbursement 
 Those who were previously providing pharmaceutical care, but had since 
abandoned it, stated it was due to lack of time, lack of space within the pharmacy, 
lack of reimbursement, lack of cooperation of staff, patients and physicians, and 
they also claimed that the practice was incompatible with working hours 
 Those who considered the implementation of pharmaceutical care as unviable 
stated that structural problems (such as lack of personnel, education, money and 
space) and the lack of acknowledgment by governing bodies were the main 
barriers94 
This was similar to the results seen in studies by Lounsbery et al.109 and Zardain et al.110, 
where the reported barriers to implementation were different to the reported barriers to 
the maintenance of the professional service. 
1.4.3 Summary of the factors influencing the provision of pharmacy 
services 
Studies on the implementation and continuing provision of pharmacy services consistently 
report lack of time as a major barrier in community pharmacy.16,53,108,115 This lack of time 
may be actual or perceived, but affects the pharmacy’s ability to implement new services 
and to continue to provide these services. Pharmacist workload is also closely linked to 
lack of time, with many studies identifying a direct relationship between the workload of 
the pharmacist and their ability to deliver additional services.99,101,103,112 
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In many countries (including Australia), the remuneration model for pharmacies is based 
largely on the prescription volume dispensed by the pharmacy. Therefore, increasing 
professional services requires alternative remuneration models in order to make it cost-
effective for the pharmacy. Despite this, the effect of reimbursement on implementation 
and continued provision of the services was varied, with some studies reporting lack of 
reimbursement as a barrier16,101,109, whereas other studies reporting no effect.99,108 Other 
organisational factors that were reported to influence the provision of services included 
pharmacy layout53,109,114, and the availability of adequately trained support staff.109 Some 
pharmacy demographics, such as chain versus independent pharmacies, also did not 
appear to affect implementation103,112, despite these pharmacies often having a larger 
prescription volume and therefore a higher pharmacist workload. 
Several studies identified that often the pharmacists themselves are a barrier, either 
through lack of motivation101,102,111, or the belief that their abilities are not appreciated by 
the employer, the patients or the physicians.16,101,105,108,109 A positive attitude towards the 
task and motivation to provide better care can influence the pharmacist to attain a higher 
level of service provision110, however practice change can be hard to achieve in 
pharmacists who lack these traits. Some studies also reported links with pharmacist 
demographics (such as gender, graduation year, current position)53,106, as well as the need 
for adequate knowledge (and training) and an adequate documentation process to 
improve the level of service provision.16,106,108,110,111,115 
It is also important to note that three studies identified that the barriers to implementing 
a professional service differed to the barriers to maintaining provision of that service, both 
within the pharmacy and the individual pharmacist94,109,110, therefore the support required 
to implement the service may differ greatly from the support required to maintain it. 
1.5 Documentation systems within Australian community 
pharmacies 
While pharmacists seem to undertake clinical interventions despite the perceived barriers, 
the current practice is not to document these interventions unless there is some 
imperative. The imperative for documentation may be to facilitate communication to 
other pharmacists involved in the patient’s care, or to adequately record details of a 
potentially litigious situation. The appropriateness and functionality of currently available 
       92 | P a g e   
 
electronic systems were examined to determine the requirements for the documentation 
system for this study. 
1.5.1 Existing documentation systems 
Documentation systems for interventions require the capacity to enter information and 
produce reports regarding intervention occurrences. Identifying and “tagging” patient 
records that have been the subject of an intervention is important, as it allows for 
information sharing and continuity of care amongst pharmacists within a pharmacy. The 
increased scope for awareness amongst pharmacy staff that a particular patient has been 
the subject of an intervention provides opportunities to follow up care with the patient to 
determine what outcomes have occurred, and to determine whether the patient requires 
further assistance. Reporting is considered important as common factors could be 
identified for improving patient health care, such as a prescriber consistently prescribing 
an inappropriate medication, or interventions occurring more frequently in a group of 
patients, such as a particular nursing home, therefore reporting may allow the pharmacist 
to educate other professionals regarding the interventions. 
The majority of community pharmacists in Australia use one of the following dispensing 
systems: Amfac® windows; Simple Retail’s Aquarius® Dispense; CDC®; FRED®; Pharmasol 
LOTS®; MINFOS®; Phoenix Rex®; or, PharmacyPro Dispense®.143 Obtaining information 
about existing intervention documentation capabilities of community pharmacy 
dispensing software was difficult, requiring a visit to a pharmacy that had the particular 
system installed, and asking the pharmacist to demonstrate how the documentation 
aspect of the system worked. It was not possible to view CDC® or PharmacyPro Dispense® 
within Tasmania so the information regarding these was obtained via email from the 
vendors. A summary of the features can be seen in Table 1-20. 
Amfac® Windows and Aquarius® Dispense dispensing systems both had the capability to 
document intervention information in the patient notes. This method was easy to use but 
did not prompt the pharmacist to provide categorising information, such as when the 
event occurred or what recommendations were made. Since the information was 
contained in the notes field in an inconsistent free text format, identifying and producing 
reports about intervention occurrences was not possible. 
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CDC® had the capability to document interventions, and several intervention classifications 
were provided, such as drug allergy or drug-drug interactions. Intervention notes could be 
made by the pharmacist and the intervention severity classifications could be set up by 
the pharmacist. CDC® provided the option to document patient outcomes and was able to 
produce intervention reports. Unfortunately, the time of an intervention was determined 
by the opening and closing of the intervention screen, which is a poor and unreliable 
indicator of the true time of an intervention. 
FRED® had the capability to document interventions, however this functionality was not 
made obvious to the user, as it was accessed via a somewhat obscure keyboard shortcut, 
‘Alt + I’. FRED® provided a list of intervention reasons, a numerical severity rating, and 
intervention notes. Reports could be generated for time periods, patient groups, and 
intervention types. This dispense vendor was involved with the previous PROMISe study81 
(see section 1.3.26), therefore many of these features had been redesigned from the trial 
and incorporated into the current software. 
Pharmasol LOTS® had the capability to document interventions, activated using a button 
on the dispensing screen. Several intervention classifications options were available, such 
as change of dose, and correcting prescriber error. Intervention notes could be made by 
the pharmacist and the time taken for the intervention could be documented. In addition, 
the intervention could be viewed and printed from the patient history. There was no 
option to produce reports or group interventions by type, patient group or time period. 
The MINFOS® system was capable of documenting basic information about an 
intervention. It had several options for the type of intervention, including change of dose, 
and doctor contacted. Once completed, an intervention symbol was shown in the patient 
history next to the intervened prescription. This system had several limitations though, 
including not having an option to provide intervention notes, produce reports, or group 
interventions by type, patient group or time period. In addition, the option to create an 
intervention was not obvious to the pharmacist. Consequently, an intervention 
documented in this system would be of limited value. 
Rex® also had the capability to document interventions, made accessible to the pharmacist 
via an intervention button located on the dispensing screen. It provided a good range of 
categories for intervention types, severity levels and time taken. Intervention notes could 
be entered and reports could be generated for time periods, patient groups and 
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intervention types. This vendor was involved with the original PROMISe pilot study144 and 
again, some of the current features had been adapted from their previous involvement.  
PharmacyPro® Dispense had the capability to document interventions. This could occur 
whilst dispensing a prescription or in the patient history. It provided a list of intervention 
options and a numeric severity level classification. Highlighting and right-clicking a 
prescription provided the option of adding an intervention. Intervention notes, and the 
time taken could be entered, and a range of reports could be produced.  
Dispensary 
software 
Able to document 
interventions? 
List of CI 
reasons 
Severity 
of CI 
Time taken 
for CI 
Notes 
Outcomes 
of CI 
Reports 
Amfac® 
      
Aquarius®  
      
CDC®       
FRED®       
LOTS®       
MINFOS®        
Rex®       
PharmacyPro®     
 

Table 1-20: Summary of intervention documentation features present in the current 
dispensing systems 
Among the dispensing systems there were a variety of intervention documentation 
options; Amfac® and Aquarius® had no formal documenting option, whereas CDC®, FRED®, 
Pharmasol LOTS®, MINFOS®, Rex® and Pharmacy Pro® Dispense had a number of options. Of 
those systems that could document interventions, there were no consistent approaches 
regarding classifying intervention types, recommendations made, intervention severity, 
time taken, or reporting options. In addition, several systems had extensive (but not 
standardised) options for classifying interventions, notes provision and reporting that 
would be useful for investigating intervention-related issues and for the transfer of 
information amongst staff. These systems included CDC®, FRED®, Rex® and Pharmacy Pro®. 
However, despite having the intervention documentation features, Pharmacy Pro® and 
FRED® did not make the feature obvious to the user. Thus, although systems for 
documenting clinical interventions existed within some of the pharmacy software systems, 
there was no consistency of definitions or accepted methodology in place, which required 
a more uniform and useful system to be developed for the PROMISe trial. 
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1.6 Aims and objectives of the project 
While pharmacists undertake clinical interventions as part of their duty of care, the 
current practice is not to routinely document these interventions unless there is some 
imperative, such as to facilitate communication to others involved in the patient’s care or 
to adequately document details of a potentially litigious situation. International 
community pharmacy studies have estimated that pharmacists perform clinical 
interventions at varying rates, ranging between 0.09% and 2.69% of 
prescriptions.61,68,70,75,79 However, there is currently no standardised documentation 
system in Australia that allows pharmacists to document these interventions.  It is 
therefore difficult to determine the frequency and type of DRPs that are occurring and 
being resolved within the community pharmacy environment. 
The aim of the third PROMISe (Pharmacy Recording Of Medication Incidents and Services 
electronic documentation system) trial was to estimate the number and nature of DRPs 
detected and clinical interventions performed within community pharmacy in Australia. In 
addition to this, it was vital to establish the viability of, and requirements for, national 
implementation of an electronic documentation system for the recodring of these 
interventions identified in community pharmacy, in order to both improve the quality of 
life for patients, as well as provide an overall cost saving to the government via a 
reduction in healthcare resource utilisation. 
To determine which software features would improve intervention rates, several versions 
of documentation software, including one which incorporated electronic decision support, 
were trialled. In addition, many participant surveys and focus groups were also utilised to 
determine influential factors that would affect documentation rates, thereby aiming to 
improve documentation rates by controlling these factors. Using these influencing factors 
to determine the effect on the intervention rates of the pharmacy and the pharmacist is a 
key component of this thesis. 
This thesis has been separated into distinct sections: Chapter 3 examines the frequency 
and type of interventions and the medications involved; Chapter 4 examines the 
participating pharmacies, their intervention rates and the factors that may have 
influenced the variation in the rates; Chapter 5 examines the participating pharmacists, 
their individual intervention rates and the individual factors that may have influenced the 
variation in the rates; Chapter 6 qualitatively analyses the observations of pharmacists 
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during the trial; and Chapter 7 discusses how the reported results could be used to further 
improve the intervention rate.  
As mentioned in section 1.2, this study defined a clinical intervention as; 
Any professional activity by the pharmacist directed towards improving the quality 
use of medicines and resulting in a recommendation for a change in the patient's 
medication therapy, means of administration or medication-taking behaviour. 
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2 Chapter 2: Methods 
The three Pharmacy Recording of Medication Incidents and Services electronic 
documentation system (PROMISe) trials were conducted over a period of ten years and 
aimed to determine the frequency and type of clinical interventions occurring within 
Australian community pharmacies. This thesis focuses on using the data from PROMISe II 
(conducted in 2007) to implement the PROMISe III trial and then the analysis of the data 
collected during the PROMISe III trial. The PROMISe I and PROMISe II trials81 were 
considered the pilot studies for the PROMISe III trial, with the project design and 
classification system being adapted from the previous iterations. Many surveys were 
included in PROMISe III due to their previous inclusion in PROMISe II or because PROMISe 
II showed results that prompted the inclusion of a survey or survey question to determine 
additional influencing factors. 
Prior to the data collection during the PROMISe III trial, documentation software needed 
to be designed to allow pharmacists to document clinical interventions, including the 
modification of the DOCUMENT DRP Classification System to allow pharmacists to classify 
their interventions. Numerous surveys were also designed to allow data to be collected 
with the intention that this data would be compared to the resulting intervention rates to 
determine any influencing factors.  
2.1 Focus groups  
Before the trial commenced, focus groups were used to identify actual and potential 
factors that could influence the documentation of the clinical interventions within 
community pharmacy. It was thought that integrating the users into the design phase of 
the system would increase the usability of the documentation system and therefore 
ultimately improve the number of clinical interventions documented within the system. 
Feedback from participants at the conclusion of the previous PROMISe project identified a 
range of implementation and documentation barriers and facilitators to the specific tasks 
of performing and documenting clinical interventions.81 As seen in Chapter 1, barriers and 
facilitators to the wider implementation of professional services were also investigated, 
and these results were incorporated into the study design.  
For the PROMISe III project, Ian DeBoos of DeBoos Associates was contracted to facilitate 
in-depth focus groups and semi-structured interviews with key stakeholders of the 
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PROMISe project. DeBoos is a qualified pharmacist and qualified social statistician and 
market researcher. He works part time in community pharmacy and has a unique 
combination of social researching skills and an understanding of community pharmacy 
issues. The research objectives of these focus groups and interviews were to determine 
the stakeholder’s views of pharmacy clinical interventions, the barriers and facilitators to 
the identification of DRPs and the subsequent performance and documentation of clinical 
interventions, and the information required for a documentation system to be successful. 
These sessions were recorded with permission from the participants. 
The 36 participants in the five focus groups were comprised of nominated pharmacy 
owners including representatives of the Pharmaceutical Society of Australia and the 
Pharmacy Guild of Australia, employee and accredited pharmacists, previous participating 
pharmacists from PROMISe II, consumers and representatives of Quality Use of Medicine 
(QUM) organisations including the Australian Commission on Quality and Safety in 
Healthcare, the National Prescribing Service and the Veterans’ Medicines Advisory and 
Therapeutic Education Services (MATES).  
The focus groups were conducted using an exploratory interview approach based on 
grounded theory, without any pre-defined hypotheses. The outcomes of the focus groups 
and interviews revealed that consumers and pharmacists regarded performing clinical 
interventions as an important aspect of community pharmacy. Pharmacists saw 
interventions as their ethical responsibility and something they performed as second 
nature. They stated they would always investigate and act on anything regarded to be a 
serious DRP, irrespective of their work demands. Consumers said they were reassured 
knowing pharmacists could identify potential DRPs and could also represent consumers’ 
best interests within the health system, in this case to prescribers. 
The focus group participants identified a number of factors that influence the appropriate 
identification of DRPs. The barriers and facilitators to identifying DRPs are detailed in 
Table 2-1, and as expected, these factors are almost identical to those already reported in 
the literature.16,108,115 
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Barriers Facilitators 
Lack of clinical knowledge Reimbursement of interventions 
Pharmacists have too many roles and 
there is not enough time to investigate 
some minor drug problems 
Existing community pharmacy protocols 
could be adapted to allow pharmacists to 
better understand patient's health status 
Pharmacists that focus on the business 
rather than the clinical aspect of their role 
Greater community interaction with 
patients and other health professionals 
Low interaction with patients, especially 
by pharmacists who remain at their 
dispensing stations 
More complete patient histories would 
enable pharmacists to have the full 
picture 
Low confidence to contact prescribers Improved clinical education 
Table 2-1: Focus group findings: Barriers and facilitators to identification of DRPs 
Participants of the focus groups also identified their requirements for an electronic 
documentation system. The functionality for this documentation system was divided into 
must have features, nice to have features and if possible features. A summary of these 
findings can be seen in Table 2-2. 
Must have features 
Simple operation (quick and easy)  
Dispensing aids or reminders such as flags or prompts 
Reporting for incomplete and complete documented interventions 
Nice to have features 
Auto save function 
Printing summary of interventions 
Pop up window link to previous interventions for that patient 
Transmission of intervention documentation to external party 
Incomplete documentation reminder 
Colour coded pop ups 
Inclusion of diagnostic data (such as space for INR recording) 
Inclusion of diagnosis space 
Ability to turn off selected pop ups to a dispenser's initials 
If possible features 
Allergic reaction notification when the problem drug is dispensed for the patient 
Table 2-2: Focus groups findings: Suggested features for PROMISe software 
The results of the focus groups and interviews conducted before the PROMISe III data 
collection period indicated several aspects that would be implemented into the design of 
the trial. The documentation software was designed using these specifications and was 
subsequently used in the PROMISe III trial.  
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2.2 DOCUMENT DRP Classification System 
As detailed in Chapter 1, the comparison between previous clinical intervention studies is 
difficult due to the number of different DRP classification systems available. The 
DOCUMENT DRP Classification System was designed for the previous PROMISe I and II 
trials, and underwent refinement prior to the PROMISe III trial, with this process the 
subject of a published article.145 The DOCUMENT system was incorporated into the 
documentation software used in PROMISe III to allow pharmacists to record clinical 
interventions more consistently. 
2.2.1 Initial DOCUMENT system 
It was felt that previous classification systems did not provide enough detail for 
reconstruction of a clinical scenario.  For example, the Hepler and Strand system1 did not 
provide coding for activities to resolve the DRP (such as actions undertaken and 
recommendations by the pharmacist to resolve the DRP), whereas the PCNE system89 
required the assessment of the cause of the DRP, which is not always possible, and did not 
allow for sufficient economic analysis of the outcomes of the DRP.86 For these reasons,  an 
open, hierarchal classification system was developed, based on the types of problems 
identified by Hepler and Strand1 and the PCNE classification system.89 The system 
facilitated the classification of five aspects of the DRP and the clinical intervention 
undertaken to resolve it. These were: 
1. the type of DRP; 
2. the actions undertaken to investigate the DRP; 
3. the recommendations made to resolve the DRP; 
4. the outcomes of the actions undertaken to resolve the DRP; and  
5. the perceived clinical significance of the DRP. 
2.2.1.1 Type of DRP 
The system consisted of eight categories (types) of DRP, with each category including 
between one and five subcategories (Appendix 1). This version of the system was used 
during the PROMISe I and PROMISe II studies, and was refined for the PROMISe III study. 
The types of DRP classified in the DOCUMENT system were defined as follows: 
 Drug selection – DRPs related to the choice of drug prescribed or taken (such as 
drug duplication, drug interaction and wrong drug) 
 Over or underdose prescribed – DRPs related to the prescribed dose or schedule of 
the drug (such as dose too high, dose too low and incorrect schedule) 
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 Compliance – DRPs related to the patient's medication-related behaviour (such as 
taking too little, taking too much, intentional drug misuse and difficulty in using a 
dosage form) 
 Untreated indications – DRPs related to actual or potential conditions that require 
management (for example, a diagnosed condition not adequately treated or 
preventative therapy required) 
 Monitoring – DRPs related to inadequate monitoring of the efficacy or adverse 
effects of a drug (such as laboratory and non-laboratory monitoring) 
 Education or information – DRPs related to patient’s knowledge of the disease or 
its management (such as requests for drug information, confusion about therapy 
or disease states and demonstration of devices) 
 Non-clinical – DRPs related to administrative aspects of the prescription 
 Toxicity or adverse reaction – DRPs related to the presence of signs or symptoms 
which are suspected to be related to an adverse effect of the drug (such as toxicity 
caused by dose, drug interaction or unknown causes) 
2.2.1.2 Actions to investigate the DRP 
The types of actions undertaken to investigate the DRP were derived from a previous 
study of community pharmacists’ interventions.144 It was identified that these activities 
would be associated with a substantial component of the total time involved with an 
intervention, and therefore may be used as a predictor for length of time taken to 
complete an intervention. In addition, some knowledge of the actions taken by the 
pharmacist was thought to complete the intervention record, and demonstrate the 
pharmacist’s ability to make decisions about the DRP. Actions classifiable in the 
DOCUMENT system are shown in Appendix 1. As seen in section 2.2.3, this option was 
removed prior to the PROMISe III trial. 
2.2.1.3 Recommendations to resolve the problem 
The codes and categories for recommendations to resolve the DRPs were also determined 
following evaluation of clinical interventions from a previous study.144 Given that a clinical 
intervention, by definition in the PROMISe trials, must involve the pharmacist making a 
recommendation to the patient or prescriber, it was vital that the details of the 
recommendations made were included in the documentation process. The documenting 
of the pharmacist’s recommendations also allowed for a complete intervention record 
which researchers or other pharmacists within the pharmacy could use to interpret the 
situation. Codes for recommendations which were thought likely to occur were also 
added. These are shown in Appendix 1.  
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2.2.1.4 Outcome/Acceptance of the recommendation 
A simple acceptance code for the recommendation was developed for the system. As 
multiple recommendations were possible for a single DRP, a category for partial 
acceptance was created to allow for the situation where only some of the 
recommendations made by the pharmacist were accepted. As seen in section 2.2.3, this 
option was removed prior to the PROMISe III trial. 
2.2.1.5 Clinical significance 
Five levels of clinical significance for the DRP were chosen. This measure was included as it 
was expected to be a good indicator of typical economic value of an intervention. A brief 
description of the clinical significance codes is shown in Appendix 1. As seen in section 
2.2.3, the levels of clinical significance were changed prior to the PROMISe III trial. 
2.2.2 Validation of the DOCUMENT system 
The DOCUMENT system was validated for reliability and internal consistency. Twenty 
scenarios were selected from the pilot dataset where each scenario described a DRP 
situation that had occurred in community pharmacy.144 The aim of the validation was to 
determine if pharmacists could appropriately classify the category and sub-category of 
DRP from a description. Of the 241 pharmacists that expressed interest, 156 assessed at 
least one scenario and 92 pharmacists assessed all 20 scenarios. The pharmacists did not 
receive any initial training on the classification system, but did have access to explanatory 
notes during the validation process. The number of correct assessments of the category 
and sub-category are shown in Table 2-3, where the majority of participants (70.2%) were 
able to identify the correct category of DRP for most of the scenarios. The level of 
agreement between the pharmacists was assessed using Fleiss’ kappa.146 The test 
returned a value of  = 0.53, which is considered indicative of moderate agreement 
between the raters. Given that the pharmacists involved in the validation exercise had no 
previous experience with the DOCUMENT system and received no training before 
undertaking the validation process, and that the majority of them completed the exercise 
in a short period of time, the level of agreement with the correct DRP category was 
considered reasonable. 
To confirm consistency of classification, a random selected sample of 40 of the 
pharmacists who originally completed the scenarios were approached to re-attempt the 
classification as an internal consistency test. Of these, 18 completed the 20 scenarios 
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again approximately one month after initial classification (see Number (%) Concordant in 
Table 2-3). There was good concordance (69.2%) between the first and second attempts in 
the selection of categories, indicating that the same pharmacist would use the same 
DOCUMENT category to code the same scenario on two separate occasions.  
Correct Type Scenario # 
Number (%) 
Correct Responses 
Number (%) 
Concordant (n=18) 
Drug selection 
1 91 (64.1%) 11 (61.1%) 
2 89 (78.1%) 16 (88.9%) 
3 89 (84.8%) 18 (100.0%) 
4 61 (57.5%) 12 (66.7%) 
5 55 (52.4%) 12 (66.7%) 
Total 385 (67.3%) 69 (76.7%) 
Over or 
underdose 
1 131 (96.3%) 17 (94.4%) 
2 95 (89.6%) 13 (72.2%) 
3 94 (89.5%) 14 (77.8%) 
Total 320 (92.2%) 44 (81.5%) 
Compliance 
1 95 (62.1%) 11 (61.1%) 
2 100 (89.3%) 12 (66.7%) 
3 74 (66.7%) 11 (61.1%) 
Total 269 (71.5%) 34 (63.0%) 
Untreated 
indications 
1 76 (63.3%) 11 (61.1%) 
2 32 (29.6%) 13 (72.2%) 
3 76 (73.1%) 12 (66.7%) 
Total 184 (55.4%) 36 (66.7%) 
Monitoring 
 
82 (76.6%) 10 (55.6%) 
Education 
 
64 (57.7%) 10 (55.6%) 
Non-clinical 
 
101 (99.0%) 16 (88.9%) 
Toxicity or 
adverse reaction 
1 80 (63.5%) 8 (44.4%) 
2 71 (64.5%) 13 (72.2%) 
3 53 (48.2%) 9 (50.0%) 
Total 204 (59.0%) 30 (55.6%) 
Total 1609 (70.2%) 249 (69.2%) 
Table 2-3: Results of the validation exercise for the DOCUMENT DRP Classification 
System 
2.2.3 Modifications to the DOCUMENT system prior to PROMISe III 
Experiences gained from the PROMISe II trial81 indicated a need to improve the 
DOCUMENT classification system so as to refine and simplify the documentation process. 
To inform this revision, a detailed examination of the interventions documented in the 
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PROMISe II trial was undertaken, including an analysis of the frequency of intervention 
types. An additional review of articles detailing clinical intervention studies was also 
performed to determine if any additional classification systems had been discussed in the 
broader international literature since 2007.78,79,84,85 The main purpose of the revision was 
to refine and simplify the documentation process to make it easier and quicker to use. 
2.2.3.1 DRP category changes 
A number of additional sub-categories were added to the ‘Drug selection’ category.  
 Incorrect strength was added to accommodate when an error has been made 
when selecting a drug strength not intended for that patient.  
 Inappropriate dosage form was reworded from ‘wrong dosage form’.  
 Contraindications apparent was added for situations where the pharmacist has 
determined that the patient has been prescribed drug therapy which is 
contraindicated with their medical condition.  
 No indication apparent was included for when there is no clear reason why the 
drug should be used in the patient.  
In the ‘Over or underdose’ category, Incorrect or unclear dosing instructions was included 
to accommodate situations where the specified dosage time was not optimal, or there 
was insufficient dosing instructions or an inappropriate dosage schedule. 
Erratic use of medication was added to the ‘Compliance’ category to encompass when the 
patient has been inconsistent with taking their medication, possibly due to poor memory 
or lack of care or knowledge.  
The category ‘Untreated indications’ was renamed to ‘Undertreated’, as some indications 
may be treated, but not adequately. The additional sub-categories Condition undertreated 
and Condition untreated allowed the pharmacist to distinguish between the two different 
interventions. 
The ‘Education or information’ category was condensed to three sub-categories from the 
five sub-categories in PROMISe II. Within community pharmacy, a patient request for 
information would be either in relation to their drug therapy or their disease, therefore 
the two main sub-categories Patient requests drug information and Patient requests 
disease management advice were felt to encompass the majority of problems relating to 
education or information. 
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The ‘Non-clinical’ category was renamed to ‘Not classifiable’. In PROMISe II, participants 
were asked to document administrative interventions, however, in PROMISe III 
pharmacists were specifically asked to not document non-clinical interventions such as 
those relating to administration of the Pharmaceutical Benefits Scheme. Therefore, this 
category was renamed to target situations where a pharmacist felt that a clinical 
intervention could not be classified under other categories. 
The ‘Toxicity’ category was condensed to one option in PROMISe III, down from four in 
PROMISe II. This was to simplify classification of any problem relating to the presence of 
signs or symptoms of toxicity that may be attributed to a medication. 
The incorporated changes and therefore the final version of DOCUMENT used in PROMISe 
III and this study can be seen in Table 2-4. 
2.2.3.2 Recommendation changes 
The recommendation classifications remained very similar to those used in PROMISe II. 
One change was made by dividing Dose change into Dose increase and Dose decrease in 
order to assist researchers with interpretation of the intervention. The incorporated 
changes to the recommendation lists can be seen in Table 2-5.  
2.2.3.3 Clinical significance category changes 
The significance codes of the intervention as allocated by the pharmacist were simplified 
in PROMISe III, by renaming the categories and by including more detailed descriptions to 
enable easier allocation. Nil significance was removed as PROMISe III pharmacists were 
asked to document only clinical interventions, not administrative tasks, and therefore, 
there should be no clinical intervention which has zero clinical significance. These changes 
can be seen in Table 2-6. 
2.2.3.4 Other changes 
The other major change to the DOCUMENT DRP Classification System was the removal of 
the Action and Outcomes components. During analysis of the PROMISe II trial, it was 
determined that knowing the actions of the pharmacist did not provide any measurable 
benefit, so it was removed to lighten the pharmacists’ workload. The Outcomes 
component was removed because PROMISe II pharmacists commented that they were 
often unable to determine the outcome of the intervention, yet were flagging the 
recommendation as ‘Accepted’ in 82.1% of cases. This suggested that the pharmacists 
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were not reporting the outcome accurately, thus this option was removed. A simple 
decision-tree was also developed to assist pharmacists in identifying the main DRP 
category (Appendix 2). 
2.2.4 Final version of the DOCUMENT system 
The final version of the DOCUMENT DRP Classification System can be seen in Table 2-4, 
Table 2-5 and Table 2-6, and more detailed explanations of the categories can be found in 
Appendix 3. The DOCUMENT classification system has been published in two separate, 
peer-reviewed articles.145,147  
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Code Description Code Description 
D 
Drug selection  D1 Duplication 
(Problems relating to the choice of drug 
prescribed or taken) 
D2 Drug interaction 
D3 Wrong drug 
D4 Incorrect strength 
D5 Inappropriate dosage form  
D6 Contraindications apparent 
D7 No indication apparent 
D0 Other drug selection problem 
O 
Over or underdose O1 Prescribed dose too high 
(Problems relating to the prescribed dose or 
schedule of a drug) 
O2 Prescribed dose too low 
O3 Incorrect or unclear dosing instructions 
O0 Other dose problem 
C 
Compliance C1 Taking too little 
 (Problems relating to the way the patient 
takes the medication) 
C2 Taking too much 
C3 Erratic use of medication 
C4 Intentional drug misuse (incl. OTCs) 
C5 Difficulty using dosage form 
C0 Other compliance problem 
U 
Undertreated  U1 Condition undertreated 
(Problems relating to actual or potential 
conditions that require management or 
prevention) 
U2 Condition untreated 
U3 Preventative therapy required 
U0 Other untreated indication problem 
M 
Monitoring M1 Laboratory monitoring 
 (Problems relating to monitoring the efficacy 
or adverse effects of a drug) 
M2 Non-laboratory monitoring 
M0 Other monitoring problem 
E 
Education or information  E1 Patient requests drug information 
(Where a patient requests further information 
about a drug or disease state) E2 
Patient requests disease management 
advice 
E0 Other education or information problem 
N 
Not classifiable 
N0 
Clinical interventions that cannot be 
classified under another category (Problems that cannot be classified under 
another category) 
T 
Toxicity or adverse reaction  
T1 
Toxicity, allergic reaction or adverse 
effect present (Problems relating to the presence of signs or 
symptoms that may be attributed to a drug) 
Table 2-4: Final DOCUMENT DRP categories and sub-categories used in PROMISe III 
       108 | P a g e   
 
R
e
co
m
m
en
d
at
io
n
s 
A change in 
therapy 
R1 Dose increase 
R2 Dose decrease 
R3 Drug change 
R4 Drug formulation change 
R5 Drug brand change 
R6 Dose frequency/schedule change 
R7 Prescription not dispensed 
R8 Other changes to therapy 
A referral 
required 
R9 Refer to prescriber 
R10 Refer to hospital 
R11 Refer for medication review 
R12 Other referral required 
Provision of 
information 
R13 Education or counselling session 
R14 Written summary of medications 
R15 Recommend dose administration aid 
R16 Other written information 
Monitoring 
R17 Monitoring: Non-laboratory  
R18 Monitoring: Laboratory test 
Other R19 No recommendation necessary 
Table 2-5: Final DOCUMENT recommendation codes used in PROMISe III 
Si
gn
if
ic
an
ce
 S1 Consequences related to information 
S2 Prevented mild symptom or improved compliance 
S3 Prevented or required a GP visit 
S4 Prevented or required a hospital admission 
Table 2-6: Final DOCUMENT significance codes used in PROMISe III 
2.3 Clinical knowledge survey 
Several previous studies that were identified during the literature review found important 
correlations between the pharmacist’s level of clinical knowledge or education, and their 
ability to provide professional services.106,108,110,115,121 Therefore, using clinical intervention 
data that was collected during the PROMISe II trial81, a survey-based clinical knowledge 
measurement tool was developed. Three clinical pharmacy researchers (including this 
author) constructed nine clinical cases with seven multiple-choice questions (63 questions 
in total) based on scenarios that were found to occur frequently in Australian community 
pharmacies.  
The questions aimed to assess a pharmacist’s ability to identify, gather relevant 
information about, and make appropriate recommendations to resolve, a DRP. 
Pharmacists were required to read a descriptive paragraph and select how relevant or 
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appropriate they felt each of several proposed actions was to the specific scenario using a 
7-point Likert scale. A 7-point scale was chosen as it was thought that more options would 
provide a more accurate representation of the pharmacist’s abilities. The pharmacist was 
required to answer each statement before they could move on to the next question (see 
Appendix 4 for all questions). 
2.3.1 Administration of the survey 
The survey was administered through the online survey builder LimeSurvey v1.8 
(http://www.limesurvey.org/) and an example screen layout can be seen in Figure 2-1. An 
online survey system was chosen to administer the tool, as it would substantially increase 
the number of pharmacists who could participate compared to a simulated patient study.  
 
Figure 2-1: The appearance of the clinical knowledge survey questions in LimeSurvey 
2.3.2 Refining the questions 
Eighteen clinical research pharmacists and academics within three Schools of Pharmacy in 
Australia (University of Tasmania, Monash University and Curtin University of Technology) 
were asked to validate the questionnaire to determine its suitability. Questions were to be 
removed if the validators’ answers created standard deviations that were greater than 
two units above the mean, and this process eliminated 11 questions. For the remaining 
questions, the answers were analysed to determine if the validators gave similar answers 
to the writers’ intentions. Any questions with responses that were too dissimilar to the 
writers’ intentions were also removed (for example, the question was written with the 
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intention of an ‘irrelevant’ response but the validators said it was ‘relevant’). A further 12 
questions were removed using this method, leaving 9 clinical cases, each with between 
three and six multiple-choice statements, resulting in a total of 40 questions for analysis. 
2.3.3 Developing a scoring system 
From the 40 questions, scores were calculated where the correct answer was defined as 
the mode of the 18 validators’ answers. Each question received a score of 2, 1 or 0 
depending on how far away the answer was from the mode. For example, if the validators 
agreed the answer was ‘Relevant’, the participant would receive a score of 2 for answering 
‘Relevant’, 1 for ‘Very Relevant’ or ‘Slightly Relevant’ and 0 for any other answer. For this 
survey, the lowest possible total score was 0 and the highest was 80, with the intention 
that a higher score would signify a higher level of clinical knowledge.  
2.3.4 Validation of the survey 
The survey was administered to Bachelor of Pharmacy undergraduate students at the 
University of Tasmania to validate the survey and consisted of 28 fourth-year, 41 third-
year, and 42 first-year students. Overall, students’ level of clinical knowledge is expected 
to increase as they proceed through each year of the pharmacy degree. That is, as seen in 
previous student knowledge questionnaires148, it was expected that the fourth-year 
students would have a higher mean score than the third-year students, who in turn would 
have a higher score than the first-year students. The scoring system derived from the 
validators’ answers was used to conduct an analysis of variance, which showed significant 
differences between the three groups of students (F(2,108) = 82.14, p < 0.001). Post-hoc 
analysis was undertaken using the Gabriel method, as the population variance proved 
normal with Levene’s test of equality but the sample sizes were unequal.149 The Gabriel 
post-hoc results showed significant differences between the first-years and the third- and 
fourth-years (p < 0.001 for both tests), but the difference between the third- and fourth-
years was only approaching significance (p = 0.054). 
 
Count Mean Std. Dev. Min. Max. 
4th years 28 52.36 6.62 42.00 68.00 
3rd years 41 48.20 6.59 33.00 58.00 
1st years 42 32.43 7.81 15.00 54.00 
Total 111 43.28 11.14 15.00 68.00 
Table 2-7: Descriptive statistics of the survey scores for the three groups of students  
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2.3.5 Measurement of inter-rater reliability 
Reliability of the survey was assessed using the Cronbach’s alpha and Fleiss’ kappa 
methods. Cronbach’s alpha is a measure of the internal reliability of a scale149 and Fleiss’ 
kappa is a statistical measure for assessing the reliability of agreement between a fixed 
number of raters when assigning categorical ratings to a set number of items.146 Fleiss’ 
kappa was considered more relevant than Cronbach’s alpha for this particular survey due 
to the use of the Likert scale categories; however, both methods were utilised.  
2.3.5.1 Cronbach’s alpha 
To ensure an accurate Cronbach’s alpha value, negatively worded questions must first be 
reversed.149 This required reversal of the scores in questions 4.2, 4.5, 5.4, 5.6, 6.6, 7.1, 7.5, 
7.6, 7.7, 8.1, 8.2, 8.5, 8.6 and 9.7. 
A Cronbach’s alpha value of 0.7 or higher is considered to show good correlation between 
the subjects.149 Analysis using SPSS (versions 17 and 18) showed that the survey had 
moderate correlation between the validators on the final 40 questions ( = 0.62) with ‘ 
with the deletion of one item’ ranging from 0.46 to 0.61, indicating that the questions had 
similar influence in the total score. When the analysis was performed on answers from 
additional groups (validators and fourth-year students, with and without third-year 
students),  = 0.63 and  = 0.70 respectively. Table 2-8 shows the reliability coefficients of 
various Cronbach’s alpha tests using different parameters.  
  
Number of 
participants 
Cronbach's 
alpha 
Validators 18 0.620 
Validators plus 4th years 46 0.630 
Validators plus 4thand 3rd years 87 0.704 
Validators plus 4th, 3rd and 1st years 129 0.843 
4th, 3rd and 1st years 111 0.828 
Table 2-8: Results of Cronbach’s alpha statistical tests using various parameters 
2.3.5.2 Fleiss’ kappa 
In addition to the Cronbach’s alpha analysis, a Fleiss’ kappa statistical test was also run in 
Microsoft Excel® on the 40 answers given by the validators. The statistical test returned a 
value of  = 0.33, which is considered a fair agreement.146 
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2.3.6 Use in PROMISe 
The final evaluation of the pharmacist’s clinical knowledge measurement tool was 
performed by administering it to Australian community pharmacists who were 
participating in the PROMISe trial. The pharmacists’ survey scores were used to determine 
whether there was a correlation between the pharmacist’s ability to detect and resolve 
DRPs and their actual rate of documenting clinical interventions during the trial.  
2.4 Development of the intervention documentation software 
In order to accurately collect the intervention data, software was designed and integrated 
into the pharmacy dispensing systems. This software communicated with a remote 
repository, which allowed easy collation of all pharmacy data for analysis.  
2.4.1 PROMISe user interface 
The two dispensing software vendors that were involved in the PROMISe project were 
FRED® (FRED Health, Melbourne, Australia) and Aquarius® (Simple Retail, Sydney, 
Australia). The FRED® dispense system had over 50% of the market share in Australian 
pharmacies150, allowing a large number of pharmacies to take part in the trial. Aquarius® 
was established in over 500 pharmacies151 (approximately 10% of the market) and had 
substantial penetration in the NSW, Victorian and Tasmanian markets. The PROMISe 
software was integrated into the dispensing systems to ensure that the PROMISe interface 
had the same “look and feel” as the dispensing system that the participating pharmacists 
were accustomed to. 
The user interface was activated by clicking on the PROMISe icon or by pressing ‘Alt + i’ on 
the keyboard. Additionally, FRED® users could also access the interface by selecting ‘New 
Intervention Note’ from the ‘Activities’ menu. Activation of the interface could be made at 
any stage of dispensing a prescription and fields would appear pre-populated where 
possible. The user interface can be seen in Figure 2-2.   
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Figure 2-2: PROMISe intervention documentation interface (FRED®) 
The DOCUMENT classifications and extra notes sections were available in the tabbed 
sections of the screen as shown in Figure 2-2. The intervention classification tabs were 
listed in order from left to right to reflect workflow in both dispensing systems – category, 
recommendations, significance, and extra information. The category tab detailed the 
DOCUMENT DRP category, the recommendation tab listed the options for the 
pharmacist’s recommendations to the patient, and the significance tab contained the four 
possible significance categories for the intervention. The pharmacist was required to 
select the most appropriate sub-category from each of these tabs. The notes or extra 
information section provided a free text box for the pharmacist to write a short 
description of the intervention. 
The time taken to perform the intervention and the pharmacist initials were both 
mandatory fields. As requested by the focus groups, a pharmacist was able to save the 
intervention as a draft and complete it at a later time to help to improve the workflow 
surrounding the documentation process.  
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By clicking the ‘Display Help Panel’ checkbox, information about the selected sub-
categories could be seen at the bottom of the intervention screen. Information displayed 
here included details of when and when not to use, and examples of use of each 
classification selection within the DOCUMENT system, as can be seen in Figure 2-3. 
 
Figure 2-3: Help function within the PROMISe interface 
Once an intervention was documented against a patient, the PROMISe logo appeared in 
the patient’s dispensing history indicating that the patient had been subject to an 
intervention, which allowed a pharmacist to access the information regarding the 
intervention in the future. The information about each completed intervention was 
transmitted to a secure repository.  
2.4.2 Feedback mechanisms 
Feedback from pharmacists in the initial focus groups indicated that encouragements and 
reminders may prompt more interventions than would otherwise have occurred. 
Therefore, several electronic feedback mechanisms, including web-based reports, a 
statistic display, non-specific reminders and specific prompts, were built into the PROMISe 
software. 
All participants were able to access the web-based reports through the PROMISe website 
that displayed individual pharmacy and pharmacist intervention details. The reports also 
provided the intervention rates for each state and a breakdown of intervention types, 
recommendations, and drug groups, which were aimed to motivate the participants. 
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A real time statistic display was incorporated into the intervention screen to provide 
accessible motivational feedback to all pharmacists, an example of which can be seen in 
Figure 2-4. The PROMISe repository was polled several times daily to update the current 
overall trial intervention rate. The display showed the entire trial intervention rate as 
shown by All in the FRED® figure and Global in the Aquarius® figure. The individual 
pharmacy intervention rate was entitled Site in the FRED® figure and Local in the 
Aquarius® figure. These screenshots were taken prior to the trial going live, therefore the 
percentages are inaccurate. 
 
Figure 2-4: Statistics display for FRED® (left) and Aquarius® (right) 
Feedback and support was also provided through pharmacy visits. The visits ranged in 
duration from fifteen to ninety minutes depending on the needs of the pharmacists. 
During the visits, the pharmacists were shown how to access the online reports and they 
were also given the opportunity to ask any questions and relay any problems back to the 
project team. The other aim of the visits was to obtain additional pharmacy data. 
Pharmacies also received reminder phonecalls at various times throughout the trial. 
2.4.2.1 Reminder 
For selected pharmacies only, a non-specific reminder was timed to appear at 11am and 
3pm. It aimed to remind pharmacists to document their interventions or to complete their 
draft interventions (Figure 2-5). 
 
Figure 2-5: The reminder built into the software 
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The timing of the reminder targeted periods of the day where the pharmacist may have 
enough time to document the interventions (morning tea and afternoon tea time). These 
times were similar to the peaks in number of interventions documented by Rupp et al., 
whose article reported that the most interventions were documented during 10-11am and 
4-5pm.57 
2.4.2.2 Prompt 
The use of a prompt for one specific intervention (the prophylactic use of aspirin in 
patients with diabetes) was trialled in the PROMISe II project to test the function of 
influencing a specific type of intervention.81 The presence of the prompt resulted in an 
increased frequency of the targeted intervention, as well as an increase in the overall 
intervention rate.136 
In PROMISe III, prescriptions of high-dose proton pump inhibitors (PPIs), specifically 
pantoprazole (Somac®) and esomeprazole (Nexium®), were targeted with a specific 
intervention prompt. This particular intervention was chosen on the basis of high publicity 
from a National Prescribing Service (NPS) media release in May 2009.152 The prompt, 
shown in Figure 2-6, was activated in selected pharmacies when pantoprazole 40mg or 
esomeprazole 40mg were chosen for dispensing. It encouraged pharmacists to discuss 
with eligible patients the possibility of reducing their medication dosage on consultation 
with their GP. The pharmacists had the choice to continue dispensing, print the patient 
information leaflet or print the pharmacist/GP information leaflet. These leaflets can be 
found in Appendices 5 and 6. 
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Figure 2-6: Specific prompt built into the PROMISe software  
2.5 PROMISe III trial 
To examine the nature and frequency of clinical interventions documented in community 
pharmacy in Australia and to determine any factors that influenced the documentation of 
these interventions, the PROMISe III trial was conducted throughout 210 Australian 
pharmacies in 2009. 
2.5.1 Ethics approvals 
All aspects of the PROMISe III project trial methodology were approved by the Tasmanian 
Health and Medical Research Ethics Committee as outlined in Table 2-9. 
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Study Approved by Reference No. 
Documenting Clinical Interventions in 
Community Pharmacy - PROMISe III 
Tasmanian Health and 
Medical Human Research 
Ethics Committee 
H0010393 
Documenting Clinical Interventions in 
Community Pharmacy - PROMISe III: Sub-
study of consumers subject to a clinical 
pharmacy intervention 
Tasmanian Social Science 
Human Research Ethics 
Committee 
H0010388 
Documenting Clinical Interventions in 
Community Pharmacy - PROMISe III: Sub-
study of random pharmacy consumers 
Tasmanian Social Science 
Human Research Ethics 
Committee 
H0010388 
An observational sub-study of 
pharmacists and the rate of interventions 
in the sales of non-prescription medicines 
Tasmanian Social Science 
Human Research Ethics 
Committee 
H0010623 
Table 2-9: Ethics approvals for PROMISe III 
2.5.2 Project outline 
The PROMISe III trial was conducted over a twelve week period and involved 210 
Australian pharmacies from across three states; Tasmania, Victoria and New South Wales. 
During the trial, an observational sub-study was conducted that involved observing 
participating pharmacists performing their usual activities in the pharmacy. These and the 
other aspects of the trial are outline in the flowchart in Figure 2-7. 
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Figure 2-7: PROMISe III trial outline 
The aspects of the consumer sub-study were not considered relevant to this thesis and 
therefore will not be discussed in detail. 
Ethics applications submitted and approved. 
Pre-trial focus groups with key stakeholders 
completed. 
Recruitment and enrolment of pharmacies 
and pharmacists 
Pharmacies allocated into software groups 
(see Figure 2-8) 
 Online and face-to-face training for all 
participating pharmacists. Pre-trial  
pharmacy and pharmacist surveys 
commenced. 
Beginning of the 12 week trial. Initial 
payment of $600 to pharmacies.  Data 
collection begins. 
Observer allocated to pharmacies 
Site visits for pharmacies commence 
Observational sub-study commences 
Consumer sub-study commences 
Observational and consumer sub-studies 
finish. Site visits completed. Surveys 
deactivated. 
12 week trial concludes.  All data collection 
ends. Final payment of $600 to pharmacies. 
Post-trial focus groups and surveys 
conducted. 
Analysis of data 
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2.5.3 Study arms 
In order to determine what influence each of the major features of the documentation 
software had on the intervention rates, a number of different trial arms were used 
throughout the study. 
2.5.3.1 No software pharmacies  
In order to collect a true representation of intervention and documentation behaviour in 
the absence of the PROMISe software, the no software pharmacies received only minimal 
information about the PROMISe project and did not have the PROMISe software installed. 
The no software pharmacy data was collected by pharmacy observers over a five-day 
period (see section 2.5.7.4 for more information). The observers recorded the 
pharmacist’s current method of documenting interventions and obtained a performed 
clinical intervention rate, as well as a documented clinical intervention rate, by noting the 
number of prescriptions dispensed and the number of interventions both performed and 
documented. The performed intervention rates recorded in the no software group were 
compared to the performed rates in the PROMISe software pharmacies to determine if 
the presence of the PROMISe software increased the rate of performing interventions, as 
well as the rate of documenting interventions. 
2.5.3.2 Software pharmacies 
Three groups of software pharmacies were established to determine the optimum 
combination of feedback and support mechanisms to facilitate a high level of uptake of 
documentation using the recording system. As described in section 2.4.2, all groups had 
access to the online repository providing electronic feedback and reports of interventions 
specific to both the pharmacy and pharmacist. In addition, they could all view a live 
intervention documentation rate on the PROMISe interface, including the rate for the 
pharmacy and the overall trial rate. The groups were therefore defined by their software 
functions: 
 Group One had the PROMISe documentation software installed with no additional 
features and was also referred to as the ‘software only’ group. 
 Group Two had the software installed with a reminder built into the system. The 
reminder, as mentioned in section 2.4.2.1, was activated at 11am and 3pm to 
encourage pharmacists to document interventions. This group was also referred 
to as the ‘software with reminders’ group. 
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 Group Three had the software installed with the reminder and the additional 
intervention prompt feature. As discussed in section 2.4.2.2, this prompt was 
activated when dispensing pantoprazole 40mg or esomeprazole 40mg. This group 
was also referred to as the ‘software with prompts and reminders’ group. 
2.5.4 Sample size calculation 
The sample size selected was limited by the resources available and logistics. In order to 
obtain a representative sample, a decision was made to examine approximately 5% of the 
pharmacies in Australia. As there were 5006 pharmacies in Australia at the time of the 
trial, a sample size of 210 (4.2%) pharmacies was selected. 
Table 2-10 shows the statistical power of three scenarios, based on the 24 no software 
pharmacies and the remaining 186 in the software pharmacy groups. All calculations were 
performed by an outside statistical consultant with the sampsi command in Stata 11 
(StataCorp LP, College Station, Texas), using a standard first-type error of α = 0.05. The 
sample size of 210 pharmacies would be able to detect a difference in intervention rate of 
at least 0.001 (1 in 1000 prescriptions) with 100% power, provided the level of data loss 
was within tolerances. A difference of 0.0005 would be detected in all cases with a power 
of approximately 90%. 
Assumption 
N* in 
treatment 
group 
N in 
control 
group 
Intervention rate 
in treatment 
group 
Intervention 
rate in 
control group 
Power 
Full cohort – 
1000 Rx/week 
2,232,000 288,000 
0.0053 
0.005 
56% 
0.0055 94% 
0.0060 100% 
Full cohort – 
900 Rx/week 
2,008,800 259,200 
0.0053 
0.005 
52% 
0.0055 91% 
0.0060 100% 
90% of cohort 
– 900 
Rx/week 
1,803,600 237,600 
0.0053 
0.005 
49% 
0.0055 89% 
0.0060 100% 
*N refers to the number of prescriptions 
Table 2-10: Power calculation for 186 software pharmacies and 24 no software 
pharmacies  
2.5.4.1 Stratification 
The group allocation is detailed in Figure 2-8. The software pharmacies were stratified 
based on the national average of PhARIA (Pharmacy Access/Remoteness Index of 
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Australia; a measure of the remoteness of the pharmacy153) and estimated annual 
prescription volume categories, as outlined in the 2008 Guild Digest.154 Once stratified 
accordingly, pharmacies were then randomly allocated across the three software groups. 
The pharmacies in the no software group were recruited and stratified separately to the 
186 software pharmacies as discussed in section 2.5.6.2. Chapter 4 will further detail 
group allocation and stratification.  
 
Figure 2-8: Allocation plan for PROMISe III project 
The no software group and the three software groups were of different sizes for two 
reasons. The no software group required an observer in the pharmacy, therefore budget 
constraints meant that only 24 no software pharmacies could be recruited. In addition, 
the software groups were deliberately weighted to have more pharmacies in the reminder 
and prompt groups, as PROMISe II had shown these groups should have a higher 
intervention rate. 
2.5.5 Observational sub-study 
The observational sub-study had two arms: 
 No software pharmacies were observed to collect information on current 
pharmacy practice 
 Software pharmacies were observed on current practice as well as the 
documentation of interventions on the installed software 
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As can be seen in Figure 2-8, a sample of pharmacies from each group were invited to 
participate on the basis of location and size, and participation was voluntary. 
2.5.5.1 Observational study design  
The observational sub study was designed to assist in determining which factors actually 
influence a pharmacist’s performance and documentation of interventions. Previous 
studies have frequently used self-reporting which only detects the perceived influencing 
factors, while an observational study has the benefit of being able to more accurately 
measure real factors. Selected pharmacists were observed performing their usual 
activities in the pharmacy by a trained pharmacist observer who collected data on paper-
based forms. Collected data included the pharmacists’ current methods of documenting 
DRPs and interventions, the performed clinical intervention rate, and the documented 
clinical intervention rate. Sixty two pharmacies participated in the observation sub-study; 
24 from the no software pharmacies and 38 from the software pharmacies (Figure 2-8). 
Twelve registered pharmacists across Tasmania, Victoria and New South Wales were 
recruited as observers for the sub-study. One Tasmanian-based observer was individually 
trained and undertook one week of pilot observation to detect any methodological issues 
with the study. This was undertaken prior to the training of the observers, as shown in the 
schedule in Table 2-11. The results of the pilot observation meant the data collection 
record forms could be improved prior to the commencement of the main study. 
The observers “shadowed” one participating pharmacist over five days (Monday to Friday 
from 9am until 5pm). On some occasions, due to rostering and staff hours, this meant 
different pharmacists were observed during the observation week. Most observers were 
employed for seven weeks: they undertook observer training for one week and observed 
for the remaining six weeks. Some observers visited fewer pharmacies than others and 
therefore were employed for less time. They also uploaded their real-time data collection 
reports to the online storage site within the six week observation period. 
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Observer 
July 
13-17 
July 
27-29 
Aug 
3-7 
Aug 
10-14 
Aug 
17-21 
Aug 
24-28 
Aug 31-
Sept 4 
Sept 
7-11 
1 Tas* 
O
b
se
rv
er
 t
ra
in
in
g 
(T
as
) 
 
Tas 
 
Tas 
  
2 
 
Tas Tas Tas Tas Tas 
 
3 
 
NSW Vic Tas Tas Tas Tas 
4 
 
NSW NSW NSW NSW NSW NSW 
5 
  
NSW NSW NSW NSW 
 
6 
  
NSW NSW NSW 
  
7 
 
Vic Vic Vic Vic Vic NSW 
8 
 
Vic Vic Vic Vic Vic Vic 
9 
 
Vic Vic Vic Vic Vic Vic 
10 
 
Vic Vic Vic Vic Vic Vic 
11 
 
Vic Vic Vic Vic Vic Vic 
12 
  
Vic Vic Vic Vic Vic 
*Pilot observation 
Table 2-11: Schedule for observers in the observational sub-study 
2.5.6 Recruitment and training 
Recruitment for the project was extensive, with both pharmacies and observers required 
for the study.  
2.5.6.1 Recruitment of software pharmacies 
Participating pharmacies were recruited in several ways. Advertisements were run in 
Pharmacy News and The Australian Pharmacist in March and April 2009, targeting users of 
the FRED® and Aquarius® dispensing software. The advertisements directed interested 
parties to view the PROMISe website, which was located at http://www.promise.org.au 
during the trial. However, the advertising did not produce the required number of 
participants. The Pharmacy Guild of Australia assisted by sending out faxes to 
approximately 3000 pharmacies within the three targeted states, asking interested parties 
to view the website, phone the project team or return the fax with their contact details. 
This resulted in an improved response, with 334 pharmacies expressing interest. The 
researchers used the details on the expression of interest form to group these pharmacies 
according to their PhARIA and estimated annual prescription volume. Pharmacies were 
selected using the inclusion and exclusion criteria as shown in Table 2-12, resulting in 186 
pharmacies invited to participate. 
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Inclusion criteria Exclusion criteria 
Fred® or Aquarius® dispensing software 
Dispensing software other than Fred® or 
Aquarius® 
Ability to be stratified according to the 
desired category of prescription turnover 
and PhARIA 
The appropriate prescription 
turnover/PhARIA category being at capacity 
All employee pharmacists committed to 
the twelve weeks of the trial 
Inability of the employee pharmacists to 
commit to the trial 
Timely expression of interest Application after the cut-off date 
Table 2-12: Inclusion and exclusion criteria of trial pharmacies 
2.5.6.2 Recruitment of no software pharmacies 
A further 24 pharmacies were recruited to make up the no software group. As these 
pharmacies did not receive the PROMISe intervention software, the pharmacy could be 
using any dispensing software and therefore the exclusion criteria were less strict (Table 
2-13). The pharmacies recruited for the no software group were mostly pharmacies 
ineligible for inclusion in the software group, due to the pharmacy using another 
dispensing system or their stratification group already at maximum capacity. 
Inclusion criteria Exclusion criteria 
Ability to be stratified according to the 
desired category of prescription turnover 
and PhARIA 
The appropriate prescription 
turnover/PhARIA category being at 
capacity 
Any dispensing software 
Remote location (impractical to be 
visited by an observer) 
Timely expression of interest Application after the cut-off date 
Table 2-13: Inclusion and exclusion criteria for no software pharmacies 
2.5.6.3 Training of the pharmacists 
Pharmacists participating in the PROMISe project were trained in the use of both the 
DOCUMENT system and the PROMISe intervention software. The training was presented 
in two ways; online and face-to-face. The online option provided practice for using the 
DOCUMENT system and short videos showing the use of the PROMISe software. It was 
necessary to provide online training, as many participants in remote areas were unable to 
attend one of the six face-to-face training sessions. The training was incentivised by 
awarding 1.5 CPD points and a $50 Coles/Myer gift voucher for completion of the 15 
training scenarios, plus an additional $50 Coles/Myer gift voucher for attending the face-
to-face training.  
       126 | P a g e   
 
Online training 
Thirty-one online training scenarios were prepared, based on a range of pharmacy specific 
situations. Scenario wording and classification codes were assigned and peer reviewed. 
Pharmacists were required to complete at least fifteen scenarios to receive their 
incentives, but were encouraged to undertake a further sixteen intervention scenarios. 
Pharmacists had to evaluate each scenario using the DOCUMENT system, and assign a DRP 
category, recommendations and significance category to the case-based scenario. At the 
completion of each scenario, the pharmacist was provided with immediate feedback 
which contained the peer-reviewed classification codes and an explanation as to why 
these codes were chosen. In addition, two videos demonstrating documentation of an 
intervention on both FRED® and Aquarius® PROMISe software were available online. The 
demonstrations were approximately fifteen minutes in length. All pharmacists were 
encouraged to complete the online training and view the demonstrations. 
Face-to-face training 
Face-to-face training sessions were held in Tasmania, Victoria and New South Wales, with 
two training sessions being run per state. The attendees assigned DOCUMENT categories, 
recommendations and significance categories to intervention scenarios that were similar 
to those seen in the online training. Each pharmacy received a training package that 
contained a welcome letter, information about their allocated group, a timeline of the 
trial, information about the sub-studies, a software “cheat sheet” guide, the DOCUMENT 
DRP Classification System booklet and a sticker to place on their computer monitor. 
Pharmacies that did not have a representative at any of the face-to-face training sessions 
were sent their training package in the mail. The aforementioned demonstration videos 
were presented at the face-to-face training, and computers were set up with the PROMISe 
software for participants to access. 
2.5.6.4 Observer recruitment and training 
The observer positions were advertised in the Australian Association of Consultant 
Pharmacy (AACP) and Pharmaceutical Society of Australia (PSA) news bulletins. A total of 
19 pharmacists expressed interest from which 12 observers were recruited. The final 12 
were selected based on their experience and location, and the selection criteria were as 
follows: 
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 At least five years of community pharmacy experience 
 Ability to observe in one of the three trial states (TAS, VIC or NSW) 
 Preference was given to candidates who had experience in similar roles for other 
studies  
Of the selected group of 12 observers, 10 (83.3%) were female with a mean age of 39 ± 
10.7 years. They had an average of 12.4 ± 8.5 years of community pharmacy experience, 
with two observers having previous experience with research projects. There were no 
particular conflicts of interest known to the project team. 
The observers underwent a two and a half day training course in Tasmania. The course 
involved intensive training in the DOCUMENT DRP Classification System and in their 
observation tasks, as shown in Table 2-14. The observers all received two folders, one with 
their training information and another with all of their forms for data recording. They also 
received pre-paid A4-sized envelopes to post their data collection forms back to the 
PROMISe team. 
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Task Description Form 
Explain study 
Discuss the project and sub-study with each 
observed pharmacist: build rapport with the 
observed pharmacists, ensuring all observed 
pharmacists place a consumer notice in the 
pharmacy. 
Consumer 
Notice 
Determine performed 
intervention rate and 
the documented 
intervention rate 
Record each and every intervention you witness in 
the pharmacy regardless of whether the 
pharmacist documented it. Record daily workload 
details of each observed pharmacist for each day. 
Intervention 
Record; 
Hourly Log  
Determine the 
pharmacist 
intervention level for 
OTC medication  
Observe and record details of any intervention 
regarding OTC medications. Record the total 
number of OTC requests dealt with by the 
pharmacist to provide a denominator statistic for 
the interventions. 
OTC 
Intervention 
Record Form; 
Hourly Log 
Recruit consumers for 
the consumer sub-
study 
Assist the enrolled pharmacists with the 
recruitment of consumers for the consumer sub-
study. 
Consumer 
Envelopes 
Undertake a ‘Time 
and Motion’ analysis 
of the pharmacy 
Record the workflow of the pharmacy, the nature 
of the pharmacist’s workload and staffing levels 
Daily Log 
Determine the 
practical barriers and 
facilitators to 
documenting clinical 
interventions 
Record the observed barriers and facilitators for 
each pharmacist. For no software pharmacies, also 
record the details of the current methods of 
documenting interventions. 
Barriers and 
Facilitators 
Record Form 
Complete data entry 
Enter all collected data online for ready access by 
the project team. Hard copies of the data 
collection forms to be mailed back to the project 
team. 
Online Survey 
Table 2-14: Outline of observer tasks 
2.5.7 Data collection 
In order to reduce implementation issues, the software pharmacies had a “rolling start” to 
the trial with the software being activated progressively over the course of two weeks. 
Each pharmacy was phoned by a member of the project team who provided them with an 
activation code, which also enabled the additional software features if allocated. Once 
activated, the pharmacy computers automatically sent data to the repository and the data 
collection period began once all pharmacies had been activated. 
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Information collected during this project needed to be sufficiently detailed for a 
reasonable “reconstruction” of the intervention, while still being relatively straightforward 
for pharmacists to record. Information relating to the intervention, the patient, the 
pharmacy, and the pharmacist were obtained. As shown in Table 2-15, information was 
collected from the repository, surveys, site visits and from the sub-studies. 
Source Data collected 
Intervention data repository 
Intervention information 
Patient information 
Prescription information 
Pharmacist information 
Background survey 
Intervention survey 
Empathy survey 
Professionalism survey 
Clinical knowledge survey 
Software survey 
Pharmacy information 
Owner/Manager survey 
Site visits 
Observation sub-study 
Intervention record 
Hourly log 
OTC intervention record 
Daily log 
Barriers and facilitators 
Consumer sub-study 
information (*not discussed) 
PROMISe consumers 
Non-PROMISe consumers 
Table 2-15: Sources of data collected during the PROMISe trial 
2.5.7.1 Intervention data repository 
The main source of data from the trial was collected through the PROMISe interface which 
was linked to the data repository. 
Intervention information 
The type of intervention, according to the DOCUMENT DRP Classification System, was 
documented by the pharmacist with each individual intervention record. Up to four 
recommendation(s) made by the pharmacist could be documented, as well as a clinical 
significance as assigned by the pharmacist. Extra information could also be entered by the 
pharmacist as free text. The drug involved and the nature of the prescription (whether it 
was an original or repeat) was automatically assigned by the dispensing system if the 
intervention was directly linked to a prescription. Otherwise, the pharmacist nominated 
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the drug involved. The time taken to conduct the intervention was also provided by the 
pharmacist. The intervention information collected from the interface was sent to the 
central repository (see Figure 2-2 for the interface appearance). 
Patient information 
The dispensing history of the patient for the past six months was automatically collated 
and sent to the repository upon transmission of each individual recorded intervention. 
This allowed for a list of other medications to be constructed for each patient that was 
subject to an intervention, allowing a patient background to be created. The documenting 
pharmacist also identified the gender and provided an estimate of the patient’s age 
bracket. 
Prescription information 
Details of all prescriptions dispensed in the pharmacy during the trial period were sent to 
the repository, so as to facilitate analysis based on the number of interventions 
documented versus the number of prescriptions dispensed, or the number of 
interventions performed within a particular group of drugs. 
2.5.7.2 Pharmacy information 
Pharmacy information was gathered in two ways. Firstly, an online survey was completed 
by owners or managers of the pharmacy, and secondly, site visits were undertaken by the 
project team. 
Owner/Manager survey  
This survey gathered information about the following areas: 
 Demographics  
o Dispensing system 
o Pharmacy location 
o Area of the pharmacy (in m2) 
o Estimated financial turnover 
o Average weekly/annual prescription turnover 
 Current practice  
o Number of trading days and hours per week 
o % of business attributable to the dispensary 
o Number of pharmacists responsible for making business decisions 
o Owner or manager operated 
o Banner group or independent 
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o Whether the pharmacy caters for an aged care facility 
o Proportion of prescriptions assembled by dispensary technicians 
o Presence of pre-registration pharmacist within the last two years 
 Services  
o PGA-funded professional services currently provided 
o DMAS (Diabetes Management Assistance Service – a trial to assess the 
feasibility of offering diabetes management services through community 
pharmacies155) 
o DAA (Dose Administration Aid trial –  a trial assessing the provision of a 
medication packing service for war veterans56) 
o PMP (Patient Medication Profile program – a trial to assess the provision 
of medication lists to consumers156) 
o PAMS (Pharmacy Asthma Management Service – a trial to assess the 
feasibility of offering asthma management services through community 
pharmacies157) 
o Mirixa – an electronic program used as a platform to deliver professional 
services within the community pharmacy158 
 Other professional services  
o Blood pressure monitoring 
o HMR (Home Medication Review) services 
o DAA (Dose Administration Aid) packing 
o Opioid dependency program 
o Diabetes screening 
o Wound care 
o Weight management program 
o MedsIndex 
This information was used to determine the ‘type’ of pharmacy and aimed to determine 
any impact that these factors had on the pharmacy’s ability to participate effectively 
within the PROMISe III trial. See Appendix 7 for the complete survey. 
Site visits 
Site visits by the project team were carried out on the software pharmacies. Information 
was gathered in the following areas: 
 Visibility and accessibility of the pharmacist and dispensary 
 Presence and type of counselling area 
 Number and type of health promotion posters or professional services advertised 
 Workflow roles/responsibilities 
 Number of dispensing terminals 
 Number of FTE staff per week 
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The site visitor was also asked to make notes on the general pace and feel of the 
pharmacy from a patient’s perspective. The site visit data collection sheet and staff roster 
template can be found in Appendices 8 and 9. 
2.5.7.3 Pharmacist information 
Information was gathered from the enrolled pharmacists before and after the trial period 
using the following surveys. 
Background survey 
The background survey gathered information about the following areas: 
 Demographics 
o Gender 
o Age range 
o Year of graduation 
o Additional pharmacy qualifications 
o Professional memberships 
 Background and current practice  
o Number of full-time years worked in community/hospital/ consultant 
pharmacy practice 
o Average number of hours of CPD completed annually 
o Current area of practice for the majority of the working week 
o Current role in community pharmacy 
o How many years in current position 
o How many hours a week in community pharmacy 
o Proportion of time spent on dispensing tasks 
o Number of other pharmacists working concurrent shifts 
o Approximate number of prescriptions dispensed per 9-hour day 
This information was used to characterise a typical pharmacist and aimed to determine 
any impact that these factors had on the pharmacist’s ability to participate effectively 
within the PROMISe III trial. See Appendix 10 for the complete survey. 
Intervention survey 
This survey collected the views of pharmacists concerning their current practice of 
performing clinical interventions in a community pharmacy setting by asking the 
pharmacists to assign their level of agreement on a 5-point Likert scale (Strongly Agree to 
Strongly Disagree) to the following statements: 
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 I believe that pharmacists are already too busy within the workplace which 
prevents them from taking on any new tasks. 
 I believe it is important for pharmacists to adapt their practice to suit the current 
pharmacy environment. 
 I would be willing to change my current practice if a new, better way was 
available. 
 I believe the future of pharmacy remuneration will consist of more than just 
dispensing prescriptions. 
 I always counsel patients with regards to their medications. 
 I believe I have a good level of clinical knowledge to perform clinical interventions. 
 I am confident in my ability to perform clinical interventions. 
 I already perform clinical interventions on a daily basis. 
 I believe the recording of interventions will increase my level of job satisfaction. 
 I am concerned it will take too long to document interventions through the 
recording system. 
 I am concerned the recording system will be hard to use 
 I believe that a 'pop up' prompt would be useful to remind pharmacists to record 
clinical interventions. 
 I believe customers should receive a printout if they are subject to an 
intervention. 
 I believe participation in research projects is an important part of pharmacy 
practice. 
This information was used to determine a pharmacist’s views on interventions and 
determine any impact that these attitudinal factors had on the pharmacist’s ability to 
participate effectively within the PROMISe III trial. The pharmacist’s pre-trial answers were 
also compared to their post-trial answers to determine if the trial had altered their views. 
See Appendix 11 for the complete survey. 
Empathy survey 
This survey was derived from the ‘Toronto Empathy Questionnaire’ developed by Spreng 
et al.159 which was a 16-item survey that enabled an empathy score to be allocated to 
each pharmacist. The marking scheme was detailed in the original article where the least 
empathetic response possible was 0 and the most empathetic response was 64.159 
Pharmacists were asked how often they agreed on a 5-point Likert scale (Always to Never) 
to the following statements: 
1. When someone else is feeling excited, I tend to get excited too 
2. Other peoples’ misfortunes do not disturb me a great deal 
3. It upsets me to see someone being treated disrespectfully 
4. I remain unaffected when someone close to me is happy 
       134 | P a g e   
 
5. I enjoy making other people feel better 
6. I have tender, concerned feelings for people less fortunate than me 
7. When a friend starts to talk about his/her problems, I try to steer the conversation 
towards something else 
8. I can tell when others are sad even when they do not say anything 
9. I find that I am ‘in tune’ with other people's moods 
10. I do not feel sympathy for people who cause their own serious illnesses 
11. I become irritated when someone cries 
12. I am not really interested in how other people feel 
13. I get a strong urge to help when I see someone who is upset 
14. When I see someone being treated unfairly, I do not feel very much pity for them 
15. I find it silly for people to cry out of happiness 
16. When I see someone being taken advantage of, I feel kind of protective towards 
him/her 
During the PROMISe II trial, female pharmacists were shown to document a higher 
number of interventions compared to males, and it was thought that this may be due to 
differences in empathy. A measure of empathy was therefore included within the surveys 
to analyse any differences empathy made on a pharmacist’s intervention rate. The 
complete survey is shown in Appendix 12. 
Professionalism survey 
This survey was derived from one designed by Chisholm et al.160, which used 18 
statements to look at six factors of professionalism within the pharmacy profession and 
provide a professionalism score. The original article was lacking in detail and did not 
provide a marking scheme or state which questions belonged in each of the six sub-scales. 
Correspondence with the author did not further clarify this as she had moved several 
times since the article was written and did not have the information available. Six 
pharmacists/researchers within the University of Tasmania were therefore given the sub-
scale definitions from the article and asked to assign each question to a sub-scale. 
Consensus between these researchers was achieved and the sub-scale consensus 
appeared to match the scoring system provided in the original article. The professionalism 
questions were divided into the sub-scales of: 
 Altruism (3 questions) 
 Duty (2 questions) 
 Honour and integrity (2 questions) 
 Accountability (2 questions) 
 Excellence (5 questions) 
 Respect for others (4 questions) 
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This allowed a valid score to be assigned to all participants where the least professional 
response was 18 and the most professional response was 90. To calculate the score, 
pharmacists were asked to assign their level of agreement on a 5-point Likert scale 
(Strongly Agree to Strongly Disagree) to the following statements: 
1. I do not expect anything in return when I help someone. 
2. I attend work daily. 
3. If I realise that I will be late, I contact the appropriate individual at the earliest 
possible time to inform them. 
4. If I do not follow through with my responsibilities, I readily accept the 
consequences. 
5. I want to exceed the expectation of others. 
6. It is important to produce quality work. 
7. I complete my tasks independently and without supervision. 
8. I follow through with my responsibilities. 
9. I am committed to helping others. 
10. I would take a job where I felt I was needed and could make a difference, even if it 
paid less than other positions. 
11. It is wrong to cheat to achieve higher rewards. 
12. I would report a medication error even if no-one else was aware of the mistake. 
13. I am able to accept constructive criticism. 
14. I treat all patients with the same respect, regardless of perceived social standing 
or ability to pay. 
15. I address others using appropriate names and titles. 
16. I am diplomatic when expressing ideas and opinions. 
17. I accept decisions from those in authority. 
18. I am respectful to individuals who have different backgrounds than mine. 
It was thought a higher level of professionalism may cause a pharmacist to perform more 
effectively in the PROMISe III trial, due to CIs being considered a professional service. A 
professionalism measure was therefore included to determine if this was correct and the 
survey is shown in Appendix 13. 
Clinical knowledge survey 
As discussed in section 2.3, a survey to assess the pharmacist’s ability to identify, gather 
relevant information about and make relevant recommendations to resolve a DRP was 
administered. Pharmacists were asked to select how relevant they felt each action was to 
the specific scenario using a 7-point Likert scale (Very relevant to Not relevant at all). For 
this survey, the lowest possible score was 0 and the highest was 80, with a higher score 
indicating a higher level of clinical knowledge. The survey and the correct answer assigned 
to each statement can be seen in Appendix 4. 
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Software survey 
In order to gain feedback after the trial period, participating pharmacists were asked to 
complete a software survey. This survey provided enrolled pharmacists the opportunity to 
offer feedback about the software and make suggestions. Some of the statements used in 
the initial intervention survey (Appendix 11) were repeated to determine if participation in 
the trial altered their responses. The survey is shown in Appendix 14. 
2.5.7.4 Observational sub-study 
Observers collected additional information for 38 software pharmacies and 24 no 
software pharmacies. The data collection forms used by the observers and their content 
were as follows:  
Intervention record 
This form was used to collect data about each actual intervention the pharmacist made, 
including patient demographics, drug involved and classification according to the 
DOCUMENT system. Also collected was the time taken by the pharmacist to perform and 
document the intervention, the resources used, and whether the pharmacist had 
documented it. Details of any prompts involved were also recorded. Collation of these 
forms provided details on the performed intervention frequency, as well as the 
documentation frequency by the pharmacist. The form is shown in Appendix 15. 
Hourly log 
This form recorded the date, approval number, pharmacist initials and opening hours. Also 
collected was the hourly data on the pharmacist's workload, including prescription count 
and other procedures, such as dispensing daily pick-ups, providing CMIs, dealing with OTC 
requests and completing administrative paperwork such as issuing safety net cards. This 
form also collected details of staffing levels for each hour and whether the interventions 
recorded by the observer were performed and/or documented by the pharmacist. The 
number of consumer packs sent out was also noted. The form is shown in Appendix 16. 
Daily log 
Completed daily, this log provided data concerning the approximate amount of time that 
the pharmacist spent on particular tasks during the course of the day. These tasks 
included dispensing, serving consumers, administrative tasks, and ordering. Data on the 
workflow in the pharmacy was also recorded, allocating approximate levels of dispensing 
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task distribution between non-dispensary staff, dispensary assistants and pharmacists. 
The form is shown in Appendix 17. 
Barriers and facilitators 
Observers collected data on potential barriers and facilitators which may have influenced 
the observed pharmacist in the documentation of clinical interventions. For the baseline 
pharmacies, information was also collected on the current level of documenting 
interventions. The forms are shown in Appendices 18 and 19. 
Halls professionalism survey 
Each of the observed pharmacists were asked to complete the modified Halls 
professionalism survey.161 As the online professionalism survey (see section 2.5.7.3) was 
previously only validated in pharmacy students, the results of the longer, validated Halls 
professionalism survey were compared to ensure a correlation between the two scores. 
The survey is shown in Appendix 20. 
2.6 Analysis method 
In order to analyse the factors that may have contributed to the differences seen in 
intervention rates between pharmacies and between pharmacists, many methods of 
analysis were employed. 
2.6.1 Intervention rates 
Intervention rates for the pharmacies were calculated from the intervention database by 
the number of documented interventions divided by the number of prescriptions 
dispensed for the whole period. The calculation was performed once the data was 
thoroughly cleansed in the following ways: 
1. Removal of all interventions documented by pharmacists that were not enrolled in 
the trial (such as locum pharmacists, recent staff additions etc.) 
2. Removal of all prescriptions dispensed by pharmacists that were not enrolled in 
the trial 
3. Removal of all interventions documented for an OTC item or a symptom-based 
request (see section 2.6.1.1) 
4. Removal of all interventions linked to the prompt in Group Three pharmacies (see 
section 2.6.1.2) 
Intervention rates for the pharmacists were calculated by the number of interventions 
documented by that pharmacist divided by the number of prescriptions dispensed by that 
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pharmacist during the trial period. Again, all OTC, symptom-based and prompted 
interventions were removed from the dataset prior to performing the calculation. This 
calculation provided the documented intervention rates and are the intervention rates 
referred to in Chapter 4 and 5, unless otherwise specified. 
2.6.1.1 OTC interventions 
OTC product sales were not recorded through the dispensing system, therefore it was 
impossible to collect data to determine the ‘denominator’ for such interventions, such as 
the number of OTC products sold within that day by that pharmacy. It was therefore 
deemed necessary to remove all interventions documented for an OTC product.  OTC 
products were identified by ATC groups87 and subsequently removed. 
2.6.1.2 Prompted interventions 
As mentioned in section 2.6.1, interventions that were deemed to be associated with the 
prompt in Group Three were removed prior to analysis. The criteria for removal of these 
interventions were as follows: 
1. Interventions associated with ATC groups87 A02BC02 (pantoprazole) and A02BC05 
(esomeprazole) 
2. At least one of the following DOCUMENT recommendation categories: R2, R3, R7, 
R13  
3. If available, reviewing the intervention notes made by pharmacists for these 
interventions to identify any anomalies. 
2.6.1.3 Performed versus documented intervention rates 
As mentioned in section 2.5.5, observers were placed in a sample of pharmacies for a 
period of five consecutive days to determine what percentage of performed clinical 
interventions were documented. Observers were present in the pharmacy for the day 
observing one pharmacist at a time, and using paper-based forms, they documented: 
 Number of prescriptions dispensed by the pharmacist 
 Number of interventions performed 
 Number of interventions documented 
 
This allowed two intervention rates to be calculated for each observed pharmacist: 
1. Performed intervention rate (number of performed interventions divided by 
number of observed prescriptions dispensed) 
2. Documented intervention rate (number of documented interventions divided by 
number of observed prescriptions dispensed) 
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The performance and documentation of interventions within observed pharmacies was 
then examined to quantify the effect that the documentation system had by comparing 
the software pharmacies with the no software pharmacies. 
2.6.2 Analysis of the frequency and types of interventions 
The intervention data was broken down into DOCUMENT categories, recommendations 
and significance to determine any differences in the frequency between each of the 
categories. The drugs involved were analysed according to their ATC grouping87 to identify 
the most commonly intervened drugs. Drugs were also analysed according to their 
dispensing volume to determine if those with higher intervention rates were actually due 
to a higher frequency of prescriptions being dispensed. The time taken to perform and 
document interventions was also analysed to ensure the documentation system was not 
majorly impacting on the pharmacist’s workload. 
2.6.3 Analysis of demographics 
Using chi-square tests, demographics of pharmacies, pharmacists and patients were 
analysed against the national averages where possible to ensure adequate sample 
representation. 
2.6.3.1 Pharmacy demographics 
Data was collected from the pharmacies participating in the trial through selected surveys, 
as detailed in section 2.5.7. Where possible, this information was then compared to 
national figures to ensure the PROMISe sample was representative. The allocation of the 
PROMISe groups was also analysed to ensure there was ample representation within each 
software group and within the no software group. 
2.6.3.2 Pharmacist demographics 
Data about each participating pharmacist was collected through the online surveys (see 
section 2.5.7) and their demographics were also analysed against national figures where 
possible. The results of the professionalism, empathy and clinical knowledge surveys were 
also compared to participating pharmacist demographics to identify any trends within the 
pharmacist group. 
       140 | P a g e   
 
2.6.3.3 Patient demographics 
The age and gender of each patient who was subjected to an intervention during the trial 
was collected and compared to the national figures to determine if there were 
demographic trends within the group of intervened patients.  
2.6.4 Analysis of factors affecting intervention rate 
Analysis between one factor and the relevant intervention rate was used to determine any 
relationships. Due to the intervention rate being non-normally distributed, non-
parametric statistical tests were utilised. 
2.6.4.1 Prescription factors 
Original prescriptions were compared to repeat prescriptions to determine any 
relationship with the documented intervention rate. 
2.6.4.2 Software groups 
The difference in the intervention rates between each of the three software groups was 
also analysed. This determined the effect of the general reminder and specific prompt that 
were built into the documentation system. 
General reminder 
The time of day data was analysed from each of the software groups to determine the 
effect of the general reminder. 
Prompt 
A simple definition of a prompted intervention was defined, such that it was possible to 
determine how many of these interventions occurred through inspection of the 
intervention and prescription data, and by comparing groups, estimate how many of these 
interventions occurred as a result of the prompt. An estimation of the rate of uptake of 
the prompted interventions was also determined using subsequent prescription data that 
was available for patients who were the target of a prompted intervention during the first 
4 weeks of the trial to determine if the effect of the prompt was evident in the following 8 
weeks of prescription data. Having an idea of the efficacy and uptake of the prompted 
interventions, as well as an understanding of the cost of the drugs involved before and 
after the intervention, some economic analysis was also undertaken by an Honours 
student, Colin Curtain.162 This was done by extrapolating forward through a 12-month 
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period, under the assumptions that the intervention continued for that 12-month period, 
that is, the patient continued to take the lower (cheaper) dose of medication, and that the 
patient would not have lowered their dosage through other means. 
2.6.4.3 Pharmacy factors 
Many pharmacy factors were analysed to determine if any affected the overall 
intervention rate of the pharmacy. Factors that were compared to the intervention rate 
included PhARIA, pharmacy type, prescription volume, pharmacist workload, size of the 
pharmacy, estimated annual financial turnover, dispensary attribution to total turnover, 
trading hours, operational structure of the pharmacy, banner affiliation, dispensing 
system, presence of graduate pharmacists, staffing levels, workflow roles/responsibilities, 
number and types of professional services offered/promoted, type of counselling area and 
pharmacist accessibility. The effect of the observation week on the pharmacy, as well as 
the impact of site visits, was also analysed. 
2.6.4.4 Pharmacist factors 
Many pharmacist factors were analysed to determine if any affected the individual 
intervention rate of the pharmacist. Factors that were compared to their intervention rate 
included age, gender, graduation year, additional qualifications, professional 
memberships, previous pharmacy experience, current practice, pharmacist’s workload, 
level of annual CPD activity, survey scores, beliefs about the intervention system and level 
of PROMISe training. 
2.6.4.5 Pharmacist workload 
An average pharmacist workload during a 38-hour week was calculated for each pharmacy 
using the number of prescriptions dispensed by the pharmacy during the trial and the 
number of full-time equivalent (FTE) pharmacists working each week. The number of FTE 
pharmacists was determined by obtaining a roster for each pharmacy during the site visits 
and calculating the number of pharmacists present during each hour the pharmacy was 
open, then dividing the number of hours by 38. For example, if the pharmacy was open for 
70 hours a week, the total number of pharmacist hours might be 100 due to two 
pharmacists being present during busy periods. This results in 2.63 FTE pharmacists 
(calculated by 100 / 38). Therefore, if the pharmacy dispensed 17,000 prescriptions during 
the trial, this would result in an average of 1416.67 prescriptions per week and an average 
pharmacist weekly workload of 538.66 prescriptions (1416.67 / 2.63). Once the average 
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pharmacist weekly workload for the pharmacy was calculated, the data was transferred 
into the pharmacy and pharmacist dataset. This meant that if there were five pharmacists 
working within the same pharmacy, they would all have the same average pharmacist 
workload.  
An average pharmacist workload during a 38-hour week was also calculated for each 
pharmacy taking into account the number of FTE dispensary technicians as well. Again, the 
number of FTE dispensary technicians was determined by obtaining a roster for each 
pharmacy and calculating the number of technicians present during each hour the 
pharmacy was open, then dividing the number of hours by 38. The FTE dispensary 
technicians were then added to the FTE pharmacists to make a ‘FTE dispensary staff’. 
Again, the total number of prescriptions dispensed during the trial was divided by 12, then 
by the FTE dispensary staff to give an average weekly workload within the pharmacy.  
2.6.5 Statistical analysis 
Statistical analysis was undertaken in SPSS® versions 17 and 18, as well as Microsoft 
Excel®. Where a chi-square analysis was required on summarised data, the StatView® 
program was used as it was felt that it handled summarised data better than SPSS®.  
2.6.5.1 Analysis of demographics 
The analysis comparing the demographics of the PROMISe pharmacies, pharmacists and 
patients compared to national averages were completed using Pearson chi-square tests. 
To meet the requirements of chi-square tests, it was always ensured that all cells had 
expected counts greater than 5. If cells had expected counts of less than 5, categories 
were merged to increase the population count within the cell. 
To ensure consistency within each software groups, chi-square tests were also conducted 
between the software groups and other categorical variables. This aimed to ensure that 
the effects seen were independent of the software group that the pharmacy and 
pharmacist were in. 
2.6.5.2 Analysis between two factors 
The intervention rate was non-parametric in nature, therefore non-parametric tests were 
used to determine relationships between independent variables and the intervention rate. 
The following tests were conducted using the intervention rate as the dependent variable: 
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 Mann-Whitney chi-square  
o Used when the independent variable was categorical with two groups 
 Kruskal-Wallis chi-square 
o Used when the independent variable was categorical with three or more 
groups 
o The Jonckheere-Terpstra statistic test was used to determine if there was 
a significant trend between the groups 
o If needed, individual Mann-Whitney tests were used to determine where 
the differences between the groups occurred. Type I error was minimised 
by calculating a new critical p-value by dividing 0.05 by the number of 
Mann-Whitney tests conducted (for example, critical p-value with 3 
categorical groups and therefore 3 Mann-Whitney tests = 0.05/3 = 0.0167) 
 Spearman’s correlation 
o Used when the independent variable was also continuous 
o Also used when comparing Likert scale questions 
 Likert scale questions are ordinal data (where 1 is better than 2) 
therefore a non-parametric correlation can be used and is usually 
better than grouped analysis. For these analyses, ‘Unknown’ was 
tagged as ‘0’ and was therefore the lowest point on the scale. 
Other factors such as prescription volumes, pharmacist workloads and survey scores were 
normally distributed, therefore some parametric data analysis was also performed.  
 Pearson’s correlation 
o Used when dependent and independent variables were both continuous 
 Paired t-tests 
o Used to analyse relationships between estimated and actual data, such as 
estimated and actual prescription volumes 
 Independent t-test 
o Used when dependent variable was continuous and independent variable 
was categorical with two groups, such as pharmacist gender compared to 
their prescription volume 
 Analysis of variance (ANOVA) 
o Used when dependent variable was continuous and independent variable 
was categorical with three or more groups, such as pharmacy size and 
prescription volume 
o Post-hoc analysis149 for ANOVA 
 Population variances were determined using Levene’s test, where 
a non-significant result shows equal variances of the populations 
 Tukey method was used if sample sizes were equal and 
population variances were equal 
 Gabriel method was used if sample sizes were slightly different 
and population variances were equal 
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 Hochberg’s GT2 method was used if sample sizes were very 
different and population variances were equal 
 Games-Howell method was used if population variances were 
unequal 
2.6.5.3 Designing a statistical model to predict the intervention rate of 
the pharmacy 
The intervention rate was not normally distributed (Kolmogorov-Smirnov D(185) = 0.187, p 
< 0.001; Shapiro-Wilk F(185) = 0.710, p < 0.001; where the Shapiro-Wilk statistic is usually 
considered a more accurate measure of distribution). 
 
Figure 2-9: Frequency histogram for pharmacy intervention rate 
Due to the skew of the histogram (Figure 2-9), it was thought that a log transformation 
would provide a more normal distribution. There were three ‘zero’ performers in the data 
(one documented no interventions and the other two documented only prompted 
interventions which were subsequently removed, resulting in three pharmacies with an 
intervention rate of zero), therefore a constant was added before transformation as zero 
cannot be logarithmically transformed. It was thought to be important to include the 
‘zero’ performers to determine any factors that may contribute to a ‘zero’ intervention 
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rate. Given that the values of the intervention rate were so small (range = 0.00 – 2.34), a 
very small constant of 0.01 was chosen. The value of 0.01 was added to each intervention 
rate, therefore increasing the range to 0.01 – 2.35.  
Logarithmic transformation 
A logarithmic transformation was performed on the CI rate plus constant, resulting in the 
following data: 
Mean -0.667 
95% CI 
Lower  -0.730 
Upper  -0.604 
5% Trimmed Mean -0.659 
Median -0.652 
Variance 0.188 
Std. Dev. 0.434 
Min. -2.000 
Max. 0.370 
Range 2.370 
IQR 0.580 
Skewness -0.313 
Kurtosis 0.541 
Table 2-16: Descriptive statistics for the log-transformed intervention rate 
The intervention rate now appeared to be normally distributed (Kolmogorov-Smirnov 
D(185) = 0.034, p < 0.20; Shapiro-Wilk F(185) = 0.987, p = 0.087), which was also evident 
from the histogram (Figure 2-10). 
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Figure 2-10: Frequency histogram for the log-transformed pharmacy intervention rate 
Multiple regression was considered to be a suitable modelling procedure since the 
dependent variable is a continuous, normally distributed variable.149 This method allows 
independent variables to be continuous or binary categorical, but cannot accommodate 
categorical variables with three or more groups. Therefore, some categorical variables had 
to be converted to ‘dummy’ variables, where ‘1’ denoted ‘membership’ within that group 
whereas ‘0’ denoted ‘no membership’. Continuous independent variables were also 
logarithmically transformed, however this still did not normalise the distribution of several 
variables, resulting in some continuous variables being transformed to categorical. 
Multiple regression 
The multiple regression model can be written as149: 
Y = β0 + β1X1 + β2X2 +….+ βkXk 
This results in a prediction for Y based on the value for each X coefficient.  
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Logistic regression 
A logistic regression was also performed to determine whether a pharmacy would have a 
‘high’ intervention rate or a ‘low’ intervention rate. After pharmacies were divided into a 
dichotomous variable (high vs low), stepwise regressions were performed to determine a 
model. 
2.6.5.4 Designing a statistical model to predict the intervention rate of 
the pharmacist 
Regression models were researched to determine which type would be suitable to model 
the factors that influenced a pharmacist’s documentation rate during the PROMISe trial. 
The modelling techniques that were considered were: 
1. Linear regression  
 Requires continuous independent and dependent variables. 
 Assumes normality, linearity, homoscedasticity and independence of residuals, 
and no multicollinearity. 
 Discrete (grouped) variables can be included using dummy variable coding, 
where group membership is denoted as 1 compared to 0. 
2. Logistic regression 
 Allows grouped variables to be incorporated into the model easily, but requires 
the dependent variable to be binary or grouped. 
 Does not assume normal distribution. 
 Calculates the odds (or probability) of membership in one group based on a 
combination of predictor variables. 
Determining which statistical model to use 
Eighty-four out of 509 pharmacists (16.5%) did not document any interventions during the 
trial, therefore they had an intervention rate of 0%. This contributed to the pharmacist 
intervention rate having a non-normal distribution. Transformation was attempted, 
however due to the excessive number of zeros, no transformation (including addition of a 
constant to each intervention rate) could normalise the large number of zero intervention 
rates (Figure 2-11). This meant that a linear regression model was not suitable, as the 
dependent variable did not meet the assumptions of linear regression. 
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Figure 2-11: Intervention rate histogram where adjusted intervention rate = 
log10(intervention rate+1) 
The logistic regression model was therefore chosen, which required the clinical 
intervention rate to be converted into a grouped variable. Using the BINNED function in 
SPSS®, the intervention rate was split into three equivalent groups, which were then 
named ‘Low CI rate’, ‘Moderate CI rate’ and High CI rate’. As the dependent variable 
resulted in three groups, a multinomial logistic regression model was used. 
Multinomial logistic regression 
The logistic regression model can be written in terms of log of the odds149,163: 
loge(π/1-π) = β0 + β1X1 + β2X2 +….+ βkXk 
This results in a likelihood estimation which predicts the likelihood (odds ratio) changes 
with each increase/decrease in the X coefficients. 
Logistic regression 
A logistic regression was also performed to determine a whether a pharmacist would 
document interventions. Pharmacists were divided into a dichotomous variable 
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(‘performer’ vs ‘non-performer’), stepwise regressions were performed to determine a 
model. 
2.6.6 Analysis of user satisfaction 
A survey seeking to determine the pharmacist user’s opinions regarding the PROMISe 
documentation software was also undertaken, particularly with regards to its limitations 
and ways it might be improved. These results have been summarised in Chapter 6. 
2.6.7 Cost saving analysis 
An expert assessment panel was recruited to determine the cost savings of a random 
sample of interventions. Twenty-four experts (consisting of 5 specialists, 11 GPs and 8 
pharmacists) assessed a random sample of 200 interventions to determine the 
consequences of the intervention occurring. Costs and savings were then applied to these 
consequences to provide a costing for each intervention, resulting in an overall value of an 
average intervention. This was done as a separate analysis by a different researcher and 
thus, was not included within this thesis. More detail on the calculation methods can be 
found in the PROMISe III final report164 and the article written by Stafford et al.165 
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3 Chapter 3: DRPs and prescription factors 
During the PROMISe III trial, data was collected on each DRP and resulting intervention 
documented by the pharmacist, as well as prescription data.  This allowed analysis to be 
conducted to determine intervention frequencies amongst certain prescription types, 
DOCUMENT classification groups and each drug group. 
For the purposes of reporting results, clinical interventions (CIs) documented in the 
PROMISe system will be referred to as documented CIs, as opposed to those CIs observed 
(whether documented or not) which will be referred to as performed CIs. Analysis of the 
observational sub-study data determined that only 49% of performed interventions were 
actually documented (see Chapter 5 for more detail), as such it is unknown exactly how 
many CIs were performed in all pharmacies. Analyses have been completed only on 
documented CIs with consideration that the actual rate of performed CIs was likely to be 
much higher.  
An outline of the interventions documented and prescriptions dispensed during the study 
is shown in Figure 3-1. During the course of the study, 776 pharmacists dispensed 
2,396,451 prescriptions for 546,717 patients and documented 7000 interventions. Of 
these, 245 pharmacists were not enrolled in the study (most likely locums or new 
employees within the pharmacy), thus having insufficient access to training for the 
PROMISe system. These pharmacists dispensed 292,528 prescriptions for 63,570 patients 
and documented 245 interventions. As these pharmacists were not enrolled, these 
instances have been excluded from the analysis (see Exclusion Box 1 in Figure 3-1). 
The remaining 531 enrolled pharmacists dispensed 2,013,923 prescriptions for 483,147 
patients and documented 6755 interventions. Of these interventions, 525 were related to 
either OTC medications or symptom-based requests to the pharmacist, and these were 
also excluded from the analysis (see Exclusion Box 2 in Figure 3-1). These interventions 
were examined separately and more detail can be found in the PROMISe III report.164 
The remaining 6230 interventions involved prescription medications. Group Three 
pharmacies undertook 282 interventions that were linked to the prompt (see Chapter 2), 
which were also removed prior to analysis. Once this data was removed, an overall 
average of 3 interventions were documented for every 1000 prescriptions dispensed or 12 
interventions per 1000 patients (Figure 3-1).  
151 | P a g e  
 
 
Figure 3-1: Breakdown of clinical interventions documented during the PROMISe trial 
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3.1 Overall number and rate of documented CIs 
The 5948 interventions resulted in an overall average of 3 interventions documented for 
every 1000 prescriptions. There was a decline in the documentation of interventions with 
time as shown in Figure 3-2, and this decline was significant (Kruskal-Wallis χ2 = 184.57, df 
= 11, p < 0.001; Jonckheere-Terpstra = -13.29, p < 0.001). 
 
Figure 3-2: Number of CIs documented and number of prescriptions dispensed  
3.2 Categories and subcategories of interventions 
The majority of documented CIs were related to either drug selection problems (1829 or 
30.7%) or educational issues prompted by patient requests (1412 or 23.7%; Table 3-1). 
Examples of the different types of documented CIs are included in Appendix 21. 
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Code Category Subcategory 
# (%) of 
category 
# % 
D 
Drug selection D1 Duplication 232 (12.7%) 
1829 30.7 
(Problems relating to the choice 
of drug prescribed or taken) 
D2 Drug interaction 265 (14.5%) 
D3 Wrong drug 223 (12.2%) 
D4 Incorrect strength 347 (19%) 
D5 Inappropriate dosage form 211 (11.5%) 
D6 Contraindications apparent 141 (7.7%) 
D7 No indication apparent 42 (2.3%) 
D0 
Other drug selection 
problem 
368 (20.1%) 
O 
Over or underdose O1 Prescribed dose too high 384 (32.5%) 
1183 19.9 
(Problems relating to the 
prescribed dose or schedule of a 
drug) 
O2 Prescribed dose too low 316 (26.7%) 
O3 
Incorrect/unclear dosing 
instructions 
392 (33.1%) 
O0 Other dose problem 91 (7.7%) 
C 
Compliance C1 Taking too little 116 (20.8%) 
557 9.4 
(Problems relating to the way 
the patient takes the 
medication) 
C2 Taking too much 101 (18.1%) 
C3 Erratic use of medication 100 (18%) 
C4 
Intentional drug misuse 
(including OTC medications) 
34 (6.1%) 
C5 Difficulty using dosage form 56 (10.1%) 
C0 Other compliance problem 150 (26.9%) 
U 
Undertreated U1 Condition undertreated 164 (60.3%) 
272 4.6 
(Problems relating to actual or 
potential conditions that require 
management or prevention) 
U2 Condition untreated 42 (15.4%) 
U3 
Preventative therapy 
required 
58 (21.3%) 
U0 Other undertreated problem 8 (2.9%) 
M 
Monitoring M1 Laboratory monitoring 42 (30%) 
140 2.4 (Problems relating to monitoring 
the efficacy or adverse effects of 
a drug) 
M2 Non-laboratory monitoring 81 (57.9%) 
M0 Other monitoring problem 17 (12.1%) 
E 
Education or information E1 Patient requests drug info 668 (47.3%) 
1412 23.7 
(Where a patient requests 
further information about a drug 
or disease state) 
E2 
Patient requests disease 
management advice 
278 (19.7%) 
E0 
Other education or 
information problem 
466 (33%) 
N 
Not classifiable 
N0 
Clinical interventions that 
cannot be classified under 
another category 
110 (100%) 110 1.8 
(Problems that cannot be 
classified under another 
category) 
T 
Toxicity or ADR 
T1 
Toxicity, allergic reaction or 
adverse effect present 
445 (100%) 445 7.5 (Problems relating to the 
presence of signs or symptoms 
that may be attributed to a drug) 
Total 5948 (100%) 5948 100.0 
Table 3-1: Categories and sub-categories of documented CIs 
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3.3 Intervention recommendations 
An average of 1.6 recommendations were made for each intervention, indicating that 
multiple recommendations were common. The most common type of recommendation 
related to a change in therapy, with 40.1% (3833 occasions) of interventions receiving 
these types of recommendations. These changes were commonly a change of drug (846 
occasions), or a dose change (642 dose increases, 652 dose decreases; Table 3-2).  
Provision of information was the next most common type of recommendation, with 34.7% 
(3312) of interventions receiving recommendations of this type. Within this type, 73.6% 
(2437 occasions) of recommendations related to, presumably, verbal provision of 
information in the form of a counselling or education session. When a referral 
recommendation was made, this was almost uniformly to the prescriber (91.3% or 1786 
occasions; Table 3-2). These two recommendations (an education or counselling session 
and referral to the prescriber) accounted for 44.2% (4223 of the 9551) of all 
recommendations made by pharmacists to resolve the identified DRP.  
Category Subcategory 
Number (%) 
of Category 
Number (%) of 
Total 
A change in 
therapy 
R1 Dose increase 642 (16.7%) 
3833 (40.1%) 
R2 Dose decrease 652 (17.0%) 
R3 Drug change 846 (22.1%) 
R4 Drug formulation change 383 (10.0%) 
R5 Drug brand change 96 (2.5%) 
R6 Dose frequency/schedule change 527 (13.7%) 
R7 Prescription not dispensed 307 (8.0%) 
R8 Other changes to therapy 380 (9.9%) 
A referral 
required 
R9 Refer to prescriber 1786 (91.3%) 
1956 (20.5%) 
R10 Refer to hospital 36 (1.8%) 
R11 Refer for medication review 76 (3.9%) 
R12 Other referral required 58 (3.0%) 
Provision of 
information 
R13 Education or counselling session 2437 (73.6%) 
3312 (34.7%) 
R14 Written summary of medications 260 (7.9%) 
R15 Recommend dose administration aid 75 (2.3%) 
R16 Other written information 540 (16.3%) 
Monitoring 
R17 Monitoring: Non-laboratory  277 (61.6%) 
450 (4.7%) 
R18 Monitoring: Laboratory test 173 (38.4%) 
Other R19 No Recommendation Necessary 111* 
 
Total 9551 9551 (100.0%) 
Table 3-2: Recommendations made to address identified DRPs (*R19 
recommendations have been excluded from analysis) 
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When the types of recommendations were compared to the initial categories of 
interventions, a number of relationships were identified (Table 3-3). Interventions where 
the recommendation was for a change in therapy were more likely to be either drug 
selection problems or dosage problems (χ2 = 2165.2, df = 7, p < 0.001). Interventions 
where a referral was required were more likely to involve a DRP associated with toxicity or 
an untreated indication requiring addition of therapy (χ2 = 659.2, df = 7, p < 0.001). 
Recommendations where information was provided were more likely to be associated 
with education or compliance issues (χ2 = 1691.3, df = 7, p < 0.001). 
Category 
Number (%) of DRPs and Recommendation Type 
A change in 
therapy 
Referral 
required 
Information 
provision 
Monitoring Total 
Drug selection 1620 (56.3%) 599 (20.8%) 534 (18.6%) 123 (4.3%) 2876 (100.0%) 
Over/underdose 1110 (62.9%) 348 (19.7%) 269 (15.2%) 37 (2.1%) 1764 (100.0%) 
Compliance 307 (32.6%) 221 (23.5%) 382 (40.6%) 32 (3.4%) 942 (100.0%) 
Undertreated 193 (35.8%) 193 (35.8%) 126 (23.4%) 27 (5.0%) 539 (100.0%) 
Monitoring 20 (7.3%) 63 (22.9%) 94 (34.2%) 98 (35.6%) 275 (100.0%) 
Education/information 207 (9.6%) 176 (8.2%) 1695 (78.8%) 74 (3.4%) 2152 (100.0%) 
Not classifiable 51 (36.2%) 56 (39.7%) 30 (21.3%) 4 (2.8%) 141 (100.0%) 
Toxicity/ADR 325 (37.7%) 300 (34.8%) 182 (21.1%) 55 (6.4%) 862 (100.0%) 
Total 3833 1956 3312 450 
9551 
(100.0%) 
Table 3-3: Recommendations made by category of intervention 
3.4 Clinical significance 
During the documentation process, pharmacists were asked to assign a clinical significance 
to the intervention. S3 interventions were those that were likely to require medical 
intervention to resolve and S4 were those that were likely to require hospitalisation to 
resolve (see Table 2-6 and Appendix 3). Almost half of the interventions (42.6% or 2535 
occasions) were classified as either of moderate (S3) or severe (S4) level of clinical 
significance by the documenting pharmacist (Table 3-4). 
  # % 
S1 908 15.3 
S2 2505 42.1 
S3 2119 35.6 
S4 416 7.0 
Total 5948 100.0 
Table 3-4: Clinical significance of the interventions as assigned by the documenting 
pharmacist 
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When compared to the recommendations made by the pharmacist, more significant 
interventions (S3 or S4) were associated with a drug change, contact with the prescriber 
or referral to a hospital, or a monitoring recommendation. Less significant interventions 
(S1 or S2) were more commonly associated with information or educational 
recommendations (Table 3-5). 
Category Subcategory 
Low Clinical 
Significance 
High Clinical 
Significance 
Total 
A change in 
therapy 
R1 Dose increase 326 (50.8%) 316 (49.2%) 642 
R2 Dose decrease 295 (45.2%) 357 (54.8%) 652 
R3 Drug change 273 (32.3%) 573 (67.7%) 846 
R4 Drug formulation change 240 (62.7%) 143 (37.3%) 383 
R5 Drug brand change 62 (64.6%) 34 (35.4%) 96 
R6 
Dose frequency/schedule 
change 
328 (62.2%) 199 (37.8%) 527 
R7 Prescription not dispensed 115 (37.5%) 192 (62.5%) 307 
R8 Other changes to therapy 184 (48.4%) 196 (51.6%) 380 
A referral 
required 
R9 Refer to prescriber 636 (35.6%) 1150 (64.4%) 1786 
R10 Refer to hospital 5 (13.9%) 31 (86.1%) 36 
R11 Refer for medication review 36 (47.4%) 40 (52.6%) 76 
R12 Other referral required 23 (39.7%) 35 (60.3%) 58 
Provision of 
information 
R13 
Education or counselling 
session 
1645 (67.5%) 792 (32.5%) 2437 
R14 
Written summary of 
medications 
181 (69.6%) 79 (30.4%) 260 
R15 
Recommend dose 
administration aid 
44 (58.7%) 31 (41.3%) 75 
R16 Other written information 443 (82.0%) 97 (18.0%) 540 
Monitoring 
R17 Monitoring: Non-laboratory  131 (47.3%) 146 (52.7%) 277 
R18 Monitoring: Laboratory test 56 (32.4%) 117 (67.6%) 173 
Total 5023 (52.6%) 4528 (47.4%) 9551 
Table 3-5: Recommendations made and their clinical significance 
The interventions of higher clinical significance were more likely to be undertreatment or 
toxicity problems (χ2 = 751.8, df = 7, p < 0.001), whilst educational interventions were 
usually graded as less significant by the documenting pharmacists (Table 3-6). 
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Category 
Low clinical 
significance 
High clinical 
significance 
Total 
Drug selection 847 (46.3%) 982 (53.7%) 1829 
Over/underdose 610 (51.6%) 573 (48.4%) 1183 
Compliance 357 (64.1%) 200 (35.9%) 557 
Undertreated 87 (32.0%) 185 (68.0%) 272 
Monitoring 66 (47.1%) 74 (52.9%) 140 
Education/information 1216 (86.1%) 196 (13.9%) 1412 
Not classifiable 67 (60.9%) 43 (39.1%) 110 
Toxicity/ADR 163 (36.6%) 282 (63.4%) 445 
Total 3413 (57.4%) 2535 (42.6%) 5948 
Table 3-6: Clinical significance of different intervention types 
The clinical significance reported by the pharmacists appeared to correlate well with the 
economic value determined by the independent expert panel (see Chapter 2 and section 
3.9). As the significance code increased, the average cost saving to the Australian 
healthcare system (as determined by the panel) also increased (Kruskal-Wallis χ2 = 17.9, df 
= 3, p < 0.001; Jonckheere-Terpstra statistic = 4.2, p < 0.001). 
3.5 ‘Other’ interventions 
Despite the refinement that the DOCUMENT DRP Classification System underwent before 
being used in the PROMISe III trial (see Chapter 2), 1210 (20.3%) interventions were still 
documented under the ‘Other’ categories. Upon analysis of a random selection of ‘Other’ 
interventions, it appeared that in most cases the pharmacist chose the correct 
DOCUMENT category, but then chose ‘Other’ as the sub-category, despite a more 
appropriate sub-category being available. Only 353 out of 2535 (13.9%) interventions of 
higher clinical significance were documented in an ‘Other’ category, compared to 857 out 
of 3413 (25.1%) interventions of lower clinical significance (χ2 = 75.53, df = 1, p < 0.001). 
3.6 Drugs involved 
For 5642 of the 5948 interventions, a specific drug was identified by the documenting 
pharmacist. A wide range of drugs (447 different generic entities) were involved, 
indicating that a range of different interventions are performed within community 
pharmacy. However, it should be noted that each intervention was listed in the database 
as being associated with the dispensed drug, although other drugs may have also been 
associated with the intervention. This design issue has some ramifications, as 
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interventions in which a drug change was made may appear to suggest that a particular 
drug was the problem, when in fact it was the solution. 
3.6.1 Number of clinical interventions 
The vast majority of medications involved in documented CIs can be grouped using a 
multilevel anatomical therapeutic category (ATC) classification code. The groupings of the 
drugs involved are shown in Table 3-7 to Table 3-10. Codes are included in the tables to 
enable determination of members of particular therapeutic classification groups. 
When the drugs involved in the interventions were considered by generic drug name 
(Table 3-7), the most common drug involved was the widely used antibiotic, amoxycillin 
(associated with 204 or 3.4% of interventions). Nearly one third of all the interventions 
were related to the top 20 generic medications shown in Table 3-7.  
Despite the removal of 282 prompted PPI interventions from the analysis, this class of 
medications was still responsible for 233 (3.9%) of the overall interventions (Table 3-8). It 
should be noted that 143 interventions were in Group One and Group Two pharmacies 
(who did not have the prompt, nor were they aware of the details of the prompt), as such 
these interventions were known to be unrelated to the prompt. The remaining 90 
interventions were in Group Three pharmacies who did have the prompt, and may have 
been related to the prompt, but not excluded under the method detailed in Chapter 2. It is 
likely that the high number of interventions in this drug group was therefore related to the 
high frequency of dispensing of this class of agents (Table 3-12). 
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ATC Code 
Level 5 
Drug Number 
% of 
interventions 
J01CA04 Amoxycillin 204 3.43 
H02AB06 Prednisolone 113 1.90 
A10BA02 Metformin 107 1.80 
J01DB01 Cephalexin 104 1.75 
A02BC05 Esomeprazole 102 1.71 
J01CR02 Amoxycillin and enzyme inhibitor 98 1.65 
N02AA05 Oxycodone 95 1.60 
C10AA05 Atorvastain 94 1.58 
N02AA59 Codeine (combinations excluding psycholeptics) 92 1.55 
R03AK06 Salmeterol and other drugs for obstructive airways 92 1.55 
R03AC02 Salbutamol 89 1.50 
C09AA04 Perindopril 83 1.40 
J01FA06 Roxithromycin 82 1.38 
N02BE01 Paracetamol 78 1.31 
N02AX02 Tramadol 75 1.26 
J01FA01 Erythromycin 68 1.14 
B01AA03 Warfarin 67 1.13 
M01AC06 Meloxicam 61 1.03 
C09DA04 Irbesartan and diuretics 60 1.01 
J01AA02 Doxycycline 57 0.96 
  Others (< 1% of all interventions) 4127 69.38 
Total 5948 100.0 
Table 3-7: Top 20 ATC level 5 coded drugs involved in interventions  
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ATC Code 
Level 4 
Drug Number 
% of 
interventions 
A02BC Proton pump inhibitors 233 3.92 
C10AA HMG CoA reductase inhibitors 210 3.53 
J01CA Penicillins with extended spectrum 204 3.43 
J01FA Macrolides 199 3.35 
N02AA Natural opium alkaloids 199 3.35 
C09AA ACE inhibitors; plain 171 2.87 
H02AB Glucocorticoids 140 2.35 
N06AB Selective serotonin reuptake inhibitors 132 2.22 
N06AX Other antidepressants 130 2.19 
C09CA Angiotensin II antagonists; plain 116 1.95 
C08CA Dihydropyridine derivatives 111 1.87 
A10BA Biguanides 107 1.80 
J01DB First-generation cephalosporins 105 1.77 
R03AC 
Selective beta-2-adrenoreceptor 
agonists 
104 1.75 
C09DA Angiotensin II antagonists and diuretics 102 1.71 
J01CR 
Combinations of penicillins; including 
beta-lactamase inhibitors 
98 1.65 
R03AK 
Adrenergics and other drugs for 
obstructive airways disease 
92 1.55 
C07AB Beta-blocking agents; selective 90 1.51 
N05BA Benzodiazepine derivatives 86 1.45 
N02BE Anilides 85 1.43 
 
Others 3234 54.37 
Total 5948 100.0 
Table 3-8: Top 20 ATC level 4 coded drug groups involved in interventions 
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ATC Code 
Level 3 
Drug Number 
% of 
interventions 
J01C Beta-lactam antibacterials; penicillins 388 6.52 
N02A Opioids 320 5.38 
N06A Antidepressants 311 5.23 
A02B 
Drugs for peptic ulcer and gastro-
oesophageal disease (GORD) 
268 4.51 
C10A Lipid modifying agents; plain 242 4.07 
M01A 
Anti-inflammatory and anti-rheumatic 
products; non-steroids 
216 3.63 
J01F 
Macrolides; lincosamides and 
streptogramins 
212 3.56 
R03A Adrenergics; inhalants 196 3.30 
C09A ACE inhibitors; plain 171 2.87 
A10B Blood glucose lowering drugs; excl. insulins 166 2.79 
J01D Other beta-lactam antibacterials 144 2.42 
H02A Corticosteroids for systemic use; plain 141 2.37 
B01A Anti-thrombotic agents 140 2.35 
C07A Beta-blocking agents 130 2.19 
C09C Angiotensin II antagonists; plain 116 1.95 
C08C 
Selective calcium channel blockers with 
mainly vascular effects 
111 1.87 
R03B 
Other drugs for obstructive airway disease; 
inhalants 
104 1.75 
C09D Angiotensin II antagonists; combinations 103 1.73 
N02B Other analgesics and antipyretics 93 1.56 
N05A Antipsychotics 93 1.56 
  Others 2283 38.38 
Total 5948 100.0 
Table 3-9: Top 20 ATC level 3 coded drug groups involved in interventions 
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ATC Code 
Level 2 
Drug Number 
% of 
interventions 
J01 Antibacterials for systemic use 866 14.56 
C09 Agents acting on the renin-angiotensin system 428 7.20 
N02 Analgesics 428 7.20 
N06 Psychoanaleptics 318 5.35 
R03 Drugs for obstructive airway diseases 302 5.08 
A02 Drugs for acid related disorders 271 4.56 
C10 Lipid modifying agents 264 4.44 
N05 Psycholeptics 236 3.97 
M01 Anti-inflammatory and anti-rheumatic products 216 3.63 
A10 Drugs used in diabetes 193 3.24 
S01 Ophthalmologicals 155 2.61 
C08 Calcium channel blockers 150 2.52 
H02 Corticosteroids for systemic use 141 2.37 
B01 Anti-thrombotic agents 140 2.35 
C07 Beta-blocking agents 130 2.19 
G03 
Sex hormones and modulators of the genital 
system 
111 1.87 
D07 Corticosteroids; dermatological preparations 106 1.78 
M05 Drugs for treatment of bone diseases 88 1.48 
C03 Diuretics 81 1.36 
C01 Cardiac therapy 79 1.33 
 
Others 1245 20.93 
Total 5948 100.0 
Table 3-10: Top 20 ATC level 2 coded drug groups involved in interventions 
As can be seen from the above tables, a wide range of drugs were associated with 
documented CIs, such as antibiotics, analgesics, psychoactive agents, cardiovascular drugs 
and drugs for respiratory disorders.  
3.6.2 Frequency of CIs for particular drug groups 
Although some conclusions can be drawn from the frequency of interventions with 
different generic drugs and drug groups, it is more appropriate to consider the frequency 
of interventions in relation to the frequency of prescriptions for those drugs. Many 
uncommon drugs were associated with an intervention, resulting in a high intervention 
frequency. Therefore, only the medications that were associated with 55 or more of the 
total interventions (approximately 1%) were included in Table 3-11. 
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ATC Level 5 
Code 
Drug # CIs # Rx’s 
Intervention 
frequency 
J01CE02 Phenoxymethylpenicillin 55 4748 1.16 
J01FA01 Erythromycin 68 6963 0.98 
H02AB06 Prednisolone 113 17788 0.64 
N02AX02 Tramadol 75 16067 0.47 
N02AA05 Oxycodone 95 20748 0.46 
R03AK06 
Salmeterol and other drugs for 
obstructive airways disease 
92 21446 0.43 
J01CA04 Amoxycillin 204 48469 0.42 
J01AA02 Doxycycline 57 13615 0.42 
J01FA06 Roxithromycin 82 20953 0.39 
J01CR02 
Amoxycillin and enzyme 
inhibitor 
98 27050 0.36 
M01AC06 Meloxicam 61 17569 0.35 
A10BA02 Metformin 107 31381 0.34 
N02AA59 
Codeine (combinations 
excluding psycholeptics) 
92 28386 0.32 
R03AC02 Salbutamol 89 28414 0.31 
J01DB01 Cephalexin 104 33870 0.31 
B01AA03 Warfarin 67 23310 0.29 
N02BE01 Paracetamol 78 33520 0.23 
C09DA04 Irbesartan and diuretics 60 27329 0.22 
C09AA05 Ramipril 56 26163 0.21 
C09AA04 Perindopril 83 40387 0.21 
A02BC05 Esomeprazole 102 50079 0.20 
C10AA07 Rosuvastatin 55 31087 0.18 
C10AA05 Atorvastatin 94 75424 0.12 
Unknown 83 49407 0.17 
Others 3878 1319750 0.29 
Total 5948 2013923 0.30 
Table 3-11: Intervention rate for ATC Level 5 medications 
The medications with the highest proportions of interventions were the antibiotics, 
phenoxymethylpenicillin and erythromycin. Typical concerns with penicillins included 
allergies and correct paediatric dosing. Erythromycin had similar concerns to penicillin, but 
also had a large number of drug interactions which may have increased the number of 
interventions required. 
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ATC Level 
4 Code 
Drug # CIs # Rx’s 
Intervention 
frequency 
J01CE Beta-lactamase sensitive penicillins 56 5162 1.08 
M01AB 
Acetic acid derivatives and related 
substances 
66 11528 0.57 
J01FA Macrolides 199 35371 0.56 
H02AB Glucocorticoids, systemic 140 25264 0.55 
N02AX Other opioids 75 16067 0.47 
R03BA Glucocorticoids, inhaled 76 16988 0.45 
R03AK 
Adrenergics and other drugs for 
obstructive airway diseases 
92 21446 0.43 
J01CA Penicillins with extended spectrum 204 48490 0.42 
S01AA Antibiotics, ophthalmic 62 15977 0.39 
J01AA Tetracyclines 62 16208 0.38 
N06AX Other antidepressants 130 35056 0.37 
J01CR 
Combinations of penicillins; including 
beta-lactamase inhibitors 
98 27146 0.36 
N02AA Natural opium alkaloids 199 56519 0.35 
M05BA Bisphosphonates 58 16828 0.34 
A10BA Biguanides 107 31381 0.34 
M01AC Oxicams 65 19087 0.34 
R03AC 
Selective beta-2-adrenoreceptor 
agonists 
104 31695 0.33 
J01DB First-generation cephalosporins 105 34256 0.31 
D07AC 
Corticosteroids; potent (group III) 
dermatologicals 
64 21095 0.30 
B01AA Vitamin K antagonists 67 23310 0.29 
N05BA Benzodiazepine derivatives 86 35251 0.24 
N06AB Selective serotonin reuptake inhibitors 132 54757 0.24 
N02BE Anilides 85 36063 0.24 
C09DA Angiotensin II antagonists and diuretics 102 49299 0.21 
C09AA ACE inhibitors; plain 171 85587 0.20 
C08CA Dihydropyridine derivatives 111 57275 0.19 
C07AB Beta-blocking agents; selective 90 46614 0.19 
A02BC Proton pump inhibitors 233 122911 0.19 
B01AC 
Platelet aggregation inhibitors; excluding 
heparin 
61 37743 0.16 
C09CA Angiotensin II antagonists; plain 116 72812 0.16 
C10AA HMG CoA reductase inhibitors 210 160129 0.13 
Unknown 83 49407 0.17 
Others 2439 697201 0.35 
Total 5948 2013923 0.30 
Table 3-12: Intervention rate for ATC Level 4 medication groups 
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ATC Level 
3 Code 
Drug # CIs # Rx’s 
Intervention 
frequency 
N07B Drugs used in addictive disorders 56 5649 0.99 
J05A Direct acting antivirals 57 6701 0.85 
J01F 
Macrolides; lincosamides and 
streptogramins 
212 36364 0.58 
H02A Corticosteroids for systemic use; plain 141 25443 0.55 
J01C Beta-lactam antibacterials; penicillins 388 85703 0.45 
M01A 
Anti-inflammatory and anti-rheumatic 
products; non-steroids 
216 49956 0.43 
J01A Tetracyclines 62 16208 0.38 
S01A Anti-infectives 62 16226 0.38 
R03A Adrenergics; inhalants 196 53141 0.37 
N02A Opioids 320 87490 0.37 
N03A Antiepileptics 68 18732 0.36 
M05B 
Drugs affecting bone structure and 
mineralisation 
88 24382 0.36 
N05A Antipsychotics 93 27889 0.33 
J01D Other beta-lactam antibacterials 144 44419 0.32 
R03B 
Other drugs for obstructive airway 
disease; inhalants 
104 33077 0.31 
A10B 
Blood glucose lowering drugs; excl. 
insulins 
166 56766 0.29 
N06A Antidepressants 311 109020 0.29 
D07A 
Corticosteroids for dermatological use; 
plain 
78 29158 0.27 
N02B Other analgesics and antipyretics 93 37176 0.25 
N05B Anxiolytics 86 35288 0.24 
C07A Beta-blocking agents 130 58996 0.22 
B01A Anti-thrombotic agents 140 63572 0.22 
C09D Angiotensin II antagonists; combinations 103 49907 0.21 
A02B 
Drugs for peptic ulcer and gastro-
oesophageal disease (GORD) 
268 132910 0.20 
C09A ACE inhibitors; plain 171 85587 0.20 
C08C 
Selective calcium channel blockers with 
mainly vascular effects 
111 57275 0.19 
N05C Hypnotics and sedatives 57 30607 0.19 
C09C Angiotensin II antagonists; plain 116 72812 0.16 
C10A Lipid modifying agents; plain 242 173169 0.14 
Unknown 87 52260 0.17 
Others 1582 438040 0.36 
Total 5948 2013923 0.30 
Table 3-13: Intervention rate for ATC Level 3 medication groups 
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ATC Level 
2 Code 
Drug # CIs # Rx’s 
Intervention 
frequency 
J05 Antivirals for systemic use 57 6701 0.85 
S02 Otologicals 69 8120 0.85 
N07 Other nervous system drugs 61 7229 0.84 
H02 Corticosteroids for systemic use 141 25443 0.55 
J01 Antibacterials for systemic use 866 196806 0.44 
M01 
Anti-inflammatory and anti-
rheumatic products 
216 50028 0.43 
N03 Antiepileptics 68 18732 0.36 
M05 
Drugs for treatment of bone 
diseases 
88 24382 0.36 
C03 Diuretics 81 23446 0.35 
R03 
Drugs for obstructive airway 
diseases 
302 88009 0.34 
N02 Analgesics 428 130181 0.33 
D07 
Corticosteroids; dermatological 
preparations 
106 32333 0.33 
C01 Cardiac therapy 79 25077 0.32 
A10 Drugs used in diabetes 193 62499 0.31 
N06 Psychoanaleptics 318 115374 0.28 
N05 Psycholeptics 236 93784 0.25 
G03 
Sex hormones and modulators of 
the genital system 
111 49119 0.23 
C07 Beta-blocking agents 130 58996 0.22 
B01 Anti-thrombotic agents 140 63572 0.22 
A02 Drugs for acid related disorders 271 134696 0.20 
S01 Ophthalmologicals 155 77343 0.20 
C08 Calcium channel blockers 150 76654 0.20 
C09 
Agents acting on the renin-
angiotensin system 
428 230415 0.19 
C10 Lipid modifying agents 264 183423 0.14 
Unknown 87 52260 0.17 
Others 903 179301 0.50 
Total 5948 2013923 0.30 
Table 3-14: Intervention rate for ATC Level 2 medication groups 
3.7 Prescription factors 
Two previous studies found that original prescriptions were subject to more interventions 
than repeat prescriptions48,73, therefore for all interventions documented within the 
PROMISe software, the type of prescription (original or repeat) was recorded within the 
database. An original prescription identified prescription items that were dispensed from 
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a new prescription; however, the item may not have been a new item for the patient (for 
example, the patient may have taken the item before but was presenting a prescription on 
original paperwork to the pharmacy that day). A repeat prescription identified items that 
had already been dispensed using that particular prescription including deferred 
prescriptions.  
3.7.1 Original versus repeat prescriptions 
Out of the 5948 interventions, there were 1777 interventions where the database did not 
have adequate information recorded for analysis (Table 3-15). This was due to incorrect 
coding by the pharmacist (for example, searching for the drug name within the software 
rather than linking the intervention to the dispensed prescription) or due to a technical 
data transfer problem. Within the remaining 4171 interventions, there was a much higher 
intervention rate on original prescription items, with 79.5% of all interventions occurring 
on originals despite them only contributing to 45.4% of all dispensed prescriptions (Table 
3-15). This was equivalent to an intervention rate of 0.36%, whereas the intervention rate 
on repeat prescriptions was much lower at only 0.08%. A chi-square test showed a 
significant difference between the two groups (p < 0.001; Table 3-15).  
  # CIs % 
Valid 
Percent 
# Rx’s % 
CI Rate per 
100 Rx’s 
Repeat 855 14.4 20.5 1098864 54.6 0.08 
Original 3316 55.7 79.5 915059 45.4 0.36 
Total 4171 70.1 100.0 2013923 100.0   
Missing 1777 29.9 Statistics: χ2 = 1947.74, df = 1, p< 0.001 
(StatView®) Total 5948 100.0 
Table 3-15: Number of interventions within each prescription category 
3.8 Patient demographics 
For all patients subject to an intervention, the pharmacist was asked to enter their age 
group and gender. The number of medications that were dispensed to each patient was 
also determined from the patient’s dispensing history and recorded within the PROMISe 
database. Out of the 5948 interventions, 362 were “duplicates” which meant the patient 
had more than one intervention documented against their unique identification number. 
Due to a technical problem early in the trial, 7 interventions did not have a patient 
identification number assigned, resulting in 5580 unique identification numbers.  
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3.8.1 Age range and gender 
Of the 5580 unique patients, 105 interventions did not have an age range or gender 
selected, with an additional 2 interventions with no age range and an additional 
intervention with no gender (Table 3-16). This occurred due to a data transfer problem 
from Aquarius® pharmacies in the first week of the trial.  
Of the 5474 patients where gender was known, 3086 (56.3%) were female, which was 
slightly higher than the Australian Bureau of Statistics 2009 report of 50.2% females in the 
Australian population.166 
 
Gender   
Female Male Unknown Total 
A
ge
 R
an
ge
 
0-3 years 77 116 0 193 
4-12 years 131 116 0 247 
13-20 years 89 67 0 156 
21-64 years 1488 1263 1 2752 
65-80 years 1021 703 0 1724 
81+ years 278 123 0 401 
Unknown 2 0 105 107 
Total 3086 2388 106 5580 
Table 3-16: Age and gender of patients involved in an intervention 
Of the 5473 patients where age was known, 2752 (50.3%) were in the adult age range of 
21-64 years old and 2125 (38.8%) were aged 65 or over. These results were significantly 
different from the Australian Bureau of Statistics 2009166 projected population 
demographics in 2010 (Table 3-17; χ2 = 913.11, df = 2, p < 0.001 [Statview®]), with 
interventions occurring much more commonly in the older population. 
 
PROMISe 
N 
% 
ABS 2010 
Projected N 
% 
A
ge
 
R
an
ge
 0-20 years 596 10.9 1040 19.0 
21-64 2751 50.3 3683 67.3 
65+ years 2125 38.8 750 13.7 
Total 5472 100.0 5472 100.0 
Table 3-17: PROMISe patient demographics compared to expected population (taken 
from the Australian Bureau of Statistics 2010 projections166) 
3.8.2 Average number of medications 
Of the 5580 patients with interventions, only 5219 could be matched to one or more 
prescriptions in the dataset. This was due to the fact that a number of the prescription 
169 | P a g e  
 
interventions were documented without linking the intervention with a dispensed 
prescription or patient history, resulting in the intervention being given a unique patient 
identifier, even though the patient may have visited the pharmacy regularly. Since it was 
known that these patients must have received at least one prescription – despite the fact 
that none could be found – it was elected to treat these values as missing for the purpose 
of calculating the average number of medications per patient, instead of treating them as 
zeros. For those 5219 patients who had medications which could be reliably counted, a 
count of unique medications, as defined by ATC87 level 5, was determined for the three 
month trial period. The median number of unique medications per patient was 4 (range = 
1 – 25; Figure 3-3).  
 
Figure 3-3: Number of patients with the number of unique medications over the trial 
period 
3.9 Cost saving analysis 
An independent expert panel was utilised to determine the average costs and cost savings 
associated with a sample of 200 interventions. This was done by assigning multiple factors 
to each intervention, such as number of GP/specialist visits or the cost of hospital 
admission, if the pharmacist had not intervened. Depending on the clinical significance of 
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the intervention, between $231 and $731 was saved (Table 3-18), with the average 
intervention resulting in a saving of approximately $360. More detail about the calculation 
of the cost saving analysis can be found in the PROMISe III final report164 and the 
methodology article by Stafford et al.165 
Parameter S1 S2 S3 S4 
Quality Adjusted Life Years 0.009 0.0077 0.0113 0.0200 
Quality Adjusted Life ‘Days’ 3.28 2.80 4.12 7.29 
Number of GP visits 1.3103 1.1554 1.7468 2.4479 
Cost of GP visits -$43.96 -$38.76 -$58.60 -$82.13 
Number of specialist visits 0.2987 0.3278 0.4590 0.9390 
Cost of specialist visits -$16.71 -$18.61 -$26.26 -$50.21 
Cost of investigations -$23.91 -$38.67 -$36.99 -$68.21 
Duration of hospital admission 0.1382 0.2412 0.2683 0.6060 
Cost of hospital admissions -$137.57 -$224.35 -$274.17 -$555.00 
Cost of medications -$9.04 $15.93 -$58.95 $24.46 
Total Health Resource Utilisation -$231.19 -$304.47 -$454.97 -$731.09 
Table 3-18: Average change in health resource utilisation due to a clinical intervention 
3.10 Discussion of types of clinical interventions 
The overall intervention rate of 0.3% was comparable to other community pharmacy 
intervention studies, both in Australia and overseas61,64,66,77,78,81,84, however it was lower 
than the previous PROMISe II study where the intervention rate was 0.55%.81 This may 
have been due in part to the longer running time, as PROMISe III ran for 12 weeks as 
opposed to the 6 week PROMISe II trial. The PROMISe III trial also saw a significant decline 
in the intervention rate over the trial period, which has been noted in several previous 
studies.34,59,66,79,136 It is possible that a degree of ‘trial fatigue’ occurred, where the 
participants become complacent in their duties, leading to a tapering level of participation 
during the trial. This phenomenon has often been discussed in relation to trials with 
computer-generated alerts, where pharmacists become ‘fatigued’ with the prompt, 
resulting in a declining effect over time.38,120,136 The participating pharmacies only received 
financial incentives before and after the trial, therefore it is possible that the lack of a ‘fee-
for-service’ reimbursement scheme also contributed to the decline. Previous studies have 
noted that some pharmacists believe that increasing the level of remuneration will 
improve their provision of services53,109, therefore it is possible that a fee-for-service 
model may lead to an improved intervention rate and help to combat the declining rate 
over time. It is unknown whether it was only the documented intervention rate that 
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declined over time, or whether the pharmacists also decreased the number of 
interventions performed. Again, a fee-for-service model may help maintain the 
documented intervention rate as the pharmacies would need to sustain adequate records 
to facilitate their payments. However, the effect on the performed intervention rate 
would continue to remain unknown. 
Pharmacists in the PROMISe III study were required to categorise the nature of the 
problem that they identified and resolved using the DOCUMENT DRP Classification 
System. This is in contrast with other studies, where researchers were used to categorise 
the problem from information provided by the documenting pharmacist.27,62,63,73,76,78,83 
Asking the documenting pharmacist to classify the problem may have led to more 
inconsistency within this study, however, the range of categories and subcategories were 
similar to those documented within the previous PROMISe II study,81 and were also in 
keeping with our understanding of the types of DRPs identified in routine community 
pharmacy practice. Over 50% of the DRPs identified related to either the selection or dose 
of the medication, with a further 24% related to education or information. The nature of 
the problems also appeared to be consistent with those typically detected by community 
pharmacists in other published studies.60,61,68,69,75,78,79,167,168 Although many studies have 
not recorded adherence issues as a clinical intervention, one study did find 9.4% of 
interventions were due to an adherence problem79, which was the same as the 9.4% 
identified in the PROMISe III study. Howard et al. identified that over 30% of preventable 
drug-related hospital admissions were due to adherence problems10, highlighting the 
importance of this type of intervention which can improve patient compliance within the 
community environment before hospitalisation is necessary. 
Patients often received more than one recommendation to resolve the DRP, with the most 
common type of recommendation related to a change in therapy, such as a change of 
drug or a dose change. Provision of information was also common, as was a referral to the 
prescriber. These two recommendations (an education or counselling session and referral 
to the prescriber) accounted for 44.2% of all recommendations made by pharmacists to 
resolve the DRP. Again, this is consistent with our understanding of community pharmacy 
practice, where potential problems are often resolved by discussion with the patient, their 
prescriber or both.  
172 | P a g e  
 
Almost half of the clinical interventions (42.6%) were classified as being at either a 
moderate or high level of clinical significance by the documenting pharmacist. It is a 
limitation of the study that pharmacists may overstate the clinical significance of an 
intervention. However, the clinical significance reported by the pharmacists did appear to 
correlate well with the economic value determined by the expert panel; as the significance 
code increased, the average cost saving to the Australian healthcare system (as 
determined by the panel) also increased. 
There are several possible explanations for the finding that around 20% of interventions 
were documented in the ‘Other’ categories. In most cases, it appeared that the 
pharmacist chose the correct DOCUMENT category, but then incorrectly chose ‘Other’ as 
the sub-category. This may have been caused by a lack of time or lack of motivation 
causing the pharmacists to select ‘Other’ rather than refer to the help files to classify a 
difficult case. This was supported by the finding that there were a significantly lower 
proportion of highly significant interventions documented within the ‘Other’ category, 
possibly indicating that pharmacists spent more time and effort classifying an intervention 
they felt was important. Within focus groups conducted post-trial, participating 
pharmacists also admitted to using the ‘Other’ sub-categories or not documenting the 
intervention at all if they found the intervention hard to classify. 
Pharmacists were asked to identify a single drug involved with the intervention, which was 
recorded in the database using the ATC classification system.87 The generic drugs 
associated with the largest total number of interventions were amoxycillin, prednisolone, 
metformin, cephalexin and esomeprazole. Common drug groups involved included proton 
pump inhibitors, HMG CoA reductase inhibitors, antibiotics, analgesics and agents acting 
on the renin-angiotensin system. This differs from the previous PROMISe II trial that 
reported drugs for diabetes, drugs for respiratory disorders and antibiotics as the most 
common drug groups. Only one other study reported interventions at the drug group 
level, where NSAIDs, beta-blockers, agents acting on the renin-angiotensin system, insulin, 
inhaled beta2-agonists and antidepressants were found to be the drugs most commonly 
associated with an intervention.78 The majority of the other studies have only reported the 
frequency of drugs within the system they work on. In these studies, drugs acting on the 
cardiovascular system, central nervous system, respiratory system and infections were 
most commonly reported.59,60,62,63,68,71,73,82,84 The type of drug involved in these 
international studies differs from those seen in the PROMISe III trial and this difference is 
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most likely due to diverse prescribing habits between countries, resulting in different 
drugs that the pharmacists intervene on. A difference was also seen between the previous 
PROMISe II study and this study, which may be due to the prompt used in PROMISe II 
which activated with each dispensing of an oral antidiabetic agent136, thus increasing the 
number of interventions on antidiabetic drugs. 
When the number of prescriptions for each group of medications was taken into account, 
medications with the highest proportions of interventions were phenoxymethylpenicillin 
and erythromycin. As mentioned previously, typical concerns with these antibiotics 
include allergies and correct paediatric dosing, as well as erythromycin having a large 
number of drug interactions which may increase the number of interventions required. In 
addition, all of these interventions were tagged as original prescriptions by the 
documentation system, not a repeat issue. This may have contributed to a high 
intervention rate for these antibiotics, due to original prescriptions being associated with 
a significantly higher number of interventions overall. It was also interesting to note the 
high number of interventions for drugs such as prednisolone, tramadol, and oxycodone, 
which all have the potential for serious adverse effects should they be used incorrectly. 
Systemic antibiotics, prednisolone, and analgesics have been identified as some of the 
most common drugs implicated in DRPs experienced by ambulatory care patients7 and 
requiring hospital admission3,10, which may indicate that pharmacists are resolving many 
DRPs that may have otherwise resulted in a drug-related hospital admission. By 
encouraging pharmacists to increase their vigilance with these medications, through the 
use of targeted education or system prompts, the number of preventable drug-related 
admissions could be considerably reduced.10 
As seen in previous studies48,73, original prescriptions were again associated with a higher 
intervention rate. This difference is most likely due to original prescriptions having a 
higher incidence of drug selection errors, drug interactions and education requirements, 
compared to repeat prescriptions. These issues are likely to be fixed with the original 
prescription, therefore subsequent repeat prescriptions do not require further 
intervention, as the pharmacist has deemed the amended original prescription as safe to 
dispense. Additionally, professional standards recommend that a pharmacist offer 
counselling to each patient, especially if the medication is new169, and this communication 
with the patient increases the opportunity to intervene. Unfortunately, many 
interventions did not have ‘original vs repeat’ information recorded within the system. 
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This was due to a design flaw within the software that was detected too late, where if the 
pharmacist recorded an intervention by selecting the drug manually (rather than 
recording the intervention against a dispensed drug in the history), the ‘original vs repeat’ 
field was left blank in the database. Ideally, the selection of ‘original vs repeat’ would be 
mandatory before an intervention could be finalised. 
The patients that were subject to an intervention were significantly older than the general 
population according to data from the Australian Bureau of Statistics 2009.166 This is likely 
to be due to the older population taking more medications, and therefore having an 
increased susceptibility to DRPs requiring intervention. There was also a higher 
percentage of females requiring interventions, which could be due to the aging population 
(which has a higher proportion of females due to longer life expectancy), and also by the 
trend of females tending to access healthcare on a more regular basis170 and tending to 
discuss their health with their family and friends more often. Due to the intervention 
database assigning a unique patient identifier to each individual patient at each pharmacy, 
it is possible that one patient could have more than one ‘identity’ within the database. For 
example, if the same patient had visited two different pharmacies with the PROMISe 
software, their prescriptions and any interventions would have been entered into the 
database under two different ID numbers. Due to privacy issues, these numbers could not 
be associated with the patient’s Medicare number, therefore this limitation was 
unavoidable within the trial environment. However, it is most likely not a large issue as 
most of the software pharmacies were located in different areas, resulting in a decreased 
likelihood that the same patient would have visited more than one PROMISe software 
pharmacy during the trial period. 
An intervention was determined to save $360 on average on healthcare expenditure. This 
shows the importance of performing clinical interventions within the community 
pharmacy environment, with even interventions of low clinical significance saving an 
average of $231. Of course, these figures were calculated through a retrospective analysis 
of what might have happened without the intervention. Ideally, a future study to 
determine actual outcomes over a longer term would allow more accurate costs and 
savings to be calculated. 
In summary, interventions tended to occur more frequently in certain drug groups (such 
as systemic antibiotics, prednisolone and opioids) and certain patient groups (such as 
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older females), as well as occurring more frequently on original prescriptions. However, 
these are not the only factors that contribute to whether an intervention is completed and 
the following two chapters will explore the pharmacy and pharmacist factors that can 
influence the performance and documentation of interventions.  
 
176 | P a g e  
 
4 Chapter 4: Pharmacy data and factors influencing 
pharmacy CI rate 
Throughout the PROMISe trial, a large amount of data was collected on each pharmacy 
and pharmacist through the PROMISe software, online surveys, site visits, and by trained 
observers during the observation weeks. This data was then used to compare the 
pharmacies with national averages to ensure the sample was representative, and also to 
determine any factors that may have influenced the CI rate at the pharmacy level. Both 
bivariate and multivariate analysis between each pharmacy’s intervention rate and any 
influencing factors will be reported within this chapter.  
4.1 Characteristics of the pharmacies 
PROMISe pharmacies were selected to ensure they were likely to be a representative 
sample of all pharmacies within Australia. PhARIA153 and estimated annual prescription 
volume were chosen as the two key measures for selection, since these factors gave some 
indication of location and workload, but also had easily accessible national data from the 
Pharmacy Guild of Australia (PGA).154 The data from the pharmacies was then statistically 
compared to the national figures from the PGA, where PhARIA data was available for 5006 
pharmacies, and prescription volume data for 2395 pharmacies.  
The composition of each of the software groups was also examined to ensure there were 
no statistical differences between the groups. In total, 210 pharmacies were recruited 
which were then divided into the two groups of 24 no software pharmacies and 186 
software pharmacies. The 186 software pharmacies were further divided into the three 
software groups. The no software pharmacies were not required to complete the same 
surveys as the software pharmacies, and so could not be compared in all categories. 
Therefore, the two groups are described separately in the following sections.  
4.1.1 No software pharmacies 
Twenty-four pharmacies were recruited for the no software group. These pharmacies had 
no software installed, but instead had an impartial observer present for five working days 
to collect data. These pharmacies were selected according to their PhARIA and estimated 
annual prescription volume so as to provide a nationally representative sample. 
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4.1.1.1 PhARIA 
Pharmacies were categorised as metropolitan (PhARIA 1) or regional (PhARIA 2-6). There 
was no significant difference between the broad PhARIA groupings of the participating no 
software pharmacies and the national distribution obtained from the PGA (χ2 = 0.00, df = 
1, p = 0.99), which ensured that the no software group was representative of pharmacies 
nationwide in terms of rurality (Table 4-1). 
  
PROMISe National 
N % N % 
PhARIA 1 20 83.3 4166 83.2 
PhARIA 2-6 4 16.7 840 16.8 
Total 24 100 5006 100 
Table 4-1: PhARIA of no software pharmacies compared to national average154 
4.1.1.2 Estimated annual prescription volume 
When grouped, there was no significant difference between the estimated annual 
prescription volume of the participating pharmacies with no software and the national 
average from the PGA (χ2 = 1.73, df = 3, p = 0.63). Therefore, the no software group was 
considered representative of pharmacies nationwide (Table 4-2). 
  
PROMISe National 
N % N % 
Less than 30,000 7 29.2 1526 30.6 
30,000 – 55,000 8 33.3 1792 35.9 
55,000 – 90,000 8 33.3 1188 23.8 
Over 90,000 1 4.2 486 9.7 
Total 24 100 4992 100 
Table 4-2: Estimated annual prescription volume of no software pharmacies 
compared to national average154 
4.1.1.3 Pharmacy location 
No software pharmacies were asked to describe the location of their pharmacy, with most 
pharmacies being located on a shopping strip (Table 4-3). There was no statistical 
difference between the location of no software pharmacies and the software pharmacies 
(χ2 = 0.73, df = 4, p = 0.95). The location of the pharmacies could not be compared to 
national averages as the PGA did not report location data. 
178 | P a g e  
 
 
No software 
pharmacies 
Software 
pharmacies 
N % N % 
Local shopping centre (less than 25 shops) 4 16.7 41 22.2 
Major shopping centre (more than 25 shops) 3 12.5 17 9.2 
Medical centre 2 8.3 17 9.2 
Shopping strip 15 62.5 109 58.9 
Other 0 0.0 1 0.5 
Total 24 100 185 100 
Table 4-3: Location of no software pharmacies compared to software pharmacies 
4.1.2 Software pharmacies 
The remaining 186 pharmacies had the PROMISe software installed into their dispensing 
system for the 12-week trial. These pharmacies were also selected according to their 
PhARIA and estimated weekly prescription volume to provide a nationally representative 
sample. Weekly prescription volume information was collected from the software 
pharmacies (but not from the no software pharmacies) and was considered more 
accurate, therefore the weekly prescription volume data was used for the software 
pharmacy comparisons. 
4.1.2.1 PhARIA and estimated weekly prescription volume 
Of the 186 participating pharmacies, 185 completed the trial successfully, with one 
pharmacy withdrawing due to the unforeseen sale of the business. Out of the 185 
pharmacies that completed the trial, 184 (99.5%) completed the owner survey and again, 
pharmacies were categorised as either metropolitan (PhARIA 1) or regional (PhARIA 2-6). 
There were no statistically significant differences between the 185 pharmacies that 
completed the trial and the population of pharmacies within Australia with regards to 
PhARIA group (Table 4-4; χ2 = 0.98, df = 1, p = 0.32) and weekly prescription volume (Table 
4-5; χ2 = 1.10, df = 4, p = 0.89). There were also no significant differences when all groups 
were compared (Table 4-6; χ2 = 8.02, df = 9, p = 0.53). 
  
PROMISe National 
N % N % 
PhARIA 1 159 85.9 4166 83.2 
PhARIA 2-6 26 14.1 840 16.8 
Total 185 100 5006 100 
Table 4-4: PhARIA of PROMISe software pharmacies compared to national average154 
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PROMISe National 
N % N % 
Up to 400 9 4.9 189 7.9 
400-800 60 32.6 812 33.9 
801-1200 53 28.8 678 28.3 
1201-2000 46 25.0 580 24.2 
Over 2000 16 8.7 137 5.7 
Total 184 100.0 2395 100.0 
Table 4-5: Weekly prescription volume of PROMISe software pharmacies compared 
to national average154 
  
PROMISe National 
N % N % 
P
h
A
R
IA
 1
 
Up to 400 8 4.3 87 3.6 
400-800 53 28.8 676 28.2 
801-1200 46 25.0 488 20.4 
1201-2000 38 20.7 457 19.1 
Over 2000 14 7.6 193 8.0 
P
h
A
R
IA
 2
-6
 Up to 400 1 0.5 34 1.4 
400-800 7 3.8 174 7.3 
801-1200 7 3.8 141 5.9 
1201-2000 8 4.3 113 4.7 
Over 2000 2 1.1 33 1.4 
Total 184 100 2395 100.0 
Table 4-6: PhARIA and weekly prescription volume compared to national average154 
The owner/manager of the pharmacy was asked to estimate the weekly prescription 
volume and this was compared to the actual average weekly prescription volume from the 
pharmacies during the trial. A paired T-test showed no significant difference between the 
estimated weekly prescription volume and the actual volume recorded during the trial 
(t(183) = 0.63, p = 0.53), indicating that the owner/manager’s estimation was reasonably 
accurate. 
4.1.2.2 Dispensing software 
Within Australia, the FRED® dispensing software system had approximately 50% market 
share150 and Aquarius® had approximately 10%151; therefore, the PROMISe sample would 
be expected to be approximately 83% FRED® and 17% Aquarius®. There were 158 FRED® 
pharmacies and 27 Aquarius® pharmacies in the PROMISe sample, which was not 
statistically different from the expected numbers (Table 4-7; χ2 = 0.57, df = 1, p = 0.45). 
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PROMISe Expected 
N % % 
FRED® 158 85.4 83.4 
Aquarius® 27 14.6 16.6 
Total 185 100 100 
Table 4-7: Dispensing software of PROMISe software pharmacies compared to 
national average150,151 
4.1.2.3 Pharmacy location and identification of pharmacy types 
During the enrolment process, pharmacies were asked if they were located in a shopping 
centre, medical centre or shopping strip, with the majority of PROMISe pharmacies 
(58.9%) being located in a shopping strip (Table 4-8). The pharmacies were separated into 
six major groups based on PhARIA and pharmacy location, and no significant differences 
between the distributions of pharmacies within each of the three principal pharmacy 
types across the PhARIA groups was seen (Table 4-9; χ2 = 3.91, df = 2, p = 0.14). 
 
N % 
Local shopping centre (less than 25 shops) 41 22.2 
Major shopping centre (more than 25 shops) 17 9.2 
Medical centre 17 9.2 
Shopping strip 109 58.9 
Other 1 0.5 
Total 185 100 
Table 4-8: Frequency of pharmacy locations 
 
PhARIA 
Total 
1 2 - 6 
Shopping centre 
PROMISe N 51 7 58 
% of Total 27.6% 3.8% 31.4% 
Medical centre 
PROMISe N 17 0 17 
% of Total 9.2% 0.0% 9.2% 
Shopping strip/other 
PROMISe N 91 19 110 
% of Total 49.2% 10.3% 59.5% 
Total 
PROMISe N 159 26 185 
% of Total 85.9% 14.1% 100.0% 
Table 4-9: Frequency of the six pharmacy types sorted by PhARIA and location 
4.1.2.4 Group allocation 
As mentioned in Chapter 2, the software group pharmacies were allocated into the three 
groups using their weekly prescription volume and PhARIA as the determinants. From the 
original 186 pharmacies, the allocation resulted in 40 pharmacies in Group One and 73 
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pharmacies each in Groups Two and Three. After removing the pharmacy that did not 
complete the trial, the pharmacies were still distributed between the three groups with 40 
in Group One, 72 in Group Two and 73 in Group Three (Table 4-10). Only 71 pharmacies 
are shown in Group Two in the table, as the pharmacy that did not complete the owner 
survey was also in this group. 
  
Group One: 
Software only 
Group Two: 
Software with 
reminders 
Group Three: 
Software with 
prompts and 
reminders 
Total 
N % N % N % N % 
P
h
A
R
IA
 1
 
Up to 400 3 7.5 0 0.0 5 6.8 8 4.3 
401 - 800 8 20 20 28.2 25 34.2 53 28.8 
801 - 1200 11 27.5 20 28.2 15 20.5 46 25.0 
1201 - 2000 11 27.5 17 23.9 10 13.7 38 20.7 
Over 2000 1 2.5 5 7.0 8 11.0 14 7.6 
P
h
A
R
IA
 2
 -
 6
 Up to 400 0 0 0 0.0 1 1.4 1 0.5 
401 - 800 2 5 2 2.8 3 4.1 7 3.8 
801 - 1200 3 7.5 2 2.8 2 2.7 7 3.8 
1201 - 2000 1 2.5 3 4.2 4 5.5 8 4.3 
Over 2000 0 0 2 2.8 0 0.0 2 1.1 
Total 40 100 71 100.0 73 100.0 184 100.0 
Table 4-10: Software groups compared by PhARIA and weekly prescription volume 
As the groups were quite small in the table above, the prescription volume groups were 
consolidated to give a larger sample within each cell and therefore a more accurate 
statistical result. A chi-square test still showed no significant differences between the 
groups in relation to their PhARIA or weekly prescription volume (Table 4-11; χ2 = 3.28, df 
= 6, p = 0.77). 
  
  
Group One Group Two Group Three Total 
N % N % N % N % 
Metro 0 - 1200 22 55.0 40 56.3 45 61.6 107 58.2 
Metro 1200+ 12 30.0 22 31.0 18 24.7 52 28.3 
Regional 0 - 1200 5 12.5 4 5.6 6 8.2 15 8.2 
Regional 1200+ 1 2.5 5 7.0 4 5.5 10 5.4 
 Total 40 100.0 71 100.0 73 100.0 184 100.0 
Table 4-11: Software groups compared by PhARIA and weekly prescription volume 
A chi-square test also showed no significant differences between the three software 
groups when compared by the pharmacy types (Table 4-12; χ2 = 6.56, df = 8, p = 0.59). 
182 | P a g e  
 
 
Group One Group Two Group Three Total 
N % N % N % N % 
P
h
A
R
IA
 1
 
    
Shopping 
centre 
12 30.0 20 27.8 19 26.0 51 27.6 
Medical 
centre 
5 12.5 6 8.3 6 8.2 17 9.2 
Shopping 
strip/Other 
17 42.5 36 50.0 38 52.1 91 49.2 
P
h
A
R
IA
 2
-6
 
  
Shopping 
centre 
0 0.0 5 6.9 2 2.7 7 3.8 
Shopping 
strip/Other 
6 15.0 5 6.9 8 11.0 19 10.3 
Total 40 100.0 72 100.0 73 100.0 185 100.0 
Table 4-12: Software pharmacy type compared to group allocation 
4.1.2.5 Pharmacy area  
Each pharmacy owner was asked to categorise their pharmacy into the same sizing groups 
used within the PGA data. According to the Guild Digest 2008154, the average pharmacy 
area was 150m2, with pharmacies located in shopping centres being larger at 169m2 on 
average, shopping strip pharmacies 147m2 on average, and medical centre pharmacies 
being a smaller 87m2 on average. Of the 184 pharmacies that answered the survey, 62 
pharmacies (33.7%) were 101-150m2 and 37 pharmacies (20.1%) were 151-250m2; 
therefore, 54.4% of the participating pharmacies were close to the national average (Table 
4-13). A chi-square test showed no statistical difference between pharmacy area and the 
three software groups (χ2 = 9.06, df = 8, p = 0.34), showing an even spread of different 
pharmacy sizes across the three groups.  
  
Group One Group Two Group Three Total 
N % N % N % N % 
Less than 100m2 7 17.5 16 22.5 16 21.9 39 21.2 
101-150m2 19 47.5 21 29.6 22 30.1 62 33.7 
151-250m2 8 20.0 16 22.5 13 17.8 37 20.1 
251-500m2 6 15.0 16 22.5 16 21.9 38 20.7 
Over 500m2 0 0.0 2 2.8 6 8.2 8 4.3 
Total 40 100.0 71 100.0 73 100.0 184 100.0 
Table 4-13: Software pharmacy area in m2 compared to group allocation 
4.1.2.6 Annual financial turnover  
The annual financial turnover of the PROMISe pharmacies in 2007/8 was fairly evenly 
distributed, with the majority of pharmacies stating a turnover of less than $2 million per 
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annum (Table 4-14). This was slightly lower than the average turnover of $2.4M in 2007, 
as reported in the Guild Digest 2008.154 A chi-square test showed no significant differences 
between the pharmacy’s annual turnover (combined into four groups for the chi-square 
test: Less than 1.5M, 1.5-2.5M, 2.5-4.0M, and Over 4.0M) and the three software groups 
(χ2 = 4.45, df = 6, p = 0.62). 
  N % 
Less than 1.0M 20 10.9 
1.0 - 1.5M 38 20.7 
1.5 - 2.0M 37 20.1 
2.0 - 2.5M 23 12.5 
2.5 - 3.0M 18 9.8 
3.0 - 4.0M 22 12.0 
4.0 - 5.0M 16 8.7 
Over 5.0M 10 5.4 
Total 184 100 
Table 4-14: Annual financial turnover of software pharmacies (categories expressed 
in million dollars)  
4.1.2.7 Percentage of turnover attributed to the dispensary 
As expected, most PROMISe pharmacies attributed the majority of their turnover to their 
dispensary, with only 19 pharmacies (10.3%) having less than 60% of their turnover 
attributable to the dispensary (Table 4-15). A chi-square test showed no significant 
difference between the pharmacy’s estimated dispensary attribution and the three 
software groups (χ2 = 4.56, df = 8, p = 0.81). 
  N % 
Less than 60% 19 10.3 
60 - 69% 21 11.4 
70 - 79% 58 31.5 
80 - 89% 70 38.0 
90 - 99% 16 8.7 
Total 184 100 
Table 4-15: Percentage of total turnover attributed to the dispensary, in software 
pharmacies 
4.1.2.8 Pharmacy trading hours 
On average, pharmacies were open six days per week (mean = 6.4 ± 0.6; mode = 6) and 
traded for an average of 60 hours per week (mean = 59.2 ± 12.5; range = 40 – 103), which 
matched the PGA data, where the average number of opening hours per week was 59.154 
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A chi-square test showed no statistical difference between pharmacy weekly trading hours 
and the three software groups (χ2 = 5.79, df = 6, p = 0.45), showing an even spread of 
pharmacy opening hours across the three groups (Table 4-16). 
  
Group One Group Two Group Three Total 
N % N % N % N % 
Up to 50 13 32.5 17 23.9 26 35.6 56 30.4 
51 – 60 15 37.5 29 40.8 20 27.4 64 34.8 
61 – 70 4 10.0 14 19.7 15 20.5 33 17.9 
Over 71 8 20.0 11 15.5 12 16.4 31 16.8 
Total 40 100.0 71 100.0 73 100.0 184 100.0 
Table 4-16: Software pharmacy trading hours per week compared to group allocation 
4.1.2.9 Pharmacy ownership 
Of the 184 owner survey respondents, 133 (72.3%) were owner-operated, with the 
remainder being run by a manager. A chi-square test showed no statistically significant 
difference between the operation of the pharmacy (owner vs. manager) and the three 
software groups (χ2 = 2.11, df = 2, p = 0.36). Owners were asked how many pharmacists 
were responsible for business decisions within the pharmacy, with an even split of 92 
pharmacies (50.0%) having one responsible pharmacist and the other 92 pharmacies 
having two or more pharmacists responsible (Table 4-17).  
 Owner Manager Total 
1 69 23 92 
2 or more 64 28 92 
Total 133 51 184 
Table 4-17: Number of pharmacists responsible for business decisions in owner vs 
manager-operated pharmacies 
On average, the pharmacies had had the same owner for 10 years, ranging from 1 year to 
47 years.  
4.1.2.10 Banner group pharmacies 
There was also an even split between independent pharmacies and banner group 
pharmacies, with 95 pharmacies (51.6%) identifying themselves as independent. Within 
the 89 banner group pharmacies, the most common groups were Amcal®, Guardian® and 
Pharmore® (Table 4-18). There was also no significant difference between membership in 
a banner group and the three software groups (χ2 = 2.96, df = 2, p = 0.23), which showed 
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an even spread of the two pharmacy types (banner vs. independent) across the three 
groups. 
Banner group Count 
Amcal® 18 
Guardian® 16 
Pharmore® 12 
Priceline Pharmacy® 8 
Capital® 6 
Quality Pharmacy® 5 
UFS Dispensary® 5 
Health Information Pharmacy® 4 
MediAdvice® 4 
Healthwise® 2 
Nova® 2 
Other banner group 7 
Independent pharmacy 95 
Total 184 
Table 4-18: Frequency of each banner group within the software pharmacies 
4.1.2.11 Staff mix 
On average, a software pharmacy had 6.7 full-time equivalent (FTE) staff (range = 2.1 – 
21.4) consisting of 2.3 pharmacists, 1.1 dispensary assistants and 3.3 pharmacy assistants 
(Table 4-19). 
 
Mean Std. Dev. Minimum Maximum Median 
FTE all staff 6.72 3.88 2.10 21.41 5.65 
FTE pharmacists 2.33 1.12 1.00 6.60 2.00 
FTE dispensary assts 1.07 1.19 0.00 6.60 1.05 
FTE pharmacy assts 3.31 2.67 0.00 13.10 2.57 
Table 4-19: Number of FTE staff in software pharmacies 
Number of FTE pharmacists 
On average, there were 2.3 full-time pharmacists per pharmacy (range = 1 – 6.6), which 
was similar to the PGA average of 2.4.154 A Kruskal-Wallis test showed no significant 
difference between the number of full-time pharmacists and the three software groups (χ2 
= 0.40, df = 2, p = 0.82). 
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Employment of pre-registration pharmacists 
During the previous two years, 64 pharmacies (34.8%) had employed a pre-registration 
pharmacist, with 43 (23.4%) pharmacies currently employing a pre-registration 
pharmacist. A chi-square test showed no significant differences between those 
pharmacies employing a pre-registration pharmacist in the last two years and the three 
software groups (χ2 = 1.12, df = 2, p = 0.61). 
4.1.2.12 Services provided by the pharmacy 
The owner/managers were also asked to indicate which professional services their 
pharmacy offered. 
Aged care 
Sixty-two of the PROMISe pharmacies (33.7%) catered for aged care facilities (ACFs) during 
the PROMISe trial. A chi-square test showed no significant differences between the 
pharmacies catering for aged care and the three software groups (Table 4-20; χ2 = 3.23, df 
= 2, p = 0.20). 
 
Group One Group Two Group Three Total 
N % N % N % N % 
Caters for ACFs 16 8.7 27 14.7 19 10.3 62 33.7 
No ACFs 24 13.0 44 23.9 54 29.3 122 66.3 
Total 40 21.7 71 38.6 73 39.7 184 100.0 
Table 4-20: Caters for ACFs compared to group allocation 
Number of professional services offered 
The majority of pharmacies offered two to four additional PGA professional programs 
(Table 4-21) and three to five additional professional services (Table 4-22). 
  N % 
0 12 6.5 
1 17 9.2 
2 45 24.5 
3 67 36.4 
4 35 19.0 
5 8 4.3 
Total 184 100 
Table 4-21: Number of PGA professional programs offered by software pharmacies 
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  N % 
0 1 0.5 
1 5 2.7 
2 16 8.7 
3 30 16.3 
4 55 29.9 
5 44 23.9 
6 19 10.3 
7 11 6.0 
8 3 1.6 
Total 184 100 
Table 4-22: Number of additional professional services offered by software 
pharmacies 
There was no significant difference between the total number of professional services 
offered by the pharmacy and the three software groups (ANOVA F(2,181) = 0.71, p = 0.50). 
Type of PGA professional programs 
During the PROMISe trial, 172 pharmacies (93.5%) were participating in other professional 
programs run by the PGA under the Community Pharmacy Agreement, with the most 
popular programs being the Dose Administration Aid (DAA) Program (164 or 89.1%) and 
the Patient Medication Profile (PMP) Program (140 or 76.1%; Figure 4-1). 
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Figure 4-1: Number of pharmacies participating in concurrent Community Pharmacy 
Agreement professional programs (Note: Mirixa is an industry-sponsored service directed at adherence) 
4.1.2.13 Type of professional services offered 
The most common professional services offered were dose administration aid packing 
(94.6% of pharmacies), Home Medication Reviews (89.1%) and blood pressure monitoring 
(83.2%; Figure 4-2). Data was available for 184 pharmacies, with only one pharmacy 
stating that they did not offer any professional services. However, this pharmacy was 
actually a compounding pharmacy, which could be considered a specialised professional 
service. It should also be noted that the MedsIndex service (which used the patient’s 
dispensing history to provide a compliance ‘score’) was partially funded externally by 
some drug companies, possibly contributing to a higher level of participation than would 
otherwise be expected. It was also largely an automated calculation, with little time 
commitment required by the pharmacist. 
DAA = Dose Administration Aid Program 
DMAS = Diabetes Medication Assistance Service  
PAMS = Pharmacy Asthma Management Service 
PMP = Patient Medication Profile Program 
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Figure 4-2: Number of pharmacies offering each professional service 
4.1.2.14 Visibility of dispensary and accessibility of the pharmacist 
In total, 184 pharmacies received a site visit from a member of the project team. The site 
visitors found that the dispensaries of 167 pharmacies (90.3%) and 156 pharmacists 
(84.3%) were considered to be clearly visible from the front entry. Of the 27 pharmacies 
(14.6%) that possessed a back entry, the dispensary could be clearly seen in 17 of those 
pharmacies (63.0%) and the pharmacist could be clearly seen in 15 pharmacies (55.6%). 
Site visitors believed that the pharmacist was easily accessible to the public in 159 
pharmacies (85.9%), with reasons for inaccessibility including elevated dispensary areas, 
high aisle shelving, pharmacists being behind two counters or the need to ask staff to 
speak to the pharmacist. 
4.1.2.15 Counselling area 
Of the 184 pharmacies that received a site visit, 78 (42.4%) had a permanent counselling 
area (such as an office with a locking door), 71 (38.6%) had a temporary counselling area 
(such as a removable screen) and 35 (19.0%) had no designated counselling area. A chi-
square test showed a significant difference between the type of counselling areas in the 
three software groups (Table 4-23; χ2 = 9.85, df = 4, p = 0.04), with Group One (software 
only) having more pharmacies than expected with no counselling areas, Group Two 
(software with reminders) having more pharmacies than expected with permanent 
counselling areas and Group Three (software with prompts and reminders) having more 
pharmacies than expected with temporary counselling areas. 
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Group One Group Two Group Three Total 
N % N % N % N % 
Permanent 11 6.0 35 19.0 32 17.4 78 42.4 
Temporary  17 9.2 22 12.0 32 17.4 71 38.6 
No counselling area 12 6.5 15 8.2 8 4.3 35 19.0 
Total 40 21.7 72 39.1 72 39.1 184 100.0 
Table 4-23: Type of counselling area compared to group allocation 
4.1.2.16 Number of dispensing terminals 
On average, there were 2.3 ± 1.1 dispensing terminals in each PROMISe pharmacy (mode 
= 2; range = 1 – 6) with only 23 (12.5%) having four or more terminals (Figure 4-3). A chi-
square test showed no significant difference between the number of dispensing terminals 
and the three software groups (χ2 = 0.90, df = 4, p = 0.93). 
 
Figure 4-3: Number of dispensing terminals in PROMISe pharmacies 
4.1.3 Discussion of pharmacy characteristics 
The pharmacies participating in the PROMISe trial appeared to be a representative sample 
of all pharmacies within Australia, with regards to regionality, location and average 
prescription volume. Therefore, it could be hoped that the results of the PROMISe trial 
may represent the results that would be achieved with a national system. The pharmacies 
were also randomly allocated to the three software groups and no statistical differences 
were seen between the measured factors and the pharmacies within each group. 
191 | P a g e  
 
One notable difference was that the annual financial turnover of the PROMISe pharmacies 
in 2007/8 was found to be slightly lower than the average turnover reported by the 
PGA.154 Since the pharmacies were asked to select from categories, rather than state their 
actual turnover, it is possible that the average turnover in PROMISe pharmacies was 
higher than reported. Pharmacies in the ‘over 5.0M’ group may have had a much higher 
turnover than $5.0M, which would elevate the average turnover in the PGA data. 
Therefore, it could be presumed that the PROMISe pharmacies would likely compare to 
the Guild data.  
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4.2 Bivariate pharmacy factors analysis 
The pharmacy characteristics reported within the previous section were then assessed to 
determine which factors may impact on the pharmacy’s overall clinical intervention rate. 
4.2.1 Determining the intervention rate of the pharmacy 
As stated in Chapter 2, data was collected over the trial period and cleansed once the trial 
was finished to determine a valid intervention rate. The 525 OTC interventions and 282 
Group Three prompted interventions were removed before the intervention rate was 
calculated. This cleansing process aimed to provide the most accurate estimate of current 
clinical intervention rates within community pharmacy, without the influence of non-
prescription items or software prompts. The remaining clinical interventions (5948) were 
divided by the total number of prescriptions dispensed by the pharmacy during the trial, 
resulting in the pharmacy’s overall intervention rate. 
The median valid intervention rate during the trial was 0.21% (range = 0.00 – 2.35) or 2.1 
CIs in every 1000 prescriptions (Table 4-24). When the prompted CIs were included for 
comparison, the median intervention rate rose slightly to 2.4 CIs in every 1000 
prescriptions (range = 0.00 – 2.38; Table 4-24).  
  Count Mean Median 
25th 
%ile 
75th 
%ile 
Min. Max. 
Valid intervention 
rate 
185 0.330 0.213 0.105 0.414 0.000 2.345 
Total intervention 
rate (including 
prompted CIs) 
185 0.355 0.239 0.112 0.441 0.000 2.376 
Table 4-24: Intervention rate for pharmacies during the PROMISe trial 
4.2.2 Software group 
The three software groups were compared to the overall pharmacy intervention rates. 
Although the median and mean intervention rate increased as the group number (and 
therefore level of software increased), a Kruskal-Wallis chi-square test showed no 
statistically significant difference between the software group and pharmacy intervention 
rate (Table 4-25; χ2 = 1.03, df = 2, p = 0.60). 
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Pharmacy 
count 
Intervention Rate 
Mean Median 
25th 
%ile 
75th 
%ile 
Min. Max. 
Group One: 
Software only 
40 0.305 0.192 0.102 0.421 0.000 1.457 
Group Two: 
Software with 
reminders 
72 0.317 0.197 0.104 0.380 0.000 2.345 
Group Three: 
Software with 
prompts and 
reminders 
73 0.358 0.235 0.112 0.445 0.000 2.276 
Total 185 0.330 0.213 0.105 0.414 0.000 2.345 
Table 4-25: Group allocation compared to pharmacy intervention rate 
4.2.3 Prescription volume (only participating pharmacists) 
The prescription volume dispensed by participating pharmacists within each pharmacy 
was collected over the 12-week trial period. The prescription volume was then compared 
to the intervention rate within the pharmacy using a Spearman’s correlation. There was a 
moderately weak, but statistically significant, negative correlation between the two 
groups (Spearman’s rho = -0.18, N = 185, p = 0.02), showing that as the prescription 
volume increased, the intervention rate tended to decrease (Figure 4-4). 
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Figure 4-4: Relationship between prescription volume and pharmacy intervention 
rate 
There appeared to be an outlier at the 30000 prescription mark, which is possibly due to 
participant error, and will be discussed at the end of this section.  
4.2.4 Prescription volume (all pharmacists within the pharmacy) 
The total prescription volume dispensed by all pharmacists within each pharmacy 
(including non-participant pharmacists, such as locums not enrolled in the trial) was also 
collected over the 12-week trial period and compared to the intervention rate within the 
pharmacy using Spearman’s correlation. Again, there was a moderately weak, but 
statistically significant, negative correlation (Spearman’s rho = -0.23, N = 185, p = 0.002), 
showing that as the prescription volume increased, the intervention rate tended to 
decrease (Figure 4-5). 
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Figure 4-5: Relationship between total prescription volume and pharmacy 
intervention rate 
4.2.5 Pharmacist workload within each pharmacy 
The pharmacist workload was calculated by determining the actual number of 
prescriptions dispensed per week by the pharmacy during the trial and dividing it by the 
number of FTE pharmacists per week, resulting in the average number of prescriptions 
dispensed by a pharmacist during a 38-hour week. This figure was then compared to the 
overall intervention rate of the pharmacy to determine how much impact the workload of 
the pharmacist had on the pharmacy’s intervention rate. A bivariate correlation test 
showed a moderately weak, but statistically significant, negative correlation between the 
two factors (Spearman’s rho = -0.18, N = 184, p = 0.015), showing that as the workload of 
the pharmacist increased, the pharmacy’s intervention rate tended to decrease (Figure 
4-6). 
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Figure 4-6: Relationship between average pharmacist workload per week and 
pharmacy intervention rate 
A workload incorporating dispensary technicians was also calculated by the actual number 
of prescriptions dispensed per week by the pharmacy divided by the number of FTE 
pharmacists and dispensary technicians per week, resulting in the average number of 
prescriptions dispensed by dispensary staff during a 38-hour week. When technicians 
were included, the bivariate correlation test was no longer significant (Spearman’s rho =    
-0.06, N = 184, p = 0.413). 
4.2.6 Metropolitan or regional (PhARIA) 
A Mann-Whitney test showed no significant difference between the intervention rate in 
metropolitan and regional/rural pharmacies (Mann-Whitney U = 1949.00, z = -0.47, p = 
0.64; Table 4-26).  
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Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Metro (PhARIA 1) 159 0.221 0.000 2.276 0.103 0.400 
Regional (PhARIA 2-6) 26 0.200 0.000 2.345 0.105 0.451 
Total 185 0.213 0.000 2.345 0.105 0.414 
Table 4-26: PhARIA compared to pharmacy intervention rate 
4.2.7 Pharmacy location 
The three location groups of pharmacies (medical centre, shopping centre, shopping 
strip/other) were assessed to determine if location was related to intervention rate, with a 
significant difference seen between the three groups (Kruskal-Wallis χ2= 6.79, df = 2, p = 
0.03). Post-hoc analysis showed that the difference lay between shopping centre and 
medical centre pharmacies, with medical centre pharmacies having a significantly higher 
median intervention rate (Mann-Whitney U = 302.00, z = -2.42, p = 0.016; Table 4-27). 
 
Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Shopping centre 58 0.189 0.022 2.345 0.078 0.264 
Medical centre 17 0.251 0.069 1.401 0.179 0.878 
Shopping strip/Other 110 0.234 0.000 2.276 0.108 0.441 
Total 185 0.213 0.000 2.345 0.105 0.414 
Table 4-27: Location compared to pharmacy intervention rate 
The pharmacies located within shopping centres had the highest average weekly 
prescription volume (1341.65 ± 643.11) followed by medical centre pharmacies (1183.00 ± 
566.18) and shopping strip pharmacies (925.25 ± 532.87), and these differences were 
significant (ANOVA F(2,182) = 10.35, p < 0.001). Shopping centre pharmacies also recorded 
the highest pharmacist prescription workload (529.45 ± 206.01) followed by shopping strip 
pharmacies (458.87 ± 196.69) and medical centre pharmacies (440.88 ± 118.18), but these 
differences were only approaching significance (ANOVA F(2,181) = 2.87, p = 0.059). As 
such, it is possible that medical centre pharmacies may have had a higher intervention 
rate due to the lighter overall prescription workload within the pharmacy, and this was 
explored within the multivariate analysis (see section 4.3). 
4.2.8 Pharmacy type 
The pharmacies were divided into the six pharmacy types that resulted from combining 
the PhARIA and location of the pharmacy (section 4.1.2.3), although there were no 
regional medical centre pharmacies, resulting in five pharmacy types being available for 
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analysis. A Kruskal-Wallis test showed no significant differences between the pharmacy 
type and the pharmacy’s intervention rate (χ2= 7.79, df = 4, p = 0.10; Table 4-28). 
 
Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Metro shopping centre 51 0.189 0.022 0.687 0.078 0.249 
Metro medical centre 17 0.251 0.069 1.401 0.179 0.878 
Metro shopping 
strip/other 
91 0.235 0.000 2.276 0.102 0.445 
Regional shopping centre 7 0.210 0.029 2.345 0.053 1.617 
Regional medical centre 0           
Regional shopping 
strip/other 
19 0.189 0.000 1.298 0.118 0.441 
Total 185 0.213 0.000 2.345 0.105 0.414 
Table 4-28: Pharmacy type compared to pharmacy intervention rate 
4.2.9 Dispensing system 
The pharmacy’s dispensing system (FRED® or Aquarius®) was compared to their 
intervention rate to determine any differences that may have indicated functional 
differences between the systems. A Mann-Whitney test showed no significant difference 
between the dispensing systems and the pharmacy’s intervention rate (U = 2096.00, z = -
0.14, p = 0.89). 
4.2.10 Pharmacy area 
The approximate area of each pharmacy in m2 was compared to the intervention rate. 
Data was only available for 184 pharmacies due to an incomplete owner’s survey. There 
was a significant relationship between the area of the pharmacy and the intervention rate 
(Kruskal-Wallis χ2= 13.28, df = 4, p = 0.01; Table 4-29). Post-hoc analysis showed that 
smaller pharmacies tended to have a significantly higher intervention rate than larger 
pharmacies (Jonckheere-Terpstra t = -2.99, p = 0.003), with additional analysis showing 
that the critical difference lay between the pharmacies with an area of less than 100m2 
and pharmacies with an area between 151 – 250m2 (Mann-Whitney U = 476.50, Z = -2.52, 
p = 0.01). 
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Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Less than 100m2 39 0.319 0.000 2.276 0.118 0.605 
101-150m2 62 0.240 0.025 2.345 0.157 0.441 
151-250m2 37 0.134 0.000 1.112 0.069 0.315 
251-500m2 38 0.192 0.028 1.617 0.098 0.396 
Over 500m2 8 0.082 0.058 0.445 0.077 0.188 
Total 184 0.217 0.000 2.345 0.106 0.419 
Table 4-29: Pharmacy area (in m2) compared to intervention rate 
As there were only 8 pharmacies with an area greater than 500m2, these were combined 
with the 38 pharmacies with areas between 251 – 500m2. Condensing the categories still 
resulted in significant differences between the groups (Kruskal-Wallis χ2= 11.15, df = 3, p = 
0.010; Jonckheere-Terpstra t = -2.87, p = 0.005). 
As expected, the larger pharmacies had a significantly higher prescription volume and 
pharmacist workload (ANOVA F(3,180) = 24.32, p < 0.001 and F(3,179) = 3.30, p = 0.022 
respectively), so it is possible that the larger pharmacies had a lower intervention rate due 
to the workload within the pharmacy. This was explored within the multivariate analysis 
(see section 4.3). 
4.2.11 Annual financial turnover 
The pharmacies were divided into four groups according to their annual financial turnover, 
which was then compared to their intervention rate. A Kruskal-Wallis test showed a 
significant difference between the intervention rates of each turnover group (χ2= 12.76, df 
= 3, p = 0.006), with a Jonckheere-Terpstra post-hoc analysis showing that as the 
pharmacy’s turnover increased, at least between the lower groups, their intervention rate 
tended to decrease (t = -2.67, p = 0.007; Table 4-30).  
 
Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Less than 1.5M 58 0.264 0.052 2.345 0.163 0.605 
1.5 - 2.5M 60 0.165 0.000 1.041 0.085 0.390 
2.5 - 4.0M 40 0.181 0.022 1.210 0.074 0.317 
Over 4.0M 26 0.224 0.025 1.617 0.108 0.414 
Total 184 0.217 0.000 2.345 0.106 0.419 
Table 4-30: Pharmacy financial turnover in 2007/8 compared to pharmacy 
intervention rate 
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Post-hoc analysis showed that the differences lay between the ‘Less than 1.5M’ group and 
the ‘1.5 – 2.5M’ and ‘2.5 – 4.0M’ groups (Mann-Whitney U = 1169.00, Z = -3.07, p = 0.002 
and U = 748.00, Z = -2.98, p = 0.002, respectively), but there was no difference between 
the ‘Less than 1.5M’ and the ‘Over 4.0M’ groups (Mann-Whitney U = 583.00, Z = -1.66, p = 
0.102). This indicates a possible ‘J-curve’ effect where the pharmacies with the lowest 
turnover had a higher intervention rate, which sharply decreased with the next turnover 
category and then increased again, with the highest turnover category showing the 
second highest intervention rate. These could be pharmacies with sufficient turnover to 
employ extra pharmacists, facilitating the performance of clinical interventions, which was 
explored within the multivariate analysis (section 4.3). 
As most of a pharmacy’s financial turnover is derived from prescription volume, the 
pharmacies with a higher financial turnover tended to have a significantly higher 
prescription volume and pharmacist workload (ANOVA F(3,180) = 80.47, p < 0.001 and 
F(3,179) = 5.58, p = 0.001 respectively) as would be expected. It is possible that the 
pharmacies with higher turnovers had a lower intervention rate due to the workload 
within the pharmacy. Again, this was explored within the multivariate analysis (see section 
4.3). 
4.2.12 Attribution of dispensary to total pharmacy turnover 
A bivariate correlation test showed no significant differences between the pharmacy’s 
estimated dispensary attribution to the total pharmacy turnover and the pharmacy’s 
intervention rate (Spearman’s rho = -0.04, N = 184, p = 0.573). 
4.2.13 Pharmacy trading hours 
A bivariate correlation test showed a moderately weak, but statistically significant, 
negative correlation between the trading hours and the pharmacy’s intervention rate 
(Spearman’s rho = -0.18, N = 184, p = 0.015), illustrating that as the number of trading 
hours increased, the intervention rate tended to decrease (Figure 4-7). 
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Figure 4-7: Relationship between trading hours and pharmacy intervention rate 
The number of weekly trading hours was expected to correspond with the prescription 
volume and the pharmacist workload within the pharmacy. As expected, there was a 
correlation between trading hours and prescription volume (Pearson’s correlation = 0.433, 
N = 184, p < 0.001) where pharmacies with longer trading hours had a higher prescription 
volume; therefore, it is possible that the pharmacies with longer trading hours had a lower 
intervention rate due to the workload within the pharmacy. This was further explored 
within the multivariate analysis (see section 4.3). Interestingly, weekly trading hours did 
not correlate with the average pharmacist workload per week (Pearson’s correlation =        
-0.008, N = 183, p = 0.911), which may be due to varied workloads amongst the 
pharmacies. 
The number of trading days per week was also approaching a significant correlation with 
the pharmacy’s intervention rate (Spearman’s rho = -0.14, N = 184, p = 0.051). 
4.2.14 Pharmacy ownership 
A Mann-Whitney test showed no significant differences between the intervention rates of 
pharmacies that were owner-operated compared to manager-operated (U = 3157.00, Z = -
0.73, p = 0.468). Additionally, a Mann-Whitney test also showed no significant differences 
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between the intervention rates of pharmacies with a sole pharmacist operator compared 
to those with two or more (U = 4099.00, Z = -0.37, p = 0.718). 
4.2.15 Banner group or independent pharmacy 
A Mann-Whitney test showed significant differences between the banner group and 
independent pharmacies, with independent pharmacies having a higher intervention rate 
on average (U = 3452.00, Z = -2.15, p = 0.029; Table 4-31). 
  Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Independent 95 0.236 0.000 2.345 0.134 0.499 
Banner group 89 0.187 0.022 1.617 0.084 0.377 
Total 184 0.217 0.000 2.345 0.106 0.419 
Table 4-31: Pharmacy branding compared to pharmacy intervention rate 
Independent T-tests showed that independent pharmacies had a significantly lower 
average weekly prescription volume and lower average pharmacist workload (Table 4-32), 
with mean differences of 498.09 (95% CI = 335.90 – 660.28) and 97.28 (95% CI = 41.77 – 
152.80), respectively. It is possible that the banner group pharmacies had a lower 
intervention rate due to the higher workload within the pharmacy. This was explored 
within the multivariate analysis (see section 4.3). 
  
Pharmacy 
Count 
Average weekly 
prescription volume 
Average pharmacist 
weekly workload 
Mean Std. Dev. Mean Std. Dev. 
Banner  89 1337.42 647.47 528.64 177.71 
Independent  95 839.33 439.16 431.35 201.01 
Total 184 1080.25 602.45 478.14 195.81 
Statistics t = -6.07, df = 153.5, p = 0.001 t = -3.46, df = 181, p = 0.001 
Table 4-32: Differences in prescription volume and pharmacist workload between 
banner group and independent pharmacies 
4.2.16 Pre-registration pharmacists 
A Mann-Whitney U test showed significant differences between the intervention rates of 
the pharmacies that had employed a pre-registration pharmacist compared to those 
pharmacies that had not (U = 3150.50, Z = -2.00, p = 0.049). The pharmacies that had 
employed a pre-registration pharmacist tended to have lower intervention rates (Table 
4-33). 
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Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Pre-reg. 64 0.188 0.000 1.617 0.094 0.295 
No pre-reg. 120 0.240 0.000 2.345 0.114 0.462 
Total 184 0.217 0.000 2.345 0.106 0.419 
Table 4-33: The presence of a pre-registration pharmacist within the previous two 
years compared to pharmacy intervention rate 
However, independent T-tests showed that pharmacies that had employed a pre-
registration pharmacist within the previous two years had a significantly higher average 
weekly prescription volume (t = -4.96, df = 106.93, p < 0.001) with a mean difference of 
461.67 (95% CI = 277.26 – 646.08). It is possible that pharmacies employing pre-
registration pharmacists had a lower intervention rate due to the higher workload within 
the pharmacy, rather than the presence of a pre-registration pharmacist, which was 
explored within the multivariate analysis (see section 4.3). 
4.2.17 Catered for ACFs 
Sixty-two pharmacies indicated that they catered for ACFs during the trial, which was then 
compared to the pharmacy’s intervention rate. A Mann-Whitney test showed significant 
differences between the groups, with pharmacies that catered for ACFs having a 
significantly lower intervention rate than pharmacies that did not (U = 2840.50, Z = -2.76, 
p = 0.006; Table 4-34). 
 
Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Caters for ACFs 62 0.156 0.000 1.617 0.078 0.315 
No ACFs 122 0.237 0.000 2.345 0.126 0.445 
Total 184 0.217 0.000 2.345 0.106 0.419 
Table 4-34: The effect of catering for an aged care facility on the pharmacy 
intervention rate 
Independent T-tests showed pharmacies that catered for ACFs had a significantly higher 
average weekly prescription volume and higher average pharmacist workload (Table 4-35) 
with mean differences of 419.88 (95% CI = 244.40 – 595.34) and 80.53 (95% CI = 21.19 – 
139.88), respectively. Again, it is possible that pharmacies catering for ACFs had a lower 
intervention rate due to the higher workload within the pharmacy. This was explored 
within the multivariate analysis (see section 4.3). 
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Pharmacy 
Count 
Average weekly 
prescription volume 
Average pharmacist weekly 
workload 
Mean Std. Dev. Mean Std. Dev. 
Caters for ACFs 62 1358.65 615.43 531.38 229.78 
No ACFs 122 938.77 545.97 450.85 170.58 
Total 184 1080.25 602.45 478.14 195.81 
Statistics t = -4.72, df = 182, p < 0.001 t = -2.44, df = 96.41, p = 0.017 
Table 4-35: Differences in prescription volume and pharmacist workload between 
pharmacies catering for ACFs  
4.2.18 Number of FTE pharmacists  
The number of FTE pharmacists working within the pharmacy was compared to the 
intervention rate with a bivariate correlation showing no relationship between the two 
factors (Spearman’s rho = -0.11, N = 184, p = 0.137). 
4.2.19 Proportion of prescriptions assembled by dispensary 
technicians 
The percentage of prescriptions assembled by dispensary technicians within the pharmacy 
was also compared to the intervention rate. A Kruskal-Wallis test showed no significant 
differences between the usage of a dispensary technician and the pharmacy’s intervention 
rate (χ2= 0.33, df = 4, p = 0.99). 
4.2.20 Number of professional services offered 
The total number of professional services and programs offered were compared to the 
pharmacy’s intervention rate. A bivariate correlation test showed a moderately weak, but 
statistically significant negative correlation between the two factors (Spearman’s rho = -
0.20, N = 184, p = 0.008), showing that as the number of professional services offered 
increased, the pharmacy’s intervention rate tended to decrease. 
When the number of additional services (including Community Pharmacy Agreement 
professional programs) offered by pharmacies were condensed into four groups, a 
Kruskal-Wallis test still showed significant differences between the number of services 
offered and the intervention rate (Table 4-36; χ2= 8.15, df= 3, p = 0.043), with the main 
difference being seen between pharmacies offering 0-3 services compared to 7-9 (Mann-
Whitney U = 390.00, Z = -2.41, p = 0.016). A Jonckheere-Terpstra test showed a generally 
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negative trend, where the intervention rate decreased as the number of services offered 
increased (t = -2.63, p = 0.009). 
 
Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
0 – 3 14 0.437 0.052 1.354 0.152 0.526 
4 – 6 58 0.233 0.026 2.276 0.145 0.483 
7 – 9 93 0.189 0.000 2.345 0.089 0.371 
10 or more 19 0.210 0.022 1.617 0.064 0.500 
Total 184 0.217 0.000 2.345 0.106 0.419 
Table 4-36: Total number of additional professional services offered compared to 
pharmacy intervention rate 
4.2.21 Participation in other PGA professional programs 
Over 90% of participating pharmacies were also participating in other PGA professional 
programs whilst completing the PROMISe trial. A bivariate correlation test showed a 
moderately weak, but statistically significant negative correlation (Spearman’s rho = -0.17, 
N = 184, p = 0.024), showing that as the number of concurrent PGA programs increased, 
the pharmacy’s intervention rate tended to decrease. Interestingly, the 12 pharmacies 
that were not participating in any other PGA programs had the highest median 
intervention rate whereas the 8 pharmacies concurrently providing 5 other programs had 
the lowest median intervention rate, and this was statistically significant (Mann-Whitney 
U = 18.00, Z = -2.32, p = 0.018). 
 
Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
0 12 0.352 0.123 1.354 0.243 0.630 
1 17 0.186 0.052 1.139 0.134 0.499 
2 45 0.234 0.028 1.401 0.126 0.414 
3 67 0.195 0.000 2.345 0.086 0.437 
4 35 0.249 0.000 0.645 0.098 0.380 
5 8 0.104 0.022 1.457 0.044 0.211 
Total 184 0.217 0.000 2.345 0.106 0.419 
Table 4-37: Number of other PGA programs being concurrently run by each pharmacy 
compared to pharmacy intervention rate 
Comparisons were also made between participation in each individual project and the 
pharmacy’s intervention rate. From the five PGA professional programs, only participation 
in the DAA and PMP program were associated with a significant difference in intervention 
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rate (Table 4-38), with the participating pharmacies tending to have lower intervention 
rates. 
Program U Z p 
DMAS 3733.50 -1.27 0.206 
DAA 986.00 -2.91 0.003 
PMP 2439.00 -2.08 0.039 
PAMS 1289.00 -0.27 0.788 
Mirixa 3835.00 -1.03 0.308 
Table 4-38: The effect of participation in other PGA programs compared to pharmacy 
intervention rate (NB:- Mirixa was not an official professional program) 
4.2.22 Other professional services 
The number and type of other professional services offered by the pharmacy were also 
compared to the intervention rate to determine any relationships. A bivariate correlation 
test showed a moderately weak, but statistically significant negative correlation 
(Spearman’s rho = -0.17, N = 184, p = 0.023), showing that as the number of professional 
services offered increased, the pharmacy’s intervention rate tended to decrease. 
Individual analysis showed that offering blood pressure monitoring and/or a dose 
administration packing service was associated with the pharmacy’s intervention rate 
(Table 4-39), with the pharmacies offering these services recording a lower intervention 
rate. 
Service U Z p 
BP monitoring 1690.00 -2.52 0.010 
HMR 1372.00 -1.19 0.233 
DAA packing 537.00 -2.03 0.042 
Opioid dependency program 3330.50 -1.63 0.106 
Diabetes screening 1875.50 -0.71 0.477 
Wound care 2991.00 -0.29 0.768 
Weight management program 3641.00 -1.57 0.114 
MedsIndex 3953.50 -0.10 0.914 
Table 4-39: The effect of offering additional professional services compared to 
pharmacy intervention rate 
4.2.23 Counselling area 
There were no significant differences between the three types of counselling area within 
the pharmacies and the intervention rate (Kruskal-Wallis χ2 = 2.81, df = 2, p = 0.25). The 
pharmacies were recoded into two groups where they either had a permanent counselling 
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area or no counselling area, with those pharmacies with a temporary counselling area 
being coded as having no counselling area. When compared to the intervention rate, there 
was still no significant differences between the presence of a permanent counselling area 
and the pharmacy’s intervention rate (Mann-Whitney U = 3538.00, Z = -1.67, p = 0.097).  
Despite a significant difference in the types of counselling area found between the three 
software groups (see section 4.1.2.15), there was no correlation between the average 
number of times per week that the counselling area was used and the pharmacy 
intervention rate (Spearman’s rho = 0.09, N = 184, p = 0.241). This indicated that the 
previous finding of differences between the software groups may not have been 
important and may also indicate that the actual use of a counselling area is a more 
relevant professional factor than simply the presence of a counselling area. 
4.2.24 Pharmacist accessibility 
A Mann-Whitney test showed no significant differences in the intervention rate between 
pharmacies where the site visitor considered the pharmacist to be easily accessible 
compared to those where the pharmacist was not easily accessible (U = 1480.00, Z = -1.48, 
p = 0.147). 
4.2.25 Number of dispensing terminals 
The number of dispensing terminals within each pharmacy was also compared to the 
intervention rate with a bivariate correlation approaching significance (Spearman’s rho = -
0.14, N = 184, p = 0.051); as the number of dispensing terminals increased, the 
intervention rate tended to decrease. When the number of terminals were recoded into 3 
groups (1 terminal, 2 terminals, and 3 or more terminals), there was a significant 
difference between the number of terminals and the intervention rate (Table 4-40; 
Kruskal-Wallis χ2 = 7.55, df = 2, p = 0.02). However, there was not a significant linear trend 
(Jonckheere-Terpstra t = -1.81, p = 0.07). Additional post-hoc analysis showed that the only 
difference lay between those pharmacies with one terminal and those with two terminals 
(Mann-Whitney U = 1271.00, Z = -2.63, p = 0.007). 
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 Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
1 45 0.315 0.058 2.345 0.163 0.526 
2 79 0.179 0.000 2.276 0.086 0.398 
3 or more 60 0.211 0.022 1.617 0.106 0.374 
Total 184 0.217 0.000 2.345 0.106 0.419 
Table 4-40: Number of dispensing terminals compared to pharmacy intervention rate 
As expected, ANOVA showed that pharmacies that had more dispensing terminals had a 
significantly higher average weekly prescription volume and higher average pharmacist 
workload (Table 4-35).  
 
Pharmacy 
Count 
Average weekly 
prescription volume 
Average pharmacist 
weekly workload 
Mean Std. Dev. Mean Std. Dev. 
1 45 559.54 172.71 395.63 159.64 
2 79 964.61 383.65 478.19 179.27 
3 or more 60 1610.19 626.31 544.00 219.51 
Total 184 1076.06 600.73 479.46 196.10 
Statistics F(2,181) = 75.81, p < 0.001 F(2,181) = 7.92, p = 0.001 
Table 4-41: Differences in prescription volume and pharmacist workload compared to 
the number of dispensing terminals 
Pharmacies were also asked to estimate how often the lack of access to a dispensing 
terminal affected the dispensary workflow by choosing one of the following categories: 
Frequently (more than 8 times a day); Occasionally/sometimes (3-8 times a day); or 
Rarely/never (less than 3 times a day). The frequency of disruption did not appear to be 
associated with the pharmacy’s intervention rate (Kruskal-Wallis χ2 = 0.83, df = 2, p = 
0.68). 
4.2.26 Health promotion 
The site visitors recorded whether the pharmacy displayed any health promotion posters 
or advertised professional services prominently within their pharmacy. Of the 184 
pharmacies that were visited, 102 (55.4%) pharmacies had health promotion or services 
displayed within their pharmacy. The presence of these promotional materials was not 
significantly associated with the pharmacy intervention rate (Mann-Whitney U = 3783.00, 
Z = -1.11, p = 0.265). 
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For the 102 pharmacies that were promoting health and services, the site visitors 
recorded what they were promoting. These comments were grouped into 11 ‘themes’ for 
analysis: 
 Diabetes; including the DMAS trial and BSL testing 
 Cardiovascular disease; including BP testing, cholesterol checks, 
counselling/advice 
 Smoking cessation 
 Asthma 
 Improving compliance; including HMRs, DAAs, PMPs, MedsIndex, MediMate (a 
program encouraging patients to keep a current list of all their medications) 
 Preventative health; including bone mineral density testing, hearing screening, 
mobility aids, eye checks (glaucoma, macular degeneration), opioid dependency 
program 
 Self-help; including health kiosks, self-care cards 
 Weight management programs 
 Additional practitioners; including naturopath, herbalist, Chinese medicine, 
pharmacy nurse 
 Child health 
 Other (including a head lice clinic, wound care etc.) 
The presence of each individual ‘themed’ health promotion did not appear to have any 
relationship with the pharmacy intervention rate (Table 4-42). 
 
U Z p 
Diabetes  3385.00 -0.57 0.566 
Cardiovascular 1482.00 -0.10 0.926 
Smoking cessation 1373.00 -1.51 0.131 
Asthma 524.00 -0.71 0.482 
Compliance 2579.00 -0.36 0.722 
Preventative health 1752.00 -0.17 0.869 
Self-help 1522.00 -1.42 0.157 
Weight management 2270.00 -1.61 0.109 
Additional practitioners 418.00 -0.27 0.798 
Child health 456.00 -1.20 0.233 
Other 411.00 -0.33 0.748 
Table 4-42: Presence of each health promotion ‘theme’ compared to pharmacy 
intervention rate 
4.2.27 Workflow roles and responsibilities 
Pharmacies were asked to estimate the percentage of time that each type of staff 
member spent on the following tasks: 
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 Collects prescription and patient details  
 Processes prescription through computer 
 Collects stock for prescription 
 Labels prescription 
 Checks prescription 
 Hands out prescription 
 Counsels patient 
 Collects payment for prescription 
The pharmacist responsibilities that appeared to correlate with the pharmacy’s 
intervention rate were the percentage of time spent collecting patient details and 
collecting payments (Spearman’s rho = 0.17, N = 184, p = 0.023 and Spearman’s rho = 0.21, 
N = 184, p = 0.005 respectively), where the higher the percentage of time that the 
pharmacist spent on these tasks, the higher the pharmacy intervention rate. All other 
factors did not correlate with the intervention rate. There was also no correlation 
between the pharmacy intervention rate and the percentage of time that dispensary and 
non-dispensary assistants spent on each task.  
4.2.28 General comments about the pharmacy 
Site visits were conducted by six different people (five pharmacists and one administration 
officer), resulting in a non-uniform ‘general comments’ section. Basic qualitative methods 
were used to group the information into the following eight themes, which were then 
used for analysis: 
 Gifts/beauty/supermarket style vs dispensary/healthcare orientated 
 Modern vs old 
 Busy vs steady vs quiet  
 Staff friendly vs not friendly 
 Small pharmacy vs large pharmacy  
 Spacious/tidy vs cramped/messy 
 Professional vs unknown 
 Distractions vs unknown 
There were many unknowns due to site visitors not entering the same information with 
each visit and, thus, many sample sizes were small. 
As can be seen in Table 4-43 and Table 4-44, the only significant differences detected 
were: 
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 Pharmacies that the site visitors listed as being healthcare orientated had a higher 
median intervention rate than those that were listed as having lots of gifts/beauty 
items or ‘supermarket’ style (Mann-Whitney U = 268.00, Z = -2.27, p = 0.02) 
 Pharmacies that the site visitors listed as being professional-looking or displaying 
professional services during the site visit had a higher median intervention rate 
than the ‘unknown’ group (Mann-Whitney U = 2912.00, Z = -1.99, p = 0.04) 
 
 
Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Healthcare orientated 25 0.259 0.088 2.276 0.195 0.500 
Gifts/beauty/ 
supermarket style 
33 0.187 0.053 1.457 0.108 0.277 
Unknown 127 0.207 0.000 2.345 0.089 0.429 
Total 185 0.213 0.000 2.345 0.105 0.414 
Table 4-43: Healthcare-orientation compared to pharmacy intervention rate 
  
Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Professional 55 0.249 0.000 2.345 0.140 0.451 
Unknown 130 0.187 0.000 2.276 0.089 0.384 
Total 185 0.213 0.000 2.345 0.105 0.414 
Table 4-44: Professional appearance compared to pharmacy intervention rate 
In total, there were 68 pharmacies that the site visitors listed as being ‘healthcare 
orientated’ and/or ‘professional’. These pharmacies were combined into one group and 
compared to the remaining 117 pharmacies, which still showed a significant difference in 
intervention rate (Mann-Whitney U = 3020.00, Z = -2.73, p = 0.006), with the more 
healthcare-orientated, more professional pharmacies being associated with a higher 
median intervention rate (Table 4-45).  
  
Pharmacy 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Healthcare 
orientated/ 
professional 
68 0.250 0.000 2.345 0.155 0.475 
 Unknown 117 0.174 0.000 1.457 0.084 0.380 
Total 185 0.213 0.000 2.345 0.105 0.414 
Table 4-45: Healthcare-orientation and/or professional appearance compared to 
pharmacy intervention rate 
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This was, at least at face value, in contrast to the results found in sections 4.2.21 and 
4.2.22, which showed that the actual provision of more services was found to be 
associated with a lower intervention rate or no change in the intervention rate. The 
offering of professional services alone, however, does not necessarily mean that the 
pharmacy has a professional image. 
4.2.29 Summary table of pharmacy bivariate factors 
The previous sections have been summarised into the following table. 
 Median CI Rate p 
Software Group 
Group One 0.192 0.60 
Group Two 0.197 
Group Three 0.235 
PhARIA 
Metropolitan 0.221 0.64 
Regional 0.200 
Pharmacy Location 
Shopping centre 0.189 0.03 
Medical centre 0.251 
Shopping strip/Other 0.234 
Dispensing System 
FRED®  0.89 
Aquarius®  
Pharmacy Area 
Less than 100m
2
 0.319 0.01 
101-150m
2
 0.240 
151-250m
2
 0.134 
251-500m
2
 0.192 
Over 500m
2
 0.082 
Annual Financial 
Turnover 
Less than 1.5M 0.264 0.01 
1.5 - 2.5M 0.165 
2.5 - 4.0M 0.181 
Over 4.0M 0.224 
Banner Group or 
Independent 
Independent 0.236 0.03 
Banner group 0.187 
Pre-registration 
Pharmacist 
Pre-reg. 0.188 0.05 
No pre-reg. 0.240 
Catered for ACFs 
Caters for ACFs 0.156 0.01 
No ACFs 0.237 
Number of additional 
professional services 
offered 
0 – 3 0.437 0.04 
4 – 6 0.233 
7 – 9 0.189 
10 or more 0.210 
Number of dispensing 
terminals 
1 0.315 0.05 
2 0.179 
3 or more 0.211 
Table 4-46: Summary table of the analysed bivariate factors compared to pharmacy 
intervention rate 
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4.2.30 Analysis of software groups 
As determined in section 4.2.2, no significant difference in the intervention rates was seen 
between the three software groups. However, additional analyses were performed to 
determine any other differences between the three groups. 
4.2.30.1 Effect of the general reminder 
During the 12-week trial, pharmacies in Group Two and Three received an automatic pop-
up reminder everyday at 11am and 3pm which encouraged the pharmacist to document 
their interventions (see Chapter 2). Although each intervention had a time stamp within 
its record, there was no equivalent time stamp with each dispensed prescription, 
unfortunately meaning an intervention rate per hour could not be reliably calculated. 
Analysis was therefore conducted on the actual number of interventions documented 
during the hour. Collation of the interventions showed the highest peak at 11am with 850 
interventions and the second highest peak at 3pm with 727 interventions (Table 4-47 and 
Figure 4-8). However, this does not necessarily reflect the time of day that interventions 
were performed, only the time they were documented and submitted as being complete.  
  
Group One Group Two Group Three Total 
N % N % N % N % 
H
o
u
r 
o
f 
d
ay
 
8 5 0.5 36 1.4 19 0.8 60 1.0 
9 83 8.4 183 7.0 156 6.6 422 7.1 
10 102 10.4 229 8.8 257 10.9 588 9.9 
11 122 12.4 379 14.5 349 14.8 850 14.3 
12 94 9.5 322 12.3 254 10.8 670 11.3 
13 91 9.2 238 9.1 215 9.1 544 9.1 
14 113 11.5 187 7.2 244 10.4 544 9.1 
15 102 10.4 352 13.5 273 11.6 727 12.2 
16 103 10.5 297 11.4 280 11.9 680 11.4 
17 107 10.9 226 8.7 183 7.8 516 8.7 
18 29 2.9 86 3.3 80 3.4 195 3.3 
19 18 1.8 48 1.8 24 1.0 90 1.5 
20 15 1.5 22 0.8 14 0.6 51 0.9 
21 1 0.1 5 0.2 4 0.2 10 0.2 
22 0 0.0 1 0.0 0 0.0 1 0.0 
Total 985 100.0 2611 100.0 2352 100.0 5948 100.0 
Table 4-47: Number of interventions documented each hour within the three 
software groups 
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Figure 4-8: Clinical interventions per hour 
There appeared to be a significant difference in the times of day that the interventions 
were recorded between Group One and the other two groups (Figure 4-9). Group One 
only had the software with neither reminders nor prompts, which resulted in a more 
consistent documentation rate. Groups Two and Three both had the reminder and 
displayed a peak of recordings at 11am, with Group Two showing another high peak at 
3pm (Figure 4-9). This indicates that the reminder provided a significant increase in the 
number of interventions in the hour following the reminder (χ2 = 73.4, df = 24, p < 0.001). 
However, as mentioned in section 4.2.2, the reminder did not appear to influence the 
intervention rate of the pharmacy overall. 
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Figure 4-9: Interventions within each software group compared to hour 
4.2.30.2 Effect of the prompt 
As mentioned in section 4.2.2, the prompt in Group Three pharmacies did not appear to 
influence the overall intervention rate. However, the prompt was expected to affect the 
intervention rate within the prompted medication groups. Analysis was undertaken to 
determine any other effects of the electronic prompt. 
Identification of clinical interventions relating to the prompt 
As discussed in Chapter 2, interventions that were deemed to be associated with the 
prompt in Group Three were identified as follows: 
1. Interventions associated with ATC codes A02BC02 (pantoprazole) and A02BC05 
(esomeprazole) 
2. At least one of the following DOCUMENT recommendation categories: R2, R3, R7, 
R13  
3. If available, reviewing the intervention notes made by pharmacists for these 
interventions to identify any anomalies. 
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These interventions were removed prior to analysis of intervention rates, but were 
included for the following analysis regarding the prompt. 
Opportunities to intervene 
Among Group Three pharmacies in the PROMISe III trial, 16,924 prescriptions for 
esomeprazole 40mg tablets (7,967 prescriptions for 4,647 individual patients) and 
pantoprazole 40mg tablets (8,957 prescriptions for 4,856 individual patients) were 
dispensed, thus there were 16,924 opportunities to intervene. 
Prompt intervention rate 
In total, 282 PPI step-down interventions were identified from the database, consisting of 
158 for esomeprazole 40mg and 124 for pantoprazole 40mg (Table 4-48). Although the 
prompt did not increase intervention rates overall, it significantly increased the number of 
interventions documented against esomeprazole and pantoprazole (p < 0.001; Table 
4-48).40 
  
PPI prompt (Group Three) Control (Groups One and Two) 
Esomeprazole 
40mg 
Pantoprazole 
40mg 
Esomeprazole 
40mg 
Pantoprazole 
40mg 
Number of interventions 158 124 32 16 
Number of prescriptions 7967 8957 12584 14883 
Intervention rate 1.98 1.38 0.25 0.11 
Overall intervention rate 1.67 0.17 
Table 4-48: The effect of the prompt 
Cost saving analysis40,162 
Potential cost savings of the prompted PPI step-down interventions were also 
investigated. Costing calculations were sub-divided into categories:  
1. Reduction of medication strength 
2. Use of another medication indicated for the treatment of gastro-oesophageal 
reflux disease (GORD), and  
3. Utilisation of health care resources 
All step-down interventions identified within the first four weeks of the trial were 
examined, as this allowed at least eight weeks of follow-up data post-intervention for each 
consumer. Using the consumer prescription history, 34 step-down interventions were 
identified in the first 28 days; 27 consumers decreased their dose, 6 consumers changed 
to a less expensive PPI and 1 consumer changed to a less expensive H2-receptor 
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antagonist. Again, using the patient prescription history post-intervention, it appeared 
that this change was maintained. The change in cost calculations were based on the 
‘Schedule of Pharmaceutical Benefits – July 2009’ available through the Pharmaceutical 
Benefits Scheme (PBS) website171 and the average cost saving of the step-down therapy 
was found to be $7.98 AUD per pharmacy per month. Extrapolation of the accumulation 
of cost saving over one year (when the prompt is only used for the first two months of the 
year) estimated a saving of $183.60 AUD per pharmacy per year, or approximately $800 
000 per year if the prompt had been active in all Australian pharmacies.40 More detail can 
be found in the article in Appendix 22. 
4.2.31 Analysis of trial phases 
As determined in section 4.2.2, no significant difference was seen between the three 
software groups with regards to overall intervention rate. The intervention frequencies for 
pharmacies based on weeks of activity in each pharmacy were also examined to 
determine if there were any differences seen between the different trial phases (arbitrary 
divisions used during post-trial data analysis).  
4.2.31.1 Trial weeks 
The data was separated into weeks of pharmacy activity, resulting in a total of 2220 weeks 
of activity to be analysed. After removing the PPI step-down interventions, an intervention 
frequency was again calculated for each week (Figure 4-10). 
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Figure 4-10: Weekly intervention rate for each software group 
As shown in Figure 4-10, there was a decline in the intervention rate over the 12 weeks of 
the trial and a gradual loss of difference between the three groups. When blocks of weeks 
were examined separately, Kruskal-Wallis tests again showed no significant differences 
between the three groups; however, the differences were approaching significance. Post-
hoc analysis with Jonckheere-Terpstra tests showed that there was a significant positive 
trend, indicating that the intervention rate was highest in Group Three even with the 
prompted interventions removed (Table 4-49). 
  
Difference between software 
groups 
Trend from Group One to Three 
First 4 weeks No (χ
2 =5.83, df = 2, p = 0.056) Yes (J-T statistic = 2.39, p = 0.016) 
First 6 weeks No (χ
2 =5.75, df = 2, p = 0.059) Yes (J-T statistic = 2.29, p = 0.023) 
First 8 weeks No (χ
2 =5.38, df = 2, p = 0.069) Yes (J-T statistic = 2.21, p = 0.029) 
12 weeks No (χ
2 =4.25, df = 2, p = 0.120) Yes (J-T statistic = 2.02, p = 0.043) 
Table 4-49: Statistical tests between each software group in different blocks of weeks 
of the trial 
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4.2.31.2 Trial phases 
There were three distinct phases of the trial: 3 weeks of no observational sub-study or site 
visits; 6 weeks during the observational sub-study and site visits; and, 3 weeks after the 
observational sub-study and site visits (Figure 4-10). When each phase of the study was 
considered, Kruskal-Wallis tests showed no significant differences between each software 
group (Table 4-50 and Figure 4-11). 
  
Difference between software 
groups 
Trend from Group One to Three 
Phase 1 No (χ
2 =2.30, df = 2, p = 0.318) No (J-T statistic = 1.53, p = 0.126) 
Phase 2 No (χ
2 =2.12, df = 2, p = 0.344) No (J-T statistic = 1.45, p = 0.141) 
Phase 3 No (χ
2 =4.27, df = 2, p = 0.115) No (J-T statistic = 0.59, p = 0.549) 
Table 4-50: Statistical tests between each software group in different phases of the 
trial 
 
Figure 4-11: Intervention rate for each phase for each software group 
4.2.32 Observed pharmacies 
During the trial, 38 software pharmacies were observed, allowing analysis of the effect of 
observation on the pharmacy’s intervention rate. 
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4.2.32.1 Effect of the observation week on pharmacy intervention rate 
When the pharmacy intervention rate for the actual observed week was compared to the 
intervention rate in the remainder of the trial (including the non-observed weeks in 
pharmacies that were allocated observers), significant differences were seen (Mann-
Whitney U = 28439.00, Z = -9.28, p < 0.001; Table 4-51 and Figure 4-12). 
  
Average intervention rate 
Observed 
week 
Non-observed 
weeks 
Group One (Software only) 0.898 0.328 
Group Two (Software with reminders) 0.824 0.330 
Group Three (Software with prompts and reminders) 0.821 0.386 
Total 0.834 0.354 
Table 4-51: Average intervention rate during the observed week compared to the 
non-observed weeks 
 
Figure 4-12: Intervention rate during observed weeks compared to non-observed 
weeks for each software group 
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4.2.33 Prescription factors 
Although the pharmacy environment was likely to have the largest influence on its overall 
intervention rate, prescription factors were also examined to determine any contribution 
they may have made to the intervention rate. 
4.2.33.1 Original and repeat prescriptions 
Despite a significantly higher intervention rate seen with original prescriptions (see 
Chapter 3), a correlation test did not show a correlation between the overall percentage 
of original prescriptions dispensed within the pharmacy and the pharmacy intervention 
rate (Spearman’s rho = -0.05, N = 185, p = 0.47).  
Analysis was also undertaken to determine if pharmacies dispensed a similar amount of 
original and repeat prescriptions. There was significant variation between the percentage 
of original prescriptions dispensed by each pharmacy, ranging from 33.5% to 84.7% (mean 
= 45.4%). A significant correlation was also detected statistically (Spearman’s rho = 0.06, N 
= 185, p = 0.412), indicating that the proportion of original prescriptions dispensed 
differed between the participating pharmacies.  
4.2.34 Discussion of bivariate analysis 
The average frequency of DRPs detected and interventions undertaken was disappointing, 
at a median rate of 1 intervention every 450 prescriptions. This was much lower than the 
intervention rates seen in older trials57,58,60,68 and it is possible that the length of the trial 
may have impacted on the intervention rate, as the PROMISe III trial was much longer and 
included more pharmacies than these previous trials. The more modern trials reported a 
similar intervention rate to the PROMISe trial.77,78,84 This may also be indicative of the 
added pressures experienced within modern pharmacy, with additional professional 
services decreasing the pharmacy’s ability to adequately complete a professional program. 
Additionally, as seen in Chapter 1, the definition of a clinical intervention differed 
significantly between the different trials, which made comparisons between the 
intervention rates difficult.  
There was also an obvious outlier with a much higher than expected intervention rate. It is 
unlikely that this pharmacist performed and documented such a significantly larger 
number of interventions, therefore it may have been caused by the pharmacist 
erroneously documenting routine counselling as a clinical intervention. Unfortunately, the 
222 | P a g e  
 
pharmacist did not regularly record additional information with each intervention and the 
significantly higher intervention rate was not detected until several months after the trial 
had finished, making further contact with the pharmacist and further analysis impossible.  
4.2.34.1 Influencing factors 
Several factors were found to be associated with the pharmacy’s intervention rate at the 
bivariate level. 
4.2.34.2 Prescription volume, pharmacist workload and staffing levels 
In an average pharmacy environment, as the pharmacy prescription volume increases, the 
individual pharmacist workload also increases, unless the staffing levels are also increased 
to compensate for the additional workload. For this reason, these three factors have been 
considered together. 
Within the bivariate analysis, the prescription volume of the pharmacy appeared to 
significantly influence the pharmacy’s intervention rate; as the prescription volume 
increased, the intervention rate decreased. The pharmacist workload within the pharmacy 
also appeared to significantly influence the pharmacy’s intervention rate; as the 
pharmacist workload increased, the intervention rate decreased. Many of the other 
significant factors were also associated with prescription volume and workload, such as 
location, catering for ACFs and participation in additional professional services. The effect 
of prescription volume and pharmacist workload has been examined both quantitatively 
and qualitatively in a number of pharmacy practice studies. Several previous intervention 
studies have also shown a significant negative correlation between intervention rate and 
prescription volume, where the pharmacies with a higher prescription volume had a lower 
intervention rate. This correlation was seen in the previous PROMISe trial80,81, as well as 
studies by Irvine-Meek et al.61 in Canada, Knapp et al.27 in the USA, Hawksworth et al.69 
and Chen et al.77 in England, and Braund et al.83 in New Zealand. A study by Christensen101 
on the factors influencing the rate of providing cognitive services within community 
pharmacy found that pharmacies dispensing less prescriptions had a higher rate of 
provision. In addition, a study by Rupp58 found that pharmacists with a smaller workload 
had significantly higher intervention rates than those with a larger workload, and 
Hawksworth et al.69 found a trend where pharmacists with a smaller workload tended to 
spend more time on each intervention. Interestingly, an Australian study published by 
Caleo et al. in 1996 reported no significant correlation between pharmacy intervention 
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rate and total prescription volume32,33, and an additional survey study found that workload 
did not influence the provision of services.100 Given the large amount of literature 
documenting a link with prescription volume and workload, it is much more likely that 
these factors can significantly impact on the pharmacy’s intervention rate. 
The result that workload affects CI rate is rational and can be explained in several ways. A 
higher prescription volume generally signifies a busier pharmacy, so the pharmacists may 
still be performing the interventions but have less time to document them, or the 
increased prescription volume may inhibit the pharmacist from initially performing the 
interventions. Although a higher volume of prescriptions may increase the number of 
opportunities for the pharmacist to intervene, it impacts heavily on the pharmacist’s 
workload and therefore decreases the amount of time that can be spent on clinical 
activities. Qualitatively, higher prescription volumes and higher pharmacist workloads are 
often reported as barriers to the provision of cognitive pharmacy services, including 
clinical interventions.99,112 Specific barriers, such as lack of adequate staffing levels, 
directly affect the pharmacist workload by decreasing the amount of time that the 
pharmacist can devote to cognitive services. This is inkeeping with a pharmacist survey in 
the USA which showed that 89.6% of pharmacists felt that inadequate staffing levels 
prevented their uptake of a medication management service109, as well as other studies 
that have identified that adequate staffing levels are required to allow pharmacies to 
provide a high level of cognitive services.53,98,107 Surveyed pharmacists also report that lack 
of time prevented them from providing an adequate level of cognitive 
services16,53,108,113,115, and this perceived ‘lack of time’ is most likely caused by a high 
workload and inadequate staffing levels. A study that altered the pharmacy workflow and 
layout to increase the level of patient counselling helped to decrease the amount of time 
that a pharmacist spent on data entry.119 
To improve the provision of cognitive services and therefore increase the documentation 
rate of interventions, pharmacies need to decrease the workload expected by each 
pharmacist. As the current business model remunerates pharmacies based on the number 
of prescriptions dispensed, a decrease in the number of prescriptions dispensed would not 
be desirable. Instead, it would be more plausible to decrease workloads by increasing the 
number of pharmacists available to complete the work. Increasing the number of 
adequately trained support staff, rather than increasing the number of pharmacists, could 
also decrease the individual pharmacist’s dispensing workload and increase the amount of 
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time a pharmacist could allocate to the provision of cognitive services such as the 
documentation of interventions. 
4.2.34.3 Financial turnover 
A negative correlation was seen between the pharmacy’s annual financial turnover and 
the intervention rate; as the financial turnover increased, the intervention rate tended to 
decrease. As seen in section 4.2.11, a type of ‘ J-curve’ was seen, where the pharmacies 
with the lowest financial turnover had a higher intervention rate, which sharply decreased 
with the next turnover category and then increased again, with the highest turnover 
category showing the second highest intervention rate. The J-curve may be explained by 
workload and staffing levels, where the pharmacies with the lower turnover have a 
smaller workload and the pharmacies with the higher turnover perhaps have adequate 
staffing levels, creating more time for both types of pharmacy to perform and document 
their interventions. The pharmacies with turnovers in the two middle groups may have 
larger workloads relative to their staffing levels, but also do not have the turnover to 
warrant employing more staff, which may lead to less time to perform and document their 
interventions. 
4.2.34.4 Aged care facilities 
The pharmacies that catered for ACFs at the time of the trial tended to have a lower 
intervention rate than the pharmacies that did not. There are three possible reasons for 
this explanation. Firstly, the pharmacies that catered for ACFs had a significantly higher 
prescription volume and higher pharmacist workload, which would impact on their 
abilities to document interventions. Secondly, catering for ACFs can often be a distraction 
from the dispensing process, due to an increase in distracting phonecalls, additional 
paperwork and checking medication packs, which may have contributed to the decrease in 
the number of interventions. Lastly, the prescription volume within pharmacies catering 
for ACFs may be disproportionate to the number of consumers they interact with. This is 
due to the pharmacies dispensing many repeat prescriptions for use in the medication 
packs using the consumer’s medication chart with no interaction with the consumer or 
ACF staff (known as ‘bulk dispensing’). As such, it is likely that less interventions were 
performed in these pharmacies, since the pharmacist may have already contacted the 
prescriber to discuss any issues when the item was first prescribed. The annual residential 
medication management review (RMMR) service provided by consultant pharmacists also 
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detects other interventions that are then resolved by the GP, and therefore are unlikely to 
be recorded within the community pharmacy’s software. In light of these facts, it is 
plausible that pharmacies that cater for a large number of aged care patients would have 
significantly higher prescription volumes with less documented interventions.  
Interestingly, and in contrast to this finding, the Australian study published by Caleo et al. 
in 1996 reported no significant correlations between the pharmacy’s intervention rate and 
the number of aged care facilities they catered for.32,33 The articles detailed an 
intervention study in 29 pharmacies, but did not state how many of these pharmacies 
catered for aged care. It is possible that the number of pharmacies catering for aged care 
was low, resulting in a non-significant correlation with the pharmacy’s intervention rate, 
thus differing from the finding in the PROMISe trial where a third of participating 
pharmacies catered for aged care facilities. 
4.2.34.5 Location 
Pharmacies that were located in a medical centre had a significantly higher intervention 
rate, on average, than pharmacies located in shopping centres or shopping strips. This 
could be due to a closer relationship with the GPs within the medical centre, thereby 
making the pharmacist more willing to perform interventions due to increased confidence 
that the prescriber will give their suggestions serious consideration. Also, the medical 
centre pharmacies were more likely to have a larger base of regular patients, which may 
also have contributed to a higher intervention rate, as the patients become more 
comfortable discussing health problems with their regular pharmacist. The medical centre 
pharmacies also tended to have significantly lower prescription volumes and workloads, 
which may have contributed to the difference between pharmacies in different locations.  
4.2.34.6 Additional services offered 
It was thought that pharmacies providing additional services would have a higher 
intervention rate due to the increased contact with consumers and the additional 
opportunity to detect DRPs, and pharmacies that were noted to look ‘healthcare-
orientated’ or ‘professional’ by the site visitors did tend to have a higher intervention rate. 
However, a weak, but statistically significant, negative correlation was seen between the 
actual number of additional services offered by the pharmacy and the intervention rate; 
as the number of professional services increased, the intervention rate decreased. 
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This may be in part due to the increase in workload that professional services can 
produce. Therefore, despite most professional services offering more opportunities to 
intervene, it also increases the pharmacist’s workload and decreases the amount of time 
available to perform and document clinical interventions. It may also indicate that 
pharmacists can become ‘fatigued’ with the provision of many different types of service, 
which decreases their ability to effectively provide all programs to an optimal level. It is 
also possible that pharmacies were documenting their findings from these additional 
pharmacy services elsewhere, such as blood pressure readings in the consumer’s 
dispensing notes, resulting in less interventions resulting from these additional services 
being documented within the PROMISe software. 
4.2.34.7 Pharmacy area  
A negative correlation was seen between the area of the pharmacy and the pharmacy’s 
intervention rate, where the intervention rate tended to decrease as the area increased 
(section 4.2.10). This is in contrast to a pharmacist survey in the USA that found that 
pharmacists perceived a lack of space as a barrier to the uptake of a professional service 
program.109 The results from the PROMISe III trial showed an opposite trend and there are 
two possible explanations for this. Firstly, smaller pharmacies may be considered more 
homely and inviting to consumers, resulting in consumers being more comfortable in 
discussing healthcare issues, increasing the pharmacist’s opportunity to intervene. 
Secondly, analysis showed that larger pharmacies also had a higher prescription volume 
and higher pharmacist workload, which may impact on the ability of the pharmacy to 
deliver professional services and consequently decrease their intervention rate. 
4.2.34.8 Pharmacy trading hours 
A negative correlation was seen between the pharmacy’s trading hours and the 
intervention rate; as the number of trading hours increased, the intervention rate 
decreased. There are three possible explanations for this finding. Firstly, a pharmacy’s 
trading hours usually reflect their prescription volume, and analysis showed that as the 
prescription volume increased, the number of trading hours also increased. Secondly, 
pharmacies with longer opening hours may employ more locum pharmacists who may not 
have been aware of the PROMISe trial and may have caused an overall decrease in the 
intervention rate. Lastly, many pharmacists working in a pharmacy with long trading hours 
are completing longer hours on average, with some reporting 12-hour shifts. It may be 
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likely that these pharmacists are simply too exhausted by the end of the shift to document 
their interventions, resulting in a lower overall intervention rate for the pharmacies with 
longer trading hours. 
4.2.34.9 Independent and banner group pharmacies 
A significant difference in intervention rate was noted between independent pharmacies 
and those that were part of a banner group, with the independent pharmacies tending to 
have a higher intervention rate. This could possibly be explained by two reasons. Firstly, 
analysis showed that the independent pharmacies tended to have a significantly lower 
prescription volume and a lower pharmacist workload, so the higher rate of interventions 
may have been due to the pharmacist being able to focus more on the consumers and the 
documenting of interventions. Secondly, there was a significant variation in the type of 
banner groups participating in the trial, with some groups promoting a much more 
professional environment than others. It is possible that the lower intervention rate in 
banner group pharmacies was due to these pharmacies being more focused on the 
commercial side of the pharmacy industry, rather than focusing on professional pharmacy 
practice, decreasing their level of participation in a trial promoting pharmacy practice. 
Two studies within the USA have examined the difference between the independent 
pharmacies and the chain store pharmacies, with Poston et al.65 finding that independent 
pharmacies had a higher average intervention rate than the chain pharmacies, whereas 
Rupp et al.58 found no difference between the two groups. It is important to note, 
however, that banner group pharmacies within Australia are still owned by pharmacists, 
whereas the chain pharmacies in the USA tend to be run by large corporations, making it 
hard to make definitive comparisons between the two pharmacy systems. 
4.2.34.10 Presence of pre-registration pharmacists 
It was expected that the presence of a pre-registration pharmacist within the last two 
years would increase the number of interventions documented, as they would likely be 
more enthusiastic about their profession due to their recent graduation and also be more 
likely to have a lower workload, resulting in more time and motivation to document 
interventions. The finding that these pharmacies tended to have a lower intervention rate 
was therefore unexpected. Again, the lower intervention rate in pharmacies that 
employed a pre-registration pharmacist may be explained by the fact that these 
pharmacies had a significantly higher weekly prescription volume during the trial. 
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4.2.34.11 Number of dispensing terminals 
A significant relationship between the number of dispensing terminals and the pharmacy’s 
intervention rate was found. Pharmacies with only one terminal had the highest 
intervention rate, pharmacies with two terminals had the lowest rate and pharmacies with 
three or more terminals had an ‘in-between’ intervention rate. It may be possible that 
these differences were similar to those seen in the financial turnover analysis (section 
4.2.11), where pharmacies with two terminals were in the ‘in-between’ group where they 
are busy, but not busy enough to employ someone else or have an additional terminal. As 
such, it is possible that the differing rate of interventions in pharmacies was due to 
different workloads within the pharmacies, rather than the number of dispensing 
terminals present.  
4.2.34.12 Pharmacy workflow 
There were positive correlations between the pharmacy’s intervention rate and the 
percentage of time the pharmacist spent collecting prescription/patient details and 
collecting payment. This can most likely be attributed to the fact that DRPs are often 
detected during conversations with the patient, so seeing the patient before and/or after 
the prescription is dispensed will increase the pharmacist’s contact time with possible 
interventions. Poor store layout has previously been noted to influence the provision of 
cognitive services in several pharmacy studies.53,99,109,114 Again, this is likely due to 
increased interactions between the pharmacist and the consumer, therefore increasing 
the amount of information exchanged. 
4.2.34.13 Non-significant factors 
The pharmacy’s intervention rate did not appear to be affected by regionality, the 
attribution of the dispensary to total pharmacy turnover, owner vs manager operation, 
number of pharmacists responsible for making business decisions, dispensing software 
system, number of FTE pharmacists per week, proportion of prescriptions assembled by 
technicians, type of counselling area, pharmacist accessibility to the public and the 
number of original prescriptions dispensed by the pharmacy. 
The Australian study published by Caleo et al. in 1996 also reported no significant 
differences in the intervention rate of metropolitan pharmacies compared to rural 
pharmacies32,33, with Leemans et al. finding no difference in intervention rates between 
urban, suburban and rural pharmacies.75 However, a study from the USA found that 
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pharmacies located in a rural area were more likely to provide cognitive services 
compared to pharmacies in a regional centre.112 The study by Leemans et al. in Belgium 
also found that the type of dispensing software in the pharmacy did not appear to affect 
the pharmacy’s intervention rate.75 
4.2.34.14 Observation 
The presence of observers was seen to increase the pharmacy’s documented intervention 
rate, which was most likely due to the Hawthorne effect.172 The presence of the observer 
may have increased the pharmacist’s awareness of the program, but the pharmacist may 
also have had a sub-conscious desire to ‘please’ the observer by documenting their 
interventions, resulting in a higher intervention rate. The differences in documentation 
rates between observed and non-observed pharmacists has previously been noted by 
Dobie and Rascati, where their study used the same methods as an observational study, 
but asked the pharmacists to self-record, resulting in a 50% decrease in the documented 
intervention rate.60 
4.2.34.15 Software groups 
The level of software present within the pharmacies did not appear to affect their 
intervention rate, with the general reminder increasing the number of interventions 
documented after the reminder appeared, but not significantly increasing the overall 
intervention rates within these groups. This finding was disappointing, as it was hoped 
that increased awareness of the trial through the use of reminders and prompts would 
increase the number of interventions documented within the system, therefore increasing 
the intervention rate. Although the software did not significantly influence the 
intervention rate overall, there did appear to be a significant trend from Group One to 
Group Three, where the intervention rate increased as the group number increased. This 
effect was also supported by the first four weeks of data, where the differences between 
the groups were approaching significance. The finding of no significant differences 
between the groups was unexpected, as Groups Two and Three had reminders and 
prompts which would increase the pharmacist’s awareness of the trial and therefore 
would be expected to increase the intervention rate within the pharmacy. Also, in the 
PROMISe II trial, a significant difference in intervention rate was seen between the two 
groups (prompt and no prompt).80,81 Again, this may be due to the fact that the PROMISe 
III trial involved more pharmacies and went for a longer time, therefore the effect of the 
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different software groups was harder to maintain. Also, the prompt was only activated 
with high dose PPIs, which made up 3.8% of the total prescriptions dispensed164, resulting 
in another 96.2% of prescriptions that did not activate a prompt. The relatively low rate of 
activation may also have contributed to no significant differences being found between 
the software groups. 
Before the trial, it was thought that the statistics display within the PROMISe system 
would be motivating for the pharmacists to document their interventions and try to 
compete with other pharmacies for a higher intervention rate. However, there is the 
possibility that the display had the opposite effect, with the pharmacists feeling that they 
were doing better or on par with the average, resulting in decreased documentation of 
their interventions. It remains unknown how much influence the statistics display had on 
the documentation of interventions. 
4.2.34.16 Prompt 
Although the PPI step-down prompt did not increase the overall intervention rate within 
the pharmacy, it significantly increased the number of interventions on PPI medications in 
Group Three pharmacies when compared to either of the other pharmacy groups. This 
finding was seen as a clearly standout effect of the system and will be discussed further 
within Chapter 6. 
The prompt appeared as a dialog box during the dispensing of esomeprazole 40mg and 
pantoprazole 40mg, and had to be acknowledged by the dispensing pharmacist by clicking 
to remove the prompt and continue the dispensing process. In essence, it was interruptive 
and had to be dealt with before dispensing workflow could continue. The prompt also 
provided pharmacists with easily accessible additional information, making the process of 
an intervention easy to complete, which may also have increased the number of 
prompted interventions performed. 
The prompt intervention that was chosen had been brought to the attention of GPs and 
pharmacists via the NPS during May 2009.152,173 This may have assisted pharmacists to be 
more comfortable with performing this type of proactive intervention. When the prompt 
was displayed, leaflets for consumers and pharmacists/GPs could be opened and printed, 
and links to the NPS article were available. This supportive information may also have 
encouraged pharmacists to perform the prompted intervention. 
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The number of prompted interventions decreased over the period of the trial, which could 
indicate pharmacist fatigue with the prompt. Additionally, those regular consumers who 
were suitable for the intervention would have been expected to receive the intervention 
within the early weeks of the trial; therefore, the subsequent weeks of the trial would 
present an increasingly limited number of opportunities to perform the intervention. The 
intervention did not attract any payment, and therefore did not provide any great 
incentive for the performing of the intervention. In fact, the prompt actually decreased 
the financial gain to pharmacy owners, as dispensing high dose PPIs attracts a higher 
payment for the pharmacy from the PBS. Despite this, many interventions were still 
performed due to the prompt. Payment for interventions, especially for those actively 
promoted through the prompt mechanism, may slow the rate of decrease over time. 
Regularly changing the prompt message would also combat prompt fatigue and may also 
stop the associated decrease in interventions seen within this trial. 
Although the Group Three pharmacies had a higher intervention rate on the PPI 
medications, it did not significantly increase their intervention rate overall. It is therefore 
unknown if the Group Three pharmacies decreased the number of interventions 
performed on other medications in substitution for this, or perhaps just decreased the 
number of interventions documented on other medications. This could suggest that the 
prompt helped the pharmacist to remember to document interventions, whilst still 
maintaining the number of interventions performed. A previous study by van Mil et al.70 
showed that electronic prompts could significantly increase the number of interventions 
documented, therefore it is likely that the presence of the prompt was beneficial. 
Analysis of the trial prescription data method to detect prompted interventions would 
have only identified a proportion of intervention recommendation adoptions and would 
likely to underestimate the true figure. For example, consumers may visit multiple 
pharmacies which prevents follow-up of prescription evidence via complete medical 
history; consumers may have not had the time to follow-up the recommendation with 
their GP during the time period of the trial or may have waited until all prescription 
repeats were dispensed prior to follow-up (particularly with pantoprazole 40mg where 
authorisation for five repeats was commonplace); and cessation of therapy would not be 
immediately obvious through this method of detection. These limitations may have 
influenced the number of prompted interventions identified in the dataset, most likely 
resulting in an underestimation of the number of interventions influenced by the prompt.  
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4.3 Multivariate statistical model for determining the 
pharmacy’s intervention rate 
Workload and prescription volume were found to be a significant influence within the 
bivariate analysis, with many factors that were significantly associated with the 
pharmacy’s intervention rate also associated with the workload and prescription volume 
of the pharmacy. A multivariate analysis was therefore performed to determine if 
workload and prescription volume continued to have a significant influence on the 
pharmacy’s intervention rate. As discussed in Chapter 2, the pharmacy intervention rate 
was not normally distributed and a logarithmic transformation was undertaken to achieve 
normality, resulting in the variable named logCI_Rate. 
4.3.1 Multiple regression modelling 
All of the bivariate analyses were re-done, where the intervention rate was substituted for 
the logCI_Rate and parametric tests were used where indicated. Although the p-values 
differed slightly in some cases, the same factors remained significant. To ensure that all 
possible influencing factors were included, a p-value of 0.1 was used as a cut-off point, 
resulting in the following bivariate factors being considered for inclusion in the multiple 
regression model: 
 Pharmacy location (p = 0.048) 
 Pharmacy area in m2 (p = 0.006) 
 Pharmacy estimated financial turnover in 2007/08 financial year (p = 0.001) 
 Estimated weekly prescription volume (p = 0.003) 
 Actual prescription volume of the pharmacy during the trial (participating 
pharmacists); p = 0.012 
 Actual prescription volume of the pharmacy during the trial (ALL pharmacists, 
including non-participants); p = 0.002 
 Average pharmacist workload (calculated by number of prescriptions divided by 
FTE pharmacists); p = 0.019 
 Banner group or independent pharmacy (p = 0.056) 
 Catered for an aged care facility (p = 0.006) 
 No. of opening hours (p = 0.013) and opening days (p = 0.051) per week 
 Pharmacy employed a pre-registration pharmacist within the last two years (p = 
0.049) 
 Participation in the DAA trial (p = 0.003) and PMP trial (p = 0.022) 
 Pharmacy provides BP monitoring (p = 0.012) and DAA packing (p = 0.047) 
 Total number of professional services offered (correlation p = 0.007) 
 Number of dispensing system terminals - 3 groups (1, 2, 3 or more); p = 0.011 
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 % of time the pharmacist collects patient details (p = 0.025) 
 % of time the pharmacist collects payment from the patient (p = 0.006) 
4.3.1.1 Missing value analysis 
A missing value analysis was conducted to determine if there were any patterns to the 
missing values, resulting in 184 full datasets. For more detail, see Appendix 23. 
4.3.1.2 Creating a list of logical variables 
In order for the multiple regression model to be useful for predictive purposes, the list of 
variables was reviewed to ensure all included variables were logical. Three measures of 
prescription volume were included in the list in section 4.3.1: estimated weekly 
prescription volume; actual prescription volume of the pharmacy during the trial 
(participating pharmacists); and actual prescription volume of the pharmacy during the 
trial according to the dispensing records (using data from all pharmacists, including non-
participants). The ‘actual prescription volume using all pharmacists’ was used, as this was 
considered a more accurate reflection of the actual prescription volume of the pharmacy, 
rather than estimated volumes or prescription volumes only including participating 
pharmacists (excluding the locum pharmacists not enrolled). 
Pharmacy opening hours per week had a stronger correlation than pharmacy opening 
days per week, and was considered to be a better reflection of the type of pharmacy. 
Therefore, it was chosen to represent the ‘availability’ of the pharmacy. 
The DAA and PMP trial were unique trials which would be unlikely to be repeated in a 
future pharmacy setting, so a new binary variable called ‘participation in additional 
pharmacy trials’ was created to make the model more useful for predictive purposes. All 
pharmacies that had indicated that they were participating in one of the four concurrent 
PGA/Community Pharmacy Agreement trials (DAA, PMP, PAMS or DMAS) were assigned 
as participants, whereas pharmacies that had not indicated they were part of these trials 
were assigned as non-participants. A Mann-Whitney test still showed a significant 
difference between the intervention rates of the two groups (U = 807.00, Z = -1.999, p = 
0.046), with participating pharmacies having a lower intervention rate than non-
participants. In addition, the number of additional professional services (such as BP 
monitoring and DAA packing) was also recreated into a new binary variable. The 
pharmacies that offered 3 or more services were grouped together, with the remaining 
pharmacies that offered 0 to 2 services placed in the other group. A Mann-Whitney test 
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also showed that there was still a significant difference between the intervention rates of 
the two groups (U = 1207.00, Z = -2.453, p = 0.013), with the pharmacies offering more 
services tending to have a lower intervention rate. 
4.3.1.3 Proving assumptions 
Multiple regression assumes normality, linearity, homoscedasticity, no outliers, no 
multicollinearity and independence of errors.149 As such, each variable was analysed to 
ensure it met these criteria. The binary variables all appeared to be acceptable. The six 
continuous variables were not normally distributed; therefore, logarithmic transformation 
was attempted in the same manner in which the CI rate had previously been 
logarithmically transformed. These transformations were not successful (see Appendix 23 
for more details); therefore, the continuous variables were condensed into categorical 
variables. 
Using the BINNED function in SPSS, the actual prescription volume was split into three 
equal groups: low, moderate and high prescription volume. Within this dataset, the low 
prescription volume represented pharmacies dispensing 0 – 504 prescriptions per week; 
moderate = 505 – 1026 prescriptions per week; and high = more than 1027 prescriptions 
per week. A Kruskal-Wallis test showed significant differences in the intervention rate 
between the three groups (χ2 = 10.17, df = 2, p = 0.006; Jonckheere-Terpstra t = -2.94, p = 
0.003). The BINNED function in SPSS was also used to split the average pharmacist 
workload into three equal groups: low, moderate and high pharmacist workload. Within 
this dataset, the low pharmacist workload represented pharmacists dispensing 0 – 388 
prescriptions per 38-hour week; moderate = 389 – 546 prescriptions per 38-hour week; 
and, high = more than 547 prescriptions per 38-hour week. A Kruskal-Wallis test again 
showed significant differences in the intervention rate between the three groups (χ2 = 
6.77, df = 2, p = 0.035; Jonckheere-Terpstra t = -2.363, p = 0.019). 
Pharmacy opening hours were split into a binary variable. The 55 pharmacies with opening 
hours of 50 hours or less per week were coded as ‘conventional’, as this number of hours 
would be achieved with a typical 5 weekdays plus Saturday morning trade. The 129 
remaining pharmacies that traded for 51 hours or more per week were coded as 
‘extended trade’, as these pharmacies traded outside the ‘conventional’ pharmacy hours. 
A Mann-Whitney test still showed significant differences in the intervention rates of these 
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groups (U = 2869.50, Z = -2.050, p = 0.041), with the ‘conventional’ pharmacies having a 
higher intervention rate than the ‘extended trade’ pharmacies. 
The two variables describing the percentage of time the pharmacist collects patient details 
and collects payments were combined into one variable. These two responsibilities within 
the pharmacy increase the amount of interaction time between the pharmacist and the 
patient; therefore, the variable was recoded into a binary variable that arbitrarily 
described the level of patient contact. The 23 pharmacies that had a patient contact 
greater than 50% of the time were coded as ‘high patient contact time’, whilst the 
remaining 161 pharmacies were coded as ‘low patient contact time’. A Mann-Whitney test 
still showed significant differences in the intervention rates of these groups (U = 1369.00, 
Z = -2.019, p = 0.043), with the ‘high patient contact time’ pharmacies having a higher 
intervention rate than the ‘low patient contact time’ pharmacies. 
4.3.1.4 Dummy coding categorical variables 
Multiple regression only allows an independent categorical variable to be binary 
categorical, so the categorical variables had to be converted to ‘dummy’ variables (where 
‘1’ denoted ‘membership’ within that group whereas ‘0’ denoted ‘no membership’).The 
following factors needed to be converted before inclusion in the multiple regression 
model: 
 Pharmacy location (3 groups: medical centre, shopping strip, shopping centre)  
 Pharmacy area in m2 (4 groups used) 
 Pharmacy estimated financial turnover in 2007/08 financial year (4 groups used) 
 Number of dispensing system terminals (1, 2, 3 or more) 
 Actual prescription volume (3 groups; low, moderate and high) 
 Average pharmacist workload (3 groups; low, moderate and high) 
4.3.1.5 Included variables 
The following variables were entered into the multiple regression model: 
 Pharmacy location (3 groups; medical centre, shopping strip, shopping centre) - 
dummy coded into 2 binary variables 
 Pharmacy area in m2 (4 groups) - dummy coded into 3 binary variables 
 Pharmacy estimated financial turnover in 2007/08 financial year (4 groups) -
dummy coded into 3 binary variables 
 Banner group or independent – binary variable 
 Catered for an aged care facility – binary variable 
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 Pharmacy employed a pre-registration pharmacist within the last two years – 
binary variable 
 Participation in other pharmacy trials – binary variable 
 Number of professional services offered; ‘0 to 2 services’ vs ‘3 or more services – 
binary variable 
 Number of dispensing system terminals (3 groups) - dummy coded into 2 binary 
variables 
 Actual prescription volume of the pharmacy during the trial (ALL pharmacists 
including non-participants) – 3 groups; dummy coded into 2 binary variables 
 Average pharmacist workload (3 groups) – dummy coded into 2 binary variables 
 Pharmacy opening hours per week; ‘conventional’ vs ‘extended trade’ – binary 
variable  
 % of patient contact time; ‘high’ vs ‘low’ – binary variable   
There were 21 variables in total. The general rule for multiple regressions is ‘number of 
samples needed ≥ 50 + 8m (where m = number of independent variables)’149; therefore, 
218 pharmacies (50+ 8*21 = 218) were needed. This was noted, as it may have been 
necessary to remove some variables. 
4.3.1.6 Step 1 (Model 1) 
Due to the large number of variables, a stepwise regression was initially run to determine 
which variables were significant to the overall model. Initially, an inclusion p-value of 0.1 
was used to ensure all valid variables were included. The variables that significantly 
contributed to the overall predictive model were: whether the pharmacy catered for ACFs; 
pharmacy area of 150-250m2; high pharmacist workload; an annual financial turnover 
between 1.5M to 2.5M or 2.5M to 4.0M; and, participation in other pharmacy trials. The 
best adjusted R2 value achieved through the stepwise regression process was 0.116, 
indicating that 11.6% of variance could be explained by the model. The Durbin-Watson 
statistic was close to 2, indicating that the errors appeared to be independent of each 
other. The ANOVA statistical tests were significant (p < 0.01) for the models, indicating 
that all models were better at predicting logCI_Rate than the constant-only model. 
Multicollinearity was also not a problem within the model, as no VIF value was greater 
than 10. 
The only outlying case had a logCI_Rate of -2, which indicated that the pharmacy had an 
intervention rate of zero (as log0.01 = -2.00). It was expected that pharmacies with an 
intervention rate of zero would be outliers in any prediction model. Analysis using Cook’s 
distance149 showed that the outlying case did not significantly influence the overall model; 
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therefore, this pharmacy was still included in the analysis. The residuals plot showed a 
fairly uniform distribution, indicating that the assumption of linearity had been met. See 
Appendix 23 for relevant tables. 
4.3.1.7 Step 2 (Model 2) 
Two of the three financial turnover dummy variables were included in the model, exerting 
a negative effect on the intervention rate. These two variables (financial turnover 
between 1.5M to 2.5M and financial turnover between 2.5M to 4.0M) were then 
combined, resulting in 3 categories of financial turnover: less than 1.5M; 1.5-4.0M; and, 
over 4.0M. 
The stepwise regression was repeated, resulting in five included variables: an annual 
financial turnover between 1.5M and 4.0M; whether the pharmacy catered for ACFs; 
participation in other pharmacy trials; location in a medical centre; and, high pharmacist 
workload. From the last model, location in a medical centre had appeared and pharmacy 
area had disappeared. Model 2 achieved a slightly improved adjusted R2 of 0.125. The 
Durbin-Watson statistic was 1.811 (indicating independent errors) and the significant 
ANOVA result (F(5,177) = 6.20, p < 0.001) indicated that the model still remained better 
than the constant-only model. See Appendix 23 for relevant tables. 
4.3.1.8 Step 3 (Model 3) 
Three of the variables (high workload, location in a medical centre and caters for aged 
care) had become less significant within model 2. Another stepwise regression was 
performed with the inclusion p-value decreased to 0.05 (exclusion p-value = 0.1). Three 
variables remained significant with the altered p-values: high pharmacist workload; annual 
financial turnover between 1.5M and 4.0M; and whether the pharmacy catered for an 
aged care facility (Table 4-54). Model 3 achieved a slightly decreased adjusted R2 of 0.101 
(Table 4-52), indicating that 10.1% of variance could be explained by the model. The 
Durbin-Watson statistic was 1.766 (indicating independent errors) and the significant 
ANOVA result (F(3,179) = 7.85, p < 0.001) indicated that the model still remained better 
than the constant-only model (Table 4-52 and Table 4-53). Multicollinearity was also not a 
problem, as no VIF value was greater than 10 (Table 4-54). All the variables remained 
statistically significant, with high pharmacist workload approaching significance (p = 0.055; 
Table 4-54). 
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Model Summaryd 
Model R R2 
Adjusted 
R2 
Std. 
Error  
Change Statistics 
Durbin-
Watson 
R
2
 
Change 
F 
Change df1 df2 
Sig. F 
Change 
1 .172
a 0.029 0.024 0.418 0.029 5.498 1 181 0.020   
2 .305
b 0.093 0.083 0.406 0.064 12.619 1 180 0.000   
3 .341
c 0.116 0.101 0.401 0.023 4.695 1 179 0.032 1.766 
a. Predictors: (Constant), High Pharmacist Workload 
b. Predictors: (Constant), High Pharmacist Workload, Pharmacy$Turnover 1.5to4.0M 
c. Predictors: (Constant), High Pharmacist Workload, Pharmacy$Turnover 1.5to4.0M, Caters for ACFs 
d. Dependent Variable: Log CI Rate 
Table 4-52: Regression model summary for model 3 
ANOVAd 
Model 
Sum of 
Squares df 
Mean 
Square F Sig. 
1 
Regression 0.962 1 0.962 5.498 .020a 
Residual 31.684 181 0.175     
Total 32.646 182       
2 
Regression 3.038 2 1.519 9.235 .000b 
Residual 29.608 180 0.164     
Total 32.646 182       
3 
Regression 3.795 3 1.265 7.848 .000c 
Residual 28.851 179 0.161     
Total 32.646 182       
a. Predictors: (Constant), High Pharmacist Workload 
b. Predictors: (Constant), High Pharmacist Workload, Pharmacy$Turnover 
1.5to4.0M 
c. Predictors: (Constant), High Pharmacist Workload, Pharmacy$Turnover 
1.5to4.0M, Caters for ACFs 
d. Dependent Variable: Log CI Rate 
Table 4-53: ANOVA for model 3 
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Coefficientsa 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B Correlations 
Collinearity 
Statistics 
B 
Std. 
Error Beta 
Lower 
Bound 
Upper 
Bound 
Zero-
order Partial Part Tolerance VIF 
1 
(Constant) -0.607 0.038   -16.088 0.000 -0.681 -0.532           
High Pharmacist Workload -0.154 0.066 -0.172 -2.345 0.020 -0.284 -0.024 -0.172 -0.172 -0.172 1.000 1.000 
2 
(Constant) -0.494 0.048   -10.189 0.000 -0.590 -0.398           
High Pharmacist Workload -0.146 0.064 -0.163 -2.289 0.023 -0.272 -0.020 -0.172 -0.168 -0.163 0.999 1.001 
Pharmacy$Turnover 1.5 to 
4.0M 
-0.214 0.060 -0.252 -3.552 0.000 -0.333 -0.095 -0.258 -0.256 -0.252 0.999 1.001 
3 
(Constant) -0.463 0.050   -9.241 0.000 -0.562 -0.364           
High Pharmacist Workload -0.124 0.064 -0.138 -1.934 0.055 -0.250 0.003 -0.172 -0.143 -0.136 0.973 1.028 
Pharmacy$Turnover 1.5 to 
4.0M 
-0.198 0.060 -0.234 -3.297 0.001 -0.316 -0.079 -0.258 -0.239 -0.232 0.984 1.017 
Caters for ACFs -0.139 0.064 -0.156 -2.167 0.032 -0.265 -0.012 -0.208 -0.160 -0.152 0.959 1.043 
a. Dependent Variable: Log CI Rate  
Table 4-54: Coefficients table for model 3 
 
240 | P a g e  
 
Only one outlying case was detected and the Cook’s distance value was less than 1; 
therefore, the case did not have a major influence on the overall model. The residuals plot 
again showed a fairly uniform distribution indicating the assumption of linearity had been 
met. See Appendix 23 for more details. 
4.3.1.9 Model interpretation –‘Pharmacy workload model’ 
Overall, the model fit was relatively poor, as the adjusted R2 was only 0.101; therefore, 
only 10.1% of variance was explained by the model. As the dependent variable had been 
logarithmically transformed, the format for interpretation is that the dependent variable 
changes by 100*coefficient percent for a one unit increase in the independent variable.174 
Therefore, with ‘membership’ to that group (‘1’ rather than ‘0’), the intervention rate will 
change by 100*coefficient percent.  
Model 
Log CI Rate = -0.463 + (-0.138*A) + (-0.234*B) + (-0.156*C) + errors 
A = High pharmacist workload (greater than 547 prescriptions per 38-hour week) 
B = Pharmacy$Turnover of 1.5Mto 4.0M  
C = Caters for ACFs 
[Where 0 = no membership to the group, and 1 = membership to the group] 
Factor Coefficient Change in DV 
High pharmacist workload -0.138 -13.8 
Pharmacy$Turnover1.5to4.0M -0.234 -23.4 
Caters for aged care  -0.156 -15.6 
Table 4-55: Percentage change in the pharmacy’s intervention rate according to the 
model  
Therefore, from Table 4-55; 
 Pharmacies with a high pharmacist workload had 13.8% lower intervention rates 
on average (compared to pharmacies with low or moderate pharmacist 
workloads)  
 Pharmacies with a turnover between $1.5 to 4.0M had 23.4% lower intervention 
rates on average (compared to pharmacies with turnovers under $1.5M or over 
$4M) 
 Pharmacies that catered for ACFs had 15.6% lower intervention rates on average 
(compared to pharmacies that did not cater for ACFs) 
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It should be noted that these percentage changes are only accurate when all other 
independent variables in the model remain unchanged. 
4.3.1.10 Prescription volume model 
Due to pharmacist workload featuring significantly in the previous model, an additional 
regression analysis was performed to determine if prescription volume had the same 
effect. The variables describing pharmacist workload were excluded, resulting in 18 
variables to include in the regression. Stepwise regression was used, resulting in a 
somewhat different set of significant variables: high prescription volume; moderate 
prescription volume; annual financial turnover $1.5 to 4.0M; location in a medical centre; 
and, participation in other pharmacy trials (Table 4-58). The ‘caters for ACFs’ variable did 
not feature within this model, indicating that any effect it exerted on the model was 
similar to the effect exerted by prescription volume. The five variables included within the 
prescription volume model achieved an adjusted R2 of 0.118, indicating that 11.8% of 
variance could be explained by the model (Table 4-56). The Durbin-Watson statistic was 
1.987 (indicating independent errors) and the significant ANOVA result (F(5,177) = 5.866, p 
< 0.001) indicated that the model still remained better than the constant-only model 
(Table 4-56 and Table 4-57). Multicollinearity was also not a problem, as no VIF value was 
greater than 10 (Table 4-58). All the variables remained significant, except moderate 
prescription volume with a p = 0.077 (Table 4-58). 
Model Summaryf 
Model R R2 
Adjusted 
R2 
Std. 
Error 
Change Statistics 
Durbin-
Watson 
R
2 
Change 
F 
Change 
df1 df2 
Sig. F 
Change 
1 .142
a 0.020 0.015 0.420 0.020 3.739 1 181 0.055   
2 .254
b 0.065 0.054 0.412 0.044 8.552 1 180 0.004   
3 .312
c 0.098 0.082 0.406 0.033 6.513 1 179 0.012   
4 .348
d 0.121 0.101 0.402 0.023 4.724 1 178 0.031   
5 .377
e 0.142 0.118 0.398 0.021 4.398 1 177 0.037 1.987 
a. Predictors: (Constant), High Prescription Volume 
b. Predictors: (Constant), High Prescription Volume, Moderate Prescription Volume 
c. Predictors: (Constant), High Prescription Volume, Moderate Prescription Volume, Pharmacy$Turnover 
1.5to4.0M  
d. Predictors: (Constant), High Prescription Volume, Moderate Prescription Volume, Pharmacy$Turnover 
1.5to4.0M, Location in a medical centre 
e. Predictors: (Constant), High Prescription Volume, Moderate Prescription Volume, Pharmacy$Turnover 
1.5to4.0M, Location in a medical centre, Participates in other pharmacy trials 
f. Dependent Variable: Log CI Rate 
Table 4-56: Regression model summary for prescription volume model 
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ANOVAf 
Model 
Sum of 
Squares df 
Mean 
Square F Sig. 
1 
Regression 0.661 1 0.661 3.739 .005a 
Residual 31.985 181 0.177     
Total 32.646 182       
2 
Regression 2.111 2 1.056 6.223 .002b 
Residual 30.535 180 0.170     
Total 32.646 182       
3 
Regression 3.183 3 1.061 6.447 .000c 
Residual 29.463 179 0.165     
Total 32.646 182       
4 
Regression 3.945 4 0.986 6.117 .000d 
Residual 28.701 178 0.161     
Total 32.646 182       
5 
Regression 4.641 5 0.928 5.866 .000e 
Residual 28.005 177 0.158     
Total 32.646 182       
a. Predictors: (Constant), High Prescription Volume 
b. Predictors: (Constant), High Prescription Volume, Moderate Prescription Volume 
c. Predictors: (Constant), High Prescription Volume, Moderate Prescription Volume, 
Pharmacy$Turnover 1.5to4.0M  
d. Predictors: (Constant), High Prescription Volume, Moderate Prescription Volume, 
Pharmacy$Turnover 1.5to4.0M, Location in a medical centre 
e. Predictors: (Constant), High Prescription Volume, Moderate Prescription Volume, 
Pharmacy$Turnover 1.5to4.0M, Location in a medical centre, Participates in other pharmacy 
trials 
f. Dependent Variable: Log CI Rate 
Table 4-57: ANOVA for prescription volume model 
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Coefficients
a
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
Correlations Collinearity Statistics 
B 
Std. 
Error 
Beta 
Lower 
Bound 
Upper 
Bound 
Zero-
order 
Partial Part Tolerance VIF 
1 
(Constant) -0.616 0.038   -16.241 0.000 -0.690 -0.541           
High Prescription Volume -0.128 0.066 -0.142 -1.934 0.055 -0.259 0.003 -0.142 -0.142 -0.142 1.000 1.000 
2 
(Constant) -0.508 0.052   -9.709 0.000 -0.611 -0.405           
High Prescription Volume -0.236 0.075 -0.262 -3.160 0.002 -0.383 -0.089 -0.142 -0.229 -0.228 0.756 1.323 
Moderate Prescription Volume -0.217 0.074 -0.242 -2.924 0.004 -0.364 -0.071 -0.113 -0.213 -0.211 0.756 1.323 
3 
(Constant) -0.460 0.055   -8.384 0.000 -0.568 -0.352           
High Prescription Volume -0.182 0.076 -0.202 -2.377 0.018 -0.333 -0.031 -0.142 -0.175 -0.169 0.698 1.432 
Moderate Prescription Volume -0.146 0.078 -0.163 -1.864 0.064 -0.300 0.009 -0.113 -0.138 -0.132 0.660 1.515 
Pharmacy$Turnover 1.5 to 4.0M -0.165 0.065 -0.195 -2.552 0.012 -0.293 -0.037 -0.258 -0.187 -0.181 0.863 1.159 
4 
(Constant) -0.478 0.055   -8.705 0.000 -0.587 -0.370           
High Prescription Volume -0.194 0.076 -0.216 -2.557 0.011 -0.344 -0.044 -0.142 -0.188 -0.180 0.694 1.440 
Moderate Prescription Volume -0.143 0.078 -0.160 -1.848 0.066 -0.296 0.010 -0.113 -0.137 -0.130 0.660 1.516 
Pharmacy$Turnover 1.5 to 4.0M -0.164 0.064 -0.193 -2.554 0.011 -0.290 -0.037 -0.258 -0.188 -0.180 0.863 1.159 
Location in/near a medical centre 0.223 0.103 0.154 2.173 0.031 0.021 0.426 0.145 0.161 0.153 0.990 1.010 
5 
(Constant) -0.249 0.122   -2.035 0.043 -0.490 -0.008           
High Prescription Volume -0.172 0.076 -0.191 -2.261 0.025 -0.321 -0.022 -0.142 -0.168 -0.157 0.681 1.469 
Moderate Prescription Volume -0.137 0.077 -0.153 -1.778 0.077 -0.288 0.015 -0.113 -0.132 -0.124 0.659 1.518 
Pharmacy$Turnover 1.5 to 4.0M -0.170 0.064 -0.201 -2.680 0.008 -0.296 -0.045 -0.258 -0.197 -0.187 0.861 1.162 
Location in/near a medical 
centre 
0.222 0.102 0.153 2.184 0.030 0.021 0.423 0.145 0.162 0.152 0.990 1.010 
Participates in other pharmacy 
trials 
-0.252 0.120 -0.148 -2.097 0.037 -0.489 -0.015 -0.161 -0.156 -0.146 0.978 1.023 
a. Dependent Variable: Log CI Rate  
Table 4-58: Coefficients table for prescription volume model 
244 | P a g e  
 
There were no outlying cases within the model and the residuals plot showed a fairly 
uniform distribution. See Appendix 23 for the residuals plot. 
Model interpretation 
The model fit remained relatively poor, as the adjusted R2 was only 0.118; therefore, only 
11.8% of variance was explained by the model. 
Log CI Rate = -0.249 + (-0.191*A) + (-0.153*B) + (-0.201*C) + 0.153*D + (-0.148*E) + errors 
A = High prescription volume (greater than 1027 prescriptions per week) 
B = Moderate prescription volume (between 505 and 1026 prescriptions per week) 
C = Pharmacy Turnover of $1.5Mto 4.0M 
D = Location in a medical centre 
E = Participation in other pharmacy trials 
[Where 0 = no membership to the group, and 1 = membership to the group] 
Factor Coefficient Change in DV 
High prescription volume -0.191 -19.1 
Moderate prescription volume -0.153 -15.3 
Pharmacy Turnover $1.5to 4.0M -0.201 -20.1 
Location in/near a medical centre 0.153 +15.3 
Participates in other pharmacy trials -0.148 -14.8 
Table 4-59: Percentage change in the pharmacy’s intervention rate according to the 
prescription volume model  
Therefore, from Table 4-59 ; 
 Pharmacies with a high prescription volume had 19.1% lower intervention rates 
on average (compared to pharmacies with low prescription volumes)  
 Pharmacies with a moderate prescription volume had 15.3% lower intervention 
rates on average (compared to pharmacies with low prescription volumes)  
 Pharmacies with a turnover between $1.5 to 4.0M had 20.1% lower intervention 
rates on average (compared to pharmacies with turnovers under $1.5M or over 
$4M) 
 Pharmacies that were located in or near a medical centre had 15.3% higher 
intervention rates on average (compared to pharmacies located in a shopping 
centre or shopping strip) 
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 Pharmacies that were concurrently participating in other pharmacy trials during 
the PROMISe trial had 14.8% lower intervention rates on average (compared to 
pharmacies that were not participating in other trials) 
Again, it should be noted that these percentage changes are only accurate when all other 
independent variables in the model remain unchanged. 
4.3.2 Logistic regression 
The multiple regression model seen in section 4.3.1.9 was a poor predictor of the 
pharmacy intervention rate. A logistic regression, based on categorising pharmacies into 
different groups according to intervention rates, was also performed to determine if a 
model could predict those pharmacies with a high intervention rate. Cut-off points of 
intervention rates greater than 1% and greater than 0.6% were chosen for the analysis. 
4.3.2.1 Intervention rates greater than 1.0% 
All pharmacies with an intervention rate greater than 1.0% were recoded as ‘high 
performers’, with 14 pharmacies meeting this criteria. The remaining 169 pharmacies 
were recoded as ‘non-performers’ for the purposes of this analysis. Therefore, the 
resultant model aimed to predict a dichotomous variable; either ‘yes’ or ‘no’. 
A forward stepwise regression was performed and identified two pharmacy variables that 
were significantly associated with a higher intervention rate: location and financial 
turnover. Pharmacies that were in a medical centre with a financial turnover of less than 
$1.5M annually were more likely to have a higher intervention rate (Table 4-60). 
 Pharmacies in a medical centre were 560%, and pharmacies in a shopping strip 
were 47%, more likely to be a high performer than pharmacies in a shopping 
centre 
 Pharmacies with a financial turnover of less than $1.5M were more likely to be a 
high performer compared to pharmacies with financial turnovers of $1.5M to 
2.5M (91% more likely), financial turnovers of $2.5M to 4.0M (75% more likely) 
and financial turnovers of over $4.0M (79% more likely) 
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B S.E. Wald df Sig. Exp(B) 
95% CI for 
EXP(B) 
Lower Upper 
Located in a shopping centre     5.264 2 0.072       
Located in a medical centre 1.887 0.959 3.869 1 0.049 6.597 1.007 43.233 
Located in a shopping strip 0.384 0.855 0.202 1 0.653 1.468 0.275 7.842 
Pharmacy $ Turnover Less 
than 1.5M 
    7.676 3 0.053       
Pharmacy $ Turnover 1.5M 
to 2.5M 
-2.457 1.078 5.199 1 0.023 0.086 0.010 0.708 
Pharmacy $ Turnover 2.5M 
to 4.0M 
-1.386 0.856 2.620 1 0.106 0.250 0.047 1.339 
Pharmacy $ Turnover Over 
4.0M 
-1.550 1.114 1.937 1 0.164 0.212 0.024 1.883 
Constant -2.128 0.816 6.793 1 0.009 0.119     
Table 4-60: Variables included in the initial logistic regression analysis 
The model provided a correct classification in 92.3% of all cases, however, 0% of the ‘high 
performers’ were correctly predicted, resulting in a poor Nagelkerke R2 value of 0.199. 
This may have occurred due to sample size of ‘high performers’ being very small, 
therefore a further logistic regression was performed using a different cut-off point.  
4.3.2.2 Intervention rates greater than 0.6% 
In this analysis, pharmacies with an intervention rate greater than 0.6% were recoded as 
‘high performers’, with 22 pharmacies meeting this criteria. The remaining 160 
pharmacies were recoded as ‘non-performers’ for the purposes of this analysis. 
A forward stepwise regression was again performed and identified three pharmacy 
variables that were significantly associated with a higher intervention rate: location, 
financial turnover and banner group. Independent pharmacies that were in a medical 
centre and with a financial turnover of less than $1.5M annually were more likely to have 
a higher intervention rate (Table 4-61). 
 Pharmacies in a medical centre were 200% more likely to be a high performer 
than pharmacies in a shopping centre, whereas pharmacies in a shopping centre 
were 47% more likely to be a high performer than pharmacies in a shopping strip 
 Pharmacies with a financial turnover of less than $1.5M were more likely to be a 
high performer compared to pharmacies with financial turnovers of $1.5M to 
2.5M (84% more likely), financial turnovers of $2.5M to 4.0M (76% more likely) 
and financial turnovers of over $4.0M (61% more likely) 
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 Independent pharmacies were 77% more likely to be a high performer than 
banner group pharmacies. 
 
B S.E. Wald df Sig. Exp(B) 
95% CIfor 
EXP(B) 
Lower Upper 
Located in a shopping centre     5.847 2 0.054       
Located in a medical centre 1.092 0.780 1.961 1 0.161 2.981 0.646 13.743 
Located in a shopping strip -0.635 0.664 0.916 1 0.339 0.530 0.144 1.946 
Pharmacy $ Turnover Less 
than 1.5M 
    
8.994 3 0.029 
      
Pharmacy $ Turnover 1.5M to 
2.5M 
-1.853 0.691 7.201 1 0.007 0.157 0.040 0.607 
Pharmacy $ Turnover 2.5M to 
4.0M 
-1.426 0.745 3.659 1 0.056 0.240 0.056 1.036 
Pharmacy $ Turnover Over 
4.0M 
-0.937 0.880 1.135 1 0.287 0.392 0.070 2.197 
Member of a banner group -1.477 0.612 5.829 1 0.016 0.228 0.069 0.757 
Constant -0.408 0.669 0.372 1 0.542 0.665     
Table 4-61: Variables included in the second logistic regression analysis 
The model provided a correct classification in 88.5% of all cases, with 99.4% of low 
performers and 9.1% of high performers correctly identified. This provided a slightly 
improved R2 value of 0.220; however, the number of high performers correctly identified 
overall remained relatively poor.  
4.3.2.3 Group of 60 ‘high performers’ 
Due to the small number of pharmacies within the ‘high performer’ group in the previous 
analysis, the 60 pharmacies with the highest intervention rates were coded as ‘high 
performers’ and an additional logistic regression analysis was performed. The model was 
not improved from the previous analysis with a correct classification provided in 69.4% of 
all cases (98.4% of low performers and 11.5% of high performers correctly identified) and 
an R2 value of 0.115.  
4.3.3 Overview of the associated factors 
The findings from this section have been summarised into Figure 4-13. The six bolded 
boxes were the factors significantly associated with the intervention rate of the pharmacy 
in the multiple regression analyses. The relationships between each of the factors have 
also been indicated with lines between the boxes. 
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Figure 4-13: Relationships between the factors significantly associated with the pharmacy’s intervention rate
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4.3.4 Discussion of the multivariate analysis 
Two multiple regression models were described that predicted the pharmacy’s 
intervention rate; the ‘pharmacist workload’ model and the ‘prescription volume’ model. 
The ‘pharmacist workload’ model featured three significant variables: high pharmacist 
workload; an annual financial turnover of $1.5 to 4.0M; and, whether the pharmacy 
catered for an aged care facility. Whereas, the multiple regression ‘prescription volume 
model’ featured five significant variables: high prescription volume; moderate prescription 
volume; an annual financial turnover of $1.5 to 4.0M; location in or near a medical centre; 
and, participation in other trials. The variables included within each model are logical and 
explainable, as seen in the discussion of the bivariate analysis (section 4.2.34), with both 
models being equally successful in the prediction of the pharmacy’s intervention rate. 
Unfortunately, the prediction success of both models was disappointingly low, with only 
10.1% and 11.8%, respectively, of the variance between pharmacies being explained by 
the model. Although the adjusted R2 value should not be used as the sole indicator of a 
model’s success175, all statistical assumptions for multiple regression analysis were met 
(see section 4.3.1.8 and 4.3.1.10) and further adjustments did not improve the model. It 
was therefore necessary to examine other reasons why the multiple regression models 
were not successful. 
There are two common problems reported in the literature that can affect the success of a 
multiple regression analysis; multicollinearity and omitted variables.176 As seen in sections 
4.3.1.8 and 4.3.1.10, multicollinearity was not a problem with the final models, with none 
of the included independent variables showing correlation with each other. On the other 
hand, models cannot be checked for omitted variables and this may be the most likely 
explanation for their poor performance. All measured variables were included in the 
multiple regression analysis, however, there is the possibility that the differences in the 
pharmacy intervention rate were due to factors that were not measured during the 
trial.175 For example, the majority of pharmacies had several individual pharmacists who 
contributed to the intervention rate and it was not possible to analyse the effect that 
differences between these individual pharmacists had on the pharmacy’s overall rate. The 
fact that multiple pharmacists contributed to the pharmacy’s intervention rate would 
have created more ‘randomness’ and ‘noise’ within the data, leading to a model with poor 
predictive capabilities.  
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In addition, the multiple regression method is not able to assess non-linear relationships 
within its analysis, so there is also the possibility that the relationships between the 
independent variables and the intervention rate were not linear.175 In order for a model to 
be used for forecasting or prediction purposes, such as predicting factors that affect a 
pharmacy’s intervention rate, a high adjusted R2 value (for example, greater than 0.7) is 
necessary.175,176 The models found within this study can, therefore, only be used as a guide 
to significant influencing factors, due to the low R2 values. It is interesting to note, 
however, that despite the poor predictive ability of the models, the same influencing 
factors kept re-occurring: high pharmacist workload; high prescription volume; an annual 
financial turnover of $1.5 to 4.0M; whether the pharmacy catered for an aged care facility; 
location in or near a medical centre; and, participation in other trials. This indicates that 
these factors do have a significant influence on the pharmacy’s intervention rate and 
altering these factors may allow a pharmacy to improve their intervention rates. 
As the multiple regression model failed to achieve a satisfactory R2 value, a logistic 
regression was also performed to determine any influential factors that increased the 
likelihood that a pharmacy would have a high intervention rate. Again, the logistic 
regression model had a poor R2 value of 0.22, where the pharmacies with a higher 
intervention rate tended to be independent pharmacies that were located in a medical 
centre and had a financial turnover of less than $1.5M annually. 
A similar study used multiple regression techniques to develop a model for predicting 
whether a pharmacy would provide cognitive services (performer vs non-performer) and a 
model for predicting the rate of cognitive service provision.101 The authors found that the 
factors affecting whether the pharmacy was a performer or non-performer was the 
attitude of the pharmacist-in-charge and the number of FTE pharmacists. No measure of 
workload was present in the resulting model. However, there were significant correlations 
between the number of FTE pharmacists and the pharmacy’s prescription volume and 
pharmacy area. The authors found that the rate of cognitive service provision was affected 
by reimbursement, monthly prescription volume and the number of government 
assistance prescriptions dispensed. Pharmacies that were reimbursed and that dispensed 
less prescriptions, but dispensed a higher percentage of government assistance 
prescriptions, had a higher intervention rate. It is important to note that the pharmacies 
were asked to record a ‘typical’ prescription volume, not record their actual volume, 
which may have decreased the accuracy of the prescription volume measurement.  
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4.4 Conclusion 
The intervention rates were varied between the pharmacies and several factors that were 
identified may have contributed to this difference. Workload and prescription volume 
appeared to have a major impact on the pharmacy’s intervention rate, with several other 
significant factors, such as financial turnover, location and catering for ACFs, also 
associated with altered workloads. Disappointingly, the predictive capabilities of the 
multiple regression models were poor. This may be due in part to several individual 
pharmacists contributing to the overall pharmacy intervention rate, as well as the 
possibility of unknown variables that were not measured. These findings, and how to 
improve the intervention rate, will be further discussed in Chapter 7.  
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5 Chapter 5: Pharmacist data and factors influencing 
pharmacist CI rate 
Prior to the PROMISe trial, participating pharmacists were asked to answer a number of 
surveys whilst completing their online training. This information was then compared to 
national averages to determine if the pharmacists were representative, and also to 
subsequently determine any factors that may have been associated with the clinical 
intervention rate. Both bivariate and multivariate analysis between the pharmacist’s 
intervention rate and any influencing factors will be reported within this chapter. 
5.1 Pharmacist demographics 
Of the 561 enrolled pharmacists, 30 were ‘duplicate’ pharmacists as they were also 
working at another pharmacy enrolled in the trial, resulting in 531 individual pharmacists 
in total. From these 531 pharmacists, 458 (86.3%) completed the background survey. Of 
these 458 pharmacists, 258 (56.3%) were female (Table 5-1). This matched the national 
demographics displayed in the Pharmacy Workforce Planning Study conducted in 2008177, 
which showed there were 15337 pharmacists nationwide in 2006 (from ABS population 
data), of whom 56% were female. 
As seen in Table 5-1, the age range with the largest number of pharmacists was 20-30 
years old, with 167 (36.5%) of the 458 pharmacists. Unfortunately, the Pharmacy 
Workforce Planning Study177, which examined all of Australia, had different age categories 
(for example, 15-24 years and 25-34 years) compared to the PROMISe survey (for 
example, 20-29 years and 30-39 years). Due to this, the PROMISe pharmacists were 
compared to the Victorian Pharmacy Workforce 2007 Study178. The Victorian data was still 
considered relevant as the majority of PROMISe pharmacists (58.6%) were based in the 
State of Victoria. There were significant differences between the demographics of the 
PROMISe pharmacists and the Victorian averages, where the PROMISe pharmacists 
generally appeared to be younger (Table 5-1).  
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Male Female Total 
Expected PROMISe Expected PROMISe Expected PROMISe 
% N % % N % % N % 
A
ge
 R
an
ge
 
20 – 30 13.73 62 13.54 25.49 105 22.93 19.61 167 36.46 
31 – 40 15.69 52 11.35 22.55 64 13.97 19.12 116 25.33 
41 – 50 20.59 40 8.73 21.57 50 10.92 21.08 90 19.65 
51 – 60 19.61 27 5.90 19.61 30 6.55 19.61 57 12.45 
Over 60 30.39 19 4.15 10.78 9 1.97 20.59 28 6.11 
Total 100 200 43.67 100 258 56.33 100 458 100 
Statistics χ
2
 = 89.57, df = 4, p < 0.01 χ
2
 = 45.67, df = 4, p < 0.01 χ
2
 = 134.63, df = 4, p <0.001 
Table 5-1: Age range of PROMISe pharmacists compared to Victorian pharmacist data 
from the Victorian Pharmacy Workforce 2007 Study178 
As seen in Figure 5-1, the largest proportion of pharmacists had graduated after the year 
2000, accounting for 180 (39.7%) of pharmacists. 
 
Figure 5-1: Graduation year of the PROMISe pharmacists 
A chi-square test showed no statistical difference between the pharmacist’s gender, age 
or graduation year and the software group that their pharmacy was in (χ2 = 0.90, df = 2, p 
= 0.64 and χ2 = 14.08, df = 8, p = 0.08 and χ2 = 11.18, df = 8, p = 0.19, respectively). 
Therefore, the distribution of pharmacists throughout the three software groups within 
the study can be considered fairly representative. 
254 | P a g e  
 
5.1.1 Qualifications 
Of the 458 respondents, only 49 (10.7%) indicated they had additional qualifications to 
their undergraduate pharmacy degree, including graduate certificates, graduate diplomas, 
and additional postgraduate degrees (Honours, Masters and Doctor of Philosophy). There 
was substantial variety in the subject of the additional qualifications, including pharmacy-
based certificates in wound care, herbal medicine, clinical pharmacy, and geriatrics, as 
well as additional qualifications outside of pharmacy, including health economics, business 
administration, and commerce. When the additional qualifications were analysed, 26 
pharmacists were considered to have additional clinical pharmacy qualifications and were 
therefore tagged to allow additional analysis later. Eighty-one pharmacists (17.7%) were 
accredited to conduct HMRs, with 11 pharmacists (2.4%) being accredited as well as 
holding an additional qualification (Table 5-2). 
 
Qualification grouping for analysis 
AACPA 
Additional 
qualifications 
‘Control’ 
PROMISe 
participants 
Total 
Accredited to perform 
medication reviews 
Yes 70 11 0 81 
No 0 15 362 377 
Total 70 26 362 458 
Table 5-2: Classification of pharmacists with additional qualifications 
5.1.2 Professional memberships 
Of the 458 respondents, the most common membership was the Pharmaceutical Society 
of Australia (PSA), with 75.8% of pharmacists belonging to this society (Table 5-3). There 
were 233 (50.9%) pharmacists who were members of only one society, 122 (26.0%) 
pharmacists were members of two societies, and 30 (6.6%) pharmacists were a member 
of three or more societies. The most common membership combinations were PSA and 
AACP, PSA and PGA or PSA and PGA and AACP (Table 5-4). Only 76 pharmacists (16.6%) 
were not a member of any society. 
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  N % 
PSA 347 75.8 
SHPA 12 2.6 
AACP 104 22.7 
AACPM 14 3.1 
APESMA 18 3.9 
PGA 70 15.3 
Total 458 100.0 
Table 5-3: Professional memberships of participating pharmacists 
  PSA SHPA AACP ACPPM APESMA PGA 
PSA 347 7 90 13 15 53 
SHPA 7 12 3 0 0 5 
AACP 90 3 104 7 3 20 
AACPM 13 0 7 14 1 3 
APESMA 15 0 3 1 18 1 
PGA 53 5 20 3 1 70 
Total 347 12 104 14 18 70 
Table 5-4: Professional membership combinations of participating pharmacists 
5.1.3 Continuing education 
The majority of pharmacists (72.7%) stated that they undertook 10-50 hours per year of 
continuing education or CPD activities (Table 5-5). To ensure the assumptions of a chi-
square test were met (where each cell has a count greater than 5), the categories of 
‘None’ and ‘Less than 10 hours’ were grouped together. The chi-square test showed no 
statistical difference between the hours of CPD activity that the pharmacist completed per 
year and the software group their pharmacy was in (χ2 = 3.90, df = 6, p = 0.69). 
 
N % 
None 3 0.66 
Less than 10 hours 45 9.83 
10 - 25 hours 175 38.21 
25 - 50 hours 158 34.50 
More than 50 77 16.81 
Total 458 100 
Table 5-5: Annual CPD activity by PROMISe pharmacists 
5.1.4 Practice background 
During their pharmacy careers, 286 (62.4%) of pharmacists had only ever worked in 
community pharmacy, with 104 (22.7%) having worked in both community and hospital 
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settings, and 33 (7.2%) having worked in both community and medication review settings. 
Thirty-three pharmacists (7.2%) had worked in all three areas (community, hospital and 
medication reviews). Twenty-eight pharmacists had also worked in other areas of 
pharmacy, such as academia/research, military/government, industry or had practised 
overseas. The largest proportion of pharmacists (205 or 49.2%) had worked in community 
pharmacy practice for 10 years or less (Table 5-6). 
 Count % 
% (unknown 
removed) 
Less than 5 years 127 27.7 30.5 
5 - 10 years 78 17.0 18.7 
10 - 15 years 57 12.4 13.7 
15 - 20 years 49 10.7 11.8 
20 - 25 years 31 6.8 7.4 
25 - 30 years 32 7.0 7.7 
30 - 35 years 17 3.7 4.1 
35 - 40 years 15 3.3 3.6 
Over 40 years 11 2.4 2.6 
Unknown 41 9.0  
Total 458 100 100 
Table 5-6: Number of years spent in community pharmacy practice by PROMISe 
pharmacists 
5.1.5 Current practice 
As expected, 436 (95.2%) pharmacists currently spent the majority of their working week 
in community pharmacy practice, with 168 (36.7%) working over 40 hours per week and 
213 (46.5%) working between 20 and 40 hours per week (Table 5-7). Of the other 
pharmacists, 10 (2.2%) worked mainly in hospital, 6 (1.3%) mainly undertook medication 
reviews and 6 (1.3%) mainly worked in other sectors (such as clinical trials, industry and 
research). A chi-square test showed a significant relationship between the age of the 
pharmacist and the number of hours they worked per week. As perhaps expected, a 
higher proportion of younger pharmacists worked over 20 hours per week, whilst a higher 
proportion of older pharmacists worked less than 20 hours per week (χ2 = 32.73, df = 9, p 
< 0.001). Pharmacists in the 31-40 year age group also tended to work less hours per week 
than expected. 
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N % 
Less than 10 hours 22 4.80 
10 - 20 hours 55 12.01 
20 - 40 hours 213 46.51 
Over 40 hours 168 36.68 
Total 458 100 
Table 5-7: Average number of hours worked in community pharmacy each week by 
PROMISe pharmacists 
Employee pharmacists made up the largest majority of participating pharmacists with 211 
(46.1%), and 360 pharmacists (78.6%) had worked in their current role for less than 10 
years (Table 5-8). A chi-square test also showed a significant relationship between the age 
of the pharmacist and their current role, with a much higher percentage of older 
pharmacists being owners and a much higher percentage of younger pharmacists being 
employees (χ2 = 92.08, df = 9, p < 0.001). A chi-square test showed no statistical difference 
between the current role of the pharmacist and the software group their pharmacy was in 
during the PROMISe trial (χ2 = 2.56, df = 8, p = 0.96).  
 Employee Owner Manager 
Locum/ 
Other 
Total % 
Less than 2 years 62 6 28 8 104 22.71 
Between 2 and 5 years 88 32 30 11 161 35.15 
Between 5 and 10 years 39 40 11 5 95 20.74 
Between 10 and 20 years 18 46 3 1 68 14.85 
20 years or more 4 23 1 2 30 6.55 
Total N 211 147 73 27 458 100 
% 46.07 32.10 15.94 5.89 100  
Table 5-8: Current role of PROMISe pharmacists and years in that role 
5.1.6 Workload 
Several determinants of workload were collected to determine the typical working 
conditions and average prescription volume dispensed by a pharmacist. 
5.1.6.1 Typical working conditions  
Of the 458 respondents, 175 (38.2%) generally worked as the sole pharmacist in their 
community pharmacy and 178 (38.9%) worked with only one other pharmacist (Table 5-9).  
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 N % 
None 175 38.2 
1 178 38.9 
2 72 15.7 
3 to 4 31 6.8 
5 or more 2 0.4 
Total 458 100 
Table 5-9: Number of other pharmacists each PROMISe pharmacist worked with 
during an average shift 
5.1.6.2 Estimated number of prescriptions dispensed per day 
Pharmacists were asked to select from five prescription categories to determine their 
current daily workload (see Table 5-10 for categories). The majority of pharmacists 
indicated that they dispensed an average of 100-150 or 150-200 prescriptions per day 
during a 9-hour shift, with 167 (36.5%) and 118 (25.8%) pharmacists, respectively (Table 
5-10). In Australia, an APESMA survey revealed that the average number of prescriptions 
dispensed ranged from 11 to 33 per hour with an average of 19, which is equivalent to 171 
per 9-hour shift.179 Prior to centralisation of the Pharmacy Boards, the Pharmacy Board of 
Tasmania recommended dispensing no more than 170 prescriptions per 9-hour shift180 
and the current Australian Board of Pharmacy states that a reasonable workload for one 
pharmacist is between 150-200 prescriptions per day169; therefore, the PROMISe 
participants were dispensing prescriptions at a lower or similar rate to the national 
standards. The chi-square test showed no statistical relationship between the average 
number of prescriptions dispensed daily and the software group their pharmacy was in (χ2 
= 9.08, df = 8, p = 0.34), indicating an even spread of pharmacists with differing workloads 
over the three groups. To ensure all chi-square cell counts were greater than 5, the 2 ‘Not 
appropriate’ answers were grouped with ‘Less than 100’. 
 
N % 
Less than 100 95 20.7 
100 - 150 167 36.5 
150 - 200 118 25.8 
200 - 250 39 8.5 
Over 250 37 8.1 
Not appropriate to my 
area of practice 
2 0.4 
Total 458 100 
Table 5-10: Estimated number of prescriptions dispensed by each pharmacist during a 
9-hour shift 
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5.1.6.3 Prescriptions dispensed during the trial 
During the 12-week trial, each pharmacist dispensed an average of 4061 prescriptions 
(Table 5-11). This equates to approximately 338 prescriptions per week or approximately 9 
prescriptions per hour in a 38-hour week. 
P
re
sc
ri
p
ti
o
n
s Mean 4060.57 
Std. Error of Mean 141.58 
Std. Deviation 3194.17 
Minimum 16.00 
Maximum 17193.00 
Table 5-11: Prescription details during the trial 
The pharmacist’s estimated number of prescriptions per day was then compared to the 
actual number of dispensed prescriptions (as recorded in the intervention database) to 
determine if the pharmacist’s estimation correlated with their actual prescriptions. As the 
estimated number of prescriptions was a grouped variable, a Kruskal-Wallis chi-square 
test was used. There were significant relationships between the groups (χ2= 41.77, df = 4, 
p < 0.001), with a significantly positive Jonckheere-Terpstra trend indicating that as the 
estimated number of prescriptions increased, so did the actual number of prescriptions 
dispensed (t = 6.61, p < 0.001). Pharmacists were therefore considered accurate at 
estimating their prescription volume. 
5.1.6.4 Approximate percentage of time spent on dispensing tasks 
Pharmacists were asked to indicate the approximate percentage of time they spent on 
dispensing-related tasks during their shift, such as taking in/dispensing/checking/handing 
out the prescription. As expected, the majority of pharmacists (401; 87.6%) spent more 
than 50% of their time on dispensing tasks (Table 5-12). 
 
Count % 
Less than 10% 6 1.31 
10 - 50% 51 11.14 
50 - 90% 299 65.28 
More than 90% 102 22.27 
Total 458 100 
Table 5-12: Approximate percentage of time spent on dispensing tasks by PROMISe 
pharmacists 
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5.1.6.5 Average pharmacist workload within the pharmacy 
The pharmacist workload was calculated by determining the actual number of 
prescriptions dispensed per week by the pharmacy during the trial and dividing it by the 
number of FTE pharmacists per week, resulting in the average number of prescriptions 
dispensed by a pharmacist during a 38-hour week (see Chapter 2 for more detail). On 
average, each pharmacy had the equivalent of 2.67 ± 1.23 FTE pharmacists (range = 1.0 – 
6.6), resulting in an average pharmacist workload of 480.83 ± 185.55 prescriptions per 38-
hour week (Table 5-13). This was notably higher than the average prescription volume of 
338 prescriptions per week seen in section 5.1.6.3, indicating that the average pharmacist 
workload calculation may not be accurate. This was due to the pharmacist workload being 
calculated using the pharmacy prescription data, rather than the pharmacist prescription 
data, which may have led to gross generalisations of the pharmacist workload at an 
individual pharmacist level. Individual pharmacist workload was unable to be calculated as 
the pharmacists were not asked to record exactly how many hours they worked at the 
pharmacy for each week of the trial, so individual workloads could not be calculated using 
actual hours worked and actual prescriptions dispensed.  
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Mean 2.67 
Std. Error of Mean 0.05 
Std. Deviation 1.23 
Minimum 1.00 
Maximum 6.60 
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Mean 480.83 
Std. Error of Mean 8.06 
Std. Deviation 185.55 
Minimum 109.62 
Maximum 1242.29 
Table 5-13: Average pharmacist workload during the trial (including non-participants) 
5.1.6.6 Effect of dispensary technicians  
A workload combining the pharmacist and technicians was also calculated (see Chapter 2 
for more detail). On average, each pharmacy had the equivalent of 3.96 ± 2.13 FTE 
dispensary staff, including pharmacists and dispensary technicians (range = 1.0 – 11.2), 
resulting in an average workload of 331.69 ± 120.15 prescriptions per 38-hour week (Table 
5-14). 
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Std. Error of Mean 0.09 
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Mean 331.69 
Std. Error of Mean 5.22 
Std. Deviation 120.15 
Minimum 90.05 
Maximum 916.58 
Table 5-14: Average pharmacist workload during the trial with technicians included 
5.1.7 Training 
A total of 215 (40.5%) pharmacists attended the face-to-face PROMISe training and 411 
(77.4%) pharmacists completed the online training scenarios, with 196 pharmacists 
(36.9%) completing both the face-to-face and online training. Although all pharmacists 
were strongly encouraged to complete the training, there were still 101 (19.0%) enrolled 
pharmacists who completed neither the face-to-face or online training (Table 5-15). 
Despite the incentives provided to pharmacists for attending the training, a 100% training 
rate was not able to be achieved as it was clearly impossible to force participation in the 
training, apart from perhaps subsequently excluding non-attendees from the trial. It 
should be noted that results from the untrained pharmacists were still used during the 
analysis. A chi-square test showed no statistical relationship between the level of training 
that the pharmacist undertook and the software group their pharmacy was in (χ2 = 6.65, df 
= 6, p = 0.35).  
 
Pharmacist 
Count 
% 
Neither online or face-to-face training 101 19.0 
Online training only 215 40.5 
Face-to-face training only 19 3.6 
Online and face-to-face training 196 36.9 
Total 531 100 
Table 5-15: Training attendance of the PROMISe participant pharmacists 
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5.1.8 Survey responses 
Before the trial began, pharmacists were asked to complete surveys evaluating empathy, 
professionalism and clinical knowledge, as well as a survey regarding their opinions about 
interventions. 
5.1.8.1 Empathy score 
Of the 531 participating pharmacists, 454 (85.5%) completed the ‘Empathy Survey’ (see 
Appendix 12) and the mean score was 46.8 ± 6.1 (range = 25 – 62; Table 5-16). An 
independent T-test showed that female pharmacists, on average, had a significantly higher 
empathy score than male pharmacists (Table 5-16; t = -4.77, df = 448, p < 0.001) with a 
mean difference of 2.7 (95% CI = 1.6 – 3.8). A bivariate correlation showed no statistical 
relationship between the pharmacist’s graduation year and their empathy score 
(Spearman’s rho = -0.05, N = 445, p = 0.32). 
 
Pharmacist 
Count 
Empathy Score 
Mean Std. Error Std. Dev. Min. Max. 
Female 253 48.0 0.4 5.8 33.0 62.0 
Male 197 45.3 0.4 6.1 25.0 61.0 
Unknown 4 43.3 5.0 9.9 30.0 53.0 
Total 454 46.8 0.3 6.1 25.0 62.0 
Table 5-16: PROMISe pharmacist empathy scores compared to gender 
5.1.8.2 Professionalism score 
Of the 531 participating pharmacists, 455 (85.7%) completed the ‘Professionalism Survey’ 
(see Appendix 13) and the mean score was 80.0 ± 7.7 (range = 19 – 90; Table 5-17). An 
independent T-test showed that the female pharmacists had a significantly higher 
professionalism score than male pharmacists (Table 5-17; t = -2.37, df = 449, p = 0.02) with 
a mean difference of 1.7 (95% CI = 0.3 – 3.2). A bivariate correlation showed no statistical 
relationship between the pharmacist’s graduation year and their professionalism score 
(Spearman’s rho = -0.01, N = 446, p = 0.88). 
 
Pharmacist 
Count 
Professionalism Score 
Mean Std. Error Std. Dev. Min. Max. 
Female 254 80.7 0.5 8.3 19.0 90.0 
Male 197 79.0 0.5 6.8 32.0 90.0 
Unknown 4 78.8 4.8 9.7 65.0 86.0 
Total 455 80.0 0.4 7.7 19.0 90.0 
Table 5-17: PROMISe pharmacist professionalism scores compared to gender 
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5.1.8.3 Clinical knowledge 
Of the 531 pharmacists participating in the trial, 433 (81.5%) completed the clinical 
knowledge survey (see Appendix 4) and the mean score was 53.0 ± 7.5 (range = 26 – 67; 
Table 5-18). An independent T-test showed that females tended to have a higher clinical 
knowledge score than males (t = -2.86, df = 338, p = 0.005) with a mean difference of 2.1 
(95% CI = 0.7 – 3.6). Interestingly, a bivariate correlation showed no statistical relationship 
between the pharmacist’s graduation year and their clinical knowledge scores 
(Spearman’s rho =-0.05, N = 427, p = 0.35), suggesting that the average PROMISE 
pharmacist’s clinical knowledge had apparently not increased or decreased substantially 
since graduation. An analysis of variance showed no statistical relationship between the 
pharmacist’s clinical knowledge score and the software group their pharmacy was in 
(F(2,430) = 0.21, p = 0.81).  
 
Pharmacist 
Count 
Clinical Knowledge Score 
Mean Std. Error Std. Dev. Min. Max. 
Female 245 53.9 0.4 6.5 34.0 67.0 
Male 187 51.8 0.6 8.5 26.0 67.0 
Unknown 1 47.0     47.0 47.0 
Total 433 53.0 0.4 7.5 26.0 67.0 
Table 5-18: PROMISe pharmacist clinical knowledge scores compared to gender 
The dataset was divided into three groups according to the additional qualifications of the 
pharmacist determined in section 5.1.1; pharmacists with additional qualifications (n=26), 
AACP pharmacists (n = 66) and ‘control’ pharmacists (n = 341). Significant differences were 
seen in the clinical knowledge score between the three groups (F(2,430) = 5.82, p = 0.003), 
with post-hoc analysis using the Hochberg method showing a significant difference 
between the pharmacists with additional qualifications and the control pharmacists (p = 
0.023; Table 5-19). The difference between AACPA pharmacists and the control 
pharmacists was approaching significance (p = 0.051). There was no significant difference 
found between the pharmacists with additional qualifications and the AACPA pharmacists 
(Table 5-20; p = 0.70), as such these two groups of pharmacists were combined. An 
independent samples T-test was performed on the resulting two groups (pharmacists with 
additional qualifications or AACPA pharmacists versus control pharmacists) and a 
significant difference was still detected (t(431) = 3.27, p = 0.001). 
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Count Mean Std. Dev. Minimum Maximum 
Other  26 56.4 6.7 40.0 65.0 
AACPA 66 54.8 7.5 37.0 67.0 
Control 341 52.4 7.5 26.0 67.0 
Total 433 53.0 7.5 26.0 67.0 
Table 5-19: Descriptive statistics for the three ‘qualification’ groups within the 
PROMISe dataset 
 
Count Mean Std. Dev. Minimum Maximum 
Other & AACPA 92 55.2 7.3 37.0 67.0 
Control 341 52.4 7.5 26.0 67.0 
Total 433 53.0 7.5 26.0 67.0 
Table 5-20: Descriptive statistics for the two ‘qualification’ groups within the 
PROMISe dataset 
5.1.8.4 Pre-trial survey 
The pharmacists were also asked simple Likert scale questions to determine their views 
regarding pharmacy practice and clinical interventions. A five point scale was available for 
the pharmacist to assign their view to a range of statements, where Strongly Agree = 1 
and Strongly Disagree = 5; as the coded number increased, the level of agreement with 
the statement decreased. Of the 531 pharmacists, 457 responded to the statements 
(Table 5-23).  
Too busy 
Answers to the statement “I believe that pharmacists are already too busy within the 
workplace which prevents them from taking on any new tasks” were mixed, with 133 
pharmacists agreeing, 192 disagreeing and 132 having neutral feelings (Table 5-23; 
median score = Neutral). 
Interestingly, the pharmacists’ beliefs about how busy they are were not reflected in the 
average pharmacy workload (Table 5-21). A bivariate correlation showed no relationship 
between the pharmacist’s perception of busyness and the pharmacy’s average pharmacist 
workload (Spearman’s rho = -0.04, N = 456, p = 0.44). 
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Pharmacist 
Count 
Average Pharmacist Workload 
Median Min. Max. 25th %ile 75th %ile 
Strongly Agree 30 500.38 249.42 916.58 391.43 609.14 
Agree 103 428.84 158.03 1242.29 337.81 533.39 
Neutral 132 491.63 109.62 1106.61 377.65 622.39 
Disagree 143 461.46 109.62 1106.61 346.86 585.43 
Strongly Disagree 49 459.82 170.93 856.37 286.16 585.43 
Unknown 74 503.35 109.62 1142.17 381.39 623.39 
Total 531 464.16 109.62 1242.29 352.55 591.61 
Table 5-21: The pharmacist’s perception of busyness compared to the average pharmacist 
workload within the pharmacy 
Adapting practice 
The majority of pharmacists (424 or 92.8%) agreed with the statement “I believe it is 
important for pharmacists to adapt their practice to suit the current pharmacy 
environment”, with a median score of Strongly Agree (Table 5-23). 
Willingness to change 
The majority of pharmacists (422 or 92.3%) agreed with the statement “I would be willing 
to change my current practice if a new, better way was available”, with a median score of 
Strongly Agree (Table 5-23). 
Good clinical knowledge 
The majority of pharmacists (328 or 71.8%) agreed with the statement “I believe I have a 
good level of clinical knowledge to perform clinical interventions”, with a median score of 
Agree (Table 5-23). 
The pharmacist’s self-assessment of their clinical knowledge also appeared to moderately 
correlate with their score on the clinical knowledge survey (section 5.1.8.3), with 
pharmacists who felt they had a good level of clinical knowledge attaining a higher score 
on the clinical knowledge survey (Spearman’s rho = -0.21, N = 430, p < 0.001; Table 5-22). 
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Pharmacist 
Count 
Clinical Knowledge Survey Score 
Median Min. Max. 25th %ile 75th %ile 
Strongly Agree 94 57.00 26.00 67.00 51.00 61.00 
Agree 234 54.00 26.00 67.00 49.00 58.00 
Neutral 104 52.00 33.00 66.00 47.00 55.00 
Disagree 21 53.00 29.00 62.00 47.00 57.00 
Strongly Disagree 4 53.00 50.00 56.00 50.50 55.50 
Unknown 74 47.00 43.00 61.00 43.00 61.00 
Total 531 54.00 26.00 67.00 48.00 58.00 
Table 5-22: The correlation between the pharmacist’s self-assessment of their clinical 
knowledge and their clinical knowledge survey score 
Confidence in their ability to perform clinical interventions  
The majority of pharmacists (339 or 74.2%) agreed with the statement “I am confident in 
my ability to perform clinical interventions”, with a median score of Agree (Table 5-23). 
Pharmacists who felt they had good clinical knowledge to perform interventions also had 
a higher level of confidence in their abilities (Spearman’s rho = 0.81, N = 445, p < 0.001). 
Already performing clinical interventions 
The majority of pharmacists (320 or 70.0%) agreed with the statement “I already perform 
clinical interventions on a daily basis”, with a median score of Agree (Table 5-23). 
Job satisfaction 
The majority of pharmacists (301 or 65.9%) agreed with the statement “I believe the 
recording of interventions will increase my level of job satisfaction”, with a median score 
of Agree (Table 5-23). 
Belief that the recording system will be hard to use 
Answers to the statement “I am concerned the recording system will be hard to use” were 
mixed, with 102 pharmacists agreeing, 199 disagreeing and 156 having neutral feelings 
(Table 5-23; median score = Neutral). 
Belief that it will take too long to record interventions 
Answers to the statement “I am concerned it will take too long to document interventions 
through the recording system” were also mixed, with 172 pharmacists agreeing, 147 
disagreeing and 138 having neutral feelings (Table 5-23; median score = Neutral). 
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5.1.8.5 Post-trial survey 
The post-trial survey aimed to determine the ease of use of the system and also 
determine if the pharmacists’ attitudes towards interventions had changed. Of the 531 
pharmacists, only 265 pharmacists answered the post-trial survey (Table 5-24). 
Ease of use of the software 
The majority of pharmacists (228 or 86.0%) agreed with the statement “I found the 
software easy to use”, with a median score of Agree (Table 5-24). 
Sufficiency of training on the software 
The majority of pharmacists (223 or 84.2%) agreed with the statement “I received 
sufficient training to use the software”, with a median score of Agree (Table 5-24). 
Answers to this statement were also compared to the level of training that the pharmacist 
received. A chi-square test showed significant differences between the groups (χ2 = 18.89, 
df = 6, p = 0.02), with more pharmacists who had completed both the online and face-to-
face training feeling that they had sufficient training, whereas more pharmacists who had 
completed only the online training felt that they did not have sufficient training. 
Unfortunately, due to the low number of respondents, the chi-square test had 5 cells with 
counts less than 5 and groups were unable to be merged further, so these statistical 
results may be inaccurate.  
Good clinical knowledge 
The majority of pharmacists (223 or 84.2%) still agreed with the statement “I have a good 
level of clinical knowledge to perform clinical interventions”, with a median score of Agree 
(Table 5-24). Pharmacists did not appear to change their views of their clinical knowledge 
ability, with those who believed they had a good level of clinical knowledge at the start of 
the trial also believing the same at the end of the trial (t(255) = 0.73, p = 0.47). 
Confidence in their ability to perform clinical interventions 
The majority of pharmacists (232 or 87.6%) still agreed with the statement “I am confident 
in my ability to perform clinical interventions”, with a median score of Agree (Table 5-24). 
Pharmacists did not appear to change their levels of confidence throughout the trial, with 
those who were confident at the start of the trial remaining so at the end of the trial 
(t(255) = 0.85, p = 0.40). 
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Trial increased awareness of clinical interventions 
The majority of pharmacists (211 or 79.6%) agreed with the statement “The trial increased 
my awareness of how many clinical interventions I perform”, with a median score of Agree 
(Table 5-24). 
Performing clinical interventions increased job satisfaction 
The majority of pharmacists (224 or 84.5%) agreed with the statement “The performing of 
clinical interventions increased my level of job satisfaction”, with a median score of Agree 
(Table 5-24). 
Recording clinical interventions increased job satisfaction 
The majority of pharmacists (169 or 63.8%) agreed with the statement “The recording of 
clinical interventions increased my level of job satisfaction”, with a median score of Agree 
(Table 5-24). 
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Strongly 
Agree 
Agree Neutral Disagree 
Strongly 
Disagree 
Median Mean Std. Dev. 
Too busy 30 103 132 143 49 3.00 3.17 1.10 
Adapting practice 251 173 15 10 8 1.00 1.58 0.81 
Willingness to change 263 159 18 6 11 1.00 1.56 0.83 
Good clinical knowledge 94 234 104 21 4 2.00 2.14 0.82 
Confidence 106 233 90 24 4 2.00 2.10 0.84 
Already performing CIs 130 190 106 25 6 2.00 2.10 0.92 
Increase job satisfaction 127 174 107 39 10 2.00 2.19 1.01 
System will be hard to use 11 91 156 142 57 3.00 3.31 1.01 
System will take too long 39 133 138 111 36 3.00 2.94 1.09 
Table 5-23: Answers to the pre-trial intervention survey questions 
  
Strongly 
Agree 
Agree Neutral Disagree 
Strongly 
Disagree 
Median Mean Std. Dev. 
Software was easy to use 74 154 24 13 0 2.00 1.91 0.75 
Received sufficient training 81 142 29 11 2 2.00 1.91 0.80 
Good clinical knowledge 34 185 39 6 0 2.00 2.06 0.60 
Confidence 41 191 27 5 0 2.00 1.99 0.58 
Increased awareness of CIs 68 143 40 9 4 2.00 2.01 0.83 
Performing CIs increased job 
satisfaction 
68 156 32 7 1 2.00 1.93 0.72 
Recording CIs increased job 
satisfaction 
42 127 67 24 4 2.00 2.32 0.90 
Table 5-24: Answers to the post-trial intervention survey questions
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5.1.9 Discussion of pharmacist demographics 
The pharmacists participating in the PROMISe trial appeared to be fairly representative 
with regards to gender, but tended to be younger than the average pharmacist, which 
may indicate that younger pharmacists were more willing to participate in the PROMISe 
trial. The younger cohort meant that pharmacists may not have been adequately 
represented within the PROMISe study and this result needs to be considered when 
assessing the results found in the next section. Despite this, the pharmacists were evenly 
spread amongst pharmacies within the three software groups and the pharmacies were 
found to be a representative sample, therefore the sample may still be fairly 
representative of the pharmacists within Australia. 
The average PROMISe pharmacist was an employee, had no additional qualifications, had 
only ever worked in community pharmacy, was a member of the PSA and undertook 10-50 
hours of continuing education each year, which at face value appears to describe a fairly 
typical Australian pharmacist. 
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5.2 Bivariate pharmacist factor analysis 
Using the information gathered in the surveys and the intervention database, pharmacist 
factors were compared against their intervention rates to determine which factors may 
impact on their individual intervention rate. As in Chapter 4, the intervention rates 
discussed are always the ‘documented’ intervention rates, unless otherwise stated. 
5.2.1 Number of pharmacists 
Of the 531 pharmacists enrolled in the trial, 22 pharmacists (4.1%) did not dispense any 
prescriptions during the trial and were therefore considered ‘inactive’. These pharmacists 
were presumed to have stopped working at the participating pharmacy before the trial. 
The remaining 509 (95.9%) were considered ‘active’ as they dispensed at least one 
prescription during the trial; however, only 425 (83.5%) of those ‘active’ pharmacists 
documented an intervention using the PROMISe software during the trial period. The data 
from the non-recording pharmacists was included in the following analyses; however, they 
were also examined separately in section 0.  
5.2.2 Determining the intervention rate of the pharmacist 
As determined in Chapter 5, data was collected over the trial period and manipulated 
once the trial was finished to determine a valid intervention rate. The 525 OTC 
interventions and 282 Group Three prompted interventions were removed before the 
intervention rate was calculated. The remaining interventions (5948) were divided by the 
total number of prescriptions dispensed by the pharmacist during the trial, resulting in the 
pharmacist’s individual intervention rate. 
The median valid intervention rate during the trial was 0.17% (range = 0.00 – 3.88) or 1.7 
interventions in every 1000 prescriptions (Table 5-25). When the prompted interventions 
were included for comparison, the median intervention rate rose slightly (Table 5-25).  
 
Count Mean Median 
25th 
%ile 
75th 
%ile 
Min. Max. 
Valid intervention 
rate 
509 0.325 0.168 0.054 0.375 0.000 3.876 
Total intervention 
rate (including 
prompted CIs) 
509 0.349 0.173 0.055 0.418 0.000 5.128 
Table 5-25: Intervention rate for pharmacists during the PROMISe trial 
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The number of pharmacists with a low intervention rate was very prominent, resulting in a 
non-parametric distribution (Figure 5-2). 
 
Figure 5-2: PROMISe pharmacist intervention rates per 100 prescriptions 
The pharmacists were separated into quartiles according to their valid intervention rate. 
The first quartile contained 84 pharmacists who did not document a valid intervention 
during the trial, resulting in a median of zero. The fourth quartile had a much higher 
median intervention rate of 0.64 CIs in 100 prescriptions (range = 0.38 – 3.88) or 6.4 CIs in 
1000 prescriptions (Table 5-26).  
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Q
u
ar
ti
le
s 1.00 128 0.000 0.000 0.053 0.000 0.025 
2.00 127 0.109 0.053 0.168 0.079 0.137 
3.00 127 0.246 0.168 0.372 0.213 0.290 
4.00 127 0.641 0.375 3.876 0.502 1.094 
Total 509 0.168 0.000 3.876 0.053 0.375 
Table 5-26: Median intervention rate for pharmacists within each quartile 
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As expected, significant differences were seen between the quartiles with a positive trend 
of increasing intervention rate as the quartiles increased (Kruskal-Wallis χ2= 478.40, df = 3, 
p < 0.001; Jonckheere-Terpstra t = 26.24, p < 0.001). Post-hoc analysis using multiple 
Mann-Whitney tests showed statistically significant differences between quartile 1 and all 
other groups (p < 0.001 for all pairs; where the critical p-value = 0.0167). 
5.2.3 Demographics 
Twelve pharmacists completed the background survey but did not dispense any 
prescriptions during the trial and were therefore ‘inactive’. This resulted in 446 ‘active’ 
pharmacists who completed the background survey. 
5.2.3.1 Gender 
A Mann-Whitney U test showed no significant relationship between the gender of the 
pharmacist and their intervention rate (N = 446, χ2= 24235.00, Z = -0.196, p = 0.84; Table 
5-27). 
 Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Male 196 0.174 0.000 2.439 0.079 0.425 
Female 250 0.203 0.000 3.876 0.062 0.423 
Unknown 63 0.015 0.000 1.096 0.000 0.138 
Total 509 0.168 0.000 3.876 0.053 0.375 
Table 5-27: Gender compared to the pharmacist’s intervention rate 
Due to a significant difference being detected between genders during the PROMISe II 
trial81, a further analysis was performed to determine if the intervention rate within the 
first four weeks was different between genders. Again, a Mann-Whitney U test showed no 
significant relationship between the gender of the pharmacist and their intervention rate 
during the first four weeks (χ2 = 26543.00, Z = -1.72, p = 0.09). 
5.2.3.2 Age range 
A Kruskal-Wallis test showed no significant differences between the age of the pharmacist 
and their intervention rate (N = 446, χ2= 6.99, df = 4, p = 0.14; Table 5-28). 
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Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
20 - 30 160 0.177 0.000 2.857 0.071 0.389 
31 - 40 113 0.205 0.000 2.616 0.074 0.428 
41 - 50 89 0.239 0.000 3.876 0.116 0.460 
51 - 60 56 0.174 0.000 2.408 0.067 0.520 
Over 60 28 0.098 0.000 1.219 0.036 0.255 
Unknown 63 0.015 0.000 1.096 0.000 0.138 
Total 509 0.168 0.000 3.876 0.053 0.375 
Table 5-28: Age range compared to the pharmacist’s intervention rate 
5.2.3.3 Graduation year 
The graduation year of the pharmacist was converted into a scale variable ‘Years since 
graduation’. A bivariate correlation test did not show any significant correlation between 
the years since graduation and the pharmacist’s intervention rate (Spearman’s rho = 
0.029, N = 443, p = 0.55). 
Pharmacists were also grouped into 5 ‘graduation year’ groups (Table 5-29) and a Kruskal-
Wallis test showed significant differences between the groups (χ2 = 13.40, df = 4, p = 
0.009). However, the Jonckheere-Terpstra test showed no trends in the data (t = -0.76, p = 
0.44). Post-hoc analysis with the ‘Before 1970’ group as the control (using Kolmogorov-
Smirnov Z tests as there were less than 25 cases in the control group) showed that, 
according to the critical p-value of 0.0125, there were significant differences between 
‘Before 1970’ and ‘1980-89’ and between ‘Before 1970’ and ‘1990-1999’ (Table 5-29). 
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Before 1970 21 0.095 0.000 1.219 0.036 0.162 
1970 - 1979 57 0.177 0.000 2.439 0.074 0.450 
1980 - 1989 85 0.266 0.000 3.876 0.109 0.570 
1990 - 1999 105 0.220 0.000 2.616 0.108 0.458 
2000 or later 175 0.159 0.000 2.857 0.062 0.348 
Unknown 66 0.024 0.000 1.097 0.000 0.138 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 5-29: Graduation year group compared to the pharmacist’s intervention rate 
5.2.4 Additional qualifications 
Although 26 pharmacists were tagged as having additional qualifications, one of these 
pharmacists did not dispense any prescriptions during the trial and consequently, their 
275 | P a g e  
 
results were not included in the analysis. A Kruskal-Wallis test showed significant 
differences between the additional qualifications of the pharmacist and their intervention 
rate (χ2= 18.53, df = 2, p < 0.001; Table 5-30). Post-hoc analysis using individual Mann-
Whitney tests (using pharmacists with no additional qualifications as the control group 
and a critical p-value of 0.025) still showed significant differences between the control 
pharmacists and AACPA pharmacists (N = 484, χ2= 11952.00, Z = -2.35, p = 0.019) and 
between the control pharmacists and pharmacists with additional qualifications (N = 439, 
χ2= 2853.50, Z = -3.78, p < 0.001). 
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Control 414 0.151 0.000 3.876 0.038 0.333 
AACPA 70 0.221 0.000 2.616 0.107 0.444 
Other quals 25 0.475 0.000 2.358 0.147 1.100 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 5-30: Additional qualifications compared to the pharmacist’s intervention rate 
(using three groups) 
When the two groups of additional qualifications were grouped together, a Mann-
Whitney U test showed a significant difference between the additional qualifications of 
the pharmacist and their intervention rate (χ2= 14805.00, Z = -3.77, p < 0.001; Table 5-31). 
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Control 414 0.151 0.000 3.876 0.038 0.333 
Other & AACPA 95 0.232 0.000 2.616 0.119 0.566 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 5-31: Additional qualifications compared to the pharmacist’s intervention rate 
(using two groups) 
5.2.5 Professional memberships 
Out of the six possible memberships that pharmacists could select from, the only 
significant effect was seen with the 103 AACPA members, where pharmacists who were 
members had a statistically significantly higher intervention rate (Table 5-32 and Table 
5-33). SHPA membership was also associated with a higher intervention rate and the 
difference was approaching significance. 
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Intervention Rate 
Count Median Min. Max. 25th %ile 75th %ile 
PSA 
Yes 337 0.205 0.000 3.876 0.074 0.423 
No 109 0.169 0.000 3.284 0.068 0.422 
SHPA 
Yes 12 0.514 0.000 3.876 0.158 1.316 
No 434 0.185 0.000 3.284 0.072 0.422 
AACP 
Yes 103 0.231 0.000 2.616 0.124 0.475 
No 343 0.171 0.000 3.876 0.062 0.391 
ACPPM 
Yes 14 0.256 0.000 0.714 0.209 0.448 
No 432 0.181 0.000 3.876 0.069 0.423 
APESMA 
Yes 17 0.171 0.025 0.714 0.054 0.353 
No 429 0.195 0.000 3.876 0.074 0.423 
PGA 
Yes 70 0.239 0.000 2.591 0.106 0.567 
No 376 0.176 0.000 3.876 0.070 0.394 
Unknown 63 0.015 0.000 1.096 0.000 0.138 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 5-32: Professional memberships compared to the pharmacist’s intervention 
rate 
  Mann-Whitney χ2 Z p 
PSA 18049.50 -0.271 0.782 
SHPA 1735.50 -1.974 0.050 
AACP 15064.50 -2.268 0.022 
ACPPM 2417.00 -1.280 0.201 
APESMA 3351.00 -0.567 0.574 
PGA 11348.50 -1.831 0.068 
Table 5-33: Statistical results for membership status compared to pharmacist’s 
intervention rate 
5.2.6 CPD activity 
As there was only one pharmacist who claimed to complete no CPD activities during the 
year, the CPD grouping was changed to ‘0-10 hours’ and incorporated the pharmacists 
from the ‘None’ and ‘Less than 10 hours’ groups (Table 5-34). A Kruskal-Wallis test showed 
significant differences between the annual level of CPD activity and intervention rate (χ2= 
18.14, df = 3, p < 0.001). A Jonckheere-Terpstra test confirmed a positive trend between 
the level of CPD activity and the intervention rate (t = 4.12, p < 0.001), showing that as the 
level of CPD activity per year increased, the intervention rate also increased. Post-hoc 
analysis using individual Mann-Whitney tests (using the ‘0-10 hours’ group as the control 
and a critical p-value of 0.0167) showed that the only significant difference was between 
‘0-10 hours’ and ‘More than 50 hours’ groups (N = 119, χ2= 1129.00, Z = -2.87, p = 0.004). 
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 Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
0 - 10 hours 44 0.133 0.000 0.964 0.064 0.297 
10 - 25 hours 170 0.150 0.000 2.193 0.047 0.326 
25 - 50 hours 157 0.229 0.000 3.876 0.077 0.508 
More than 50 hours 75 0.272 0.000 2.358 0.133 0.593 
Unknown 63 0.015 0.000 1.097 0.000 0.138 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 5-34: Annual CPD activity compared to the pharmacist’s intervention rate 
5.2.7 Role of the pharmacist 
A Kruskal-Wallis chi-square test showed no significant differences between the 
pharmacist’s current role in community pharmacy and their intervention rate (χ2= 6.66, df 
= 3, p = 0.08; Table 5-35). 
 Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Owner 144 0.219 0.000 3.876 0.099 0.449 
Manager 74 0.215 0.000 2.291 0.083 0.365 
Employee 203 0.173 0.000 3.284 0.055 0.461 
Locum/Other 25 0.108 0.000 2.408 0.000 0.247 
Unknown 63 0.015 0.000 1.097 0.000 0.138 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 5-35: Role of the pharmacist compared to the pharmacist’s intervention rate 
5.2.8 Pharmacy experience 
Pharmacists were asked how many years of community pharmacy experience they had, 
but unfortunately, there were several apparent anomalies indicating that the question 
may have been misunderstood. For example, a pharmacist who graduated in 1958 
indicated that they had only worked for 0.5 years in community pharmacy, but had not 
worked anywhere else during this period (such as hospital or other pharmacy fields). Also, 
recent graduates appeared to count their undergraduate and pre-registration experience 
as well, such as a 2008 graduate indicating they had six years of experience. This data field 
was therefore deemed unreliable and removed from the analysis. 
Pharmacists were also asked how many years they had worked in a hospital environment 
and this was converted to a dichotomous (Yes/No) variable detailing hospital experience. 
A Mann-Whitney test showed the pharmacists with hospital experience tended to have a 
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higher intervention rate, but the difference was only approaching significance (N = 446, χ2 
= 18612.50, Z = -1.91, p = 0.06). 
5.2.9 Percentage of working week in community pharmacy 
Pharmacists were asked to choose a grouping that reflected the estimated number of 
hours (1 – 10, 10 – 20, 20 – 40 and over 40 hours per week) and approximate percentage 
of their working week (0 – 20%, 20 – 40%, 40 – 60%, 60 – 80% and 80 – 100%) that they 
spent working in a community pharmacy. When these factors were compared to the 
pharmacist’s intervention rate, there did not appear to be any significant influence of 
either factor (Kruskal-Wallis χ2 = 0.65, df = 3, p = 0.89 and Kruskal-Wallis χ2 = 8.06, df = 4, p 
= 0.09, respectively). 
5.2.10 Effect of the individual pharmacist’s workload 
Several determinants of workload, such as typical working conditions and average 
prescription volume, were analysed to determine any effects on the pharmacist’s 
intervention rate. Data that remained unknown, such as when the pharmacist had not 
answered the survey, was excluded from the analysis. 
5.2.10.1 Typical working conditions  
A Kruskal-Wallis chi-square test showed no significant differences between the number of 
other pharmacists present during the pharmacist’s shift and their intervention rate (χ2 = 
2.86, df = 4, p = 0.59; Table 5-36). 
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
None 174 0.207 0.000 3.876 0.068 0.460 
1 175 0.185 0.000 2.857 0.077 0.398 
2 69 0.173 0.000 3.284 0.047 0.297 
3 - 4 26 0.200 0.000 0.893 0.113 0.348 
5 or more 2 0.102 0.055 0.149 0.055 0.149 
Unknown 63 0.015 0.000 1.097 0.000 0.138 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 5-36: Number of other pharmacists each pharmacist worked with during an 
average shift 
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5.2.10.2 Prescription volume 
Pharmacists were asked to estimate the number of prescriptions dispensed during a 9-
hour shift and choose from the following groupings: Less than 100; 100 – 150; 150 – 200; 
200 – 250; Over 250 prescriptions. A Kruskal-Wallis chi-square test showed no significant 
differences between the estimated number of prescriptions dispensed and their 
intervention rate (χ2 = 3.21, df = 4, p = 0.53). The actual number of prescriptions dispensed 
during the trial was also compared to the pharmacists’ intervention rates, and a bivariate 
correlation test showed no correlation between the two (Spearman’s rho = 0.06, N = 509, 
p = 0.21). 
5.2.10.3 Percentage of time spent on dispensing tasks 
The percentage of time pharmacists spent on dispensing tasks, such as taking 
in/dispensing/checking/handing out the prescription (grouped as follows: Less than 10%; 
10-50%; 50-90%; Over 90%), was compared to their intervention rate and a Kruskal-Wallis 
chi-square test showed no significant differences (χ2 = 3.73, df = 3, p = 0.30). 
5.2.10.4 Average pharmacist workload within the pharmacy 
The average workload (see Chapter 2 for explanation of the calculation used) was 
compared to the individual pharmacists’ intervention rates, and a bivariate correlation 
test showed a weak, but statistically significant, correlation (Spearman’s rho = -0.09, N = 
508, p = 0.044). 
5.2.10.5 Effect of dispensary technicians  
The average workload of pharmacists plus technicians was compared to the pharmacists’ 
intervention rates, and a bivariate correlation test showed no correlation between the 
two factors (Spearman’s rho = -0.04, N = 508, p = 0.39). 
5.2.11 Training 
A Kruskal-Wallis test showed significant differences between the intervention rates 
between the different training groups (χ2 = 62.58, df = 3, p < 0.001). The Jonckheere-
Terpstra test showed a positive trend between the level of training and the intervention 
rate (t = 7.55, p < 0.001), indicating that those pharmacists who completed both types of 
training had a higher intervention rate. Post-hoc analysis using individual Mann-Whitney 
tests (using ‘No training’ as the control group and the critical p-value of 0.0125) showed 
significant differences between the ‘No training’ and ‘Online training only’ groups (N = 
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303, χ2= 6097.50, Z = -5.17, p < 0.001) and between the ‘No training’ and ‘Online and face-
to-face training’ groups (N = 280, χ2= 3908.00, Z = -7.47, p < 0.001). There was no 
significant difference seen between the ‘No training’ and the ‘Face-to-face only’ training 
groups (N = 110, χ2= 618.00, Z = -1.74, p = 0.08). 
 Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Neither online or 
face-to-face training 
92 0.041 0.000 2.616 0.000 0.150 
Online training only 211 0.166 0.000 2.857 0.056 0.321 
Face-to-face training 
only 
18 0.101 0.000 1.219 0.029 0.419 
Both online and 
face-to-face training 
188 0.269 0.000 3.876 0.121 0.546 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 5-37: Level of training compared to the pharmacist’s intervention rate 
5.2.12 Survey responses 
The pharmacists’ answers to the surveys administered before and after the trial were 
compared to the pharmacist’s intervention rate to determine any relationships with the 
pharmacist’s opinions. 
5.2.12.1 Empathy survey 
Of the 454 pharmacists who completed the empathy survey, only 442 dispensed a 
prescription during the trial and therefore had an intervention rate calculated. A bivariate 
correlation showed no statistical relationship between the pharmacist’s empathy score 
and their intervention rate (Spearman’s rho = 0.05, N = 442, p = 0.30). 
5.2.12.2 Professionalism score 
Of the 455 pharmacists who completed the empathy survey, only 443 dispensed a 
prescription during the trial and therefore had an intervention rate calculated. A bivariate 
correlation showed no statistical relationship between the pharmacist’s professionalism 
score and their intervention rate (Spearman’s rho = 0.03, N = 443, p = 0.58). Using the six 
professionalism sub-scales determined by a team of researchers (see Chapter 2), the sub-
scale score for each pharmacist was compared to their intervention rate. Although each 
sub-scale showed varying correlations with the pharmacist’s intervention rate, none of the 
relationships were significant (Table 5-38).  
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  Spearman’s rho p-value 
Altruism score 0.05 0.32 
Duty score 0.08 0.12 
Honour score -0.05 0.32 
Accountability score 0.05 0.33 
Excellence score 0.05 0.35 
Respect score 0.00 0.94 
Total Professionalism score 0.03 0.58 
Table 5-38: Correlation between the pharmacist’s professionalism sub-scale scores 
and their intervention rate 
5.2.12.3 Clinical knowledge 
Of the 433 pharmacists who completed the clinical knowledge survey, only 421 dispensed 
a prescription during the trial and had an intervention rate calculated. A bivariate 
correlation showed there was a moderate, but statistically significant, correlation between 
the pharmacist’s clinical knowledge score and their intervention rate (Spearman’s rho = 
0.19, N = 421, p < 0.001), where the pharmacist’s intervention rate tended to increase as 
their clinical knowledge score increased (Figure 5-3). 
 
Figure 5-3: Relationship between the pharmacist’s clinical knowledge score and 
intervention rate 
When the pharmacists’ scores were split into quartiles, a Kruskal-Wallis chi-square test 
also showed significant differences between the average intervention rate of each quartile 
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(χ2= 13.94, df = 3, p = 0.003), with a post-hoc Jonckheere-Terpstra test showing a 
significant positive trend, so that as the survey score increased, so did the pharmacist’s 
intervention rate (t = 3.60, p = 0.001; Table 5-39). 
  
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 25th %ile 75th %ile 
Q
u
ar
ti
le
 0 - 25% 104 0.145 0.000 3.284 0.055 0.282 
25 - 50% 118 0.183 0.000 3.876 0.083 0.447 
50 - 75% 97 0.209 0.000 2.616 0.075 0.461 
75 - 100% 102 0.283 0.000 2.591 0.126 0.563 
Total 421 0.200 0.000 3.876 0.077 0.444 
Table 5-39: Clinical knowledge survey score quartiles compared to the pharmacist’s 
intervention rate 
Pharmacists who indicated that they completed more than 50 hours of annual CPD also 
tended to have a higher clinical knowledge score than the pharmacists completing less 
annual CPD hours (ANOVA F(2,417) = 2.95, p = 0.053). 
5.2.12.4 Pre-trial survey 
The pharmacists’ answers from their pre-trial survey were compared to their intervention 
rate to determine any relationships. See Appendix 24 for the relevant tables. 
Too busy 
Answers to the statement “I believe that pharmacists are already too busy within the 
workplace which prevents them from taking on any new tasks” appeared to be related to 
the pharmacist’s intervention rate, with those pharmacists who agreed with the 
statement having a lower intervention rate than the pharmacists who disagreed 
(Spearman’s rho = 0.14, N = 445, p = 0.002). This indicates that a pharmacist’s perception 
of how busy they already are may affect their ability to successfully take on additional 
tasks. See Appendix 24 for the relevant table. 
Adapting practice 
Answers to the statement “I believe it is important for pharmacists to adapt their practice 
to suit the current pharmacy environment” did not appear to be related to the 
pharmacist’s intervention rate (Spearman’s rho = -0.08, N = 445, p = 0.09). See Appendix 
24 for the relevant table. 
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Willingness to change 
Answers to the statement “I would be willing to change my current practice if a new, 
better way was available” did not appear to be related to the pharmacist’s intervention 
rate (Spearman’s rho = -0.09, N = 445, p = 0.07). See Appendix 24 for the relevant table. 
Good clinical knowledge 
Answers to the statement “I believe I have a good level of clinical knowledge to perform 
clinical interventions” appeared to be related to the pharmacist’s intervention rate. 
Pharmacists who agreed that they had a good level of clinical knowledge tended to have a 
higher intervention rates than those who disagreed (Spearman’s rho = -0.12, N = 445, p = 
0.013). See Appendix 24 for the relevant table. 
Confidence in their ability to perform clinical interventions  
Answers to the statement “I am confident in my ability to perform clinical interventions” 
appeared to be related to the pharmacist’s intervention rate. Pharmacists who felt 
confident in performing interventions tended to have a higher intervention rate than 
those who did not feel confident (Spearman’s rho = -0.14, N = 445, p = 0.003). See 
Appendix 24 for the relevant table. 
Already performing clinical interventions 
Answers to the statement “I already perform clinical interventions on a daily basis” 
appeared to be related to the pharmacist’s intervention rate. Pharmacists who believed 
they were already performing interventions tended to have a higher intervention rate 
than those who did not (Spearman’s rho = -0.17, N = 445, p < 0.001). See Appendix 24 for 
the relevant table. 
Job satisfaction 
Answers to the statement “I believe the recording of interventions will increase my level 
of job satisfaction” appeared to be related to the pharmacist’s intervention rate. 
Pharmacists who believed that recording interventions would increase their level of job 
satisfaction tended to have a higher intervention rates than those who did not 
(Spearman’s rho = -0.11, N = 445, p = 0.02). See Appendix 24 for the relevant table. 
Belief that the recording system will be hard to use 
Answers to the statement “I am concerned the recording system will be hard to use” 
appeared to be related to the pharmacist’s intervention rate. Pharmacists who believed 
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that the recording system would be hard to use tended to have a lower intervention rate 
than those who did not (Spearman’s rho = 0.15, N = 445, p = 0.002). See Appendix 24 for 
the relevant table. 
Other pre-trial questions 
Answers to the statements “I am concerned it will take too long to document 
interventions through the recording system” and “I believe that a ‘pop up’ prompt would 
be useful to remind pharmacists to record clinical interventions” did not appear to 
associated with the pharmacist’s intervention rate (Spearman’s rho = 0.05, N = 445, p = 
0.28 and Spearman’s rho = 0.03, N = 445, p = 0.56, respectively). 
5.2.12.5 Post-trial survey 
The pharmacists’ answers from their post-trial survey were also compared to their 
intervention rate to determine any relationships.  
Ease of use of the software 
Answers to the statement “I found the software easy to use” appeared to be related to 
the pharmacist’s intervention rate. Pharmacists who agreed the recording system was 
easy to use tended to have a higher intervention rate than those who disagreed 
(Spearman’s rho = -0.21, N = 260, p = 0.001). See Appendix 24 for the relevant table. 
Sufficiency of training on the software 
Answers to the statement “I received sufficient training to use the software” appeared to 
be related to the pharmacist’s intervention rate. Pharmacists who felt they had received 
sufficient training tended to have a higher intervention rate than those who did not 
(Spearman’s rho = -0.23, N = 260, p < 0.001). See Appendix 24 for the relevant table. 
Good level of clinical knowledge 
Answers to the post-trial statement “I have a good level of clinical knowledge to perform 
clinical interventions” did not appear to be related to the pharmacist’s intervention rate 
(Spearman’s rho = -0.01, N = 259, p = 0.13). This is in contrast to the pre-trial statement, 
which did correlate with the intervention rate (see section 5.2.12.4).  
Confidence in their ability to perform clinical interventions 
Answers to the statement “I am confident in my ability to perform clinical interventions” 
appeared to be related to the pharmacist’s intervention rate. Pharmacists who were 
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confident in their abilities tended to have a higher intervention rate than those who did 
not (Spearman’s rho = -0.14, N = 259, p = 0.03). See Appendix 24 for the relevant table. 
Trial increased awareness of clinical interventions 
Answers to the statement “The trial increased my awareness of how many clinical 
interventions I perform” appeared to be related to the pharmacist’s intervention rate. 
Pharmacists who felt that the trial increased their awareness tended to have a higher 
intervention rate than those who did not (Spearman’s rho = -0.30, N = 259, p < 0.001). See 
Appendix 24 for the relevant table. 
Performing clinical interventions increased job satisfaction 
Answers to the statement “The performing of clinical interventions increased my level of 
job satisfaction” appeared to be related to the pharmacist’s intervention rate. Pharmacists 
who felt that performing interventions increased their job satisfaction tended to have a 
higher intervention rate than those who did not (Spearman’s rho = -0.25, N = 259, p < 
0.001). See Appendix 24 for the relevant table. 
Recording clinical interventions increased job satisfaction 
Answers to the statement “The recording of clinical interventions increased my level of job 
satisfaction” appeared to be related to the pharmacist’s intervention rate. Pharmacists 
who felt that recording interventions increased their job satisfaction tended to have a 
higher intervention rate than those who did not (Spearman’s rho = -0.20, N = 259, p = 
0.001), although the four pharmacists who strongly disagreed had the highest median 
intervention rate. See Appendix 24 for the relevant table. 
Comparison between the estimated number of documented CIs and the number 
actually documented 
During the post-trial survey, pharmacists were asked to estimate their average number of 
interventions per 100 prescriptions. Comparisons between the pharmacist’s estimated 
percentage and the number actually documented showed that pharmacists were not good 
at predicting their documentation rates (Wilcoxon Z = -11.91, N = 290, p < 0.001). Only 39 
pharmacists correctly estimated their intervention rate, whilst 216 pharmacists had an 
actual documentation rate of less than their prediction and 74 pharmacists attained a 
documentation rate better than their prediction. 
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5.2.13 Summary table of pharmacist bivariate factors 
The previous sections have been summarised into the following table. 
 
 
Median CI 
Rate 
p 
Gender 
Male 0.174 
0.84 
Female 0.203 
Age Range 
20 - 30 0.177 
0.14 
31 - 40 0.205 
41 - 50 0.239 
51 - 60 0.174 
Over 60 0.098 
Graduation Year 
Before 1970 0.095 
0.01 
1970 - 1979 0.177 
1980 - 1989 0.266 
1990 - 1999 0.220 
2000 or later 0.159 
Additional 
Qualifications 
Control 0.151 
<0.001 
AACPA/Other quals 0.232 
CPD Activity 
0 - 10 hours 0.133 
<0.001 
10 - 25 hours 0.150 
25 - 50 hours 0.229 
More than 50 hours 0.272 
Role of the 
Pharmacist 
Owner 0.219 
0.08 
Manager 0.215 
Employee 0.173 
Locum/Other 0.108 
Training 
Neither  0.041 
<0.001 
Online only 0.166 
Face-to-face only 0.101 
Both  0.269 
Surveys 
Empathy  0.30 
Professionalism  0.58 
Clinical Knowledge  <0.001 
Table 5-40: Summary table of the analysed bivariate factors compared to pharmacy 
intervention rate 
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5.2.14 Non-performing pharmacists 
Out of the 509 pharmacists who dispensed a prescription during the trial, 84 did not 
document any interventions and were therefore examined separately as ‘non-performers’ 
to determine any distinguishing factors.  
5.2.14.1 Descriptives 
Of the 84 non-performers, 30 pharmacists did not complete the online surveys and one 
pharmacist worked in the pharmacy that did not receive a site visit, therefore some data 
was missing. Three of the pharmacists were also observed during the observational sub-
study. 
Gender 
Of the non-performing pharmacists, 37 were female, 17 were male and 30 were unknown. 
Compared to the overall trial, where 56.3% pharmacists were female and 43.7% were 
male (Table 5-1), there was a higher percentage of female pharmacists who were non-
performers and this difference was approaching significance (χ2 = 3.88, df = 1, p = 0.05). 
Age range 
The age ranges of the non-performing pharmacists were spread fairly evenly, but 
comparison with the overall ages of the PROMISe pharmacists indicated that a slightly 
higher proportion of older pharmacists did not participate (Table 5-41); however, these 
differences were not statistically significant (χ2 = 2.64, df = 4, p = 0.63). 
 
Non-performing pharmacists 
All PROMISe 
pharmacists 
N % 
% removing 
unknown 
N % 
20 - 30 15 17.9 27.7 167 36.46 
31 - 40 13 15.5 24.1 116 25.33 
41 - 50 13 15.5 24.1 90 19.65 
51 - 60 9 10.7 16.7 57 12.45 
Over 60 4 4.8 7.4 28 6.11 
Unknown 30 35.7    
Total 84 100 100 458 100 
Table 5-41: Age ranges of non-performing pharmacists  
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Graduation year 
The graduation years of the non-performing pharmacists were also spread fairly evenly, 
but comparison with the overall graduation years of the PROMISe pharmacists showed 
that a slightly higher proportion of pharmacists who graduated before 1970 or between 
1980 – 1989 tended to not participate (Table 5-42), although these differences were not 
statistically significant (χ2 = 1.92, df = 4, p = 0.75). 
  
  
Non-performing 
pharmacists 
All PROMISe 
pharmacists 
N % 
% removing 
unknown 
% 
G
ra
d
u
at
io
n
 Y
ea
r Before 1970 4 4.8 7.4 4.6 
1970 - 1979 7 8.3 13.0 12.8 
1980 - 1989 12 14.3 22.2 19.0 
1990 - 1999 10 11.9 18.5 23.8 
2000 or later 21 25.0 38.9 39.7 
Unknown 30 35.7     
Total 84 100 100 100 
Table 5-42: Graduation years of non-performing pharmacists 
5.2.14.2 CPD activity 
The majority of non-performing pharmacists completed more than 10 hours of CPD 
activity, with the spread fairly consistent with the CPD activity of all PROMISe pharmacists 
(Table 5-43; χ2 = 1.53, df = 3, p = 0.68). 
  
Non-performing 
pharmacists 
All PROMISe 
pharmacists 
N % 
% removing 
unknown 
N % 
C
P
D
 a
ct
iv
it
y 
None 1 1.2 1.9 3 0.7 
Less than 10 hours 5 6.0 9.3 45 9.8 
10 - 25 hours 24 28.6 44.4 175 38.2 
25 - 50 hours 17 20.2 31.5 158 34.5 
More than 50 7 8.3 13.0 77 16.8 
Unknown  30 35.7       
 Total 84 100 100 458 100 
Table 5-43: CPD activity of non-performing pharmacists 
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5.2.14.3 Empathy score 
The non-performing pharmacists had similar empathy scores (46.20 ± 5.73; range = 33 – 
59) to the overall PROMISe pharmacists (46.80 ± 6.12; range = 25 – 62), with no statistical 
difference seen (Mann-Whitney χ2= 9618.00, Z = -0.98, p = 0.33). 
5.2.14.4 Professionalism score 
The non-performing pharmacists had similar professionalism scores (78.59 ± 8.87; range = 
32 – 90) to the overall PROMISe pharmacists (79.97 ± 7.74; range = 19 – 90), with no 
statistical difference seen (Mann-Whitney χ2= 9322.50, Z = -1.34, p = 0.18). 
5.2.14.5 Clinical knowledge score 
The non-performing pharmacists had similar clinical knowledge survey scores (51.76 ± 
7.84; range = 26 – 66) to the overall PROMISe pharmacists (52.98 ± 7.50; range = 26 – 67), 
with no statistical difference seen (Mann-Whitney χ2 = 8259.00, Z = -1.63, p = 0.11). 
5.2.14.6 Training 
In comparison with the overall PROMISe pharmacists, a considerably larger percentage of 
non-performing pharmacists completed no training during the trial and a lower 
percentage completed both types of training (Table 5-44), with a chi-square test showing 
the differences were statistically significant (χ2= 45.88, df = 3, p < 0.001). 
  
Non-performing 
pharmacists 
All PROMISe 
pharmacists 
N % N % 
Tr
ai
n
in
g 
Neither online or face-to-face training 36 42.9 101 19.0 
Online training only 31 36.9 215 40.5 
Face-to-face training only 3 3.6 19 3.6 
Online and face-to-face training 14 16.7 196 36.9 
Total 84 100 531 100 
Table 5-44: Training attendance of the non-performing pharmacists 
5.2.14.7 Average pharmacist workload 
The non-performing pharmacists had a lower average pharmacist workload of 462.10 ± 
185.93 (range = 109.62 – 1142.17) compared to the overall PROMISe average of 480.83 ± 
185.55 (range = 109.62 – 1242.29). However, this difference was not significant (Mann-
Whitney χ2 = 16967.50, Z = -0.68, p = 0.49). 
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5.2.14.8 Software group 
Each software group contained similar numbers of non-performing pharmacists with 
Group One having 25 non-performing pharmacists, Group Two having 22 and Group Three 
having 37. However, there were significant differences between the groups that 
performing and non-performing pharmacists were in, with respect to the proportions of 
each group (χ2 = 7.97, df = 2, p = 0.02). Group One contained more than expected non-
performers and less than expected performers. Group Two contained less than expected 
non-performers and more than expected performers. Group Three contained the 
approximate number of expected performer and non-performers (Table 5-45). 
  Performer Non-performer Total 
Group One 
Count 81 25 106 
Expected Count 88.5 17.5 106.0 
% of Total 15.9% 4.9% 20.8% 
Group Two 
Count 173 22 195 
Expected Count 162.8 32.2 195.0 
% of Total 34.0% 4.3% 38.3% 
Group Three 
Count 171 37 208 
Expected Count 173.7 34.3 208.0 
% of Total 33.6% 7.3% 40.9% 
Total 
Count 425 84 509 
Expected Count 425.0 84.0 509.0 
% of Total 83.5% 16.5% 100.0% 
Table 5-45: Percentage of performers compared to non-performers 
5.2.14.9 Prompted interventions 
As PPI step-down interventions were excluded for analysis, non-performing pharmacists 
were analysed to determine if they did document any PPI step-downs and consequently, 
did actually participate in the trial. Three non-performing pharmacists each documented 
one PPI step-down intervention and all were in Group Three. The recalculated 
intervention rates still remained low (Table 5-46). 
Pharmacist 
Number 
of CIs 
Number of 
prescriptions 
CI rate 
incl PPIs 
CI rate 
excl PPIs 
1 1 2126 0.047 0 
2 1 1079 0.093 0 
3 1 893 0.112 0 
Table 5-46: Intervention rates of non-performing pharmacists who documented a 
prompted PPI step-down intervention 
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5.2.15 Discussion of the bivariate analysis 
During the trial, 509 pharmacists dispensed at least one prescription, however, only 425 of 
those pharmacists documented an intervention. Due to the 84 pharmacists who did not 
document an intervention and therefore had an intervention rate of zero, the median 
intervention rate was quite low at 0.17% (range = 0.00 – 3.88). Comparisons between the 
PROMISe study and previous studies was again difficult due to the different definitions of 
an intervention and also because many studies did not report individual pharmacist 
intervention rates, only pharmacy intervention rates. Despite a higher maximum 
intervention rate, the median rate of the pharmacists was lower than the median 
pharmacy intervention rate of 0.21% (range = 0.00 – 2.35), which was most likely due to 
the large number of ‘zero’ intervention rates within the pharmacist group. 
5.2.15.1 Influencing factors on pharmacist intervention rate 
As with the pharmacies, much data was collected on the individual pharmacist to 
determine internal and external factors that may have influenced their intervention rate. 
Demographics 
Age and graduation year did not appear to influence the pharmacist’s intervention rate, 
even with a slightly higher proportion of older pharmacists documenting no interventions 
during the trial. This result was quite interesting, as it is a common belief that pharmacist 
knowledge and enthusiasm decreases as the number of years since graduation increases, 
however, this dataset showed that the age and graduation year were not associated with 
the pharmacist’s intervention rate. A possible explanation to this finding may be that the 
older pharmacists who agreed to participate in the trial were more likely to be proactive 
with their education and be more willing and enthusiastic to participate. As such, it is 
possible that these results may not be applicable to all older pharmacists throughout 
Australia. In addition, the PROMISe pharmacists had a younger average age than 
Australian pharmacists, which may have caused unequal representation within the 
PROMISe trial; therefore, the true effect of age may not be adequately determined from 
the PROMISe results. Despite the expectation that older pharmacists would have a lower 
intervention rate, another study by Leemans75 also found that the age of the pharmacist 
did not appear to influence the number of interventions documented. 
The PROMISe II trial showed that female pharmacists appeared to have a higher 
intervention rate than their male counterparts.81 However, unlike the PROMISe II dataset, 
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the larger PROMISe III dataset did not show the same differences between the genders. 
There was also no difference between the genders when only using the intervention rate 
from the first four weeks of the trial. As the PROMISe III dataset was a larger sample that 
spanned a longer timeframe, it could be considered a better representation of the 
pharmacist population, so it is possible that there is no difference between the 
intervention rates of males and females, and the trend seen in the PROMISe II dataset was 
not representative. This finding was also supported by a previous study by Blake that also 
found that gender did not appear to influence whether a pharmacist would provide 
professional services.115 
Pharmacists who were AACP members had a significantly higher intervention rate than 
non-members. It is likely that AACP members have an increased ability to detect and 
resolve DRPs encountered in community pharmacy, as the accreditation process requires 
the pharmacist to undertake additional clinical knowledge training. It should also be noted 
that although only 81 pharmacists indicated that they were accredited to perform 
medication reviews (and thus were separated as the AACPA group for some analyses), 103 
pharmacists were members of AACP. This was most likely due to the remaining 22 
pharmacists being in the process of becoming accredited. 
SHPA membership was also associated with a much higher intervention rate and the 
difference was approaching significance. Members of SHPA generally work in the hospital 
sector and the majority of the 12 SHPA members participating in PROMISe indicated that 
they were presently working or had previously worked in the hospital environment. This 
result showing that hospital pharmacists tended to have an increased intervention rate 
was most likely linked with two main factors. Firstly, hospital pharmacists may be better 
equipped at dealing with the detection and resolution of DRPs, as this is a skill that they 
would use on a daily basis within the hospital environment. Secondly, hospital pharmacies 
often have additional software that allows pharmacists to document their interventions, 
therefore the hospital pharmacists may not have had to undergo the ‘practice change’ to 
document their interventions (see discussion on page 296). Either of these factors may 
have led to a higher intervention rate by the hospital pharmacists, however, the sample of 
12 pharmacists was too small to make definitive conclusions. Given that their intervention 
rates were much higher than for the average pharmacist, these pharmacists should be 
more closely studied within the future to determine any attributes that could be modified 
within the general population of pharmacists to improve intervention rates. 
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Pharmacists who were members of the PGA tended to have higher intervention rates than 
non-members, although this difference was only approaching significance. Only pharmacy 
owners can be members of the PGA and it was expected that owner pharmacists would 
have a lower intervention rate, as they are generally busier and more business-focused 
than employee pharmacists, thus being less likely to use a system that took additional 
time out of their working day. Despite this theory, the opposite trend was found in the 
PROMISe data. This finding was also supported by the results showing no differences 
between the intervention rates of owner pharmacists and the employee/manager 
pharmacists, despite the expectation that owner pharmacists would have had lower 
intervention rates. The owners were responsible for enrolling their pharmacy in the 
PROMISe trial and, therefore, may have already been more proactive within their 
profession compared to other owners. Owners may also be more hard-working and highly 
motivated within their profession, which may also have resulted in higher intervention 
rates. Therefore, these results may not be representative of all pharmacy owners in 
Australia, but be more applicable to those who are interested in and encourage 
professional services within their pharmacy. 
Clinical knowledge 
When the pharmacists were grouped according to their additional qualifications, the 
pharmacists with additional clinical pharmacy qualifications had a higher intervention rate 
than pharmacists with no additional qualifications. It is likely that this finding was due to 
the additional clinical knowledge and training that the pharmacists with extra 
qualifications had undertaken, thereby increasing their ability to detect and resolve the 
DRPs encountered in community pharmacy. However, it is also possible that pharmacists 
with more training are naturally more enthusiastic about their profession, and as such 
may have been more likely to take part in the PROMISe trial, as they would see the benefit 
of participation. This result was also described by Westerlund68, who found that 
pharmacists had a higher rate of DRP detection compared to prescriptionists (University-
trained dispensing technicians) and pharmacy technicians, indicating that a higher level of 
clinical training corresponded to a higher intervention rate. Another study by Blake115 
found that the pharmacist’s educational background was associated with the likelihood 
that the pharmacist would provide professional services, highlighting that the more highly 
trained professionals were often the more motivated individuals that were more likely to 
participate effectively. 
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There was also a significant correlation between the pharmacist’s intervention rate and 
their score on the clinical knowledge survey, indicating that the pharmacists with a higher 
intervention rate also had a higher level of clinical knowledge. Again, a higher level of 
clinical knowledge would increase their ability to detect and resolve DRPs, therefore 
possibly increasing the documentation rate of the interventions as well. Another study 
examining the DRP reporting rate amongst Spanish pharmacists found that pharmacists 
with a higher DRP knowledge (according to a survey administered during the trial) were 
more likely to have a higher documentation rate.106 The study also found that pharmacists 
who had previously participated in specific DRP training were also more likely to report 
DRPs106, indicating that relevant clinical knowledge training may further increase the 
number of interventions performed and documented. PROMISe pharmacists tended to be 
good at assessing their own clinical knowledge, with a correlation seen between the 
pharmacist’s self-assessment of their clinical knowledge and their score of the clinical 
knowledge survey. This may indicate that pharmacists could identify gaps in their own 
knowledge, which could be improved using targeted education. 
Interestingly, the influence of additional qualifications and a higher clinical knowledge 
survey score was not detected in the observational sub-study, where there were no 
significant differences between these groups of pharmacists. This may have been due to 
the smaller sample size, or due to the pharmacists with ‘poor’ clinical knowledge trying to 
‘impress’ the observers, thereby inflating their intervention rates, whilst the pharmacists 
with good clinical knowledge were more confident in their abilities (as seen in the 
opinions survey in section 5.1.8.4) and consequently did not feel they needed any 
additional effort.  
CPD activity 
The number of hours each pharmacist spent on CPD annually was significantly correlated 
with their individual intervention rate, with the most significant difference seen between 
the pharmacists who completed 0-10 hours per year compared to the pharmacists who 
completed more than 50 hours per year. As expected, the pharmacists with a higher level 
of annual CPD activity had a higher intervention rate and there are two possible 
explanations for this finding. Firstly, it is likely that CPD activity increases the clinical 
knowledge of the pharmacist and therefore improves their ability to detect and resolve 
DRPs in the community pharmacy environment. Secondly, it is also likely that pharmacists 
who attend education sessions and complete additional training on their own time are 
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more proactive within their profession, and are therefore more likely to participate 
effectively in a professional program. This correlation was also found in a previous study 
by Benrimoj34, which showed that the group of pharmacists who had a higher level of 
participation in CPD activities prior to the trial appeared to have a higher baseline 
intervention rate. 
However, it is important to remember that this was a self-reported level of annual CPD 
activity, which means the pharmacists may have over-estimated the hours they actually 
completed. Adequate CPD hours have been a mandatory requirement in Australia since 
July 1st 2010 and the pharmacists participating in PROMISe in 2009 would have been 
aware of the changes about to take place and as a result may not have wanted to indicate 
if their CPD activity was sub-optimal. The new CPD regulations still rely on the pharmacist 
self-reporting their activity with approximately 10% of pharmacists being audited each 
year, so the actual level of CPD activity of an individual pharmacist may never be 
accurately known. Also, pharmacists may attend CPD activities, but may not absorb the 
education into their practice, so CPD could be considered a crude measure of a 
pharmacist’s abilities. In an attempt to disentangle these uncertain elements, this result 
should be considered together with the pharmacist’s clinical knowledge survey score 
discussed in the previous section.  
As detailed in the demographics discussion, it was expected that age or graduation year 
may have been associated with intervention rate. However, this association was not found 
to be significant. To identify if this was due to the older pharmacists participating in more 
education, a chi-square test was used to determine if there was a difference between the 
age or graduation year and the level of annual CPD activity. The results showed a fairly 
even split between the age or graduation year and the annual CPD activity ([χ2 = 19.69, df 
= 12, p = 0.07] and [χ2 = 15.34, df = 12, p = 0.22] respectively), indicating that all age and 
graduation groups undertook a similar level of annual CPD activity. 
Training 
The level of training correlated significantly with the pharmacist’s intervention rate, with 
the pharmacists who completed both types of training having a higher intervention rate. 
Analysis also showed that a much larger proportion of pharmacists who documented no 
interventions also completed no training. This finding may be due to two reasons. Firstly, 
the pharmacists did not complete the training because they were not interested in 
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participating in the trial, resulting in no interventions being documented. Alternatively, 
the pharmacists did not complete the training and subsequently, did not feel comfortable 
participating in the trial. 
Disappointingly, nearly 20% of the participants did not complete any type of training and 
so it is unknown what effect training would have made on these pharmacists. However, it 
is likely that training would have improved their intervention rate as the relationship 
between the two factors was significant. A poor training attendance was also noted by 
Knapp27, where all pharmacies were represented at the training sessions, but not all 
participating pharmacists were present, leaving the authors uncertain with regards to 
what effect the training had on the reported intervention rate. 
Pharmacist attitude and practice change 
The factors already discussed can also be linked to the pharmacist’s attitude towards the 
profession of pharmacy. Pharmacists who have higher clinical knowledge and complete 
more annual CPD and targeted training, such as the PROMISe training, are more likely to 
be motivated and enthusiastic about their profession, and more likely to participate in 
trials to further improve their pharmacy practice. Several studies have previously 
commented on the influence that the pharmacist’s attitude can have on their ability to 
provide cognitive services. It was first noted by Rupp58, who hypothesised that a 
pharmacist’s willingness and ability to intervene was more a function of the individual 
pharmacist rather than the pharmacy itself. Westerlund102 found that interest in 
participating in an electronic documentation project was significantly associated with the 
documentation rate during the project, indicating that pharmacists who were more 
enthusiastic about participation in professional programs would be more likely to have a 
higher participation rate. A study by Zardain110 also identified that pharmacists would be 
more likely to implement pharmacy programs if they had a more positive attitude, were 
confident in their abilities and observed other colleagues performing the service. 
Enthusiasm was also noted in the study by Blake, where pharmacists indicated that, if 
given the chance, they were more likely to work in a pharmacy that provided professional 
services.115 Pharmacists who felt they had a good clinical knowledge also had a higher 
level of confidence in their abilities, and both of these opinions significantly correlated 
with intervention rates during the trial. Therefore, the pharmacist’s attitude appeared to 
be closely linked with their intervention rate with the more motivated and enthusiastic 
pharmacists participating more effectively in the trial. 
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Another survey also determined that the most influential factor that affected a 
pharmacist’s behaviour was their past behaviour141, where the ability of pharmacists to 
provide professional services may be influenced by their previous behaviour. This may 
suggest that the pharmacists who are more willing to change may be more motivated to 
provide improved professional services as they can visualise the benefits of improving 
their services. This was not found in the PROMISe trial, as the pharmacist’s answer to the 
statement “I believe it is important for pharmacists to adapt their practice to suit the 
current pharmacy environment” did not appear to be correlated to their intervention rate. 
It is possible, however, that this question was interpreted in a different way to what was 
intended. The question intended to identify if the pharmacists believed that practice 
adaption was necessary to advance the pharmacy profession. However, in retrospect, 
pharmacists may have interpreted the statement to mean that they would change their 
practice to suit the pharmacy environment, even if that meant lowering their standards. 
Therefore, the pharmacists who disagreed with this statement may have been stating that 
they would not change their practice to suit the pharmacy, for example, not counselling 
patients because the pharmacy was too busy. For this reason, the answers to this question 
should be disregarded from the analysis.  
Pharmacists who felt they were too busy to take on additional tasks appeared to have 
lower intervention rates than their less busy counterparts. Interestingly, there was no 
correlation seen between the pharmacist’s perception of busyness and the pharmacy’s 
average workload. This may suggest that the pharmacist’s perception of their busyness 
was inaccurate or that the measure of workload used within this study was too 
generalised and inaccurate to provide useful analysis. Pharmacists who were confident in 
their ability to perform interventions also tended to have higher intervention rates than 
their less confident counterparts, and their self-assessment of their confidence did not 
change over the course of the trial. This indicates the importance of self-perception and 
the effect that a pharmacist’s attitude can have on their ability to perform professional 
services. 
The pharmacists who believed the system would be too hard to use before the trial did 
not use the system as often and finished the trial with a lower intervention rate. This 
highlights the effect that the pharmacist’s state of mind can have on their abilities to use 
the documentation system. This result was also seen by Christensen101 who found that the 
pharmacist’s perception of how burdensome the task of documentation significantly 
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contributed to whether the pharmacist would perform any cognitive services. Those 
pharmacists who did not find the documentation process burdensome were much more 
likely to perform cognitive services than those pharmacists who found the process 
burdensome. Again, this highlights the effect that the pharmacist’s attitude can have on 
the delivery of professional services, and the more motivated and enthusiastic the 
participant is at the beginning of the trial, the more successful their participation will be. 
There were also four pharmacists who felt strongly that recording interventions did not 
increase their job satisfaction. This may have been due to these pharmacists recording 
things that were not interventions, creating a higher workload for themselves, which may 
have resulted in these pharmacists finding the process tedious and unnecessary. 
Participating pharmacists achieved a mean empathy score of 46.8 ± 6.1 (range = 25 – 62), 
which was comparable to the results in the original article, which surveyed university 
students studying healthcare, where the mean score over three studies was 46.3 ± 7.6 in 
undergraduate students.159 A mean professionalism score of 80.0 ± 7.7 (range = 19 – 90) 
was also achieved. This was slightly higher than results in the original article where the 
mean score was 77.8 ± 5.9, achieved with 231 pharmacy students and recent pharmacy 
graduates in the United States. Despite this, there was not a significant link between the 
empathy or professionalism of the pharmacist and their intervention rate. This was 
disappointing, as it was thought the empathy and professionalism scores may provide 
insight into the attitudes and work practices of the pharmacist. This finding may be due to 
two reasons. Firstly, it may indicate that professionalism and empathy do not have any 
effect on the pharmacist’s ability to document interventions. Alternatively, it may indicate 
that the professionalism and empathy measures used did not accurately predict the 
pharmacist’s attitudes; however, both measures were validated within the literature159,160, 
therefore this is unlikely. 
Interestingly, statistical analysis of the non-performing pharmacists found that there were 
more than expected non-performing pharmacists in Group One, compared to Groups Two 
and Three. This may indicate that the software did have an impact on the pharmacist and 
may have resulted in an increase in participation rates. Provision of an effective and 
intuitive software system may therefore improve interventions rates amongst community 
pharmacists.  
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Workload and staffing levels 
The pharmacy intervention rate was significantly associated with prescription volume and 
pharmacist workload, however, the correlation was not as strong at the individual 
pharmacist level. There was no correlation between the actual number of prescriptions 
dispensed by the pharmacist and the pharmacist’s intervention rate. This was unexpected, 
given the results from the pharmacy analysis, and may indicate that other pharmacy 
factors have more impact on the pharmacist’s intervention rate than the actual number of 
prescriptions dispensed. This finding was also in contrast to the studies by Rupp58 and 
Christensen101, which both found that as the number of prescriptions dispensed by the 
pharmacist increased, the number of cognitive services that were documented decreased. 
Interestingly, individual pharmacists were dispensing prescriptions at a lower or similar 
rate to the national average during the trial, which may indicate that the participating 
pharmacists had a lower than average prescription volume and thus, perhaps, having 
available capacity to take on additional tasks. However, this did not appear to result in a 
higher intervention rate. 
The pharmacist workload was calculated from the number of prescriptions dispensed 
divided by the average number of pharmacist hours per week, resulting in an average 
within the pharmacy. The average workload could be used as a measure of how busy the 
pharmacy is. For example, as the workload increases, the intervention rate decreases as 
the pharmacists may not have enough time to perform or document interventions. 
However, each pharmacist may have been under different workload pressures, which the 
average value did not adequately describe, implying that the workload measure may have 
been too simplistic to be of benefit. It remains unknown how accurate the workload 
calculation was at the individual pharmacist level.  
The effect of dispensary technicians was examined using an adjusted workload calculation 
that included technicians, however, there was no correlation between the pharmacist’s 
intervention rate and the adjusted workload accounting for technicians. This was 
interesting, as the addition of dispensary technicians caused the workload to become a 
non-significant factor in the determination of intervention rate. It might be expected that 
the additional staff would allow the pharmacist to increase their intervention rate, but this 
was not found. This shows that workload is a tangible entity and can be extremely hard to 
define in the community pharmacy environment. Alternatively, the addition of dispensary 
technicians may decrease the number of interventions being performed, as several of the 
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points of contact that allow the pharmacist to detect a DRP have been removed. For 
example, the pharmacist may not access the patient’s history or converse with the patient 
as often when they are working with a dispensary technician. The effect of the dispensary 
technicians on the pharmacist’s intervention rate remains largely unknown.  
The percentage of time that the pharmacist spent on dispensing tasks also did not 
correlate with the pharmacist’s intervention rate. It was logical to assume that 
pharmacists who spent more time dispensing would have a higher intervention rate as 
they had access to more patient and prescription information that may allow detection of 
a DRP, so it was interesting that the pharmacists with a higher proportion of time spent on 
dispensing tasks were not the pharmacists with the higher intervention rates. There are 
two possible explanations for this. The first is that the pharmacists who spend a higher 
proportion of their time on dispensing tasks may be more focused on the actual 
dispensing of the medications (processing the prescription, collecting and labelling stock 
etc.), rather than patient care. This means that their contact time with the patient may be 
decreased, which reduces their potential to detect interventions. Alternatively, the 
proportion of time spent on dispensing tasks may have increased when the pharmacist 
was working with a technician, as the amount of time required to check prescriptions 
increased.  
There are several solutions that may help to overcome the barrier of workload. A study 
analysing workflow redistribution found that when one pharmacist was asked to only 
perform clinical duties (such as analysing drug therapies, counselling patients and 
documenting interventions) whilst a second pharmacist completed all administrative 
duties, the number of interventions documented was significantly increased with 
significant benefits for the patients, without altering the staffing levels within the 
pharmacy.118 A study that altered workflow within a pharmacy by improving the use of 
space within the dispensary and increasing the technician’s responsibilities also found that 
the level of pharmacist interaction with the patients was significantly increased.119 
Additionally, decreasing the pharmacist workload by increasing the number of 
pharmacists may also help to overcome both the perceived and actual barrier of 
workload. 
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5.3 Multivariate statistical modelling  
During the bivariate analysis, many pharmacists were identified as ‘non-performers’ of 
clinical interventions. Multivariate analysis was performed to determine if a statistical 
model could predict whether a pharmacist would be a ‘performer’. An additional 
multivariate analysis was also performed to determine if a model could predict the 
intervention rate of the pharmacist using the influencing factors previously found in 
section 5.2. 
5.3.1 Model to identify documenting pharmacists 
A logistic regression was performed to determine if a model could possibly predict those 
pharmacists who would document interventions and those who would not. For this 
analysis, there were 412 pharmacists who had complete sets of data for analysis. All 
pharmacists who had documented at least one intervention during the trial were recoded 
as ‘performers’, with 361 pharmacists meeting this condition. The remaining 51 did not 
document any interventions and were therefore recoded as ‘non-performers’. The 
resultant model aimed to predict a dichotomous variable; either ‘performer’ or ‘non-
performer’. 
A forward stepwise regression was performed and identified five variables that were 
significantly associated with documenting interventions: level of training, membership to 
APESMA, role, working in a pharmacy that was manager-operated and average weekly 
prescription volume of the pharmacy. Pharmacists were more likely to be ‘performers’ if 
they were members of APESMA, were owners or managers, participated in both forms of 
PROMISe training, worked in owner-operated pharmacies and worked in a pharmacy with 
a slightly higher prescription volume (Table 5-47). 
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B S.E. Wald df Sig. Exp(B) 
95% CI 
Lower Upper 
Training - none     13.672 3 0.003       
Training - online only 1.278 0.527 5.886 1 0.015 3.588 1.278 10.072 
Training - face-to-
face only 
0.596 0.821 0.528 1 0.468 1.816 0.363 9.073 
Training - both 1.983 0.563 12.420 1 0.000 7.266 2.411 21.891 
APESMA member 20.278 9041.936 0.000 1 0.998 6.4x10
8
 0.000 . 
Role - owner     15.693 3 0.001       
Role - manager 1.232 0.730 2.843 1 0.092 3.426 0.819 14.341 
Role - employee -0.697 0.397 3.088 1 0.079 0.498 0.229 1.084 
Role - locum/other -1.580 0.593 7.108 1 0.008 0.206 0.064 0.658 
Manager run -0.806 0.361 4.997 1 0.025 0.447 0.220 0.905 
Average weekly 
prescription volume 
0.001 0.000 5.526 1 0.019 1.001 1.000 1.001 
Constant 0.384 0.589 0.423 1 0.515 1.468     
Table 5-47: Variables included in the logistic regression analysis 
The model provided a correct classification in 87.1% of all cases, with 99.2% of performers 
correctly identified, but only 2.0% of non-performers correctly predicted. This resulted in a 
poor Nagelkerke R2 value of 0.187, where only 18.7% of the variance could be explained 
by the model, resulting in a model that was unlikely to accurately predict participation. 
5.3.2 Statistical model for determining the pharmacist’s 
intervention rate 
As discussed in Chapter 2, a multinomial logistic regression was used to design a statistical 
model for determining a pharmacist’s intervention rate because a multiple regression 
could not be used due to the non-parametric nature of the data. The three intervention 
rate groups used in the analysis were ‘Low CI rate’, ‘Moderate CI rate’ and High CI rate’ 
(Table 5-48). 
 
Clinical intervention rate 
Count Median Min. Max. 
25th 
%ile 
75th 
%ile 
Low CI rate 170 0.014 0.000 0.091 0.000 0.054 
Moderate CI rate 170 0.168 0.091 0.276 0.128 0.223 
High CI rate 169 0.563 0.279 3.876 0.377 0.893 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 5-48: Intervention rates seen in each CI rate group used in the multinomial 
logistic regression model 
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5.3.2.1 Bivariate analysis 
Bivariate analysis was conducted on all available factors within the data to determine 
which ones were influential to the multivariate model. The following factors were 
considered for inclusion in the logistic regression: 
 Additional qualifications  
o None/AACP accreditation vs additional University postgraduate 
qualification  
o Pearson χ2= 16.94, df = 4, p = 0.001 
 CPD hours  
o Combined into 3 groups (0-25 hours, 25-50 hours, over 50 hours)  
o Pearson χ2= 13.60, df = 4, p = 0.009 
 Clinical knowledge  
o Correlation using continuous clinical knowledge score and 3 CI rate groups 
o Kendall’s tau = 0.136, p < 0.001 
 Training level 
o 4 groups: none, face-to-face only, online only, both  
o Pearson χ2= 66.79, df = 6, p < 0.001 
To decrease the number of groups within the training level variable, chi-square analyses 
were performed to determine which groups could be combined. There were no significant 
differences between the rate for pharmacists with no training and face-to-face training 
(Pearson χ2 p = 0.08; also supported by statistics in section 5.2.11); therefore, these two 
groups were combined. A significant difference was still maintained between the 
pharmacists with online only and both training (Pearson χ2 p = 0.001); therefore, these two 
groups were kept separate. This resulted in three training groups: none/face-to-face; 
online only; and both online and face-to-face training. 
In addition, pharmacist opinions had previously been shown to influence the number of 
interventions performed101 and their intervention rates (section 5.2.12.4), so two scores 
were derived from six pre-trial Likert scale survey questions. An ‘adaptability/willingness 
to change’ score (where the lower the score, the more adaptable/willing to change the 
pharmacist was) was calculated from answers to the following three statements: 
 I believe that pharmacists are already too busy within the workplace which 
prevents them from taking on any new tasks. 
 I would be willing to change my current practice if a new, better way was 
available. 
 I believe it is important for pharmacists to adapt their practice to suit the current 
pharmacy environment. 
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This score correlated with the 3 groups of CI rate used in the multinomial logistic 
regression (Kendall’s tau = -0.126, p < 0.001), which showed that as the CI rate increased, 
the pharmacist became more ‘adaptable/willing to change’; therefore, this measure was 
included in the logistic regression. 
A ‘confidence’ score (where the lower the score, the more confident the pharmacist) was 
calculated from answers to the following three statements: 
 I believe I have a good level of clinical knowledge to perform clinical interventions. 
 I am confident in my ability to perform clinical interventions. 
 I already perform clinical interventions on a daily basis. 
Again, this score correlated with the 3 CI rate groups (Kendall’s tau = -0.119, p = 0.002), 
which showed that as the CI rate increased, the pharmacist became more ‘confident’. 
However, when the two scores were compared, a significant correlation was seen 
between the confidence score and the adaptability score (Kendall’s tau = 0.209, p < 
0.001). As regression models need to minimise the amount of multicollinearity present 
between the variables, it was decided that only the adaptability score would be included 
in the logistic regression as it appeared to be the stronger factor of the two. 
To provide a measure of workload, the average pharmacist workload within the pharmacy 
was also included. It is important to note, however, that the data may not accurately 
reflect the pharmacist’s actual workload because the calculation assigned an average 
number of prescriptions per pharmacist within the pharmacy. 
Therefore, the final factors that were trialled in the logistic regression analysis were: 
 Additional qualifications 
o 2 groups (none/AACPA vs additional postgraduate University qualification) 
 CPD hours  
o 3 groups (0-25 hours, 25-50 hours, over 50 hours)  
 Training 
o 3 groups: none/face-to-face only, online only, both  
 “Adaptable/willingness to change” score as a continuous variable 
 Clinical knowledge score as a continuous variable 
 Average workload per pharmacist within the pharmacy as a continuous variable 
Gender, age, graduation year, professional memberships, number of other pharmacists 
present during an average shift, actual number of prescriptions dispensed during the trial, 
percentage of time spent on dispensing tasks, number of years of experience, previous 
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experience working in a hospital, number of hours worked in community pharmacy per 
week, empathy score and professionalism score were not found to be associated with the 
pharmacists’ individual intervention rates. These factors were therefore not included in 
the logistic regression. 
5.3.2.2 Missing value analysis 
A missing data analysis was performed to determine any patterns to the missing values, 
resulting in 416 full datasets. See Appendix 25 for more detail. 
5.3.2.3 Multinomial logistic regression 
As the aim of this modelling research was to determine which factors influenced a higher 
CI rate, the high CI rate category was used as the ‘base’ category to determine the 
probability of the pharmacist having a high CI rate based on the included factors. 
The initial model was found to be significantly different from the constant model, 
indicating that the variables reliably predicted membership to the three CI rate groups 
(χ2(16, N = 416) = 60.074, p < 0.001). There was a good model fit (discrimination among 
groups) with the included predictors (χ2(816, N = 416) = 848.137, p = 0.211 when using the 
deviance criterion and χ2(816, N = 416) = 831.846, p = 0.342 when using the Pearson 
criteria). Nagelkerke R2 was 0.151, indicating that 15.1% of variance in the pharmacist’s 
documented CI rate could be explained by the model. The likelihood ratio tests (Table 
5-49) indicated that the variables of adaptability score, clinical knowledge score and 
training differed significantly between the three CI rate groups, but the remaining 
variables were not significant. 
Effect 
 
Model Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log Likelihood of 
Reduced Model 
Chi-
Square 
df Sig. 
Intercept 848.137a 0.000 0 . 
Adaptability score 854.521 6.384 2 0.041 
Clinical knowledge score 856.432 8.295 2 0.016 
Average pharmacist workload 848.276 0.139 2 0.933 
Additional qualifications 851.484 3.347 2 0.188 
CPD 857.484 9.347 4 0.053 
Training 865.977 17.840 4 0.001 
a. This reduced model is equivalent to the final model because omitting the effect does not increase the 
degrees of freedom. 
Table 5-49: Likelihood ratio tests for the initial model 
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Table 5-50 shows that the ability of the model to classify the cases was unimpressive, with 
only 48.9% of cases being correctly predicted. However, this was improved for 
pharmacists in the high CI rate, where 64.6% of cases were correctly classified. 
Observed 
Predicted 
Low CI 
rate 
Moderate CI 
rate 
High CI 
rate 
Percentage 
Correct 
Low CI rate 35 41 37 31.0% 
Moderate CI rate 16 67 63 45.9% 
High CI rate 13 43 102 64.6% 
Overall Percentage 15.3% 36.2% 48.4% 48.9% 
Table 5-50: Percentage of correct predictions from initial model 
5.3.2.4 Refining the model 
The model was then re-run by removing the non-significant variables (Table 5-51). 
Average workload and additional qualifications were removed, but CPD was approaching 
significance (p = 0.053) and was therefore retained. 
Case Processing Summary 
 N 
Marginal 
Percentage 
CI rate BINNED 
into 3 groups 
Low CI rate 114 27.3% 
Moderate CI rate 146 34.9% 
High CI rate 158 37.8% 
CPD 
0-25 hours 203 48.6% 
25-50 hours 145 34.7% 
Over 50 hours 70 16.7% 
Training 
None or F2F 39 9.3% 
Web 199 47.6% 
Both 180 43.1% 
Valid 418 100.0% 
Missing 91  
Total 509  
Subpopulation 337a  
a. The dependent variable has only one value observed in 296 (87.8%) 
subpopulations. 
Table 5-51: Covariate factors included in the refined multinomial logistic regression  
Again, the refined model was found to be significantly different from the constant model, 
indicating that the variables reliably predicted membership to the three CI rate groups 
(χ2(12, N = 337) = 57.066, p < 0.001). There was also a good model fit (discrimination 
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among groups) with the included predictors (χ2(660, N = 337) = 714.020, p = 0.071 when 
using the deviance criterion and χ2(660, N = 337) = 681.800, p = 0.270 when using the 
Pearson criteria). Nagelkerke R2 was 0.144; indicating that a slightly lower percentage of 
variance (14.4%) was explained by the refined model. The likelihood ratio tests showed 
that all of the variables were now significant factors in the model for CI rate group 
prediction (Table 5-52 and Table 5-53). 
Effect 
Model Fitting 
Criteria 
Likelihood Ratio Tests 
-2 Log Likelihood of 
Reduced Model 
Chi-
Square 
df Sig. 
Intercept 779.674a 0.000 0 . 
Adaptability score 786.163 6.488 2 0.039 
Clinical knowledge score 789.266 9.592 2 0.008 
Training 798.266 18.591 4 0.001 
CPD 791.315 11.641 4 0.020 
a. This reduced model is equivalent to the final model because omitting the effect does not 
increase the degrees of freedom. 
Table 5-52: Likelihood ratio tests for the refined model 
308 | P a g e  
 
 
 
B 
Std. 
Error Wald df Sig. Exp(B) 
95% CI for Exp(B) 
Lower Upper 
Lo
w
 C
I r
at
e
 
Intercept -0.005 1.203 0.000 1 0.997       
Clinical knowledge score -0.053 0.018 8.351 1 0.004 0.948 0.915 0.983 
Adaptability score 0.182 0.075 5.866 1 0.015 1.200 1.035 1.391 
CPD 0-25hrs vs CPD over 50hrs 1.220 0.415 8.652 1 0.003 3.386 1.502 7.631 
CPD 25-50hrs vs CPD over 50hrs 0.734 0.427 2.959 1 0.085 2.084 0.903 4.813 
None/F2F vs both training 1.318 0.455 8.408 1 0.004 3.736 1.533 9.106 
Web only vs both training 0.865 0.281 9.447 1 0.002 2.375 1.368 4.124 
M
o
d
er
at
e
 C
I r
at
e 
Intercept 1.217 1.107 1.208 1 0.272       
Clinical knowledge score -0.040 0.017 5.356 1 0.021 0.961 0.929 0.994 
Adaptability score 0.039 0.070 0.306 1 0.580 1.040 0.906 1.193 
CPD 0-25hrs vs CPD over 50hrs 0.589 0.323 3.325 1 0.068 1.803 0.957 3.397 
CPD 25-50hrs vs CPD over 50hrs 0.077 0.335 0.053 1 0.819 1.080 0.560 2.080 
None/F2F vs both training 0.215 0.490 0.192 1 0.662 1.239 0.474 3.239 
Web only vs both training 0.680 0.246 7.635 1 0.006 1.974 1.219 3.197 
a. The reference category is: High CI rate. 
Table 5-53: Parameter estimates for the refined model 
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Even after removing the non-significant variables, the ability of the model to classify cases 
remained unimpressive. Overall, the correct classifications decreased slightly to 47.1% of 
cases, but the number of correct classifications for the high CI rate was slightly improved 
to 65.2% of cases (Table 5-54). 
Observed 
Predicted 
Low CI 
rate 
Moderate 
CI rate 
High CI 
rate 
Percent 
Correct 
Low CI rate 35 42 37 30.7% 
Moderate CI rate 18 59 69 40.4% 
High CI rate 13 42 103 65.2% 
Overall Percentage 15.8% 34.2% 50.0% 47.1% 
Table 5-54: Percentage of correct predictions from the refined model 
To account for the inflation in the family-wise error rate associated with 10 predictors, the 
p-value was recalculated and the critical p-value was 0.05/10 = 0.005.149 All of the 
variables showed significance according to the critical p-value, except the adaptability 
score and CPD 25-50 vs CPD over 50. 
Using the parameter estimates seen in Table 5-53, the following suggestions could be 
drawn. Compared to pharmacists with a low CI rate, pharmacists with a high CI rate were: 
 More likely to have a lower adaptability score (more adaptable/willing to change)  
 More likely to have a higher score on the clinical knowledge survey 
 3.74 times more likely to have done both types of training compared to 
none/face-to-face and 2.38 times more likely to have done both types of training 
compared to online only 
 3.39 times more likely to have done 50 hours of CPD per year compared to 0-25 
hours and 2.08 times more likely to have done 50 hours of CPD per year compared 
to 25-50 hours  
To interpret the continuous variables, the differences in mean were examined between 
the three CI rate groups (Table 5-55). Pharmacists with a high CI rate had a significantly 
higher clinical knowledge survey score (mean = 54.9 ± 6.9, p = 0.004) compared to those 
with a low CI rate (mean = 51.4 ± 8.2). Pharmacists with a high CI rate also had a lower 
adaptability score (where Strongly Agree = 1 and Strongly Disagree = 5), therefore 
signifying a more positive attitude (high CI rate mean = 5.7 ± 1.8 and low CI rate mean = 
6.4 ± 2.1, p = 0.015). 
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Count 
Adaptability score Clinical knowledge score 
Mean 
Std. 
Error 
Std. 
Dev. 
Mean 
Std. 
Error 
Std. 
Dev. 
Low CI rate 170 6.43 0.18 2.06 51.41 0.77 8.18 
Moderate CI rate 170 5.86 0.12 1.51 52.56 0.58 7.02 
High CI rate 169 5.67 0.14 1.75 54.88 0.55 6.88 
Total 509 5.96 0.09 1.79 53.12 0.36 7.43 
Table 5-55: Descriptive data for the two continuous variables in the refined model 
5.3.2.5 Overview of influencing factors 
The relationships between the influential factors found in the previous analyses can be 
seen in Figure 5-4. The bold text shows the four factors found to be significant within the 
multinomial logistic regression analysis, with the remaining two factors being significant 
within the bivariate analysis.
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Figure 5-4: Relationships between the significant factors found in the bivariate and multinomial logistic regression analyses
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5.3.3 Discussion of the multivariate analysis 
No statistical differences in characteristics were seen in the initial analysis between the 
pharmacists who documented an intervention and those who documented none. 
However, the stepwise regression model was successful in predicting whether a 
pharmacist would document an intervention (‘performer’) in 87% of cases by using five 
variables. Pharmacists were more likely to be ‘performers’ if they were APESMA members, 
were owners or managers, participated in both forms of PROMISe training, worked in 
owner-operated pharmacies and worked in a pharmacy with a slightly higher prescription 
volume. Unfortunately, only 18.7% of variance could be accounted for in the model, 
indicating that the likelihood of the pharmacist performing at least one intervention could 
not be predicted in many cases if used on a wider population. 
Using the data from the 509 ‘active’ pharmacists, a multinomial logistic regression model 
was successful in predicting whether the pharmacist would have a high intervention rate 
in 65.8% of cases according to the pharmacist’s number of annual CPD hours, the level of 
training, clinical knowledge survey score and adaptability score. Considering that the aim 
of the model was to predict those pharmacists who would be expected to have a higher 
intervention rate, the model could be considered sufficient for predicting those with a low 
intervention rate compared to a high intervention rate. The variables included in the 
multinomial logistic regression were all reasonable as explained in the previous discussion 
in section 5.2.15. Pharmacists with a higher number of annual CPD hours, a higher level of 
training and a higher clinical knowledge may have a better ability to detect DRPs, thus 
increasing their intervention rate. The inclusion of the adaptability score variable also 
corresponds with previous trials that have noted the importance of the pharmacist’s 
attitude on their ability to provide professional services.101,110 
Training was a significant variable included in both multivariate analyses, where a higher 
level of training was seen in pharmacists who documented at least one intervention 
(compared to documenting none) and in pharmacists with a higher intervention rate. This 
is most likely due to the training increasing the awareness and understanding of the 
project. The importance of targeted training such as this has previously been shown to be 
more effective at improving the pharmacists’ clinical knowledge and other skills.124,126 A 
study that provided extensive DRP training for pharmacists resulted in a significant 
improvement in the ability of the pharmacist to manage DRPs.121 However, such a high 
level of commitment may be unrealistic for the majority of pharmacists. The advantage of 
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the PROMISe training was that the majority of it could be completed online, reducing the 
disadvantage for rural pharmacists. In addition, the pharmacists who indicated that they 
had received sufficient training in the post-trial survey had a higher intervention rate than 
their less satisfied counterparts, indicating the importance that training may have on the 
pharmacist’s ability to participate in professional programs. 
Although the average pharmacist workload was significantly associated with the 
pharmacist’s intervention rate, it did not appear in the multivariate analysis. No amount of 
manipulation allowed the inclusion of workload into the multivariate model. The process 
of multinomial logistic regression analysis includes variables based on the strength of their 
correlation with the dependent variable, possibly indicating that the workload may not 
have accurately reflected the individual pharmacist’s workload. Additionally, unlike in the 
pharmacy model, the workload was not associated with any of the included variables, 
therefore it is thought that the pharmacist’s workload calculation was not a good 
predictor of performance at the individual pharmacist level. The FTE pharmacist 
calculation was based on the average weekly roster with the pharmacy, and therefore 
included non-participant pharmacists in most pharmacies, such as locums or casual 
pharmacists not aware of the trial. The average pharmacist workload within their 
pharmacy was also higher than the average prescription volume dispensed per pharmacist 
during the trial. This may be due to all pharmacists (including non-participants) being 
counted in this calculation, which may suggest that the non-participant pharmacists had a 
higher workload than the participant pharmacists. As such, it is unknown how accurate 
the workload calculation was at the individual pharmacist level and this is likely to have 
affected its inclusion in the final multivariate model. 
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5.4 Observational sub-study 
As discussed in Chapter 2, the main aim of the observation period was to determine what 
percentage of performed clinical interventions were actually documented. For each 
observed pharmacist, two intervention rates were calculated: 
 Performed intervention rate (number of observed interventions divided by 
number of observed prescriptions dispensed) 
 Documented intervention rate (number of documented interventions divided by 
number of observed prescriptions dispensed) 
It is important to note that these intervention rates are calculated only on the 
interventions and prescriptions observed, and are therefore the rates seen during the 
observational week, not the whole trial. 
5.4.1 Observed pharmacists 
A total of 149 pharmacists were observed during the trial, with 90 pharmacists being 
observed in the 38 software pharmacies and the remaining 59 pharmacists being observed 
in the 24 no software pharmacies. The majority of the pharmacists within the software 
pharmacies completed the online surveys, resulting in 78 complete sets of demographic 
data for observed pharmacists. Although pharmacists in the no software pharmacies did 
not have access to the PROMISe intervention recording system, they were still observed to 
record some interventions. The observers found that 57% of no software pharmacists 
used the notes section within their dispensing system to record interventions, however 
the recording of interventions was not consistent and the remaining 43% of pharmacists 
were not observed recording any interventions during the observational period. 
5.4.1.1 Performance rates compared to documentation rates 
Observed pharmacists performed 779 interventions but only documented 293 (37.6%) of 
them. When the no software pharmacies were excluded, the software pharmacies 
documented 279 of the 565 observed interventions (49.4%; Table 5-56). The 
documentation rate was much lower in the no software pharmacies, with these 
pharmacists only documenting 14 in 214 interventions (6.5%). Pharmacists were observed 
to be performing interventions at an average rate of 2.34 per 100 prescriptions, but only 
documenting at an average rate of 0.85 per 100 prescriptions. Again, when the no 
software pharmacies were excluded, pharmacists performed interventions at an average 
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rate of 2.77 per 100 prescriptions and documented interventions at an average rate of 
1.33 per 100 prescriptions (Table 5-56). 
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  Count Sum Mean Std. Error Std Dev. Minimum Maximum Median 25th %ile 75th %ile 
N
o
 s
o
ft
w
ar
e 
Performed CIs 24 214 9 1 5 1 24 8 6 12 
Documented CIs 24 14 1 0 1 0 4 0 0 1 
Pharmacist prescriptions 24 13522 563.42 43.58 213.48 259 1121 522.50 389.50 694.00 
Performed CI Rate 24   1.66 0.19 0.94 0.28 3.90 1.54 0.98 2.12 
Documented CI Rate 24   0.10 0.04 0.18 0.00 0.59 0.00 0.00 0.19 
Pharmacy prescriptions 24 19241 801.71 93.89 459.95 259 2126 746.00 534.00 1043.50 
So
ft
w
ar
e 
Performed CIs 38 565 15 1 8 3 36 13 10 20 
Documented CIs 38 279 7 1 4 1 19 6 4 10 
Pharmacist prescriptions 38 24724 650.63 71.67 441.81 163 2890 580.00 457.00 732.00 
Performed CI Rate 38   2.77 0.29 1.78 0.42 9.66 2.53 1.60 3.58 
Documented CI Rate 38   1.33 0.13 0.81 0.10 3.33 1.10 0.75 1.88 
Pharmacy prescriptions 38 35359 930.50 108.61 669.50 166 3750 710.00 583.00 1075.00 
To
ta
l 
Performed CIs 62 779 13 1 7 1 36 12 7 17 
Documented CIs 62 293 5 1 5 0 19 4 0 8 
Pharmacist prescriptions 62 38246 616.87 47.08 370.70 163 2890 562.50 450.00 712.00 
Performed CI Rate 62   2.34 0.20 1.60 0.28 9.66 2.06 1.37 3.00 
Documented CI Rate 62   0.85 0.11 0.88 0.00 3.33 0.63 0.00 1.51 
Pharmacy prescriptions 62 54600 880.65 75.74 596.36 166 3750 719.50 548.00 1075.00 
Table 5-56: Descriptive statistics of interventions and prescriptions within observed pharmacies 
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When the performed and documented intervention rates were compared with the 
number of prescriptions dispensed by the pharmacist and the pharmacy, significant 
correlations were seen between the number of prescriptions dispensed and the 
intervention performance rate of the pharmacist (Table 5-57 and Figure 5-5). 
  
Performed CI rate Documented CI rate 
Spearman's 
rho 
N p 
Spearman's 
rho 
N p 
Pharmacy prescriptions -0.293 62 0.021 -0.001 62 0.995 
Pharmacist prescriptions -0.378 62 0.002 -0.152 62 0.239 
Table 5-57: Correlations between prescription numbers with performed and 
documented intervention rates  
 
Figure 5-5: Correlation graph between performed CI rate and prescription volume 
Within the group of observed pharmacists, the intervention rates decreased as the 
number of prescriptions increased, indicating that the performance of interventions may 
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also have been affected by workload. Although only a smaller number of pharmacists 
were observed, this may indicate that workload may have a greater effect on the 
performance of interventions rather than the documentation. This finding will be explored 
more within the discussion. 
5.4.2 Influencing factors on performance and documentation rates 
Analysis did not reveal any factors that had a significant relationship with the pharmacist’s 
intervention performance or documentation rates. This included factors such as additional 
qualifications, CPD activity and training which had previously been shown to be correlated 
with the intervention rate. See Appendix 26 for more detail on the analysis. 
5.4.3 Descriptive statistics of workloads 
Observers were asked to keep a detailed record of all details affecting the pharmacist’s 
working day. 
5.4.3.1 Additional tasks 
The additional jobs undertaken by the observed pharmacists were used obtain an 
accurate picture of their workloads. During an average week, pharmacists dispensed 617 
prescriptions and served 317 patients. They also fixed 9 owing prescriptions, served 11 
daily dose pick-up patients, offered 14 CMIs to patients, assisted with 66 OTC requests 
including 6 pseudoephedrine sales, recorded 3 pseudoephedrine sales through Project 
STOP and issued 4 Safety Net cards (administrative paperwork required by the Australian 
Government that can be time-consuming) (Table 5-58). Mann-Whitney test showed no 
significant differences between the tasks undertaken by no software and software 
pharmacies.
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  Count Sum Mean 
Std. 
Error  
Std. 
Deviation 
Minimum Maximum Median 
Percentile 
25 
Percentile 
75 
N
o
 s
o
ft
w
ar
e 
Owing prescriptions 24 193.00 8.04 3.14 15.38 0.00 75.00 3.00 1.00 10.00 
Daily pickups 24 197.00 8.21 2.75 13.47 0.00 46.00 1.00 0.00 12.00 
CMIs offered 24 307.00 12.79 2.55 12.51 0.00 45.00 8.50 4.50 15.00 
OTC requests 24 1486.00 61.92 6.34 31.04 17.00 141.00 55.00 43.50 75.50 
Pseudoephedrine sales 24 160.00 6.67 1.28 6.27 0.00 25.00 5.00 2.50 8.00 
Project STOP 24 77.00 3.21 0.97 4.74 0.00 21.00 1.50 0.00 4.50 
Number of SN cards issued 24 94.00 3.92 0.57 2.78 0.00 9.00 3.50 2.00 6.50 
So
ft
w
ar
e 
Owing prescriptions 38 385.00 10.13 2.27 13.97 0.00 77.00 5.50 2.00 12.00 
Daily pickups 38 507.00 13.34 3.69 22.76 0.00 123.00 6.00 0.00 18.00 
CMIs offered 38 583.00 15.34 3.23 19.89 0.00 114.00 10.00 3.00 23.00 
OTC requests 38 2586.00 68.05 8.34 51.41 10.00 287.00 53.00 40.00 79.00 
Pseudoephedrine sales 38 183.00 4.82 0.66 4.07 0.00 19.00 3.00 2.00 8.00 
Project STOP 38 80.00 2.11 0.47 2.92 0.00 12.00 1.00 0.00 3.00 
Number of SN cards issued 38 144.00 3.79 0.47 2.91 0.00 14.00 4.00 2.00 5.00 
To
ta
l 
Owing prescriptions 62 578.00 9.32 1.83 14.44 0.00 77.00 4.00 2.00 11.00 
Daily pickups 62 704.00 11.35 2.51 19.73 0.00 123.00 4.00 0.00 13.00 
CMIs offered 62 890.00 14.35 2.20 17.33 0.00 114.00 9.50 4.00 21.00 
OTC requests 62 4072.00 65.68 5.65 44.45 10.00 287.00 53.50 41.00 79.00 
Pseudoephedrine sales 62 343.00 5.53 0.64 5.07 0.00 25.00 4.00 2.00 8.00 
Project STOP 62 157.00 2.53 0.47 3.73 0.00 21.00 1.00 0.00 4.00 
Number of SN cards issued 62 238.00 3.84 0.36 2.84 0.00 14.00 4.00 2.00 5.00 
Table 5-58: Descriptive statistics for the types of tasks undertaken by observed pharmacists 
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When compared to the intervention performance and documentation rates within the 
observed pharmacists, only one correlation was seen between the intervention 
performance rate and the number of Safety Net cards issued (Table 5-59). As the number 
of Safety Net cards issued by the pharmacist increased, the intervention performance rate 
decreased. 
  
Performed CI rate Documented CI rate 
Spearman's 
rho 
N p 
Spearman's 
rho 
N p 
Owing prescriptions 0.127 62 0.327 0.118 62 0.359 
Daily pickups 0.066 62 0.611 0.028 62 0.826 
CMIs offered 0.000 62 0.998 0.132 62 0.306 
OTC requests 0.048 62 0.712 -0.084 62 0.515 
Pseudoephedrine 
sales 
0.069 62 0.597 -0.207 62 0.106 
Project STOP 0.165 62 0.200 0.060 62 0.644 
Number of SN cards 
issued 
-0.264 62 0.038 -0.099 62 0.444 
Table 5-59: Correlations between pharmacist’s additional tasks and their performed 
and documented intervention rates 
5.4.3.2 Staffing levels 
The observers also recorded the number of other staff members present during each hour 
of the pharmacist’s shift. Each week on average, there was the equivalent of 59 
pharmacist hours, 24 technician hours, 10 graduate pharmacist hours and 98 pharmacy 
assistant hours (Table 5-60).
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  Count Sum Mean 
Std. 
Error 
Std. 
Deviation 
Minimum Maximum Median 
Percentile 
25 
Percentile 
75 
N
o
 s
o
ft
w
ar
e FTE pharmacist hours 24 1407.77 58.66 4.90 24.00 35.00 126.00 47.50 40.00 74.23 
FTE technician hours 24 417.21 17.38 4.59 22.49 0.00 93.50 8.21 0.00 30.50 
FTE graduate pharmacist hours 24 270.50 11.27 4.22 20.66 0.00 70.50 0.00 0.00 16.00 
FTE pharmacy assistant hours 24 2564.07 106.84 13.63 66.78 0.00 245.50 87.50 60.75 156.29 
So
ft
w
ar
e 
FTE pharmacist hours 38 2253.58 59.30 3.30 20.34 39.75 108.50 53.38 41.25 69.50 
FTE technician hours 38 1089.91 28.68 5.55 34.23 0.00 192.00 32.25 0.00 43.00 
FTE graduate pharmacist hours 38 332.50 8.75 2.83 17.44 0.00 78.50 0.00 0.00 3.00 
FTE pharmacy assistant hours 38 3525.25 92.77 11.46 70.67 0.00 371.50 75.38 42.50 123.00 
To
ta
l 
FTE pharmacist hours 62 3661.35 59.05 2.75 21.64 35.00 126.00 49.50 40.00 71.45 
FTE technician hours 62 1507.12 24.31 3.88 30.53 0.00 192.00 17.50 0.00 37.50 
FTE graduate pharmacist hours 62 603.00 9.73 2.37 18.63 0.00 78.50 0.00 0.00 7.00 
FTE pharmacy assistant hours 62 6089.32 98.21 8.76 68.98 0.00 371.50 83.00 48.25 128.00 
Table 5-60: Descriptive statistics for the staffing levels during the shift of an observed pharmacist 
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When the staffing levels were compared to the performed and documented intervention 
rates, no significant correlations were seen (Table 5-61).  
  
Performed CI rate Documented CI rate 
Spearman's 
rho 
N p 
Spearman's 
rho 
N p 
FTE pharmacist hours -0.090 62 0.485 0.111 62 0.391 
FTE technician hours -0.139 62 0.282 0.088 62 0.496 
FTE pre-registration hours -0.232 62 0.069 -0.119 62 0.358 
FTE pharmacy assistant hours -0.217 62 0.090 -0.101 62 0.433 
Table 5-61: Correlations between pharmacy’s staffing levels and the pharmacist’s 
performed and documented intervention rates 
5.4.4 Discussion of observational substudy 
Observed pharmacists in the software groups were found to document only 49% of the 
interventions they performed, with an average performance rate of 2.77% but an average 
documentation rate of 1.33%. The documentation rate was much higher than the overall 
intervention rate seen during the trial, which was most likely due to the presence of an 
observer increasing the documentation (and possibly the performance) of clinical 
interventions. The effect of observers was previously seen in the Rupp58 and Dobie60 
articles. Both authors used the same documentation system for the interventions, except 
Rupp used observers to document the intervention, whilst Dobie asked the intervening 
pharmacist to document the intervention. As shown in Chapter 1, the intervention rate 
found by Rupp was double the intervention rate found by Dobie, which is very similar to 
the results found in the PROMISe trial. It is possible that the number of interventions 
performed increased with the presence of an observer, as the pharmacist may be more 
likely to perform interventions whilst an observer is present. However, it is more likely 
that the proportion of interventions that were documented was different between the 
groups of observed and unobserved pharmacists. This could be due to the pharmacist not 
wanting to document the intervention due to lack of time or motivation, or the 
pharmacist may not have realised it was an intervention in the first place. This may 
indicate that the actual proportion of interventions that were documented during the trial 
may be even lower than the observed documentation rate of 49%. 
Although only a small number of pharmacists were observed, it was possible to analyse 
the factors that may have contributed to a higher intervention performance rate as well as 
a higher documentation rate. Interestingly, none of the previously identified factors (level 
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of training, CPD hours, clinical knowledge survey and adaptability score) correlated with 
the observed intervention rates. It is unknown if this was due to the small sample size or 
due to the presence of the observer. The small sample size of 78 pharmacists may have 
been too small to detect influencing factors, as the intervention rate was an extremely 
small number in most cases. It is also possible that the observer’s presence strongly 
influenced the pharmacist’s intervention rate, negating the effect of the other factors on 
the rate. In addition, the only correlation seen was between the intervention performance 
rate and the number of Safety Net cards issued, where the intervention performance rate 
decreased as the number of Safety Net cards issued by the pharmacist increased. This may 
indicate that the issuing of Safety Net cards has a significant impact on the pharmacist’s 
workload, resulting in less time to perform interventions, again indicating the impact of 
workload on the pharmacist’s ability to perform and document clinical interventions. 
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5.5 Time taken to do clinical interventions 
Participating pharmacists were asked to note the time, in minutes, that it took to perform 
each clinical intervention. Additionally, the observing pharmacists were asked to record 
the time taken by the pharmacist to document the intervention. It should be noted that 
both the FRED® and Aquarius® dispensing systems had the opportunity to enter a precise 
number, whereas the FRED® dispensing software also had ‘quick selection’ buttons for 2 
minute intervals (2, 4, 6, 8 and 10 minutes) which may have affected the pharmacists’ 
records. 
5.5.1 Time to perform the intervention 
The median time for the 5948 interventions was 4 minutes (range = 0 – 45; Figure 5-6). 
The influence of the ‘quick selection’ buttons can also be seen, with the most frequently 
recorded times being 4, 2 and 6 minutes (Figure 5-6). 
 
Figure 5-6: Time taken to perform an intervention 
Answers to the statement “I am concerned it will take too long to document interventions 
through the recording system” also correlated with the time that the pharmacist recorded 
against the intervention. Pharmacists who believed it would take too long to document an 
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intervention tended to record higher median intervention times (Spearman’s rho = -0.10, 
N = 423, p = 0.04). 
There were significant differences between the time taken to perform the intervention 
and the category of intervention (Kruskal-Wallis χ2 = 122.64, df = 7, p < 0.001), with 
compliance, undertreatment, monitoring and toxicity interventions having a higher 
median time than other interventions (Table 5-62).  
  Count Mean 
Std. 
Error 
Std. 
Dev. 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
D 1829 6.06 0.11 4.56 4.00 1.00 30.00 4.00 8.00 
O 1183 5.73 0.13 4.29 4.00 0.00 30.00 3.00 7.00 
C 557 7.31 0.25 5.88 6.00 0.30 45.00 4.00 10.00 
U 272 6.87 0.32 5.22 6.00 1.00 45.00 4.00 10.00 
M 140 7.64 0.49 5.72 6.00 1.00 30.00 4.00 10.00 
E 1412 5.27 0.10 3.70 4.00 1.00 30.00 2.00 6.00 
N 110 7.85 0.83 8.59 4.50 1.00 45.00 2.00 10.00 
T 445 6.36 0.20 4.16 6.00 1.50 30.00 4.00 8.00 
Total 5948 6.06 0.06 4.66 4.00 0.00 45.00 4.00 8.00 
Table 5-62: Time taken to perform an intervention compared to its DOCUMENT 
category 
Interventions that were associated with a referral and situations where a dose 
administration aid was recommended also required significantly longer time to complete 
(Table 5-63; Kruskal-Wallis χ2 = 9691.00, df = 18, p < 0.001). 
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Count Mean 
Std. 
Error 
Std. 
Dev. 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
R1 642 5.77 0.17 4.39 4.00 1.00 45.00 4.00 6.00 
R2 652 6.19 0.18 4.69 5.00 0.00 30.00 4.00 8.00 
R3 846 6.78 0.18 5.14 6.00 0.30 45.00 4.00 10.00 
R4 383 5.91 0.24 4.64 4.00 1.00 30.00 4.00 7.00 
R5 96 5.17 0.38 3.74 4.00 2.00 20.00 2.00 6.00 
R6 527 5.93 0.19 4.34 5.00 1.00 30.00 3.00 8.00 
R7 307 7.52 0.33 5.60 6.00 1.00 45.00 4.00 10.00 
R8 380 6.57 0.25 4.86 6.00 1.00 30.00 4.00 8.00 
R9 1786 7.16 0.12 5.23 6.00 1.00 45.00 4.00 10.00 
R10 36 10.57 1.52 9.01 10.00 2.00 45.00 4.00 15.00 
R11 76 10.19 0.90 7.80 7.00 2.00 45.00 5.00 12.00 
R12 58 11.11 1.04 7.84 10.00 2.00 40.00 6.00 15.00 
R13 2437 6.18 0.09 4.41 5.00 1.00 45.00 4.00 8.00 
R14 260 6.70 0.33 5.26 4.00 1.00 30.00 4.00 8.00 
R15 75 10.19 0.91 7.84 8.00 2.00 45.00 5.00 15.00 
R16 540 5.71 0.18 4.11 4.00 1.00 45.00 4.00 8.00 
R17 277 7.24 0.36 5.92 6.00 2.00 45.00 4.00 8.00 
R18 173 7.42 0.43 5.69 6.00 2.00 30.00 4.00 10.00 
R19 111 4.53 0.43 4.50 2.00 1.00 30.00 2.00 6.00 
Total 5948 6.06 0.06 4.66 4.00 0.00 45.00 4.00 8.00 
Table 5-63: Time taken to perform the intervention compared to recommendation 
made (see Chapter 2 or Appendix 3 for definitions of the recommendation codes) 
There was also a clear relationship between the time taken to perform an intervention 
and the documented clinical significance (Kruskal-Wallis χ2 = 122.64, df = 7, p < 0.001; 
Jonckheere-Terpstra t = 20.72, p < 0.001), with those clinical interventions that were 
deemed more significant (S3 or S4) taking a longer time to perform (Table 5-64). 
  
Count Mean 
Std. 
Error 
Std. 
Dev. Median Min. Max. 
25th 
%ile 
75th 
%ile 
S1 908 4.95 0.13 3.88 4.00 1.00 30.00 2.00 6.00 
S2 2505 5.20 0.08 3.73 4.00 0.00 45.00 2.00 6.00 
S3 2119 6.81 0.11 4.85 6.00 0.30 45.00 4.00 10.00 
S4 416 9.85 0.35 7.07 8.00 2.00 45.00 5.00 12.00 
Total 5948 6.06 0.06 4.66 4.00 0.00 45.00 4.00 8.00 
Table 5-64: Time taken to perform an intervention compared to its significance(see 
Chapter 2 or Appendix 3 for definitions of the significance codes) 
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5.5.2 Time to document the intervention 
The participating pharmacists were asked to record only the time taken to perform the 
intervention. Each observer noted how long each intervention took to perform and 
document; therefore, the observer data was used to determine the time required to 
document interventions. The average time taken to document the 279 observed 
interventions was 2.02 ± 1.07 minutes (range = 0 – 8). 
5.5.3 Discussion of time taken to perform and document 
interventions 
On average, it took the pharmacist four minutes to perform the intervention and an 
additional two minutes to document the intervention. In the FRED® dispensing software, 
there was a set of ‘quick selection’ buttons available for 2 minute intervals (2, 4, 6, 8 and 
10 minutes) which appeared to have an effect on the performance time recorded by the 
pharmacists. The most commonly recorded times were 4, 2 and 6 minutes, which 
indicated that the pharmacists mostly used the ‘quick selection’ buttons rather than 
entering their own time in the text box. This may have led to an incorrect assessment of 
the time it took to perform an intervention. However, the results still confirm that the 
average time to perform most interventions is minimal and would have only a small 
impact on the daily workload of a pharmacist. 
The category of intervention appeared to affect the time taken to perform the 
intervention with compliance, undertreatment, monitoring and toxicity interventions 
having a higher median time than the other categories. This was likely caused by these 
interventions requiring more patient interaction and more counselling, and therefore 
requiring more of the pharmacist’s time to resolve. Pharmacists also reported that the 
more significant interventions took longer to perform, which would again be the 
interventions that took more time to resolve. 
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5.6 Conclusion 
Pharmacists had varied intervention rates during the trial, with several factors identified 
that may have contributed to these differences. The multivariate model revealed several 
factors that were important in the prediction of a pharmacist’s intervention rate: number 
of annual CPD hours, the level of training, clinical knowledge survey score and adaptability 
score. Pharmacists with a higher number of annual CPD hours, a higher level of training 
and a higher clinical knowledge may have a better ability to detect DRPs and be more 
aware of the trial, thus increasing their intervention rate. The inclusion of the adaptability 
score variable also indicated the importance of the pharmacist’s attitude on their ability to 
provide professional services. Chapter 6 will examine ways in which intervention rates can 
be improved through utilising this information. Workload did not appear to be an 
important factor in predicting a pharmacist’s intervention rate, which could be attributed 
to the workload measure being used for this analysis being a poor predictor for actual 
workload at an individual pharmacist level. 
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6 Chapter 6: Qualitative analysis of influencing factors 
In addition to the characteristics of the pharmacy and pharmacist that could be 
quantitatively measured, the barriers and facilitators to performing and documenting 
clinical interventions were also analysed qualitatively. The data for this analysis was 
obtained via three methods: focus groups, observation and a software usability survey. 
 Focus groups were conducted with 30 owners and managers of participating 
pharmacies to establish their opinions and perspectives on clinical interventions. 
 Each observer was asked to document the barriers and facilitators they noticed for 
each pharmacist and pharmacy they observed. These observations were also 
discussed and explored in a focus group attended by all observers. 
 A software usability survey (see Appendix 14) was sent to 531 participating 
pharmacists. A total of 304 completed surveys were returned giving a response 
rate of 57%. 
A number of factors were identified by the participants of the focus groups and the 
respondents of the software survey. Figure 6-1 illustrates these factors, which will be 
discussed within this chapter. 
 
Figure 6-1: Summary of influencing factors to performing and documenting 
interventions 
6.1 Pharmacy factors 
The qualitative themes that were identified at a pharmacy level will be discussed within 
the following section. 
330 | P a g e  
 
6.1.1 Dispensing volume 
Some observers commented that in some pharmacies with high prescription volume, the 
pressure to maintain a high prescription output lessened the chances for the identification 
of DRPs. This was also raised in the owner/manager focus groups who reported that 
pharmacies often focus on processing the greatest number of prescriptions possible, as 
they are remunerated largely through the dispensing of prescriptions. Both focus groups 
reported that this trend reduces the pharmacists’ ability to recognise and document 
clinical interventions as they are spending less time with consumers, where a number of 
interventions could be detected through these interactions. 
Interestingly, and to the contrary, some observers also reported that the some of the 
quieter pharmacies with a low prescription turnover also performed a lower number of 
interventions. This was possibly due to decreased ‘flow’ of consumers coming into the 
pharmacy, resulting in a decreased opportunity to perform interventions. The observers 
also noted that the staff in quieter pharmacies tended to be more focused on business 
activities rather than clinical activities, therefore decreasing the number of interventions 
performed. 
6.1.2 Staff experience 
Observers reported that poorly trained staff were a barrier to interventions, as these staff 
were receiving and handing out prescriptions to consumers, but may not have the training 
to bring potential DRPs to the attention of the pharmacist. One observer stated that; 
“Your staff should have a minimum amount of training to recognise when there 
could be a potentially dangerous situation and refer back to you.” 
Another observer described an experience as; 
“There was an instance where a girl in the shop came into the dispensary and got a 
pack of 72 Nurofen Plus® and sold it before the pharmacist had a chance to stop it. 
That was because the staff weren’t trained or didn’t care” (NB:- at the time of the 
trial, a 72-pack of Nurofen Plus® was a ‘Pharmacist Only’ or schedule 3 product, 
and therefore the pharmacist was legally required to be involved with the sale) 
Observers reported that pharmacists and pharmacy assistants who had clearly defined 
roles within the pharmacy facilitated the performance of clinical interventions. They 
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suggested having one pharmacist concentrating on counselling consumers and another on 
dispensing tasks. This increases consumer contact and incorporates more routine 
counselling whilst improving the potential for identifying DRPs. Observers also suggested 
that pharmacy assistants should have a clear understanding of their role, and of the 
responsibilities of the other staff members. When there are no gaps in responsibilities, 
there would be an increased chance of DRPs being identified and acted upon. 
6.1.3 Staffing levels 
Both observer and owner/manager focus groups revealed that time restrictions were a 
barrier to performing some interventions and to documenting them. The observers 
reported that some pharmacies with low staffing levels (high prescription to dispensary 
staff ratio) had less time for consumer counselling. One observer stated; 
“I think the staff are a major issue… if you haven’t got that support you are 
overwhelmed and you can’t make interventions that you should do” 
Furthermore, low staffing levels within a pharmacy meant that many pharmacists worked 
longer shifts with few meal breaks which increased fatigue, reduced concentration and, 
ultimately, inhibited ability to recognise DRPs. One of the observers reported that: 
“I think one of the barriers is the long hours, they are there almost 12 hours, and 
they are stuffed and tired. It is mind numbing. They are not interested in doing any 
interventions” 
6.1.4 Dispensary workflow practices and routine 
Observers reported that pharmacy layouts including forward dispensing arrangements 
and easily accessible consumer counselling areas enabled pharmacists to interact more 
with consumers and facilitated the performance of interventions. This was supported by 
the owner/managers who said that, in some cases, it was easier to record the intervention 
into a consumer’s history at the forward terminal. They reported that only a few 
pharmacies had terminals at the receiving point for dispensed prescriptions, so there was 
potential to improve the level of documentation with additional computer terminals.  
“We’ve got enough computers too….We’ve got them on the front, we’ve got one on 
each bench, and then one in the consulting rooms as well, so it doesn’t matter, 
you’ve got to take like 5 steps and you're on a computer, it makes it easy” 
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From the observers’ point of view, there were two main work systems that seemed to 
facilitate clinical interventions. The first was adequate dispensary staffing, as mentioned in 
section 6.1.3. Pharmacies with adequate numbers of dispensing staff or with work rosters 
that avoided long dispensary shifts tiring pharmacists facilitated the performance of 
interventions. The owner/managers also noted that some pharmacies were dispensing 
above the recommended 150-200 prescriptions per day per pharmacist169, suggesting that 
some pharmacies needed to employ more staff. Two of the owner/managers stated that: 
“If you are doing 500 to 600 prescriptions a day the last thing they will want to do 
is document clinical interventions.” 
“A lot of places are working on (a basis of) staff turnover but we need to think of 
staff to workload in the dispensary. There needs to be adequate dispensary staff to 
enable adequate staff to patient contact.” 
The observers also recognised that balanced pharmacy roles facilitate clinical 
interventions. In particular, pharmacists should have equilibrium between their business 
and clinical roles. One observer reported that: 
“Some (pharmacists) get into stock control and they don’t want to do anything 
else.” 
Aged care facility medication packing and related administrative issues were also 
considered a distraction from dispensing, as well as telephone calls, and patients talking to 
the pharmacist during the dispensing process.  
6.1.5 Professional services 
The observers generally noted that some pharmacies with more professional services had 
lower intervention rates due to the increased pharmacist time needed to offer the service. 
On the other hand, some observers noted that these professional services actually 
increased the intervention rates within some pharmacies. Again, this may be due to the 
staffing within the pharmacy. If the staffing levels are adequate, then the pharmacist can 
devote more time to delivering the professional services and, therefore, have more time 
to perform clinical interventions. 
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6.1.6 Community  
The observers also felt that the surrounding community also had an influence on the 
number of interventions performed, including the local GP practices and the typical 
patient demographics (e.g. young versus an elderly population) within the area. 
6.1.6.1 General practitioners 
The observers felt that the receptiveness of the local GPs influenced the resolution of the 
DRPs. For example, one observed pharmacist was apprehensive about contacting the local 
GP due to a previous adverse discussion. As a result, they were more comfortable 
dismissing the intervention rather than making contact. In areas where the GPs were 
approachable and the pharmacy had good rapport with the surgery, there seemed to be 
an increase in the number of interventions that were resolved. 
6.1.6.2 Consumers 
Consumers were observed to affect the pharmacy intervention rate in several ways. 
Firstly, pharmacies where the ‘traffic’ tended to be regular patients (as opposed to tourists 
or one-off patients, for example) appeared to have a higher intervention rate. This was 
thought to be due to the pharmacies having extensive histories for these consumers, as 
well as the consumers being familiar with the staff and more likely to interact. 
Secondly, language barriers also influenced the performance of interventions. Observers 
noted that several pharmacies had a large consumer base of migrants who did not speak 
English. This sometimes meant that the pharmacist was relying on the shop assistants to 
act as translators between themselves and the consumers, thus some information may be 
lost in translation and some DRPs may not have been identified. 
Lastly, the attitude of the consumers also affected the intervention rate. The observers 
noted that some pharmacies had consumers that believed the doctor was always right and 
were very resistant to any change suggested by the pharmacist. This made the 
implementation of the intervention difficult. One observer noted that one pharmacy had 
consumers that felt the following way: 
“I am here for you to dispense and then I leave. I don’t want to listen to this 
nonsense about you wanting to save my life” 
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6.1.7 Computer issues 
Computer issues were one of the main factors influencing documenting interventions and, 
as such, the observers and owner/managers recognised good computer capabilities as a 
main facilitator. 
6.1.7.1 Access to a terminal 
The observers reported that pharmacies with only one computer terminal were less likely 
to document their interventions. This was due to the terminal always being used for 
dispensing purposes and pharmacists did not want to interrupt the dispensary workflow. 
One observer commented: 
“Sometimes it is about the number of computers. I had one pharmacy that had one 
computer and if they are dispensing, they were dispensing, they are not going to 
record as well” 
The observers felt that an additional computer terminal to allow documentation without 
interrupting the dispensing process would facilitate documentation. The observers 
suggested that it could be in the counselling area, as used in forward dispensing, or in the 
dispensary. 
6.1.7.2 Speed of the computer 
In general, the results of the software survey showed that respondents reported no 
barriers to the use of the PROMISe software interface. However, there appeared to be 
mixed reports regarding the effect of the PROMISe interface on the speed of the 
dispensary computers. Twenty-nine percent of participants reported the speed of their 
computer slowed due to the PROMISe software, whereas 47% of participants disagreed 
and 24% of participants felt no effect. In addition, two pharmacists (one each from FRED® 
and Aquarius®) reported that during the trial that the user interface slowed their 
computer to the extent that they required technical support from the software company. 
6.1.8 Software 
The observers noted that some pharmacies were documenting clinical interventions in 
another system (as this was already the practice within the pharmacy), which increased 
the workload of the pharmacist by duplicating the process. This was occurring as the 
pharmacy was aware that the PROMISe system would be switched off at the end of the 
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trial and therefore the records may not continue in the form they were used to. This 
barrier would most likely be overcome if the software system was permanently installed 
as the pharmacist can use the PROMISe system without the fear that the records would be 
lost.  
The lack of available software within the no software pharmacies was also identified as a 
barrier. Therefore, the existence of an easy to use documentation system for clinical 
interventions itself (such as the PROMISe software) created greater awareness of DRPs 
and their documentation. An observer reported that: 
“If the documentation process is easy and simple then they will document… or if 
they perceive it to be easy” 
6.1.9 Discussion of the qualitative analysis of pharmacy factors 
Many of the same factors that were identified within the bivariate analysis and 
multivariate analysis (see Chapter 4) were also reiterated within the qualitative analysis. 
As seen in the bivariate and multivariate analyses, the observational study and the post-
trial focus groups also reported that higher prescription volumes decreased the chances to 
detect DRPs and document interventions. However, the observers also identified that very 
low prescription volumes also led to a decreased number of interventions being 
performed, due to less opportunity to intervene. This ‘J-curve’ effect was also noted by 
Rupp et al. in his original study in 198857, where the authors commented that the number 
of interventions performed would increase as prescription volume increased, until a 
theoretical ‘cut-off point’ was reached, and thereafter the number of interventions would 
decrease due to the high workload. It is also possible that pharmacists working in less busy 
pharmacies also have a decreased ability to detect DRPs as their skills would not be used 
as regularly. This may lead to a decrease in the number of interventions performed due to 
a lack of experience and possibly a lack of confidence. The effect of the pharmacist’s 
attitude will be explored further later in this chapter. 
The observational study also revealed that workload can be affected by the level of 
adequate staffing within the pharmacy. They identified two components that contributed 
to adequate staffing levels, with both an adequate number of staff being required within 
the pharmacy to handle the workload and the staff also needing to be adequately trained 
to cope with the demands of the workload. The pharmacists working with pharmacy 
336 | P a g e  
 
assistants that had additional training and clearly defined roles within the pharmacy often 
had higher intervention rates. This was most likely due to an increased ability of the 
pharmacy assistant to detect possible DRPs, which were then referred to the pharmacist, 
resulting in an increase in completed interventions. Additionally, adequately trained staff 
may decrease the pharmacist’s workload and increase the time available for the 
pharmacist to detect and resolve DRPs. 
The finding that catering for ACFs decreased the intervention rate within the pharmacy 
was also noted in the observational sub-study. The observers found that catering for ACFs 
could be a distraction from the dispensing process, due to an increase in phonecalls, 
additional paperwork and checking medication packs. In turn, this decreased the amount 
of time that the pharmacist spent on performing and documenting interventions, thus 
decreasing the pharmacy’s intervention rate. 
The finding that offering professional services decreased intervention rates was also seen 
within the observational study, where the observers found that an increased number of 
professional services increased the amount of time that the pharmacist spent on these 
additional services. This decreased the available time that the pharmacist could spend on 
detecting and resolving DRPs, resulting in a lower intervention rate. 
Both software and no software pharmacies were observed during the observational study, 
with observers reporting that the presence of the PROMISe software increased the 
documentation of interventions and therefore, increased the pharmacy’s intervention 
rate. This was expected, as the presence of the software would increase the pharmacist’s 
awareness of the trial, resulting in a larger number of interventions being documented. 
6.2 Pharmacist factors 
The study also aimed to identify the perceived and actual barriers and facilitators to an 
individual pharmacist performing and documenting clinical interventions. Again, Figure 6-1 
shows the factors that may have influenced the pharmacist’s intervention rate. 
The findings from the focus groups revealed that some interventions may not have been 
documented because pharmacists failed to recognise them as an intervention or were not 
rewarded for the documentation. It appears the reasons for this are twofold; intervening 
is routine practice for pharmacists and therefore pharmacists fail to recognise an 
intervention, and, in addition, some pharmacists lack the clinical knowledge to recognise 
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the need for a clinical intervention in the first place. Many of the qualitative findings 
reinforced the results found during the quantitative analysis. 
6.2.1 Intervening is second nature 
The owner/manager group discussion revealed that pharmacists often did not identify 
their recommendations for minor DRPs as interventions, since intervening is second 
nature to most pharmacists. This conclusion was supported by the results of the observer 
focus group which showed that pharmacists would perform interventions instinctively, 
without actually recognising their actions were an intervention. The observers estimated 
that only approximately 50% of the interventions they observed were actually 
documented by pharmacists and those that were missed were suspected not to be 
recognised as interventions. 
6.2.2 Clinical knowledge 
The observers reported that in many cases the pharmacist’s clinical knowledge and how 
they used this knowledge was an important driver in the performance of interventions. 
One observer stated that; 
“The knowledge has to be there to do interventions…” 
And another extended this by saying; 
“I think it is more about the practice, which is to say, if you have got into the habit 
of being vigilant for interventions then you are more likely to do it… You can have 
all the knowledge… but it doesn’t occur to you to make an intervention” 
However, observers also reported some interventions that were missed by pharmacists 
who were not equipped with adequate clinical knowledge. As one observer said; 
“I was in two pharmacies that were really, really quiet and things that could have 
been done were completely missed and that probably goes back to the knowledge 
of the pharmacist. So staffing is not the only reason interventions are not done.” 
The results of the software survey showed that 83% of participants believed that they had 
good clinical knowledge compared to 2% who disagreed and 15% who reported neutral 
feelings. In addition, 80% of participants believed that the trial had increased their 
awareness of how many clinical interventions they performed. 
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The observers said that continuing education and staff training could be used to improve 
clinical knowledge. The observers found that AACPA pharmacists tended to be more 
clinically aware and performed a greater number of clinical interventions than other 
pharmacists. One observer reported that; 
“Accredited pharmacists on staff made a difference as they were looking for them 
(interventions)” 
6.2.3 Purpose for documenting 
The outcome of the observer focus group found that the observers believed there was 
little incentive for employee pharmacists to document interventions because the $1200 
participation payment for the trial was made only to pharmacy owners (who could choose 
to pass on the remuneration if desired). The owner/managers reported a similar facilitator 
stating that there was a need to reward employee pharmacists to ensure that 
documentation of clinical interventions was carried out. Furthermore, it was reported that 
some employee pharmacists believed that there was no tangible purpose to documenting 
minor interventions. They perceived no health benefits and in turn saw documenting 
simply as an addition to their workload. 
6.2.3.1 Personal satisfaction 
The owner/manager focus group felt that a pharmacist’s sense of personal satisfaction 
was a driver for performing and documenting interventions. In particular, the 
documentation of the intervention was a confirmation of its importance and this 
perceived importance would induce some pharmacists to conduct and document more 
interventions. One owner/manager reported that;  
“I found it pretty rewarding as it reminds you of the job you are actually doing. All 
the things you can take for granted you are actually documenting.” 
6.2.3.2 Medico-legal concerns 
The observers reported that pharmacists were most likely to document clinical 
interventions in cases where they have dispensed an item against their better judgement, 
for example, when there has been a disagreement with the prescriber. An observer 
reported that; 
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“Some who have their hand forced to dispense something they are not completely 
comfortable with, will document” 
6.2.3.3 Good feedback 
The observers noted that a driver for documenting interventions was when pharmacists 
received good feedback. Pharmacists would benefit from positive reinforcement on 
interventions and it would be useful to know that a GP had responded to a 
recommendation and the outcome. As one observer put it; 
“At the end of the day ultimately we are all like lab rats… we all like a pat on the 
back… now whether that reward is money, CPD points or the knowledge that you 
have done a good thing… we all want that pat on the back…But what we want is 
payback, some reward for doing a good job” 
The observers and the owner/managers suggested that allocating CPD points directly to 
employee pharmacists could overcome this issue and improve intervention rates. 
6.2.4 Interactions with the consumer  
The observers stated that some pharmacists had low consumer contact due to them being 
‘wedded’ to their dispensing terminals, and the owner/manager focus group reinforced 
this conclusion. They both agreed that the minimal interaction with patients reduced the 
chance of pharmacists identifying DRPs and performing interventions. One observer 
reported; 
“They (some pharmacists) put the dispensed script there for someone else to hand 
out. They don’t want to go out into the pharmacy” 
The focus groups felt that one way to overcome this and to drive an increase in the level 
of interventions would be to encourage pharmacists to counsel consumers when handing 
out all prescriptions. 
The observers reported that pharmacists with good communication skills and a willingness 
to engage consumers in conversation were more likely to have higher intervention rates. 
One observer described a situation with a pharmacist who engaged the patient; 
“There were so many things that came up in conversation which were not directly 
asked about” 
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Furthermore, the observers noticed that recommendations from pharmacists were more 
accepted by consumers when rapport and trust had been established in the relationship. 
As mentioned previously, good communication between GPs and pharmacists also 
encouraged pharmacists to intervene and make clinical interventions, particularly when 
GPs provided pharmacists with feedback from the actions taken as a result of a 
recommendation. 
6.2.5 Workload 
The most commonly reported barrier amongst the observed pharmacists was the amount 
of ‘other’ tasks that the pharmacist was performing. Many observed pharmacists were the 
owners that had administration tasks to attend to during the day, thereby decreasing the 
amount of time spent dispensing and interacting with the consumers.  
The observers also noted that overall higher workloads within the pharmacies and the 
dispensaries decreased the abilities of the individual pharmacists to perform and 
document interventions. This was generally due to inadequate staffing levels or poorly 
trained staff, which decreased the amount of time the pharmacist could spend on clinical 
services. 
The observers reported that when pharmacists were busy, only the more potentially 
serious interventions were performed. In addition, the owner/manager respondents 
reported that some pharmacies were so busy in periods that there was no time to 
document immediately after an intervention occurred, where pharmacists would 
document later in the day if they remembered. An observer stated that; 
“It is not the time taken to document but rather when it happens you may not have 
time to deal with it then” 
6.2.6 Entrenched work practices 
The owner/managers pointed out that the adoption of a new procedure took time to 
establish into a dispensary workflow. During the trial, pharmacists adapted their workflow 
by using strategies to incorporate the documentation of interventions. The software also 
had features to improve documentation, such as the ability to save an empty draft in a 
patient’s history as a reminder to later document the intervention. One pharmacy was 
observed to have a highlighted tag system so dispensing assistants could initiate a draft in 
a patient’s history for the pharmacist to complete at a later time. Pharmacists were also 
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seen to make notes on a writing pad with the patient’s name. An owner/manager 
reported that strategies such as these should be included in training;  
“It would be good to have it as the first point of training…It is like scanning as that 
was hard to get used to.” 
Both the owner/manager and observer focus group participants reported the physical 
dispensing routine being a barrier to identifying interventions. The owner/managers 
reported that pharmacists have difficulty incorporating the documentation of clinical 
interventions into the current workflow of pharmacies, as it requires a change to their 
current dispensing routine. 
“You would not put a script through and not put a label on as it is part of the 
process… if you make interventions (and documentation) part of the process by 
saving a draft, then it will happen” 
Observers reported that some pharmacists already had poor dispensing systems, where, 
for example, the supervision of the provision of Pharmacist Only (or schedule 3) medicines 
was not always performed, patient history checks were not always completed during the 
dispensing process if conducted by a dispensary assistant, and where pharmacy assistants 
would take in prescriptions and hand out dispensed items. This may further decrease the 
likelihood that the pharmacist would change their practice, as they already had a poor 
practice in place. Due to this, the observers felt that pharmacists who adhered to quality 
practice guidelines, such as Pharmacist Only medicine counselling and checking patients’ 
histories, were more likely to perform interventions. 
6.2.7 Remembering to document 
Owner/manager pharmacists reported that one of the greatest causes of low 
documentation rates was due to forgetting to enter the intervention details into the 
computer software. Some of the owner/managers reported that even when there was 
time to create a draft and save it under the patient history, they could not recall the 
specific intervention details when it came time to completing the draft at the end of the 
day. It was suggested that unless dispensing routines were modified to include 
documentation, then documentation was often forgotten. One respondent reported; 
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“If they were in a middle of a pile of scripts and they needed to document 
something, then often it was forgotten” 
Another observer stated that; 
“I have been in both Promise II and Promise III so I have a good idea what an 
intervention is, but it is remembering to document it” 
Similarly, observers reported that pharmacists would become distracted by internal and 
external factors which meant that the rate of which interventions were performed was 
reduced. One observer reported; 
“There were always things that were distractions which prevented them from doing 
it. Another script comes in and they forget” 
6.2.8 Attitude 
The observers noted that the pharmacist’s attitude to their pharmacy practice largely 
influenced their intervention rate. Those pharmacists who were more pro-active and 
engaged with the patients on a regular basis were more likely to perform and document 
interventions. 
Some observers reported experience as being a driver for performing interventions, 
whereas others reported higher intervention rates in the graduate or newly registered 
pharmacists. It is possible that this was linked with the level of clinical knowledge (section 
6.2.2), where both experience within the pharmacy and also recent graduation could 
increase the pharmacist’s level of clinical knowledge and their ability to detect DRPs. 
6.2.9 Training 
The owner/managers also recognised both the face-to-face and online training as a driver 
for identifying DRPs and documenting interventions, as they improved the pharmacist’s 
knowledge in the area of DRPs. The respondents said that case histories with the inclusion 
of the classification and likely outcome should an intervention not occur were a good 
means of training in PROMISe III. The owner/managers mentioned that including the 
documentation of clinical interventions into undergraduate training would be important if 
the system becomes commonplace. 
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The observers also noted that the level of training within the PROMISe software and 
DOCUMENT system also affected the pharmacist’s intervention rate. For example, locum 
pharmacists who were observed were unfamiliar with the system and therefore this 
decreased the number of interventions performed and documented. Conversely, 
pharmacists who had completed training and were aware of the definition of a clinical 
intervention were more likely to perform and document interventions. 
This underscores the importance of continuing education to maintain a high standard of 
clinical and practical knowledge, and thereby increase the identification of DRPs. 
Furthermore, good staff training means that pharmacy assistants are more likely to 
recognise potential DRPs and refer to the pharmacist. 
6.2.10 Software 
As mentioned in the previous section, observers felt that the presence of the PROMISe 
software increased the number of interventions performed and documented. From the 
software survey, it also appeared that the majority of pharmacists (86%) felt the overall 
system was easy to use. However, the observers noted that pharmacists with poor 
computer skills had a decreased intervention rate, which may be due to their inability, or a 
perceived difficulty, to use the software. These pharmacists may have also been unlikely 
to complete the online surveys, making it difficult to interpret their thoughts about the 
software. For these pharmacists, they received an opportunity to comment on these types 
of problems during the post-trial focus groups, however, very little negative feedback was 
received with this survey. 
6.2.10.1 Complex classification system 
The findings from the owner/manager focus group revealed that some pharmacists had 
difficulties with the classification of interventions. Some respondents reported that when 
problems arose with classifying interventions, there was a tendency to delete the 
intervention rather than spend time on its categorisation. One of the respondents stated 
that; 
“If I am still not sure how to classify an intervention, I just cancel out of it.” 
In addition, respondents to the software survey reported that; 
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“Sometimes I find it hard to classify the type of intervention and putting into 
category as each scenario tends to be unique.” 
“Even with all the practice examples and DOCUMENT system help, I personally still 
find it difficult to categorise interventions and it tends to stop me doing them.” 
Despite these results, it appears that the majority of the participants were satisfied with 
the number of classifications. When asked if ‘the number of DOCUMENT intervention 
classifications should be increased’, 231 (87%) pharmacists responded ‘No’ and 36 (13%) 
responded ‘Yes’. When asked if ‘the number of DOCUMENT intervention classifications 
should be decreased’, 225 (84%) pharmacists responded ‘No’ and 42 (16%) responded 
‘Yes’. Overall, 190 (71%) pharmacists thought that the number of classification categories 
was optimal, responding with ‘No’ to both questions.  
6.2.10.2 Prompts 
There were differing opinions about the use of the prompt from the owner/managers; 
some thought it was useful whereas others found it annoying. The most annoying times 
for the prompt to appear was when a patient had been counselled at a previous 
dispensing on the same issue, and when the dispensary was busy and the identified DRP 
was minor. As such, the owner/managers suggested that pharmacists should have control 
over the appearance of the prompt. These suggestions included the ability to turn the 
prompt off, restricting the prompt to a pharmacist’s initials and restricting the prompt to 
certain times of the year or public health events. 
The respondents of the software survey were also asked about the prompt. Of the 89 
pharmacists who answered the question, 34 (38%) felt the prompt was annoying, with 28 
(32%) disagreeing and 27 (30%) having neutral feelings. The majority also reported 
wanting the function to switch off the prompt for patients and/or switch off the prompt 
completely (77% and 92% respectively). Interestingly, 83% preferred not to restrict the 
prompt to pharmacist’s initials. The respondents also reported wanting the prompt to 
change regularly to avoid repetition (67%), with many believing the best option was to 
coincide the prompt with NPS releases (48%). 
All owner/managers agreed that it is beneficial to coordinate prompts with public health 
initiatives, such as diabetes and cardiovascular disease campaigns. 
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“I’ve seen some very clever pop ups … you’ve got somebody on diabetic medication 
and it does a check and sees if they’re on aspirin, …, and then you go out and say 
‘are you on aspirin’ and then you do that until you’ve done it to death, and you go 
in and switch it off and say ‘I’ve had enough of that pop up’ you know, and you’ve 
got a function in there that you can actually turn it off, and then next month you 
might get another one and you can have a go at that…” 
The observers also pointed out that a prompt or report to remind pharmacists of 
incomplete records within the system would facilitate intervention documentation. 
However, the majority of respondents to the software survey (69%) reported that a more 
prominent reminder to complete draft interventions was not necessary, while only 31% 
reported it was necessary. Of the respondents, 58% believed that a button on the 
dispensing screen to log a draft intervention for later completion would be beneficial. 
6.2.10.3 General reminder 
Of the pharmacists who completed the software survey, 208 were exposed to the general 
reminder during the trial. Of these pharmacists, 77 (37%) felt the reminder was annoying, 
with 62 (30%) disagreeing and 69 (33%) having neutral feelings. 
6.2.11 Discussion of qualitative analysis of pharmacist factors 
Many of the influencing factors identified within the quantitative analyses were also noted 
as influential within the observational substudy and post-trial focus groups, with 
workload, clinical knowledge and pharmacist attitude being common themes throughout 
the qualitative analysis. 
Workload was the most commonly reported barrier amongst the observed pharmacists, 
with many ‘other’ tasks impacting on the number of interventions performed and 
documented. Despite this, the observational sub-study workload analysis only showed one 
significant correlation with intervention rate, where the intervention rate decreased as 
the number of Safety Net cards issued increased (see section 5.4.3). This is most likely due 
to Safety Net cards taking extra time; therefore, increasing the pharmacist’s workload and 
resulting in a decreased number of interventions performed. None of the other 
pharmacist tasks correlated with intervention rates within the observational sub-study, 
despite the observers noting that the amount of administrative tasks the pharmacist 
undertook was a barrier to performing and documenting interventions (section 6.2.5). 
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Two Irish studies have previously reported that around 20% of a pharmacist’s time was 
spent on non-professional activities that could be performed by non-pharmacist 
staff116,117; therefore, by decreasing the amount of time pharmacists spend on non-
professional duties, the number of interventions performed and documented could be 
increased. 
Lack of adequate staff tends to lead to a higher pharmacist workload, as evidenced by the 
observer data (section 6.2.5), which may lead to a decreased intervention rate. This is 
inkeeping with a pharmacist survey in the USA which showed that 89.6% of pharmacists 
felt that inadequate staffing levels prevented their uptake of a medication management 
service.109 The pharmacists within the PROMISe trial and the observational sub-study also 
reported that lack of staff was a significant contributor to their intervention rate. 
Interestingly, the number of other pharmacists present during the pharmacist’s shift did 
not appear to correlate with their intervention rate. It would be expected that the number 
of pharmacists present would be an indicator of the workload within the pharmacy, so it 
was interesting that the average number of other pharmacists present was not associated 
with the intervention rate of the pharmacist, and may indicate that the belief of not 
having enough staff has a stronger influence on pharmacist participation than the actual 
lack of staff. 
Perhaps the most interesting finding in regards to workload was within the observational 
sub-study, where a significant correlation between prescription volume and performed 
intervention rate was found whilst no correlation was found between prescription volume 
and documented intervention rate (Table 5-57). This may indicate that workload does not 
affect the number of interventions that are documented, however it does affect the 
number of interventions that are performed. It is possible that a heavy workload impacts 
on the number of time-consuming, or perhaps less important, interventions that are 
performed, where the pharmacist finds themselves too busy at that particular time to 
perform the intervention. Although only a small sample of pharmacists were observed, if 
this finding was extrapolated out to the general pharmacist population, it could indicate 
that many interventions were simply not performed due to workload and the number of 
missed interventions will never be known. 
Clinical knowledge was closely linked with the pharmacist’s intervention rate within the 
bivariate and multivariate analysis, and the observers also commented that clinical 
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knowledge was extremely important as they had seen several missed intervention 
opportunities due to the pharmacists’ lack of knowledge. 
The attitude and motivation of the pharmacist was also noted to be an influential factor 
on the intervention rate of observed pharmacists, with observers noting that the more 
motivated and enthusiastic pharmacists tended to have a higher intervention rate than 
their less enthusiastic counterparts. The observed pharmacists who were more proactive 
and engaged with the patients on a regular basis were more likely to perform and 
document interventions. Entrenched work practices, which specifically reflect a 
pharmacist’s past behaviour, were also reported as a major barrier to performing and 
documenting interventions during the observational sub-study. This result was also found 
by Odedina et al.141, who found that the most important predictor of behaviour was past 
behaviour. This indicates that practice change is required before a pharmacist can 
effectively offer additional professional services, as the pharmacist’s attitude appeared to 
be closely linked with their intervention rate with the more motivated and enthusiastic 
pharmacists participating more effectively in the trial.  
The PROMISe focus groups also revealed that intervening is second nature for many 
pharmacists and that they perform interventions automatically without stopping to realise 
that their action was an intervention. The observers also noted that interaction with 
consumers is one of the main drivers to performing interventions and the level of 
interaction was often a factor of the pharmacist’s attitude. Distractions were also a 
problem for many pharmacists, which could also be attributed to the pharmacist’s 
attitude and work practice, as the level of disruption that the distraction causes may be 
dependent on the individual pharmacist. 
6.3 Conclusion 
The qualitative analysis of the results from the focus groups, software survey and 
observational sub-study reinforced many of the findings within the bivariate and 
multivariate analyses within Chapters 4 and 5. Workload and dispensing volumes were 
found to significantly impact on the pharmacist’s ability to perform and document 
interventions, both within the qualitative and quantitative analyses. However, the 
qualitative analysis revealed that it is not absolute volumes that are always the biggest 
impact, but that factors such as inadequate staff training, additional professional services 
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and pharmacist attitude can also significantly impact on workload and cause further 
decreases in the pharmacist’s ability to perform and document clinical interventions. 
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7 Chapter 7: Improving intervention rates 
There are two facets to improving the documentation intervention rate; increasing the 
number of interventions performed and also increasing the number of interventions 
documented. As was seen in Chapter 3, an average clinical intervention performed in 
community pharmacy saved the Australian Government $360164, so it is reasonable to 
assume that improving the number of interventions performed would have a substantial 
positive impact on reducing healthcare expenditure within Australia. A reduction in 
healthcare expenditure has also been shown in other clinical intervention studies.32,168 The 
observational sub-study found that pharmacists only documented half of the 
interventions they performed. Although an increased documentation rate may not 
increase the actual number of CIs performed, improvements in the documentation rate 
are clearly desirable, as this will lead to more comprehensive patient records, and also 
provide key insights into the nature of DRPs that are resolved by pharmacists. 
7.1 Improving the documentation rate of the pharmacy 
Several factors were found to be associated with the intervention rate of the pharmacy 
and modifying these factors may help to promote a higher rate of intervention 
documentation. The results from both the bivariate and multivariate analyses have been 
considered within this section. 
7.1.1 Software 
The PROMISe software was integrated into the dispensing systems of participating 
pharmacies, and pharmacists typically found it was intuitive and easy to use. It was also 
successful in capturing the required data for subsequent analysis by the research team. 
Overall, the software was considered a success, with the feedback gained from 
participants being very positive. However, before a national implementation of this 
program could be considered, the PROMISe final report recommended that several minor 
flaws be addressed.164 These amendments aimed to improve usability of the system as 
well as promote a more complete patient health record. These amendments included: 
 Capturing the date and time that the intervention screen was activated (rather 
than the date and time of submission to the database) to improve reporting for 
workload analysis, so that it is known more accurately when the intervention was 
performed, rather than documented 
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 Capturing the intervening pharmacist’s initials as well as the original dispensing 
pharmacist’s initials, so that it is known more precisely who actually performed 
the intervention, rather than just who dispensed the prescription 
 Real-time separation of the prescription-linked and non-prescription interventions 
to allow separate intervention rate calculations to be provided within the 
feedback displays 
 Improved indication to the users of completed interventions, such as a descriptive 
note in the patient’s dispensing history  
 A context-sensitive information input box to be activated by certain 
recommendation codes (for example, if ‘Dose decrease’ was selected, the 
documenting pharmacist would be asked for the dose before and after the 
intervention) and a mandatory notes section to help ensure that adequate 
information was documented with each intervention 
 The ability to link with e-health records in the future to increase the accuracy of 
patient histories 
 Improved messaging systems and regular auditing to ensure consistent data 
within the database 
 Creation of a reminder to encourage patient follow-up after an intervention 
 Allowing intervention documentation with point-of-sale (POS) software to 
improve the documenting of OTC interventions 
 Standardising the drug codes used by the dispensing software companies to allow 
more consistent data records within the database 
Adjustments to the software system, such as the abovementioned improvements, would 
lead to improved usability of the documentation system, as well as a more accurate 
patient record.  This would also hopefully increase the intervention rate of the 
pharmacies, as the documentation system may be seen as easier to use. It would also 
enable more comprehensive analyses and the subsequent development of 
recommendations to optimise the performance of clinical interventions. 
7.1.1.1 Prompt 
Although the prompt did not appear to significantly influence the intervention rate 
overall, there did appear to be a significant trend from Group One (software only) to 
Group Three (software with reminders and prompts), where the intervention rate 
increased as the group number increased. This non-significant finding was most likely due 
to the specificity of the targeted medications, as the prompt was only activated on 3.8% of 
the total prescriptions dispensed, which may not have been a large enough percentage of 
prescriptions to influence the overall intervention rate. The prompt significantly increased 
the number of interventions documented for esomeprazole and pantoprazole, the two 
medications that triggered the appearance of the prompt. As discussed in Chapter 4, this 
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was assisted by the prompt being interruptive and having to be dealt with before the 
dispensing process could continue. There was also no software feature that allowed the 
pharmacist to indicate that the intervention was due to the prompt and as a result, it is 
possible that the prompt data extraction method would have underestimated the true 
number of prompted interventions. Therefore, it is possible that the actual number of 
prompted interventions was higher than reported. 
The prompt feature was seen as a major advantage of the PROMISe system. It encouraged 
the pharmacists to undertake a specific intervention and, therefore, could be used as a 
platform to increase the pharmacist’s knowledge in certain therapeutic areas. For 
example, the prompts could be linked to NPS campaigns and other national health 
initiatives. This suggestion has beneficial outcomes as the pharmacist’s clinical knowledge 
would improve through the use of educational material linked to the prompt181, as well as 
targeted patients receiving improved medication or disease management as a result. It 
could also be beneficial to target specific medications, such as screening for adverse 
effects of a newly registered medication. 
Some pharmacists reported that the prompt was annoying, and expressed an interest in 
controlling when and how the prompts appeared. A feature that could be explored in the 
future would be the ability to turn off the prompt for a particular patient or for particular 
dispensing pharmacists. For example, it may be appropriate to have the ability to 
deactivate the prompt for specific patients if that particular issue had already been 
addressed with the patient, or they were deemed unsuitable for the intervention by the 
pharmacist. This alone would reduce subsequent inappropriate displays of the prompt, 
and also reduce the effect of prompt fatigue39,134, as fewer irrelevant prompts would 
subsequently be displayed. It may also be an option for a deactivated prompt to 
automatically reactivate after a certain time frame so the patient can be reassessed by the 
pharmacist. 
The number of interventions triggered by the prompt decreased over the period of the 
trial, which could indicate pharmacist fatigue with the prompt. The decline may also have 
been attributed to the group of eligible patients being exhausted after the first six weeks. 
A method for combating this decline could be the introduction of rotating prompts. Focus 
groups with the observers and pharmacists suggested that the prompts could change to 
target a number of specific health-related issues. Prompts could be rotated periodically, 
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for example, during one month it may be triggered by certain diabetic medications 
encouraging pharmacists to discuss issues related to diabetes, and the next month it may 
target patients with asthma. Related professional development modules could be 
developed corresponding with each prompt, or as mentioned previously, the prompts 
could coincide with NPS campaigns (usually four campaigns per annum), which would 
already provide the essential training and assessment for the pharmacist.181 Remuneration 
for the prompted interventions may also provide an incentive to document interventions 
linked to the prompt and, therefore, provide a more consistent rate of intervention. 
As was seen in Chapter 4 and Appendix 22, the prompt feature within the PROMISe 
system was shown to be a cost-saving measure, with the average cost saving being 
$183.60 per pharmacy per year40, leading to a decrease in healthcare expenditure. In 
addition, the prompt has the ability to deliver additional clinical education to the 
pharmacist, which is likely to increase the number of interventions performed and 
improve patient outcomes. 
7.1.1.2 General reminder 
The general reminder significantly increased the number of interventions documented in 
the hour after the reminder appeared. Although this did not appear to influence the 
overall intervention rate of the pharmacy, the spike in the number of interventions 
documented after the reminder was displayed implied that it may have improved the 
pharmacist’s awareness of the trial. Therefore, simple reminders that encourage the 
pharmacist to document their interventions would be beneficial to the system, as this may 
help to combat the declining intervention rate discussed in Chapter 3, in combination with 
the specific prompts. 
7.1.2 Workload 
Pharmacy factors, such as increased prescription volume and pharmacist workload, were 
associated with a decreased intervention rate within the PROMISe trial and have been 
reported within the previous literature.27,61,77,83 Therefore, strategies to overcome these 
barriers need to be developed. Pharmacy owners and managers need to be educated 
about balancing the workload of their pharmacists with professional services, such as 
performing and documenting interventions. The Australian Pharmacy Board and the PGA 
need to start enforcing the recommended maximum prescription volume per hour to 
ensure satisfactory workload models. The PROMISe trial showed that participating 
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pharmacists were seemingly dispensing similar or lower prescription volumes compared 
to the recommended volumes. If pharmacists with lower than recommended workloads 
and prescription volumes are finding that their workloads are significantly impacting on 
their ability to document their clinical interventions, then pharmacists working in 
pharmacies that dispense the recommended ‘safe’ levels would feel an even bigger 
impact. This may indicate that the current ‘safe’ levels also need to be reviewed, which 
may improve the workloads and ability to provide professional services within the current 
pharmacy environment. 
As the current business model remunerates pharmacies based on prescription volume, a 
different model that remunerates pharmacies based on other professional services may 
assist with overcoming barriers associated with workload by providing the potential for 
employing additional staff. For example, remuneration received from a professional 
service, such as documenting clinical interventions, may provide funds to employ an 
additional staff member, thus enabling more clinical interventions to be performed and 
documented, resulting in more remuneration. In addition, the pharmacy media reports a 
current oversupply of pharmacy graduates within Australia182, which unfortunately may 
eventually result in pharmacists working for lower wages. Again, this may provide 
adequate funds to employ an additional pharmacist. Either way, this additional employee 
would decrease the other pharmacists’ workloads and increase the amount of time they 
can allocate to professional services, which in turn would likely increase the number of 
interventions performed and documented. 
Prescription volume and pharmacist workload featured heavily within the bivariate 
analysis, as the majority of factors associated with the pharmacy’s intervention rate were 
also related to prescription volume and pharmacist workload. The size of the pharmacy, 
financial turnover and trading hours were all negatively correlated with intervention rate. 
This was most likely due to the bigger, busier pharmacies having a much higher 
prescription volume and, therefore, usually a higher pharmacist workload, which would 
decrease the amount of time that the pharmacist could spend on professional services.  
The two multiple regression models found that the most significant factors to predict a 
pharmacy’s intervention rate were: prescription volume; pharmacist workload; annual 
financial turnover; location in or near a medical centre; participation in other pharmacy 
trials; and, whether the pharmacy catered for aged care facilities. Prescription volume and 
354 | P a g e  
 
pharmacist workload were also individually related to the other factors and were most 
likely the driving force behind the inclusion of several of these variables. The pharmacies 
with higher financial turnovers and that catered for ACFs had higher prescription volumes 
and pharmacist workloads, whilst the pharmacies located in or near medical centres had 
lower prescription volumes and pharmacist workloads. This showed the major impact that 
prescription volume and pharmacist workload can have on the pharmacy’s intervention 
rate.  
The observational sub-study revealed that the pharmacy and pharmacist prescription 
volumes were significantly associated with performed intervention rate, but not the 
documented intervention rate within the observed pharmacists. This may indicate that 
workload has variable effects on the number of interventions documented, but can also 
affect the number of interventions performed. This finding may indicate that improving 
the workload within the pharmacy will increase the number of interventions performed, 
thus improving patient care. 
Overall, improving the pharmacist’s workload would most likely increase the number of 
interventions performed and documented, increasing the pharmacy’s intervention rate. 
Due to the current remuneration model where pharmacies receive payment for each 
prescription dispensed, pharmacies would not want to decrease their overall prescription 
volume. Therefore, improving the pharmacist’s workload could be best achieved by 
increasing the number of pharmacists and/or trained support staff, resulting in a 
reduction in the pharmacist’s workload without decreasing the pharmacy’s prescription 
volume. Additional remuneration to allow the pharmacy to employ additional staff would 
be most accessible through the remuneration of professional services. The need for 
adequate staffing levels has also been identified in previous studies, where sufficient 
staffing levels have improved participation rates and increased the level of 
participation.53,97,107,109 As suggested by Pai118 and Angelo119, minor alterations to the 
dispensary workflow could also help to improve the pharmacist’s workload, without the 
need for additional staff. 
7.1.3 Professionalism 
During the bivariate analysis, pharmacies that were part of a banner group were also 
shown to have a decreased intervention rate when compared with independent 
pharmacies. Typically, banner group pharmacies tend to be more commercial and 
355 | P a g e  
 
‘supermarket-style’ rather than being ‘professional’ (orientated towards delivering better 
healthcare in a professional manner). This finding has also been noted in previous studies, 
where independent pharmacies in Canada had a higher intervention rate than chain 
pharmacies.65 PROMISe pharmacies that the site visitors remarked as looking ‘healthcare-
orientated’ or ‘professional’ were also associated with higher intervention rates, 
therefore, it may be beneficial to switch the focus of these ‘chain-style’ pharmacies. A 
targeted education campaign within banner group or ‘supermarket-style’ pharmacies in 
the future may help to shift their focus from commercialism to professionalism, which 
may then increase the intervention rate. 
On the other hand, participation in other pharmacy trials was a negative influence on the 
pharmacy intervention rate within the multivariate analysis, where participating 
pharmacies had a lower intervention rate on average compared to non-participating 
pharmacies. It would be logical that pharmacies participating in other trials would have 
been more professional, as participation in these trials aims to further the pharmacy 
profession; however, these pharmacies had a lower intervention rate. This is likely due to 
an increased demand on the pharmacist’s time that additional trials require that may not 
have been measurable using prescription volumes and the pharmacist workload measure. 
Pharmacies need to be encouraged to keep a balance by participating in research to 
improve the profession, but not to overextend themselves, resulting in their multiple 
participations being of poor quality. 
Increasing the professionalism of the pharmacy is especially important with the recent 
decrease in pharmacy reimbursement under the PBS. Previously, pharmacies were 
remunerated for their prescription volume, with bigger profits to be made when 
pharmacies dispensed certain generic brands of medications. From April 1st 2012, price 
disclosure laws came into effect within Australia.183 This lead to the Government dropping 
the remuneration on each brand of medication, which in turn decreased the payments 
available to pharmacies to dispense these medications. In addition, a large number of 
frequently prescribed medications will be coming off patent in 2012, which will lead to an 
even larger number of generic brands hitting the market. This means that pharmacies will 
need to look to additional sources, such as professional services, to increase their income. 
Pharmacy owners and managers therefore need to accommodate this changing 
remuneration model and aim to increase the professionalism of their pharmacy through 
offering professional services. 
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7.1.4 Additional factors 
The multivariate analysis showed that pharmacies located in a medical centre had higher 
intervention rates on average. This is most likely due to the pharmacy having a good 
relationship with the GPs within the medical centre, increasing the pharmacist’s 
confidence and motivation to perform clinical interventions with the knowledge that the 
GPs will seriously consider their suggestions. Although adjusting the location of the 
pharmacy is not achievable in most situations, pharmacies can always strive to improve 
relationships with the local GPs. Encouraging the pharmacies to build better relationships 
with local physicians may increase the number of interventions performed and 
documented. This was also identified by Roberts et al.107 who found that having good 
rapport with local physicians was a key factor in successful change management. 
The multivariate analysis also showed that pharmacies that catered for ACFs had a lower 
intervention rate than pharmacies that did not. This may have been due to two factors. 
Firstly, these pharmacies have an increased number of distractions associated with the 
facilities, such as interruptive phonecalls, additional paperwork and medication checking. 
Secondly, these pharmacies process many prescriptions that do not require interaction 
with the patient, most likely decreasing the number of interventions performed. The 
pharmacies would not wish to lose their contracts with the ACFs, as they provide an 
additional source of income; therefore, other measures need to be adjusted. Improving 
the workloads within these pharmacies, such as utilising a technician to field phonecalls 
and process the paperwork, would increase the time available for the pharmacist to 
document their interventions. Encouraging the pharmacy to document the interventions 
they perform on the medication charts received from the ACFs, as these charts are 
effectively a prescription, may also improve their intervention rate. 
7.1.5 Conclusion 
From the results of the PROMISe III trial, it appears that the intervention rate of the 
pharmacy could be increased by improving the pharmacist’s workload. This could be 
achieved through the regulatory enforcement of appropriate dispensing volumes and the 
employment of additional staff when required. Other pharmacy factors that were 
correlated with the pharmacy’s intervention rate, such as annual financial turnover, 
pharmacy location and catering for aged care, may not be as easily modifiable as 
workload; however, additional support for these pharmacies may allow an increase in 
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their intervention rate. Encouraging the pharmacies to be more selective with the number 
of trials they concurrently participate in may also improve their intervention rate. The use 
of prompts and reminders could also contribute to an improved intervention rate by 
encouraging pharmacists to perform and document interventions that they may not have 
otherwise done. The prompts could be activated to coincide with educational programs 
offered by organisations, such as the NPS, which would facilitate improved health within 
the community as well as improve the pharmacist’s therapeutic knowledge.  
7.2 Improving the documentation rate of the pharmacist 
When provided with the right tools, such as the PROMISe software, all pharmacists have 
the capability to document their interventions. However, individual and environmental 
factors appeared to be associated with their intervention rate. During the individual 
pharmacist analysis, several additional factors were also identified within the pharmacist 
dataset that may help to improve intervention rate of the individual pharmacists, which in 
turn would improve the intervention rate of the pharmacy and, ultimately, improve 
patient outcomes. 
7.2.1 Demographics 
There did not appear to be any association between the pharmacist demographics and 
their intervention rate during the PROMISe trial. This was also seen in previous studies on 
factors influencing the provision of professional services75,115, and indicates that other 
factors, such as attitude, may be more important. During the bivariate analysis, some 
professional memberships were associated with a higher intervention rate, such as AACP 
and SHPA. However, simply joining these organisations would obviously not automatically 
increase the pharmacist’s intervention rate. It is likely that the member pharmacists 
already had a higher clinical knowledge (due to the nature of these organisations) and, 
therefore, an improved ability to detect DRPs. These pharmacists may also be more 
motivated and enthusiastic within their profession, naturally leading to a higher 
participation rate in professional services. 
During the trial, only 425 of the 509 active pharmacists documented an intervention, 
resulting in 84 or 16.5% non-performing pharmacists. There did not appear to be many 
differences in the measured parameters between the performing and non-performing 
pharmacists, with the only significant difference in the level of training, where the non-
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performing pharmacists were significantly more likely to have not completed training. 
Improving the participation rate would be expected to increase the overall intervention 
rate, with the analysis of non-performing pharmacists suggesting that encouraging 
training may facilitate an increased participation rate. 
7.2.2 Multivariate analysis 
A multinomial logistic regression was used to model the pharmacist’s intervention rate, 
with four variables contributing significantly to the model: number of annual CPD hours, 
level of clinical intervention training, clinical knowledge survey score and adaptability 
score. As discussed in Chapter 5, pharmacists with a higher number of annual CPD hours, a 
higher level of training, a higher clinical knowledge and an ‘adaptable’ attitude had higher 
intervention rates.  
7.2.2.1 CPD activity and incentive CPD points 
The number of hours each pharmacist spent on CPD annually was significantly correlated 
with their individual intervention rate, with the pharmacists with a higher level of annual 
CPD activity having a higher intervention rate. As discussed in Chapter 5, it is likely that 
CPD activity increases the clinical knowledge of the pharmacist and therefore improves 
their ability to detect and resolve DRPs in the community pharmacy environment. It is also 
likely that pharmacists who attend education sessions and complete additional training in 
their own time are more proactive within their profession, and are therefore more likely 
to participate effectively in a professional program. This has been seen previously in other 
studies, where the pharmacists who attended educational sessions and additional training 
were more likely to participate in professional programs or have higher rates of 
participation.34,106,110 
One of the main facilitators that arose from both the focus groups and the online survey 
was that incentives for pharmacists will encourage the performance and documentation 
of interventions. It was thought that CPD points would be a sufficient incentive, especially 
since annual pharmacist registration with the Australian Pharmacy Board now requires 
that a certain number of CPD points be gained annually before re-registration is approved. 
Pharmacist intervention rates may therefore be improved by allocating CPD points to each 
documented intervention or by allocating a set number of CPD points per year if the 
pharmacist adequately participates in the documentation of interventions. In turn, this 
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would increase the number of interventions documented, and may also increase the 
number of interventions performed, ultimately improving patient outcomes. 
7.2.2.2 Clinical knowledge and training 
The outcomes of the observer focus groups showed that one of the main barriers and 
facilitators to performing clinical interventions was the clinical knowledge of the 
pharmacist. This was also seen with the pharmacists with additional qualifications, as 
pharmacists who had undergone additional clinical knowledge training had a higher 
intervention rate, a finding that has been reported previously in the literature.68 A higher 
score in the clinical knowledge survey administered during the trial was also associated 
with a higher intervention rate, which has also been found in previous studies.106,115 In 
order to meet professional pharmacy standards, it is important that pharmacists undergo 
continuing education to improve and maintain their clinical knowledge, thus leading to an 
increased intervention rate. Any learning activity which improves the pharmacist’s clinical 
knowledge can reasonably be expected to improve their intervention rate. This may 
include any number of educational activities, such as attendance at conferences, journal 
readings or self-directed learning. As discussed in section 7.1.1.1, professional 
development modules could be provided regularly in conjunction with prompts within the 
intervention documentation software. The PSA and NPS could be key providers of this 
ongoing education, which would increase the knowledge of the pharmacists, thus 
contributing to a higher intervention rate and improved patient outcomes. 
Extensive online and face-to-face pharmacist training modules were developed and 
administered to the pharmacists prior to the PROMISe trial. The level of training that the 
pharmacists completed was significantly correlated with their intervention rate during the 
trial, and many non-performing pharmacists also completed no training. Encouraging all 
pharmacists to complete the online intervention training is therefore likely to significantly 
increase their intervention rate. The number of pharmacists completing the training could 
be improved through incentives, such as additional CPD points, which should increase the 
intervention rates of pharmacists and, in turn, improve the intervention rates of their 
pharmacies and health of their patients. 
7.2.2.3 Attitude and practice change 
There was a significant correlation between the pharmacist’s opinions about interventions 
and their intervention rate, with the pharmacists whose answers indicated they were 
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more motivated and enthusiastic having a higher intervention rate during the trial. 
Unfortunately, altering the motivation and enthusiasm of an individual is extremely 
difficult, and could only be done if the pharmacist was willing to change. The effect of 
attitude on a pharmacist’s ability to provide professional services has been noted in 
previous studies, with the more motivated, confident and positive pharmacists tending to 
have a higher level of participation.101,102,110 
It is therefore important to educate pharmacists on the importance and significance of 
interventions, hopefully motivating them to change their practice and facilitate the 
documentation of interventions. This has been previously identified by Roberts et al. 
stating that “too much emphasis is still being placed on the skills, knowledge and attitude 
of the individual pharmacist”.97 Pharmacists, and pharmacies, need to be equipped with 
tools to adapt their practice to successfully provide these services and to maintain long-
term provision of these services. Another study by Roberts et al.107 identified seven factors 
that facilitated practice change within the pharmacy environment, many of which were 
also identified within the PROMISe trial: good rapport with local physicians; remuneration; 
appropriate pharmacy layout (such as a private consultation area); patient expectation to 
provide the service; sufficient staffing levels; good communication and teamwork; and 
adequate external support and assistance.107 By identifying which factors will improve 
practice change within individual pharmacist and pharmacy level, and by providing 
adequate assistance to implement the professional service, an intervention 
documentation system is likely to be more successful and more consistently used within 
the pharmacy. This in turn will lead to an increased and sustained intervention rate. 
Pharmacists need to be assisted with implementing practice change to ensure that 
interventions continue to be documented. Practice change could be assisted by targeting 
pharmacy students whilst they are still at University. If the documentation of interventions 
was established as routine pharmacy workflow in the early part of a pharmacist’s career, it 
would be much easier for the pharmacist to incorporate it into their dispensing routine 
once qualified. It is therefore essential that pharmacists begin to recognise that routine 
documentation of interventions will not only raise their professional profile and secure 
their future, but also improve their job satisfaction.  
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7.2.3 Conclusion 
The intervention rate of the pharmacist could be improved through targeted education 
and training on the documentation system and the identification of DRPs within the 
community pharmacy environment. Due to the large number of non-participants, it may 
also be beneficial to improve the individual participation rate, rather than just the 
intervention rate. Helping the pharmacist to facilitate practice change and alter their 
dispensing workflow to increase the number of interventions documented would 
hopefully increase the number of pharmacists participating in this important professional 
program.  
7.3 Remuneration 
The PROMISe II trial showed no significant differences between remunerated and non-
remunerated pharmacies81; therefore, the effect of remuneration was not measured 
within the PROMISe III trial. Only a small upfront and completion payment was used 
within this trial and therefore, it is unknown what effect a ‘per intervention’ remuneration 
scheme would have had in the PROMISe III trial. Lack of remuneration is often cited as a 
barrier to implementing and maintaining a professional service within the 
literature16,100,107,109,115, with the multivariate analysis within one study revealing that 
adequate remuneration significantly increased the rate of provision of cognitive 
services.101 
Recognising that remuneration may have an effect on the overall intervention rate, 
consultation work was completed by Deloitte184 to determine the best method to fully 
compensate pharmacies for their participation and facilitate optimal levels of clinical 
intervention performance and documentation. This work determined that the 
remuneration options should include four main elements, as follows. 
 An upfront payment to cover private costs to pharmacies associated with training 
and setup of the system. 
 A per-intervention payment that is either general or targeted for high and low 
value interventions. 
 A quarterly incentive payment that is made to pharmacies that have achieved the 
pre-determined minimum intervention rate. 
 CPD points to incentivise individual pharmacist participation. 
The different combination of payments to the pharmacies and pharmacists aimed to 
improve the levels of participation by pharmacists and therefore the intervention rate. 
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This in turn would help to determine the potential health and economic benefits of the 
clinical interventions. 
Through multiple indepth analyses, Deloitte determined that the greatest reduction in 
healthcare spending by the Australian Government would occur if each pharmacy were 
remunerated $4,000 as an upfront payment, $20 per prescription intervention and a 
$1000 quarterly incentive payment. In addition, CPD points would also provide an 
additional incentive for pharmacists to participate in the program. Under the Fifth 
Community Pharmacy Agreement negotiated in 2010, the Department of Health and 
Ageing allocated $97M towards clinical interventions, which should provide adequate 
remuneration for most of the pharmacies within Australia.  
It is also important to note that the payments are given directly to the pharmacies, not the 
participating pharmacists, and it would be at the discretion of the pharmacy owner 
whether the employee pharmacists would receive any of the allocated remuneration. This 
was also cited as a potential limitation by Knapp27, who also attributed a low intervention 
rate to pharmacies not passing on the incentive payments to staff. It is therefore 
extremely important to introduce a CPD point allocation system to ensure the pharmacists 
are receiving some form of individual payment for the professional service they are 
providing. 
Co-contributional funding from the consumer would be unlikely to provide enough 
remuneration for the pharmacy to continue the service. Currently, pharmacies receive a 
dispensing fee from the Government for dispensing medications with the patients paying 
the remaining cost of the medication up to a set amount. Very few nationwide schemes 
require additional payment from the consumer, resulting in many consumers feeling that 
it is the Government’s responsibility to fund their healthcare. Co-contributional funding is 
therefore unlikely to provide a viable source of income unless education is directed 
towards consumers to increase their understanding of a pharmacist’s role. This was also 
noted in a survey of New Zealand pharmacists, where the pharmacists were reluctant to 
charge patients directly for services, as such a payment system had not previously 
existed.16 
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7.4 Targeted interventions 
The benefit of an intervention system that transmits data to a central repository is that an 
extensive database of common interventions is created. For example, the PROMISe trial 
identified that the medications with the highest intervention rates were 
phenoxymethylpenicillin, erythromycin, prednisolone, tramadol and oxycodone. In the 
future, an extensive database would allow information to be collated to further increase 
the number of interventions performed on medications associated with high numbers of 
DRPs, for example, using the database to formulate specific education programs for 
pharmacists. The database could also be used to formulate new prompts to be created, by 
targeting simple, common interventions that have the potential to substantially reduce 
healthcare resource utilisation and thus expenditure. 
As expected, older patients were more likely to require an intervention compared to 
younger patients, probably due to an increase in the number of concurrent medications as 
well as a possible decrease in cognition, hearing and/or vision.6 By educating pharmacists 
to be aware of common interventions experienced by this consumer group, it is possible 
that the number of important interventions would increase, therefore possibly decreasing 
healthcare utilisation. 
7.5 Limitations 
During the PROMISe trial, some limitations were detected that may impact on the future 
implementation of an effective intervention documentation system. 
7.5.1 Recruitment 
A potential limitation of this trial was that pharmacies were invited to participate; as such 
it is possible that only proactive pharmacy owners were recruited. This selection bias 
could have resulted in a positively skewed intervention frequency. However, it is felt that 
this self-selection bias may have been counteracted by the pharmacists, since many of the 
involved pharmacists were told to participate by their pharmacy owner, rather than 
choosing to participate themselves. Therefore, the effect of the recruitment process is 
unknown. Documentation of clinical interventions has recently become a requirement of 
the Quality Care Pharmacy Program (QCPP) accreditation185, which may increase the 
intervention rate as the QCPP pharmacies aim to meet their re-accreditation 
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requirements. In addition, offering CPD points may also improve the participation rate, 
leading to an increase in the number of interventions documented. 
7.5.2 Consumers 
A limitation of this study was the lack of an adequate consumer sub-study to determine 
the actual effectiveness of clinical interventions. Further research into the area should 
include an intervention outcomes measurement, for example, a long term study (such as 
12 months) to follow all intervention outcomes. This may improve the understanding of 
how many interventions are fulfilled within the community and the outcomes of these 
interventions. It would also allow more accurate costs and savings to be calculated to 
provide to the government for inclusion in the next Community Pharmacy Agreement. It 
would not be feasible to have a control group, as ignoring detected interventions would 
impinge on the professionalism of the pharmacist as well as on the health of the patient; 
therefore, a follow-up study would be the most ethically feasible. 
7.5.3 Workload measure 
As identified in section 7.1.2, the measure of pharmacist workload had a varied correlation 
with the intervention rate of the pharmacy and the pharmacist. The average pharmacist 
workload was calculated using the prescriptions dispensed by the pharmacy divided by the 
number of FTE pharmacists per week (see Chapter 2 for calculation). This resulted in an 
average workload being calculated for the entire trial, which was not specific to each 
pharmacist within the pharmacy or each week within the trial. This indicated that 
although the workload was a good estimate at the pharmacy level, it was not accurate and 
may have been too generalised to provide consistent results within the individual 
pharmacist statistical analysis. The prescription volumes dispensed were accurate, as each 
dispensed prescription was tagged with the date and dispensing pharmacists. Ideally, a 
more accurate average workload could be generated by asking each pharmacist to record 
the number of hours worked within the pharmacy each week. This would allow for a more 
accurate workload per pharmacist per week and workload per pharmacy per week to be 
calculated.   
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8 Chapter 8: Recommendations and conclusions 
8.1 Conclusion 
The PROMISe III software was successfully implemented in 185 pharmacies in three States 
of Australia. The trial resulted in the documentation of 5948 interventions from 2,013,923 
prescriptions with a median intervention rate of 0.21%. The rates of individual pharmacies 
ranged from 0.00% to 2.35% and individual pharmacists ranged from 0.00% to 3.88%, 
indicating the potential intervention frequency that could be achieved. 
Several factors were found to contribute to the variation in intervention rates between 
the pharmacies and the pharmacists. Within the multivariate analysis, prescription volume 
and/or pharmacist workload, financial turnover, location, catering for an aged care facility 
and participation in additional pharmacy trials appeared to significantly affect the 
pharmacy intervention rate. The busier pharmacies tended to have a lower intervention 
rate, suggesting that adequate staffing levels with appropriate workloads would increase 
the level of interventions performed and documented within pharmacies.  
The intervention rates of individual pharmacists tended to be associated with their level of 
training, their clinical knowledge and their professional attitude. Pharmacists who 
completed both face-to-face and online PROMISe training tended to have a higher 
intervention rate than other pharmacists. A higher clinical knowledge score was also 
associated with a higher intervention rate, which may be due to these pharmacists having 
an improved ability to detect DRPs. The results suggest that by providing ample PROMISe 
training and additional clinical training, with additional assistance to adapt their practice, 
the intervention rate of community pharmacists could be increased. 
Increasing the intervention rate of both pharmacies and pharmacists will be of immense 
value to the community, since the average intervention was estimated to save 
approximately $360 to the healthcare system (including medication savings).164 
Extrapolation estimates showed that if the PROMISe software was installed in every 
pharmacy in Australia, an additional $290M in healthcare costs could be avoided annually. 
8.1.1 Recommendations 
The full PROMISe software used by Group Three is recommended for national 
implementation. Although Group Three did not have a significantly higher overall 
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intervention rate than the other groups, the use of the general reminder and specific 
prompt is thought to increase the pharmacist’s awareness of documenting clinical 
interventions, and, therefore, may help the pharmacist to adapt to the change in practice. 
The use of the specific prompt would also improve the pharmacist’s clinical knowledge 
and allow the Government to specifically target problem medications. Specific prompts 
that rotated on a 4-8 week basis would decrease pharmacist prompt fatigue, and 
hopefully lead to an increased intervention rate, and therefore, improved patient 
outcomes and increased cost savings to the Australian healthcare system. 
Use of the system could be improved through adequate training, which should also 
contribute to a higher intervention rate, as seen in Chapter 5. It would be recommended 
that at least two pharmacists from each pharmacy be required to complete the training in 
order to ensure the information was translated adequately back to the pharmacy. The 
training should be provided through a mix of virtual classroom (online) courses and face-
to-face seminars, thus minimising the costs of training as well as ensuring all pharmacists 
were able to access the training. 
A key component to the PROMISe software would be the use of the data collected from 
the central database. This could be used for the ongoing education of pharmacists and by 
providing pharmacists with additional clinical knowledge training, the intervention rate 
could be further increased. This database could also be used to improve prescribing 
practices through analysis of interventions by groups, showing another fundamental 
benefit of the PROMISe system. 
The PROMISe III trial showed that CPD points could be used as an incentive to increase a 
pharmacist’s intervention documentation rate. Therefore, it would be necessary to ensure 
CPD points were allocated appropriately for the performance and documentation of valid 
interventions, and not just awarded to a pharmacist for performing their necessary 
professional duties. The attitude and motivation of the pharmacist was also associated 
with their intervention rate within the trial; therefore, assistance for the pharmacists to 
implement change management strategies would help them adapt their practice to 
include the documentation of clinical interventions and increase their intervention rate. 
Ideally, a prospective trial conducted on data collected by the implemented program 
would also allow confirmation of the healthcare resource utilisation benefits that could 
only be predicted within the constraints of the PROMISe trial. It is envisaged that random 
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samples of consumers subjected to an intervention could be identified and contacted to 
determine their actual health resource utilisation. This would allow more accurate 
economic values to be assigned to all types of interventions and therefore more precise 
extrapolations to be applied nationwide, and would become the new gold standard 
reference for the economic and clinical value of pharmacist-performed clinical 
interventions worldwide. This prospective study would in turn allow policy makers to 
better measure the efficacy of the program, and to better target high value areas of 
interest throughout the health system.  
8.1.2 National implementation 
Since the PROMISe III trial, the Department of Health and Ageing has allocated $97M from 
the Fifth Community Pharmacy Agreement towards the documentation of clinical 
interventions. Currently, the Mirixa GuildCare® software158 (a PGA commercial product 
which is not formally part of the Community Pharmacy Agreement) is the platform for the 
documentation of interventions. However, this is a separate program from the dispensing 
software meaning that the intervention records are not adequately attached to the 
patient’s history and there is no centralised collection of clinical interventions. 
Unfortunately, the system falls well short of what the PROMISe III trial utilised and 
recommended for a future national rollout. Each dispensing software vendor is currently 
modifying the PROMISe III software for inclusion into their dispensing system and it is 
hoped that the software will be available for use during 2012. 
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8.1.3 Summary of contributions 
 The PROMISe trial was the largest and longest clinical intervention trial to be run 
in community pharmacies in Australia, and one of the largest in the world. 
 The database collected allowed the frequency of intervention types and the 
medications commonly involved in clinical interventions to be identified and 
analysed for trends. 
 Several factors were identified that contributed to the different intervention rates 
between pharmacies, such as prescription volume, pharmacist workload, financial 
turnover, location, catering for an aged care facility and participation in pharmacy 
trials. Several factors were also identified that contributed to the different 
intervention rates between pharmacists, such as their level of training, their 
clinical knowledge, their commitment to continuing education and their 
professional attitude. Some of these factors have previously been identified in the 
literature, however, this thesis applied an extensive multivariate analysis which 
has not been done in association with any clinical intervention trials previously. 
 The innovative prompt system used in the PROMISe trial has many benefits if used 
in the future and would result in better patient outcomes. 
 The PROMISe trial estimated that each intervention saves approximately $360 to 
the healthcare system, resulting in the allocation of $97M from the Fifth 
Community Pharmacy Agreement towards the documentation of clinical 
interventions. 
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Appendix 2: DOCUMENT flowchart 
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Appendix 3: Final DOCUMENT scope notes (used in 
PROMISe III) 
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Appendix 4: Clinical knowledge survey 
*Statements appearing in red were not included in the final 40 statements 
For Cases 1-3 
 Very relevant = 7 
 Moderately relevant = 6 
 Only slightly relevant = 5 
 Neutral = 4 
 Only slightly irrelevant = 3 
 Moderately irrelevant = 2 
 Totally irrelevant = 1 
 
Case 1: 
A slightly overweight, 51yo female patient who regularly visits your pharmacy presents a 
prescription for perindopril 5mg. The dispensing records indicate that the last 
antihypertensive agent prescribed for this patient was the perindopril/indapamide 
combination and it was last dispensed 3 months ago. Please indicate how relevant each 
piece of additional information would be in this case. 
 Researchers 
Writer’s 
answer Mode Mean 
Std 
Dev 
 Discuss with the patient whether the medication 
change was intentional. 
7 6.89 0.32 7 
 Discuss with the patient's doctor whether the 
medication change was intentional. 
7 6.28 1.13 7 
 Obtain the patient’s blood pressure to determine 
current efficacy of her antihypertensive treatment. 
5 5.11 1.53 1 
 Determine the patient's smoking history. 5 4.67 1.64 1 
 Discuss with the patient their compliance with the 
antihypertensive agent. 
7 6.50 1.42 7 
 Determine if the patient has had a cholesterol 
level done recently. 
5 4.72 1.45 1 
 Discuss a weight management program with the 
patient. 
5 5.06 1.55 1 
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Case 2: 
A frail 80yo male patient presents to collect his last repeat from his glyceryl trinitrate 
sublingual spray prescription. On dispensing, the pharmacist notices that this is the third 
time this medication has been dispensed in the last two weeks. Please indicate how 
relevant each piece of additional information would be in this case. 
 Researchers Writer’s 
answer Mode Mean Std Dev 
 Determine if the pain the patient is feeling is 
actually due to angina. 
7 6.89 0.32 7 
 Determine if the patient has any expired 
bottles of GTN spray at home. 
5 4.56 1.98 1 
 Ask the patient to demonstrate his 
administration technique. 
7 6.67 0.59 7 
 Establish whether the patient has a new 
script for GTN spray at home. 
5 4.22 1.99 1 
 Determine how long since the patient's GP 
has reviewed his angina treatment. 
7 6.94 0.24 7 
 Determine how efficacious the GTN spray is. 7 6.44 1.54 7 
 Determine if the patient has changed his 
diet in the last fortnight. 
1 2.89 2.14 1 
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Case 3: 
A 58kg, 35yo female presents to the pharmacy to collect a prescription for methotrexate 
10mg weekly from her rheumatologist which is a new medication for her. Please indicate 
how relevant each piece of additional information would be in this case. 
 Researchers Writer’s 
answer Mode Mean Std Dev 
 Determine if the patient has had baseline liver 
function tests. 
7 6.78 0.43 7 
 Determine if the patient has had a negative 
pregnancy test and is currently taking/using 
adequate contraception. 
7 7.00 0.00 7 
 Determine if the side-effects of methotrexate 
have been explained to the patient. 
7 6.94 0.24 7 
 Determine if the patient has been instructed 
to take folic acid. 
7 6.39 0.85 7 
 Determine if the patient is also taking regular 
paracetamol. 
5 4.06 2.07 1 
 Determine how often the patient drinks 
alcohol. 
6 5.83 1.47 7 
 Determine if the patient is currently taking any 
over-the-counter antacids. 
2 3.89 2.25 1 
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For Cases 4-6 
 Highly likely = 7 
 Moderately likely = 6 
 Only slightly likely = 5 
 Neutral = 4 
 Only slightly unlikely = 3 
 Moderately unlikely = 2 
 Highly unlikely = 1 
 
Case 4: 
A 65kg, 45yo female patient comes into the pharmacy to enquire about possible side-
effects. She was commenced paroxetine 20mg daily a few days ago and has been 
experiencing increasing anxiety (which is the reason the paroxetine was initially started), 
sweating and tachycardia. She has a medical history of atrial fibrillation and severe lower 
and is also taking digoxin, ramipril, tramadol and methadone. Please indicate how likely 
each drug-related problem would be in this case.  
 Researchers Writer’s 
answer Mode Mean Std Dev 
 The commencement of the paroxetine may 
have resulted in an increase in anxiety for the 
patient. 
6 5.78 1.35 7 
 This dose of paroxetine is unlikely to be 
controlling the patient's anxiety symptoms and 
an increase in her dose should be considered. 
1 2.50 1.62 1 
 The paroxetine may have interacted with the 
tramadol to cause the patient's symptoms. 
7 6.61 0.78 7 
 The paroxetine may have interacted with the 
methadone to cause the patient's symptoms. 
7 4.50 2.23 7 
 The paroxetine may have interacted with the 
digoxin to cause the patient's symptoms. 
1 3.00 1.88 1 
 The patient may be experiencing digoxin 
toxicity and should be referred back to her GP. 
1 2.89 2.19 1 
 The patient's symptoms could be due to 
worsening atrial fibrillation and her digoxin 
dose should be increased. 
1 3.00 2.00 1 
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Case 5: 
A slightly overweight, 78yo female patient with a history of hypertension and mild heart 
failure presents with prescription for frusemide 20mg D to treat her swollen ankles. She is 
also currently taking lercanidipine 20mg and ramipril 2.5mg D, plus amitriptyline 10mg N 
for sleep. Please indicate how likely each drug-related problem would be in this case. 
 Researchers Writer’s 
answer Mode Mean Std Dev 
 The patient's symptoms are likely to indicate a 
worsening of her heart failure. 
6 6.50 0.51 7 
 The swollen ankles may be due to an increased 
fluid intake caused by a dry mouth from the 
amitriptyline. 
5 4.56 1.34 1 
 Lercanidipine could be causing peripheral 
oedema. 
7 6.67 0.59 7 
 The swollen ankles may be due to an increased 
fluid intake resulting from hyperglycaemia. 
2 3.22 1.70 1 
 The patient may need to increase her level of 
exercise to improve blood flow in her ankles. 
5 3.67 1.78 1 
 The patient may have SIADH which has led to 
swollen ankles. 
3 3.39 1.65 1 
 The patient may have been experiencing an 
arrhythmia which has decreased her cardiac 
output and caused her swollen ankles. 
4 4.11 1.53 1 
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Case 6: 
A lady comes into the pharmacy to collect her elderly husband’s prescriptions for him 
while he is recuperating home. She states there is a new prescription for ‘Imdur® 60mg M’ 
that was started in the hospital last week, new medication doesn’t seem to be working 
and her husband is still experiencing chest pain. The husband’s history regular dispensing 
of Somac® 40mg N, Iscover® 75mg M, Lipitor® 20mg N, Duride® 60mg N, Coversyl® 5mg 
Spiriva® 18mcg M and GTN spray PRN. Please indicate how likely each drug-related 
problem would be in this case. 
 Researchers Writer’s 
answer Mode Mean Std Dev 
 Her husband may be experiencing a decrease 
in symptom control for his COPD and his 
shortness of breath is causing the chest pain. 
5 4.56 1.50 7 
 Her husband may be experiencing nitrate 
tolerance if he has continued to take the 
Duride® brand that he was initially prescribed, 
as well as the Imdur® from the hospital. 
7 6.61 0.70 7 
 Her husband needs a higher dose of 
isosorbide mononitrate to control his 
symptoms. 
1 3.72 2.27 7 
 Her husband could be experiencing an 
interaction between clopidogrel and 
pantoprazole resulting in an exacerbation of 
coronary symptoms. 
2 3.22 1.73 7 
 Her husband needs to increase the use of his 
GTN spray to improve his symptoms. 
1 3.56 2.09 1 
 Her husband should have aspirin added to 
decrease his chest pain symptoms. 
1 2.83 1.82 1 
 Her husband needs to increase his dose of 
pantoprazole because his chest pain may be 
due to worsening reflux. 
5 4.56 1.72 1 
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For Cases 7-9 
 Very appropriate = 7 
 Moderately appropriate = 6 
 Only slightly appropriate = 5 
 Neutral = 4 
 Only slightly inappropriate = 3 
 Moderately inappropriate = 2 
 Totally inappropriate = 1 
 
Case 7: 
A slightly overweight, 70yo male patient is currently taking warfarin (dose is 5mg/4mg on 
alternate days). He dental prescription for an abscess for amoxycillin 500mg TDS and 
metronidazole 400mg TDS. Please indicate how appropriate each recommendation would 
be in this case. 
 Researchers Writer’s 
answer Mode Mean Std Dev 
 Cease the warfarin whilst taking the antibiotics. 1 1.78 1.52 1 
 Discuss the interaction with the patient and 
recommend an increase in INR monitoring 
whilst taking the antibiotics. 
7 6.89 0.32 7 
 Discuss the signs and symptoms of an 
increased INR with the patient. 
7 6.83 0.38 7 
 Recommend the dentist change the 
metronidazole to clindamycin. 
2 3.89 2.37 1 
 Recommend ibuprofen for pain relief for the 
dental abscess. 
1 1.44 0.86 1 
 Halve the warfarin dose whilst taking the 
antibiotics. 
1 2.44 1.89 1 
 Change the warfarin to aspirin whilst using the 
antibiotics. 
1 1.11 0.32 1 
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Case 8: 
A 65yo female with airways disease has a recent dispensing history containing Seretide® 
250/25 (2 puffs BD) Ventolin® inhaler (1-2 PRN). She presents a 3 month old prescription 
to the pharmacist for prednisolone 25mg reads ‘25mg BD for three days, then 12.5mg BD 
for three days’. On further discussion, the pharmacist determines patient is currently 
experiencing a worsening of the respiratory symptoms and is unsure what dose of 
prednisolone should be taking. Please indicate how appropriate each recommendation 
would be in this case. 
 Researchers Writer’s 
answer Mode Mean Std Dev 
 Advise the patient not to take the 
prednisolone 25mg at all. 
1 2.11 1.88 1 
 Commence OTC pantoprazole 20mg daily to 
decrease the risk of GI bleeds whilst taking the 
prednisolone. 
1 2.28 1.41 1 
 Dispense the prescription as written and 
instruct the patient to take it with food. 
1 3.89 2.40 1 
 Contact the patient's GP and determine what 
prednisolone dose she should currently be 
taking. 
7 6.67 0.84 7 
 Advise the patient to cease the Seretide® 
whilst she is taking the prednisolone tablets. 
1 1.06 0.24 1 
 Advise the patient to increase the use of her 
Ventolin® inhaler in preference to using the 
prednisolone. 
1 1.89 1.28 1 
 Advise the patient to discuss with her doctor 
about increasing the strength of her Seretide® 
to the 500/50 Accuhaler. 
6 4.78 2.07 7 
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Case 9: 
A 120kg, 40yo male smoker with osteoarthritis is taking esomeprazole 40mg daily, but 
currently has no GI symptoms. only other medication he is currently taking is regular 
paracetamol for his OA pain that he buys over-the-counter, dispensing history shows 
ketoprofen and cephalexin dispensed several months ago. Please indicate how 
appropriate each recommendation would be in this case. 
 Researchers Writer’s 
answer Mode Mean Std Dev 
 Dispense the prescription with dietary advice 
about avoiding reflux triggers. 
5 4.17 1.79 1 
 Recommend the patient return to the GP to 
reduce his dose to 20mg daily. 
7 6.06 1.16 7 
 Recommend the patient return to the GP to 
trial using esomeprazole on a PRN basis. 
7 5.83 1.42 7 
 Discuss a weight management program with 
the patient. 
6 6.33 0.59 7 
 Discuss smoking cessation with the patient. 6 5.89 1.41 7 
 Recommend the patient have his vitamin B12 
levels checked. 
4 3.67 1.85 4 
 Recommend the patient stop the regular 
paracetamol and change back to ketoprofen to 
control his OA pain. 
1 1.22 0.73 1 
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Appendix 5: Patient leaflet for prompt 
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Appendix 6: Pharmacist leaflet for prompt 
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Appendix 7: Owner/manager survey 
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Appendix 8: Site visit form 
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Appendix 9: Site visit staff roster template 
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Appendix 10: Pharmacist background survey 
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Appendix 11: Pharmacist intervention opinions survey 
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Appendix 12: Pharmacist empathy survey 
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Appendix 13: Pharmacist professionalism survey 
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Appendix 14: Pharmacist software survey (post-trial) 
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Appendix 15: Observer intervention record form 
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Appendix 16: Observer hourly log form 
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Appendix 17: Observer daily log form 
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Appendix 18: Observer barriers/facilitators form 
(software pharmacies) 
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Appendix 19: Observer barriers/facilitators form (no 
software pharmacies) 
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Appendix 20: Halls professionalism survey 
Pharmacist Name:___________________   Pharmacy Approval No.:____________ 
Halls' Pharmacist Survey  
Please choose the appropriate response for each item: 
 
* 1: My professional organisation competently represents my views on pharmacy 
issues. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 2: If I do not monitor patient drug therapy, an unfavourable therapeutic outcome is 
probable. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 3: My pharmacy colleagues and I should be the only ones who determine and set 
standards for our practice. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 4: I often wish that I had chosen another occupation. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 5: My employer should establish specific guidelines for making professional 
decisions in my work. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 6: I can maintain an acceptable standard of practice without undertaking continuing 
education programs. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 7: My professional organisation fails to promote advancement of the profession of 
pharmacy. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
  
476 | P a g e  
 
 
 
* 8: Patients probably would not be harmed if I failed to instruct them concerning the 
proper use of their medications. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 9: The only professional standards I will accept are those established by my 
pharmacy colleagues. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 10: There is no occupation I could be happier in than pharmacy. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 11: The opportunity to exercise professional judgement in my work should be 
determined by my employer. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 12: Continuing education such as self-study or seminars is essential for my work. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 13: My professional organisation does not help to ensure quality practice. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 14: Optimal drug therapy for the patient is impossible to achieve without my 
services. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 15: I would be willing to modify the basic standards which guide my practice in 
order to conform to the wishes of the public. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
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* 16: The practice of pharmacy is gratifying and satisfying to me. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 17: My employer has the right to review and change the professional decisions I 
make. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 18: My daily practice is all the continuing education I need. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 19: My professional organisation provides me with a better understanding of the 
values and beliefs of my profession. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 20: The health care of the patient would suffer without my services. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 21: Only another pharmacist is qualified to judge the competence of my work. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 22: If I had the opportunity to begin over again, I would still choose to practice 
pharmacy. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 23: I would depart from my employer's policies when I judge it professionally 
necessary. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
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* 24: I would attend continuing education seminars only if they were required for re-
registration. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 25: The official statements and standards of my professional organisation are 
important guides to my practice. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 26: Patient care would suffer very little if I failed to provide drug information to the 
doctor. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 27: Pharmacists who violate professional standards should be judged only by their 
pharmacy colleagues. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 28: I feel dedicated to pharmacy because I believe in my work. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 29: My employer has the right to influence my professional decisions because my 
employer is the one who pays my salary. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 30: My involvement with drug therapy has little consequence on the prevention of 
adverse drug reactions to the patient. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
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* 31: Standards for professional competence which guide my practice are best defined 
and established via government regulation. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 32: Continuing education is of little importance to my practice. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 33: The practice of pharmacy promoted by my professional organisation is close to 
my personal ideal. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 34: Patient care would be unsatisfactory without my services. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 35: The public should be allowed input into the development of standards for 
professional competence which guide my practice. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 36: I want others to enter pharmacy because I am proud of the unique skills and 
knowledge they would acquire. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 37: My employer has no right to place limitations on the decisions I make 
concerning professional matters. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 38: My practice would suffer if I did not undertake continuing education programs. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
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* 39: Patient drug compliance is improved by my explanation of drug therapy to 
patients. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
* 40: I would modify the professional standards which guide my practice only in 
response to recommendations made by my pharmacy colleagues. 
 
 
 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
      
 
 
 
Thank you for completing this survey.   
Please ensure your name is written on the top of the survey and  
return it to your observer or fax it to: (03) 6226 8534. 
 
You will receive your $50 Coles/Myer voucher once this survey is returned to the 
Project team. 
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Appendix 21: Examples of recorded interventions 
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Appendix 22: Article detailing the analysis of the prompt 
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Appendix 23: Pharmacy multivariate analysis  
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Multivariate analysis of pharmacy factors  
One pharmacy owner only answered the initial online survey (not the subsequent survey), therefore data for opening hours, number of professional services, 
pharmacy size in m2, financial turnover in 2007/08, banner group membership, catering for an aged care facility and whether they have had a pre-registration 
pharmacist in the last 2 years was missing.  A different pharmacy did not receive a site visit, therefore data for collecting prescription details/payments and 
number of dispensing terminals was missing. 
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  N Mean 
Std. 
Deviation 
Missing No. of Extremes
a
 
Count Percent Low High 
LogCIRate 185 -0.667 0.434 0 0.0 3 0 
Actual Prescription Volume 185 12953.790 7210.841 0 0.0 0 4 
Average Pharmacist Workload Per 
Week 
184 479.458 196.098 1 0.5 0 5 
Pharmacy Opening Hours per Week 184 59.220 12.496 1 0.5 0 4 
Total Number of Professional Services 
Offered 
184 6.902 2.262 1 0.5 0 0 
% of time pharmacist collects 
prescription details from patient  
184 25.840 25.580 1 0.5 0 10 
% of time pharmacist collects payment 
from patient 
184 18.510 24.029 1 0.5 0 10 
Location 185     0 0.0     
Pharmacy Size in m2 184     1 0.5     
Pharmacy $ Turnover in 2007/08 184     1 0.5     
Member of a Banner Group  184     1 0.5     
Cater for aged care facility  184     1 0.5     
Pharmacy has had a pre-registration 
pharmacist within the last 2 years 
184     1 0.5     
Number of Dispensing Terminals  184     1 0.5     
a. Number of cases outside the range (Q1 - 1.5*IQR, Q3 + 1.5*IQR). 
Table 9-1: Missing value analysis 
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Proving assumptions 
For dichotomous variables (including dummy coded variables), a split of less than 90/10 was desirable, otherwise the influence of the values in the smaller 
group can be influential.  Binary variables all appeared to be acceptable.  The following factors had equal to or less than 90/10 split, therefore could be used as 
grounds for exclusion at a later date. 
 Medical centre (17; 9.2%) vs other (168; 92.8%) 
 Participates in additional pharmacy trials (170; 92.4%) vs non-participants (14; 7.6%) 
 Provides 3 or more professional services (162; 88.0%) vs 0-2 professional services (22; 12.0%) 
Several continuous variables also had non-normal distribution. 
1. Actual prescription volume - Kolmogorov-Smirnov D(185) = 0.145, p < 0.001; Shapiro-Wilk F(185) = 0.919, p < 0.001; improved with a log 
transformation (Kolmogorov-Smirnov D(185) = 0.052, p =0.020; Shapiro-Wilk F(185) = 0.990, p = 0.020). However, the decision was made to 
separate this variable into a categorical variable to improve its performance within the model. 
2. Average pharmacist workload - Kolmogorov-Smirnov D(184) = 0.059, p = 0.020; Shapiro-Wilk F(184) = 0.959, p < 0.001; not greatly improved with a 
log transformation (Kolmogorov-Smirnov D(184) = 0.064, p = 0.063; Shapiro-Wilk F(184) = 0.979, p = 0.007), therefore the variable was converted to 
a categorical variable.  
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3. Pharmacy opening hours per week - Kolmogorov-Smirnov D(184) = 0.141, p < 0.001; Shapiro-Wilk F(184) = 0.903, p < 0.001; not improved with a log 
transformation (Kolmogorov-Smirnov D(184) = 0.107, p < 0.001; Shapiro-Wilk F(184) = 0.948, p < 0.001), therefore the variable was converted to a 
binary variable – ‘conventional’ vs ‘extended trade’.  
4. Total number of professional services offered - Kolmogorov-Smirnov D(184) = 0.126, p < 0.001; Shapiro-WilkF(184) = 0.973, p < 0.001, however the 
histogram appeared normal.  Not greatly improved with a log transformation (Kolmogorov-Smirnov D(184) = 0.064, p = 0.063; Shapiro-Wilk F(184) = 
0.979, p = 0.007), therefore the variable was converted to a binary variable – ‘0-2 services’ vs ‘3 or more services’. 
5. Percentage of time the pharmacist collects prescription details and collects payment - Kolmogorov-Smirnov D(184) = 0.200,  p< 0.001 and Shapiro-
Wilk F(184) = 0.845, p < 0.001; Kolmogorov-Smirnov D(184) = 0.274, p< 0.001; Shapiro-Wilk F(184) = 0.763, p < 0.001 respectively, however there 
were a large number of zeros within the variable (for example, many pharmacists collected prescription details and payment 0% of the time), 
therefore transformation was not attempted. Variable was converted to a binary variable – ‘high’ vs ‘low’ patient contact time. 
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Model 1 (tables) 
Model Summary
g
 
Model R 
R 
Square 
Adjusted 
R Square 
Std. 
Error of 
the 
Estimate 
Change Statistics 
Durbin-
Watson 
R
2
 
Change 
F 
Change df1 df2 
Sig. F 
Change 
1 .208a 0.043 0.038 0.415436 0.043 8.157 1 181 0.005   
2 .269b 0.072 0.062 0.410204 0.029 5.646 1 180 0.019   
3 .307c 0.094 0.079 0.406417 0.022 4.37 1 179 0.038   
4 .330d 0.109 0.089 0.404325 0.014 2.857 1 178 0.093   
5 .361e 0.13 0.106 0.400497 0.022 4.419 1 177 0.037   
6 .381f 0.145 0.116 0.39821 0.015 3.039 1 176 0.083 1.799 
a. Predictors: (Constant), Caters for aged care 
b. Predictors: (Constant), Caters for aged care, Pharmacy area 150 to 250m2 
c. Predictors: (Constant), Caters for aged care, Pharmacy area 150 to 250m2, High Pharmacist Workload 
d. Predictors: (Constant), Caters for aged care, Pharmacy area 150 to 250m2, High Pharmacist Workload, Pharmacy$Turnover 
1.5to2.5M 
e. Predictors: (Constant), Caters for aged care, Pharmacy area 150 to 250m2, High Pharmacist Workload, Pharmacy$Turnover 
1.5to2.5M, Pharmacy$Turnover 2.5to4.0M 
f. Predictors: (Constant), Caters for aged care, Pharmacy area 150 to 250m2, High Pharmacist Workload, Pharmacy$Turnover 
1.5to2.5M, Pharmacy$Turnover 2.5to4.0M, Participates in pharmacy trials 
g. Dependent Variable: Log CI Rate 
Table 9-2: Stepwise regression model for all variables  
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ANOVA
g
  
Model Sum of Squares df Mean Square F Sig. 
1 
Regression 1.408 1 1.408 8.157 .005
a
 
Residual 31.238 181 0.173     
Total 32.646 182       
2 
Regression 2.358 2 1.179 7.006 .001
b
 
Residual 30.288 180 0.168     
Total 32.646 182       
3 
Regression 3.08 3 1.027 6.215 .000
c
 
Residual 29.566 179 0.165     
Total 32.646 182       
4 
Regression 3.547 4 0.887 5.424 .000
d
 
Residual 29.099 178 0.163     
Total 32.646 182       
5 
Regression 4.256 5 0.851 5.306 .000
e
 
Residual 28.39 177 0.16     
Total 32.646 182       
6 
  
Regression 4.737 6 0.79 4.979 .000
f
 
Residual 27.908 176 0.159     
Total 32.646 182       
a. Predictors: (Constant), Caters for aged care 
b. Predictors: (Constant), Caters for aged care, Pharmacy area 150 to 250m2 
c. Predictors: (Constant), Caters for aged care, Pharmacy area 150 to 250m2, High Pharmacist Workload 
d. Predictors: (Constant), Caters for aged care, Pharmacy area 150 to 250m2, High Pharmacist Workload, Pharmacy$Turnover 1.5to2.5M 
e. Predictors: (Constant), Caters for aged care, Pharmacy area 150 to 250m2, High Pharmacist Workload, Pharmacy$Turnover 1.5to2.5M, Pharmacy$Turnover 2.5to4.0M 
f. Predictors: (Constant), Caters for aged care, Pharmacy area 150 to 250m2, High Pharmacist Workload, Pharmacy$Turnover 1.5to2.5M, Pharmacy$Turnover 2.5to4.0M, Participates in pharmacy trials 
g. Dependent Variable: Log CI Rate 
Table 9-3: ANOVAs for stepwise regression model for all variables 
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Model 
Unstandardised 
Coefficients 
Standardised 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B Correlations 
Collinearity 
Statistics 
B 
Std. 
Error Beta 
Lower 
Bound 
Upper 
Bound 
Zero-
order Partial Part Tolerance VIF 
1 
(Constant) -0.595 0.038   -15.748 0.000 -0.669 -0.520           
Caters for aged care -0.185 0.065 -0.208 -2.856 0.005 -0.313 -0.057 -0.208 -0.208 -0.208 1.000 1.000 
2 
(Constant) -0.567 0.039   -14.539 0.000 -0.644 -0.490           
Caters for aged care -0.159 0.065 -0.178 -2.451 0.015 -0.288 -0.031 -0.208 -0.18 -0.176 0.972 1.029 
Pharmacy area 150 to 250 m2 -0.184 0.077 -0.173 -2.376 0.019 -0.337 -0.031 -0.203 -0.174 -0.171 0.972 1.029 
3 
(Constant) -0.529 0.043   -12.366 0.000 -0.614 -0.445           
Caters for aged care -0.136 0.065 -0.152 -2.081 0.039 -0.265 -0.007 -0.208 -0.154 -0.148 0.943 1.060 
Pharmacy area 150 to 250 m2 -0.192 0.077 -0.181 -2.505 0.013 -0.344 -0.041 -0.203 -0.184 -0.178 0.969 1.032 
High Pharmacist Workload -0.136 0.065 -0.151 -2.090 0.038 -0.264 -0.008 -0.172 -0.154 -0.149 0.970 1.031 
4 
(Constant) -0.500 0.046   -10.874 0.000 -0.591 -0.409           
Caters for aged care -0.139 0.065 -0.156 -2.143 0.033 -0.268 -0.011 -0.208 -0.159 -0.152 0.942 1.061 
Pharmacy area 150 to 250 m2 -0.164 0.078 -0.154 -2.097 0.037 -0.318 -0.010 -0.203 -0.155 -0.148 0.924 1.082 
High Pharmacist Workload -0.128 0.065 -0.143 -1.981 0.049 -0.256 0.000 -0.172 -0.147 -0.14 0.966 1.035 
Pharmacy$Turnover 1.5 to 2.5M -0.110 0.065 -0.123 -1.690 0.093 -0.239 0.018 -0.166 -0.126 -0.12 0.951 1.052 
5 
(Constant) -0.456 0.050   -9.089 0.000 -0.555 -0.357           
Caters for aged care -0.123 0.065 -0.138 -1.892 0.060 -0.251 0.005 -0.208 -0.141 -0.133 0.929 1.077 
Pharmacy area 150 to 250 m2 -0.133 0.079 -0.126 -1.692 0.092 -0.289 0.022 -0.203 -0.126 -0.119 0.893 1.120 
High Pharmacist Workload -0.130 0.064 -0.145 -2.031 0.044 -0.257 -0.004 -0.172 -0.151 -0.142 0.966 1.036 
Pharmacy$Turnover 1.5 to 2.5M -0.169 0.070 -0.188 -2.401 0.017 -0.308 -0.030 -0.166 -0.178 -0.168 0.801 1.249 
Pharmacy$Turnover 2.5 to 4.0M -0.168 0.080 -0.163 -2.102 0.037 -0.326 -0.010 -0.124 -0.156 -0.147 0.818 1.222 
6 
(Constant) -0.277 0.114   -2.423 0.016 -0.502 -0.051           
Caters for aged care -0.118 0.065 -0.133 -1.830 0.069 -0.246 0.009 -0.208 -0.137 -0.128 0.927 1.079 
Pharmacy area 150 to 250 m2 -0.118 0.079 -0.111 -1.491 0.138 -0.273 0.038 -0.203 -0.112 -0.104 0.881 1.135 
High Pharmacist Workload -0.117 0.064 -0.130 -1.824 0.07 -0.244 0.010 -0.172 -0.136 -0.127 0.952 1.050 
Pharmacy$Turnover 1.5 to 2.5M -0.185 0.071 -0.206 -2.624 0.009 -0.325 -0.046 -0.166 -0.194 -0.183 0.787 1.271 
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Pharmacy$Turnover 2.5 to 4.0M -0.171 0.079 -0.165 -2.146 0.033 -0.327 -0.014 -0.124 -0.16 -0.15 0.818 1.222 
Participates in pharmacy trials -0.197 0.113 -0.124 -1.743 0.083 -0.420 0.026 -0.145 -0.13 -0.122 0.958 1.043 
a. Dependent Variable: Log CI Rate  
Table 9-4: Coefficients for stepwise regression model for all variables 
Casewise Diagnosticsa 
Case 
Number 
Std. 
Residual LogCIRate 
Predicted 
Value Residual 
185 -3.071 -2.000 -0.777 -1.223 
a. Dependent Variable: Log CI Rate 
Table 9-5: Outlying case for model 1 
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Figure 9-1: Residual plot for model 1 (the clumps of data are likely due to all the included variables being of a binary nature) 
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Model 2 (tables) 
Model Summaryf 
Model R 
R 
Square 
Adjusted 
R Square 
Std. 
Error of 
the 
Estimate 
Change Statistics 
Durbin-
Watson 
R2 
Change 
F 
Change df1 df2 
Sig. F 
Change 
1 .258
a 0.067 0.061 0.410296 0.067 12.925 1 181 0   
2 .313
b 0.098 0.088 0.404516 0.031 6.21 1 180 0.014   
3 .345
c 0.119 0.104 0.400788 0.021 4.365 1 179 0.038   
4 .368
d 0.136 0.116 0.39812 0.017 3.407 1 178 0.067   
5 .386
e 0.149 0.125 0.396173 0.013 2.754 1 177 0.099 1.811 
a. Predictors: (Constant), Pharmacy$Turnover 1.5to4.0M 
b. Predictors: (Constant), Pharmacy$Turnover 1.5to4.0M, Caters for aged care 
c. Predictors: (Constant), Pharmacy$Turnover 1.5to4.0M, Caters for aged care, Participates in pharmacy trials 
d. Predictors: (Constant), Pharmacy$Turnover 1.5to4.0M, Caters for aged care, Participates in pharmacy trials, 
Location in a medical centre 
e. Predictors: (Constant), Pharmacy$Turnover 1.5to4.0M, Caters for aged care, Participates in pharmacy trials, 
Location in a medical centre, High Pharmacist Workload 
f. Dependent Variable: Log CI Rate 
Table 9-6: Stepwise regression model 2 
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Coefficients
a
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B Correlations 
Collinearity 
Statistics 
B 
Std. 
Error Beta 
Lower 
Bound 
Upper 
Bound 
Zero-
order Partial Part Tolerance VIF 
1 
(Constant) -0.539 0.045   -12.044 0.000 -0.628 -0.451           
Pharmacy$Turnover 1.5 to 4.0M -0.219 0.061 -0.258 -3.595 0.000 -0.339 -0.099 -0.258 -0.258 -0.258 1.000 1.000 
2 
(Constant) -0.496 0.047   -10.446 0.000 -0.589 -0.402           
Pharmacy$Turnover 1.5 to 4.0M -0.200 0.060 -0.236 -3.302 0.001 -0.319 -0.080 -0.258 -0.239 -0.234 0.984 1.016 
Caters for aged care -0.159 0.064 -0.178 -2.492 0.014 -0.284 -0.033 -0.208 -0.183 -0.176 0.984 1.016 
3 
(Constant) -0.279 0.114   -2.442 0.016 -0.504 -0.054           
Pharmacy$Turnover 1.5 to 4.0M -0.208 0.060 -0.246 -3.469 0.001 -0.327 -0.090 -0.258 -0.251 -0.243 0.979 1.021 
Caters for aged care -0.148 0.063 -0.165 -2.331 0.021 -0.273 -0.023 -0.208 -0.172 -0.163 0.977 1.023 
Participates in other pharmacy trials -0.234 0.112 -0.147 -2.089 0.038 -0.455 -0.013 -0.145 -0.154 -0.147 0.990 1.011 
4 
(Constant) -0.294 0.114   -2.590 0.010 -0.518 -0.070           
Pharmacy$Turnover 1.5 to 4.0M -0.209 0.060 -0.247 -3.508 0.001 -0.327 -0.092 -0.258 -0.254 -0.244 0.979 1.021 
Caters for aged care -0.135 0.063 -0.151 -2.125 0.035 -0.259 -0.010 -0.208 -0.157 -0.148 0.965 1.036 
Participates in other pharmacy trials -0.240 0.111 -0.151 -2.158 0.032 -0.460 -0.021 -0.145 -0.160 -0.150 0.989 1.012 
Location in/near a medical centre 0.188 0.102 0.129 1.846 0.067 -0.013 0.390 0.145 0.137 0.129 0.987 1.013 
5 
(Constant) -0.283 0.113   -2.502 0.013 -0.507 -0.060           
Pharmacy$Turnover 1.5 to 4.0M -0.207 0.059 -0.244 -3.486 0.001 -0.324 -0.090 -0.258 -0.253 -0.242 0.979 1.022 
Caters for aged care -0.119 0.064 -0.133 -1.869 0.063 -0.245 0.007 -0.208 -0.139 -0.130 0.944 1.059 
Participates in other pharmacy trials -0.221 0.111 -0.139 -1.982 0.049 -0.441 -0.001 -0.145 -0.147 -0.137 0.978 1.023 
Location in/near a medical centre 0.180 0.102 0.124 1.770 0.078 -0.021 0.381 0.145 0.132 0.123 0.985 1.016 
High Pharmacist Workload -0.106 0.064 -0.117 -1.659 0.099 -0.231 0.020 -0.172 -0.124 -0.115 0.960 1.042 
a. Dependent Variable: Log CI Rate  
Table 9-7: Coefficients for regression model 2 
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Model 3 (tables) 
Casewise Diagnosticsa 
Case Number 
Std. 
Residual 
Log CI 
Rate 
Predicted 
Value 
Residual 
Cook’s 
Distance 
185 -3.336 -2.000 -0.661 -1.339 0.045 
a. Dependent Variable: Log CI Rate   
Table 9-8: Outlying case for model 3 
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Figure 9-2: Residuals plot for model 3 
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Figure 9-3: Residuals plot for prescription volume model 
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Appendix 24: Tables from the ‘Pharmacist Opinions’ 
analysis 
Pre-trial survey answers: 
“I believe that pharmacists are already too busy within the workplace which prevents 
them from taking on any new tasks”  
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
To
o
 b
u
sy
 
Strongly Agree 29 0.083 0.000 1.124 0.047 0.173 
Agree 99 0.178 0.000 2.408 0.056 0.353 
Neutral 129 0.198 0.000 3.876 0.056 0.365 
Disagree 139 0.221 0.000 2.564 0.091 0.472 
Strongly Disagree 49 0.265 0.000 3.284 0.118 0.582 
Unknown 64 0.017 0.000 1.097 0.000 0.144 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-9: The pharmacist’s perception of busyness and their intervention rate 
 
“I believe it is important for pharmacists to adapt their practice to suit the current 
pharmacy environment” 
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
A
d
ap
t 
p
ra
ct
ic
e 
Strongly Agree 245 0.202 0.000 3.876 0.088 0.458 
Agree 168 0.197 0.000 2.857 0.059 0.359 
Neutral 14 0.103 0.000 1.451 0.067 0.378 
Disagree 10 0.327 0.000 2.358 0.126 0.588 
Strongly Disagree 8 0.011 0.000 0.985 0.000 0.268 
Unknown 64 0.017 0.000 1.097 0.000 0.144 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-10: The pharmacist’s ability to adapt and their intervention rate  
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“I would be willing to change my current practice if a new, better way was available”  
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
W
ill
in
gn
es
s 
to
 
ch
an
ge
 
Strongly Agree 259 0.191 0.000 3.876 0.078 0.498 
Agree 153 0.215 0.000 2.857 0.091 0.372 
Neutral 16 0.121 0.000 0.562 0.047 0.214 
Disagree 6 0.000 0.000 0.422 0.000 0.126 
Strongly Disagree 11 0.075 0.000 0.985 0.000 0.448 
Unknown 64 0.017 0.000 1.097 0.000 0.144 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-11: The pharmacist’s willingness to change and their intervention rate 
 
“I believe I have a good level of clinical knowledge to perform clinical interventions” 
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
G
o
o
d
 le
ve
l o
f 
 
cl
in
ic
al
 k
n
o
w
le
d
ge
 Strongly Agree 93 0.219 0.000 2.591 0.079 0.508 
Agree 230 0.210 0.000 3.284 0.088 0.458 
Neutral 97 0.162 0.000 3.876 0.056 0.297 
Disagree 21 0.111 0.000 0.964 0.027 0.422 
Strongly Disagree 4 0.031 0.000 0.985 0.000 0.524 
Unknown 64 0.017 0.000 1.097 0.000 0.144 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-12: The pharmacist’s self-assessment of their clinical knowledge and their 
intervention rate 
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“I am confident in my ability to perform clinical interventions” 
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
C
o
n
fi
d
en
ce
 in
 a
b
ili
ty
 
Strongly Agree 105 0.279 0.000 2.616 0.083 0.694 
Agree 228 0.170 0.000 3.284 0.082 0.404 
Neutral 84 0.199 0.000 3.876 0.064 0.317 
Disagree 24 0.109 0.000 0.964 0.019 0.401 
Strongly Disagree 4 0.031 0.000 0.985 0.000 0.524 
Unknown 64 0.017 0.000 1.097 0.000 0.144 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-13: The pharmacist’s confidence in performing CIs and their intervention rate 
 
“I already perform clinical interventions on a daily basis” 
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
A
lr
e
ad
y 
p
er
fo
rm
 
in
te
rv
e
n
ti
o
n
s 
Strongly Agree 128 0.263 0.000 2.616 0.122 0.589 
Agree 187 0.177 0.000 3.876 0.076 0.398 
Neutral 102 0.144 0.000 2.564 0.047 0.297 
Disagree 22 0.258 0.000 0.771 0.062 0.422 
Strongly Disagree 6 0.123 0.000 0.985 0.000 0.450 
Unknown 64 0.017 0.000 1.097 0.000 0.144 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-14: The pharmacist’s current level of performing CIs and their intervention 
rate 
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“I believe the recording of interventions will increase my level of job satisfaction” 
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
In
cr
ea
se
 jo
b
 
sa
ti
sf
ac
ti
o
n
 
Strongly Agree 126 0.210 0.000 3.284 0.091 0.546 
Agree 170 0.204 0.000 2.857 0.086 0.475 
Neutral 102 0.177 0.000 3.876 0.060 0.332 
Disagree 37 0.109 0.000 0.617 0.038 0.290 
Strongly Disagree 10 0.357 0.000 2.591 0.056 0.964 
Unknown 64 0.017 0.000 1.097 0.000 0.144 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-15: The pharmacist’s belief in increased job satisfaction and their intervention 
rate 
“I am concerned the recording system will be hard to use” 
 
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
B
e
lie
f 
th
at
 s
ys
te
m
 
w
ill
 b
e
 h
ar
d
 t
o
 u
se
 Strongly Agree 11 0.268 0.000 1.908 0.095 0.391 
Agree 89 0.147 0.000 3.876 0.052 0.310 
Neutral 153 0.162 0.000 2.857 0.048 0.398 
Disagree 137 0.219 0.000 3.284 0.091 0.448 
Strongly Disagree 55 0.314 0.000 2.193 0.168 0.649 
Unknown 64 0.017 0.000 1.097 0.000 0.144 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-16: The pharmacist’s belief that the system would be hard to use and their 
intervention rate 
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Post-trial survey answers: 
“I found the software easy to use” 
  
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
So
ft
w
ar
e 
w
as
 e
as
y 
to
 u
se
 
Strongly Agree 73 0.290 0.000 3.284 0.154 0.597 
Agree 152 0.220 0.000 3.876 0.087 0.508 
Neutral 23 0.128 0.000 1.451 0.036 0.328 
Disagree 12 0.121 0.000 1.908 0.045 0.752 
Strongly Disagree 0   
Unknown 249 0.100 0.000 2.857 0.000 0.249 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-17: The pharmacist’s assessment of the ease of use of the system and their 
intervention rate 
 
“I received sufficient training to use the software”  
  
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
R
e
ce
iv
e
d
 s
u
ff
ic
ie
n
t 
so
ft
w
ar
e
 t
ra
in
in
g Strongly Agree 79 0.320 0.000 3.284 0.171 0.712 
Agree 140 0.208 0.000 3.876 0.075 0.425 
Neutral 28 0.134 0.000 2.591 0.110 0.343 
Disagree 11 0.310 0.000 0.985 0.056 0.595 
Strongly Disagree 2 0.176 0.036 0.315 0.036 0.315 
Unknown 249 0.100 0.000 2.857 0.000 0.249 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-18: The pharmacist’s assessment of sufficient software training and their 
intervention rate 
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“I am confident in my ability to perform clinical interventions”  
  
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
C
o
n
fi
d
en
ce
 in
 a
b
ili
ty
 
to
 p
er
fo
rm
 C
Is
 Strongly Agree 41 0.235 0.028 2.358 0.132 0.725 
Agree 186 0.248 0.000 3.876 0.119 0.533 
Neutral 27 0.219 0.000 1.451 0.034 0.498 
Disagree 5 0.041 0.027 0.310 0.036 0.074 
Strongly Disagree 0   
Unknown 250 0.104 0.000 2.857 0.000 0.249 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-19: The pharmacist’s confidence in their abilities post-trial and their 
intervention rate 
 
“The trial increased my awareness of how many clinical interventions I perform”  
  
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
Tr
ia
l i
n
cr
e
as
e
d
 
aw
ar
e
n
e
ss
 o
f 
C
Is
 Strongly Agree 68 0.425 0.000 3.876 0.217 0.703 
Agree 141 0.222 0.000 2.616 0.114 0.467 
Neutral 37 0.125 0.000 2.591 0.058 0.206 
Disagree 9 0.328 0.034 1.563 0.139 0.570 
Strongly Disagree 4 0.144 0.036 1.888 0.074 1.032 
Unknown 250 0.104 0.000 2.857 0.000 0.249 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-20: The pharmacist’s assessment of the trial increasing awareness and their 
intervention rate 
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“The performing of clinical interventions increased my level of job satisfaction” 
  
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
P
e
rf
o
rm
in
g 
C
Is
 
in
cr
ea
se
d
 jo
b
 
sa
ti
sf
ac
ti
o
n
 
Strongly Agree 68 0.329 0.025 3.284 0.180 0.709 
Agree 151 0.220 0.000 3.876 0.119 0.460 
Neutral 32 0.112 0.000 2.591 0.056 0.306 
Disagree 7 0.139 0.027 1.563 0.056 0.566 
Strongly Disagree 1 0.111 0.111 0.111 0.111 0.111 
Unknown 250 0.104 0.000 2.857 0.000 0.249 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-21: The pharmacist’s assessment of performing interventions increasing job 
satisfaction and their intervention rate 
 
“The recording of clinical interventions increased my level of job satisfaction” 
  
Pharmacist 
Count 
Intervention Rate 
Median Min. Max. 
25th 
%ile 
75th 
%ile 
R
e
co
rd
in
g 
C
Is
 
in
cr
e
as
e
d
 jo
b
 
sa
ti
sf
ac
ti
o
n
 
Strongly Agree 42 0.497 0.000 2.358 0.149 0.725 
Agree 123 0.235 0.000 3.876 0.126 0.562 
Neutral 66 0.163 0.000 1.899 0.058 0.389 
Disagree 24 0.211 0.027 1.563 0.118 0.324 
Strongly Disagree 4 1.000 0.036 2.591 0.074 2.240 
Unknown 250 0.104 0.000 2.857 0.000 0.249 
Total 509 0.168 0.000 3.876 0.054 0.375 
Table 9-22: The pharmacist’s assessment of recording interventions increasing job 
satisfaction and their intervention rate 
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Appendix 25: Pharmacist logistic regression analysis 
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Logistic regression for pharmacist intervention rate  
From the database, all pharmacists have a known CI rate (including rates of zero), known training level (as participation was recorded) and known ‘additional 
qualifications’ (as they were coded as ‘none’ if unknown).  One pharmacist did not have a workload recorded as the pharmacy did not receive a site visit, 
therefore the number of full-time equivalent pharmacists was not recorded.  The other missing values are due to the pharmacists not completing the surveys 
(Table 9-23).   
 N Mean 
Std. 
Deviation 
Missing No. of Extremesa 
Count Percent Low High 
CI rate 509 0.325 0.491 0 0.0 0 43 
Adaptability score 445 5.955 1.794 64 12.6 0 16 
Confidence score 445 6.299 2.311 64 12.6 0 38 
Clinical knowledge score 419 53.120 7.425 90 17.7 11 0 
Average pharmacist workload 508 478.037 185.158 1 0.2 0 9 
Additional qualifications  509   0 0.0   
CPD 446   63 12.4   
Training 509   0 0.0   
a. Number of cases outside the range (Q1 - 1.5*IQR, Q3 + 1.5*IQR). 
Table 9-23: Missing value analysis 
Table 9-24 shows the differences in mean between the pharmacists with the data present and not present.  The mean CI rate was much higher in the group 
where the surveys were answered, indicating that the pharmacists who answered the surveys may have been more motivated.  
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 t df # Present 
# 
Missing 
Mean(Present) Mean(Missing) 
Adaptability score 7.7 256.2 445 64 0.357 0.104 
Clinical knowledge score 6.8 326.6 419 90 0.367 0.132 
CPD 7.8 249.0 446 63 0.357 0.010 
Table 9-24: Separate variance t-tests 
Table 9-25 shows that 416 cases have all data, 24 are missing only the clinical knowledge score and 59 are missing all survey data.  As seen previously, the 
remaining case is missing a figure for the pharmacist workload. 
No. of 
Cases 
Missing Patternsa 
Complete if 
...b 
CI 
Rate 
Additional 
quals 
Training 
Average 
pharmacist 
workload 
CPD 
Adaptability 
score 
Clinical 
knowledge 
score 
416        416 
24       X 440 
59     X X X 508 
Patterns with less than 1% cases (5 or fewer) are not displayed. 
a. Variables are sorted on missing patterns. 
b. Number of complete cases if variables missing in that pattern (marked with X) are not used. 
Table 9-25: Missing data patterns 
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Ideally, the MCAR test should be non-significant, as this means the distribution of missing values is unpredictable.  For this dataset, the MCAR test was 
approaching significance and may therefore be predictable (p = 0.06).  However, this is expected, because the pharmacists who did not fill out one survey, often 
did not fill out another survey, resulting in a predictable missing value distribution (Table 9-26).  
 
EM Correlationsa 
 
CI 
Rate 
Adaptability 
score 
Clinical 
knowledge 
score 
Average 
pharmacist 
workload 
CIRate 1    
Adaptability score -0.160 1   
Clinical knowledge score 0.127 -0.168 1  
Average pharmacist workload -0.083 0.098 -0.028 1 
a. Little's MCAR test: Chi-Square = 19.044, DF = 11, Sig. = .060 
Table 9-26: Distribution of missing values 
 
  
516 | P a g e  
 
Appendix 26: Observational data analysis 
Influencing factors on performance rates 
During the sub-study, 90 pharmacists were observed in software pharmacies, with 6 of 
these pharmacists performing no interventions and 19 recording no interventions. 
Therefore, 5 pharmacists did not perform or record any interventions, 14 performed 
interventions but did not record any, and 1 pharmacist recorded an intervention but did 
not perform any (indicating that the pharmacist recorded something that the observer did 
not feel was an intervention). Transformation did not improve the data (Kolmogorov-
Smirnov statistic = 0.16, df = 65, p< 0.001); so non-parametric statistical tests were used. 
Demographics 
Of the 78 pharmacists who completed the surveys, 44 were female and 34 were male, 
with no significant difference in intervention performance rate between the two genders 
(Mann-Whitney U = 644.50, Z = -1.04, p = 0.29). Age range was related to performance 
rate with pharmacists over 50 years of age having the highest performed intervention rate 
followed by pharmacists in the 20-30 year age range (Kruskal-Wallis χ2 = 16.76, df = 3, p = 
0.001); however, there was no relationship seen between graduation year and the 
performed intervention rate (Spearman’s rho = 0.03, N = 78, p = 0.79). 
Additional qualifications 
Interestingly, there was no apparent relationship between pharmacists with additional 
qualifications and their intervention performance rate (Kruskal-Wallis χ2 = 2.05, df = 2, p = 
0.37), despite a trend being seen in the overall analysis of pharmacist’s documented 
intervention rates (see section 5.2.4). HMR accreditation was also not an influencing 
factor, with no difference seen between the 15 accredited and 63 non-accredited 
pharmacists (Mann-Whitney U = 392.00, Z = -1.02, p = 0.31). 
CPD activity 
CPD activity also did not appear to have a relationship with intervention performance rate 
in this group of pharmacists (Kruskal-Wallis χ2 = 5.91, df = 3, p = 0.12). 
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Workload 
There did not appear to be a relationship between the intervention performance rate and 
the average pharmacist workload within the pharmacy (Spearman’s rho = -0.15, N = 85, p 
= 0.16). 
Professionalism score 
The professionalism score that was run on PROMISe pharmacists had only previously been 
tested on undergraduate pharmacy students. Therefore, it was compared to the Hall’s 
Professionalism Survey that was completed by observed pharmacists (see Appendix 20). 
Of the 149 pharmacists, 143 completed the Hall’s Professionalism Survey for 
Pharmacists;161 however, only 77 of these pharmacists had completed the original 
professionalism survey. Analysis showed good correlation between the scores 
(Spearman’s rho = 0.355, N = 77, p = 0.002) indicating that the initial professionalism 
survey was a good predictor of the Hall’s professionalism score. 
For the pharmacists within the software pharmacies, there did not appear to be a 
relationship between the intervention performance rate and either professionalism score 
(Spearman’s rho = 0.12, N = 77, p = 0.29 for the initial professionalism survey; Spearman’s 
rho = -0.07, N = 83, p = 0.51 for the Hall’s professionalism survey). 
Empathy score 
Seventy-six observed pharmacists completed the empathy survey. There did not appear to 
be a relationship between the intervention performance rate and the pharmacist’s 
empathy score (Spearman’s rho = -0.02, N = 76, p = 0.84). 
Clinical knowledge survey score 
Seventy-one observed pharmacists completed the clinical knowledge survey. There did 
not appear to be a relationship between the intervention performance rate and the 
pharmacist’s clinical knowledge score (Spearman’s rho = 0.11, N = 71, p = 0.37). 
Training level 
There did not appear to be a relationship between the intervention performance rate and 
the pharmacist’s level of training (Kruskal-Wallis χ2 = 2.98, df = 3, p = 0.40). 
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Adaptability/willingness to change score 
There did not appear to be a relationship between the intervention performance rate and 
the pharmacist’s adaptability/willingness to change score (Spearman’s rho = -0.03, N = 78, 
p = 0.78). See Chapter 5 for the calculation process. 
Confidence score 
There did not appear to be a relationship between the intervention performance rate and 
the pharmacist’s confidence score (Spearman’s rho = -0.03, N = 78, p = 0.83). See Chapter 
5 for the calculation process. 
 
Influencing factors on documented rates 
Of the 90 pharmacists who were observed in software pharmacies, 19 did not record any 
interventions during their observation period, resulting in 66 pharmacists who had an 
observed intervention recording rate. Again, transformation did not improve the data 
(Kolmogorov-Smirnov statistic = 0.12, df = 65, p= 0.02); therefore, non-parametric 
statistical tests were used. The effect of the observation week on the observed 
pharmacies was discussed previously in Chapter 4. 
Demographics 
There was no significant difference in intervention recording rate between the two 
genders (Mann-Whitney U = 694.00, Z = -0.55, p = 0.59) or the age range of the pharmacist 
(Kruskal-Wallis χ2 = 5.83, df = 3, p = 0.12). There was also no relationship seen between 
graduation year and intervention recording rate (Spearman’s rho = 0.01, N = 78, p = 0.91). 
Additional qualifications 
Again, there was also no apparent relationship between pharmacists with additional 
qualifications and their intervention recording rate (Kruskal-Wallis χ2 = 4.37, df = 2, p = 
0.10), despite a trend being seen in the overall pharmacist group (see Chapter 5 for 
details). HMR accreditation was also not an influencing factor, with no difference between 
the accredited and non-accredited pharmacists with regards to their recording rates 
(Mann-Whitney U = 374.50, Z = -1.25, p = 0.21). 
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CPD activity 
CPD activity also did not appear to have a relationship with intervention recording rate in 
this group of pharmacists (Kruskal-Wallis χ2 = 0.77, df = 3, p = 0.86). 
Workload 
There did not appear to be a relationship between the intervention recording rate and the 
average pharmacist workload within the pharmacy (Spearman’s rho = -0.01, N = 85, p = 
0.94). 
Professionalism score 
There did not appear to be a relationship between the intervention recording rate and 
either professionalism score (Spearman’s rho = 0.01, N = 77, p = 0.39 for the initial 
professionalism survey; Spearman’s rho = 0.05, N = 83, p = 0.64 for the Hall’s 
professionalism survey). 
Empathy score 
There did not appear to be a relationship between the intervention recording rate and the 
pharmacist’s empathy score (Spearman’s rho = 0.01, N = 76, p = 0.91). 
Clinical knowledge survey score 
There did not appear to be a relationship between the intervention recording rate and the 
pharmacist’s clinical knowledge score (Spearman’s rho = 0.03, N = 71, p = 0.78). 
Training level 
There did not appear to be a relationship between the intervention recording rate and the 
pharmacist’s level of training (Kruskal-Wallis χ2 = 5.83, df = 3, p = 0.12). 
Adaptability/willingness to change score 
There did not appear to be a relationship between the intervention recording rate and the 
pharmacist’s adaptability/willingness to change score (Spearman’s rho = -0.06, N = 78, p = 
0.61). See Chapter 5 for the calculation process. 
Confidence score 
There did not appear to be a relationship between the intervention recording rate and the 
pharmacist’s confidence score (Spearman’s rho = -0.06, N = 78, p = 0.61). See Chapter 5 
for the calculation process. 
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Appendix 27: PROMISe Trial article in AnnPharm 2011 
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Appendix 28: DOCUMENT article in IJCP 2012 
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Appendix 29: Clinical knowledge tool article in IJPP 2012 
